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Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorder in reproductive-
aged females, with the main hormonal abnormality being androgen (testosterone) excess. 
Although it is well-established that there is a higher prevalence of depression in PCOS, little 
research has examined the direct relationship between androgen levels, depression and 
associated cognitive impairment. The current study conducted a simultaneous investigation of 
the relationship between androgen levels, mood, cognitive function and emotion processing in 
females with PCOS, before and after 12 weeks of anti-androgen treatment. Elucidating the 
relationship between androgens and mood in females could have significant benefit in 
determining optimal treatment for the subset of females whose symptoms of depression may be 
related to an underlying androgen excess.  
 
Objectives 
 To describe differences between the PCOS (n = 53) and non-PCOS control (n = 54) groups 
on measures of mood, anxiety, cognitive function and emotion processing, 
 To determine whether correlations exist between androgen levels and symptoms of 
depression and anxiety, cognitive function, and emotion processing in the entire sample 
with varying androgen levels, 
 To determine whether symptoms of depression relate to aspects of cognitive function and 
emotion processing, 
 To determine whether anti-androgen treatment is associated with changes in mood, anxiety, 





Fifty-three females with PCOS and 54 age-matched females without PCOS completed an 
assessment of androgen levels from blood samples, depression-rating scales, and cognitive and 
emotion processing measures at two-time points; baseline and 12 weeks. The PCOS group 
commenced anti-androgen treatment following baseline assessment.  
 
Results 
 Females with PCOS had more symptoms of depression but not anxiety, and showed worse 
performance on the cognitive domains of psychomotor speed and emotion processing 
compared with the control group. 
 Higher testosterone levels were significantly associated with worse mood and worse 
cognitive function in sub-tests within the domains of verbal and visuospatial learning and 
memory, psychomotor speed and emotion processing across the entire sample.  
 Significant correlations were found between worse mood and anxiety and poorer cognitive 
performance on aspects of verbal and visuospatial learning and memory, and attention and 
executive function measures. 
 Anti-androgen treatment was associated with significant improvements in psychomotor 
speed and aspects of emotion processing in the PCOS group. 
 Following anti-androgen treatment, a significant improvement was observed in symptoms 
of depression and anxiety and on performance on verbal and visuospatial learning and 
memory and emotion processing measures within the PCOS group. 
 Improvement in symptoms of mood was associated with improved performance on 
measures of psychomotor speed, attention and executive function and improved 





Females with PCOS showed greater symptoms of depression and worse cognitive function 
compared with non-PCOS control participants. Additionally, higher testosterone levels were 
associated with greater symptoms of depression and worse cognitive performance. Anti-
androgen treatment appeared to have a significantly beneficial effect on mood and aspects of 
cognitive function in the PCOS group. 
Results from the current study thus provide preliminary evidence that testosterone excess in 
females with PCOS is associated with greater depressive symptoms and worse cognitive 
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Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in reproductive-
aged females (Azziz, Woods, et al., 2004; Franks, 1995; McGowan, 2011), affecting up to five 
to 22% of females depending upon the diagnostic criteria used (Azziz et al., 2016; Farquhar, 
Birdsall, Manning, Mitchell, & France, 1994; Goodarzi & Azziz, 2006; Mueller, Grissom, & 
Dohanich, 2014; Sirmans & Pate, 2014; Teede, Deeks, & Moran, 2010). It is well-established 
that the primary hormonal abnormality in PCOS is androgen excess (Azziz, Carmina, Dewailly, 
Diamanti-Kandarakis, Escobar-Morreale, Futterweit, Janssen, Legro, Norman, & Taylor, 
2006), mainly Free Testosterone excess (Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2004). Although a greater rate of psychiatric illnesses, such as 
depression and anxiety disorders, have been found in PCOS (Cooney & Dokras, 2017; Cooney, 
Lee, Sammel, & Dokras, 2017; Dokras, Clifton, Futterweit, & Wild, 2011, 2012), very little 
research has directly examined the relationship between abnormal androgen levels and 
symptoms of depression and anxiety in females with or without PCOS.  
Major depressive disorder (MDD) is a common and debilitating condition which affects more 
than 322 million individuals of all ages worldwide (World Health Organisation, 2017). It is 
projected to be one of the three leading causes of disease burden in 2030 (Mathers & Loncar, 
2006) and has an enormous cost of illness and impairment in individuals’ functioning (Johnson, 
Weissman, & Klerman, 1992; Kessler & Bromet, 2013; Spijker et al., 2004). Females are twice 
as likely to suffer from mood and anxiety disorders as males, and symptoms of mood and 
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anxiety are often of greater severity in females (Karger, 2014; Noble, 2005; Weissman et al., 
1993; Weissman & Olfson, 1995). Research has consistently found impairment in cognitive 
function, including deficits in memory, attention and executive function, and emotion 
processing in individuals with MDD (Douglas & Porter, 2009; Douglas, Porter, Knight, & 
Maruff, 2011; Hsu, Young-Wolff, Kendler, Halberstadt, & Prescott, 2014; Porter, Bourke, & 
Gallagher, 2007; Porter, Gallagher, Thompson, & Young, 2003; Porter, Robinson, Malhi, & 
Gallagher, 2015; Rock, Roiser, Riedel, & Blackwell, 2013; Zalkanis, Leach, & Kaplan, 1998). 
However, current first-line pharmacological treatments for MDD have limited efficacy and 
unwanted side-effects (Arroll et al., 2009) and do little to improve cognitive impairment found 
in MDD (Airaksinen, Wahlin, Larsson, & Forsell, 2006; Porter et al., 2016; Shilyansky et al., 
2016). Thus, there are likely to be many females in the general population who have depression 
and cognitive impairment as a result of untreated androgen abnormalities, however, the 
relationship between androgen levels, mood and associated cognitive function has not been 
investigated directly. Normalising androgens may be a more effective and logical treatment 
strategy than antidepressant treatment. This thesis presents data from a longitudinal study which 
examined in detail associations between androgen levels and symptoms of depression, 
cognitive functioning and emotion processing in females of reproductive age, with and without 
PCOS, before and after 12 weeks of anti-androgen treatment in the PCOS group. 
 
1.2 RATIONALE AND AIMS  
The current study aimed to investigate the relationship between androgen levels and mood, 
cognitive function and emotion processing, and for this purpose included reproductive-aged 
females with PCOS, with abnormally elevated levels of testosterone, as well as reproductive-aged 
non-PCOS control females. Females newly referred to a gynaecological-endocrine clinic were 
assessed and a treatment plan was put in place by the treating Gynaecological-Endocrinologist. 
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Standard clinical medication included anti-androgen agents to either decrease or block androgen 
levels. Before commencement of anti-androgen treatment, the baseline assessment including 
mood and cognitive assessment was carried out, as one of the main goals of the current study was 
to examine the associations between androgen levels, symptoms of mood, cognitive function and 
emotion processing at baseline. This also helped to determine whether treating abnormalities in 
the androgen system in the patient group affected symptoms of mood, anxiety and cognitive 
function. Additionally, an investigation was carried out to examine whether a change in mood 
following treatment in the PCOS group was associated with a change in cognitive function and 
emotion processing variables. This is the first study to simultaneously examine the association 
between androgen levels and mood, cognitive function and emotion processing in reproductive-
aged females with and without PCOS, and to examine the association between change in mood 
and change in cognitive function and emotion processing variables in the PCOS group following 
anti-androgen treatment. Findings from the current thesis may help facilitate a healthy 
collaboration between the fields of psychiatry and endocrinology.  
For the main purpose of determining whether a relationship exists between androgen levels, 
depressive symptoms and cognitive function, the main tests consisted of: 
1. Clinical measures – clinician-administered and self-report mood and anxiety rating 
scales, 
2. Cognitive measures - assessment of domains including verbal and visuospatial 
learning and memory, attention and executive function, psychomotor speed, and 
emotion processing, 
3. Medical and endocrinological measures - laboratory assessment included androgen 
levels and other important hormone levels from blood samples, along with an 





1.3 THESIS STRUCTURE 
The current thesis has the following structure: 
Chapter Two presents an overview of MDD, with a discussion of the heterogeneous nature of 
depression, and the key symptoms and causes involved. Associated features of cognitive 
impairment, impairment in emotion processing and comorbid anxiety, along with treatment 
strategies, are also discussed. 
Chapter Three presents an overview of the main types and sources of androgens and normal 
androgen activity in healthy females. The second part of the chapter focuses on the 
neurobiology of androgens along with an overview of disorders related to androgen-excess in 
females. 
Chapter Four provides a detailed discussion of PCOS, with an overview of the clinical features 
involved and the diagnostic criteria and classification. The second part of the chapter discusses 
its epidemiology, risk factors, biological mechanisms and the treatment for PCOS. Following 
this, findings related to mood, cognitive function and emotion processing in females with PCOS 
are reviewed. 
Chapter Five presents the findings of a systematic literature review of studies assessing mood, 
anxiety, cognitive function and emotion processing in relation to androgen levels in females of 
reproductive age with and without PCOS.  
Chapter Six describes the methodology used in subsequent chapters. 
Chapter Seven presents findings from baseline analyses examining associations between 
androgen levels, mood and anxiety symptoms, and performance on measures of cognitive 
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function, and emotion processing in females with PCOS compared with non-PCOS control 
females, and in the entire group as a whole, followed by a discussion of the results. 
Chapter Eight presents longitudinal mood and cognitive findings over the course of the 12-
week anti-androgen treatment in females with PCOS compared with non-PCOS control 
females receiving no treatment, followed by a discussion of the results.  
Chapter Nine presents an overall summary of findings, their implications and directions for 









2.1 INTRODUCTION  
This chapter presents an overview of major depressive disorder (MDD) with a discussion of the 
heterogeneous nature of MDD, the key symptoms and causes involved, and the reasons behind 
gender differences in mood and anxiety disorders. Following this, associated features of 
cognitive impairment, emotion processing impairment, and comorbid anxiety are described. 
Lastly, treatment strategies for depression are discussed. 
 
2.2 MAJOR DEPRESSIVE DISORDER 
2.2.1 Key symptoms 
Major depressive disorder is widely recognised as a common and debilitating condition, 
characterised by pervasive low mood or sadness. Depression is a heterogeneous disorder with 
a variable course. It is distinct from fluctuations in mood in healthy individuals and is associated 
with diminished quality of life, impaired social function, medical morbidity and mortality 
(Kessler, Berglund, Demler, & et al., 2003; Kessler & Bromet, 2013; Noble, 2005). The 
Diagnostic and Statistical Manual of Mental Disorders - 5th edition (DSM-5) states that the 
diagnosis of MDD requires the presence of depressive symptoms involving a distinct change in 
mood characterised by irritability and/or sadness, accompanied by several features including 
loss of interest in otherwise pleasurable activities, sleep disturbance, changes in appetite and 
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weight, feelings of worthlessness or hopelessness, lack of focus and concentration, and suicidal 
ideation. These symptoms must last for a minimum of two weeks and cause clinically 
significant distress or role impairment in social and occupational functioning or in other areas 
of life important to the individual. A major depressive episode may occur in the context of 
MDD (involving exclusively depressed mood) or bipolar disorder (in which hypomanic or 
manic episodes may be present at other times). 
It is understood that the symptoms of depression occur on a continuum of severity, with greater 
severity of symptoms being positively associated with higher psychiatric comorbidity (Kessing, 
2007; Lewinsohn, Solomon, Seeley, & Zeiss, 2000). Since the clinical picture of depression is 
heterogeneous and involves variability in the degree of severity of symptoms (Snaith, 1987), it 
is important to acknowledge the spectrum on which this condition lies, ranging from mild to 
severe depression. Although a larger proportion of depression-related literature focuses on the 
diagnosable clinical state of depression, the overall prevalence rates of individuals with 
symptoms of depression is still high (Angst & Merikangas, 1997).  In the current thesis, the 
term ‘depression’ will be used unless referring to studies that talk specifically about MDD as a 
diagnostic classification.  
 
2.3 PREVALENCE 
2.3.1 Global burden of depression and prevalence in New Zealand, and internationally 
The World Health Organisation (WHO) reports that more than 322 million people of all ages 
live with MDD globally (at one time-point), with more females (5.1%) affected compared with 
males (3.6%) (World Health Organisation, 2017). The total estimated number of individuals 
with depression increased by 18.4% between 2005 and 2015. Currently, MDD is the leading 
cause of disease-related disability worldwide (Flint & Kendler, 2014) and has an enormous cost 
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of illness and impairment in individuals’ functioning (Cassano & Fava, 2002; Johnson et al., 
1992; Kessler & Bromet, 2013; Spijker et al., 2004). Consequently, MDD is a priority condition 
for WHO and is covered by their Mental Health Gap Action Programme (World Health 
Organisation, 2008). In New Zealand, the burden of MDD is high. The New Zealand Mental 
Health Survey (Te Rau Hinengaro) reported a high prevalence of MDD in adults (14.3%), with 
significantly higher rates in females closer to reproductive age (35 to 44 years) (17.9%) 
compared with males (10.4%) (Oakley-Browne, Wells, & Scott, 2006).  
Similar findings have been documented worldwide, with MDD affecting twice as many females 
as males in adulthood (Karger, 2014; Kessler, 2003; Kessler et al., 1994; Noble, 2005; Piccinelli 
& Wilkinson, 2000; Weissman et al., 1993; Weissman & Olfson, 1995). The National Institutes 
of Mental Health (United States) report that females are 70% more likely to suffer from 
depression compared with males. This gender difference in prevalence of depression has been 
consistently found despite variability in ethnic groups and cultures (Waraich, Goldner, Somers, 
& Hsu, 2004).  
 
2.4  RISK FACTORS FOR MAJOR DEPRESSIVE DISORDER  
The aetiology of MDD is still not fully understood due to its heterogeneity. However, multiple 
theories have been postulated to explain the development and progression of MDD, including 
genetic (Flint & Kendler, 2014; Kendler & Karkowski-Shuman, 1997; Kendler et al., 2010; 
Silberg et al., 1999), neurobiological (neurotransmitter systems including noradrenaline and 
serotonin) (Delgado & Moreno, 2000; Malhi, Parker, & Greenwood, 2005; Nestler et al., 2002; 
Ressler & Nemeroff, 2000) and neuroendocrinological theories (Belmaker & Agam, 2008; 
Checkley, 1996; Drevets, Price, & Furey, 2008), together with psychological and social 
explanations (Beck, 1979; Bonde, 2008; Hagerty & Williams, 1999; Peterson & Seligman, 
1984) and an interaction between models has also been suggested (Beck, 2008; Nemeroff & 
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Vale, 2005). Other risk factors may include adverse childhood experiences (D. Chapman et al., 
2004), and life events including trauma or stress (Kendler & Karkowski-Shuman, 1997). The 
hormonal causes of depression are more relevant to the current thesis, and therefore, will be 
discussed in detail.  
2.4.1 Neuroendocrinological risk factors for major depressive disorder 
2.4.1.1 Sex hormones 
There is a higher prevalence and greater symptom severity of MDD in females compared with 
males (see Figure 2.1) (Bebbington, 1996; Kessler, 2003; Noble, 2005; Nolen-Hoeksema & 
Hilt, 2013; Piccinelli & Wilkinson, 2000). Additionally, an earlier age of onset, atypical features 
and dysthymia (a chronic and persistent form of depressive disorder) are more frequently 
observed in females compared with males (Angst & Merikangas, 1997). The observed gender 
difference in the prevalence of symptoms has piqued research interest in the investigation of 
the relationship between sex hormones and mood in individuals with MDD (Baischer, Koinig, 
Hartmann, Huber, & Langer, 1995; Bromberger, Schott, & Kravitz, 2010; Dokras, 2012; 
Dokras et al., 2011; Rohr, 2002; Yonkers, 2003). For at least some females, depression may 
have hormonal underpinnings, although the exact hormonal determinants have not been entirely 





Figure 2.1  
Major depression rates by age and sex 
(Steiner, 2009; Weissman, Bruce, Leaf, Florio, & Holzer, 1991). 
 
2.4.1.2  Female-specific sex hormonal factors 
Studies have investigated oestrogen (primary female sex hormone) and progesterone (female 
hormone important in maintaining pregnancy) levels in relation to mood in females. Fluctuating 
levels of sex hormones (oestrogen, progesterone and testosterone) through variations in 
reproductive phases including puberty, menarche, pregnancy and menopause can be 
accompanied by conditions affecting mood, such as premenstrual syndrome, postpartum and 
postmenopausal depression (Lawrie, Herxheimer, & Dalton, 2000; Steiner, Dunn, & Born, 
2003; Yonkers, 2003; Zsido, Villringer, & Sacher, 2017). Such patterns indicate an effect of 
sex hormones on mood. Furthermore, there is a marked increase in the incidence of depression 
in females from puberty onwards, which declines following menopause. Steiner et al. (2009) 
reported that the constant fluctuation of oestrogen and progesterone during various reproductive 
stages in females may contribute to frequently altered sensitivity in neurotransmitter systems 
or suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis (see page 13), further leading 
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to the development of depression. Although progesterone has been frequently examined in 
females with postnatal depression, evidence regarding this relationship is still weak and requires 
more investigation (Granger & Underwood, 2001; Klier et al., 2007).  
On the other hand, there is relatively consistent evidence regarding an inverse relationship 
between oestrogen levels and an increased incidence of depression (Slowik, Lammerding, 
Hoffmann, & Beyer, 2018; Wharton, Gleason, Sandra, Carlsson, & Asthana, 2012; Young, 
Midgley, Carlson, & Brown, 2000; Zheleznova, Medvedev, & Kalinin, 2013). Oestrogen is 
thought to act on the hippocampus in a similar manner to antidepressants that selectively inhibit 
serotonin (one of the main neurotransmitters involved in depression) reuptake. Lower oestrogen 
levels have been associated with an impaired central adrenergic function (including disrupted 
norepinephrine and epinephrine function), which has been related to depression (Klaiber, 
Broverman, Vogel, & Kobayashi, 1979). Studies have found some benefit in oestrogen 
supplementation as an adjunct to the pharmacological treatment of MDD and symptoms of 
depression in samples including females with postnatal depression or perimenopausal and 
postmenopausal females (de Novaes Soares, Almeida, Joffe, & Cohen, 2001; Halbreich & 
Kahn, 2001; Klaiber et al., 1979; P. J. Schmidt et al., 2000; Zweifel & O'Brien, 1997). 
2.4.1.3 Androgens 
Although androgens are primarily male sex hormones, they play an important physiological 
role in both males and females. As the current thesis is focused on the relationship between 
androgen levels and mood, Chapters 3 and 4 involve a thorough description of androgens, and 
a discussion of conditions (mainly Polycystic Ovarian Syndrome (PCOS), involving 
chronically elevated levels of androgens) that are associated with increased rates of depression. 
Chapter 5 presents a detailed review of studies investigating associations between androgens 
and mood in reproductive-aged females.   
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2.5 THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS  
The Hypothalamic Pituitary Adrenal (HPA) axis is a feedback system which plays an important 
role in human adaptation to physical and psychological stress. In a normal individual, following 
a perceived stressor, the HPA axis activity regulates secretion of the adrenocorticotrophic 
hormone-releasing hormone (CRH) and arginine-vasopressin from the hypothalamus, which 
stimulates the secretion of adrenocorticotrophic hormone (ACTH) from the pituitary. 
Adrenocorticotrophic hormone then acts on the adrenal cortex to produce cortisol, which is a 
glucocorticoid stress hormone. Cortisol has crucial effects on multiple tissues in the brain and 
body (Burke, Davis, Otte, & Mohr, 2005). Cortisol binds to its receptors in the hypothalamus 
and inhibits secretion of CRF and ACTH, respectively, both during and after the stressful event 
has receded. This, in turn, leads to lowered cortisol secretion by the adrenal cortex, known as 
the negative feedback mechanism of the HPA axis. This inhibitory feedback mechanism works 
at the level of the hypothalamus, pituitary gland, and hippocampus to restore homeostasis 
through self-regulation.  
A relatively consistent neuroendocrine abnormality found in depression is hyperactivity of the 
HPA axis (Pariante & Lightman, 2008; Porter & Gallagher, 2006; Schatzberg et al., 2013). 
Evidence suggests that excess cortisol production or hypercortisolism as a result of a 
dysfunctional HPA axis is associated with symptoms of depression (Burke et al., 2005; De 
Kloet, 2004; Peeters, Nicholson, & Berkhof, 2003), and that cortisol suppression helps to 
improve low mood (Murphy, 1991). Dysfunction in the HPA axis may be associated with 
cognitive impairment (see section 2.6.1) (Porter & Gallagher, 2006). Some studies have 
suggested that the HPA axis is more reactive to stress in females compared with males (Nolen-
Hoeksema & Hilt, 2013; Oldehinkel & Bouma, 2011) and that ovarian hormones modulate 
regulation of the HPA axis, which contributes to HPA dysfunction (Young & Korszun, 1999). 
The HPA axis not only regulates physiological mechanisms but has a significant effect on the 
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brain, affecting mood and cognition (Holsboer, 2000; Keller et al., 2016; Porter & Gallagher, 
2006; S. Watson & Mackin, 2006)  
Sex hormones may play a mediating role in HPA axis function (Da Silva, 1999; Handa, 
Burgess, Kerr, & O'Keefe, 1994). Of interest to the current thesis is the hypothesis that since 
the adrenal glands are an important source of androgens, including testosterone, 
androstenedione (60 to 70%), and precursor androgen dehydroepiandrosterone (DHEA), any 
disruptions in the HPA axis may ultimately affect androgen synthesis. In certain sub-groups of 
mood disorders, such as bipolar disorder and MDD with psychotic features, HPA axis 
abnormalities are more pronounced. There is also evidence of a disrupted HPA axis in 
individuals with severe or melancholic MDD (Cowen, 2009; Keller et al., 2016; Pariante & 
Lightman, 2008). However, it is beyond the scope of the current thesis to discuss in detail the 
clinical features of depression which are associated with the HPA axis abnormalities, or the 
nature of melancholic depression and whether this is a distinct and definable subtype. Studies 
have shown antidepressant medication may help resolve abnormalities in the HPA system 
(Jensen et al., 1999; Mason & Pariante, 2006). 
 
2.6 ASSOCIATED FEATURES OF MAJOR DEPRESSIVE DISORDER 
Major depressive disorder is a heterogeneous disorder with associated features including 
impairment in cognitive function and in emotion processing, which has a major impact on 
individuals’ overall quality of life (Porter et al., 2007; Porter et al., 2015; Rock et al., 2013). 
This section will discuss the nature of cognitive impairment in depression and describe key 





2.6.1 Cognitive impairment in depression  
Cognitive impairment is well-established as a core feature of depression (Douglas & Porter, 
2009; Douglas et al., 2011; Hsu et al., 2014; McDermott & Ebmeier, 2009; Porter et al., 2007; 
Porter et al., 2003; Rock et al., 2013; Zalkanis et al., 1998). Studies have linked poor response 
to treatment with cognitive deficits, including poorer attention and executive function, and 
psychomotor speed (Dunkin et al., 2000; Etkin et al., 2014; Gudayol‐Ferré et al., 2012; B. 
Taylor et al., 2006; Withall, Harris, & Cumming, 2009), however,  data is still inconclusive in 
adult samples. Until now, no conventional antidepressant treatment has been thoroughly 
examined to show pro-cognitive benefits in individuals with MDD (McIntyre et al., 2013). 
Cognitive impairment contributes to substantial problems in occupational and interpersonal 
functioning and such residual impairment in psychosocial functions may continue after 
remission from depression (Hasselbalch, Knorr, & Kessing, 2011; Jaeger, Berns, Uzelac, & 
Davis-Conway, 2006; Kennedy, Foy, Sherazi, McDonough, & McKeon, 2007). 
The following sections will provide an overview of the main types of cognitive domains and 
key areas of impairment found in depression. 
2.6.2 Cognitive domains impaired in depression  
Categorising cognitive functions into specific domains is complex since most cognitive tasks 
assess multiple cognitive processes, however, most tasks are related to a specific domain more 
completely than other domains. Therefore, the following categories are generally recognised as 





The construct of attention extends back to the start of experimental psychology, however, to 
date, no universally accepted definition of attention exists (Lezak, 2004). Attention refers to 
multiple different processes involved in how the individual becomes receptive to stimuli. Some 
cognitive tasks require higher levels of attention compared with other cognitive domains, and 
are thus, known as measures of attention. Four aspects of attention are clinically relevant: i) 
focused or selective attention- this is the most studied type of attention, and refers to the capacity 
to prioritise one or two salient stimuli while at the same time suppressing other competing 
stimuli (concentration), ii) sustained attention - the ability to keep continuous focus on a 
particular task, over a period of time (Langner & Eickhoff, 2013), iii)  divided attention - the 
capacity to focus and respond to several stimuli simultaneously, and iv) alternating attention - 
this involves flexibility to mentally switch between different tasks, as required. Traditional tests 
of attention are usually global measures of attention rather than tasks that specifically measure 
one of these components. For example, the Paced Auditory Serial Addition Task (PASAT) 
(Diehr, Heaton, Miller, & Grant, 1998) and Rapid Visual Information Processing (Coull, Frith, 
Frackowiak, & Grasby, 1996). Prefrontal, parietal and cortical brain areas have been implicated 
to be involved in attentional processes with an increased activation found in these areas 
following tasks measuring attention (for example visual tracking) (Culham, Cavanagh, & 
Kanwisher, 2001; Sauseng et al., 2005). 
2.6.2.2 Executive functions 
Executive functions can be described as a group of capacities that enable an individual to 
successfully engage in independent, purposive and self-serving behaviour (Lezak, 2004). These 
functions are often referred to as ‘higher-order’ cognitive processes and include planning, 
organisation, strategy selection, set-shifting, problem-solving, inhibition, and performance 
monitoring (Fossati, Ergis, & Allilaire, 2002). Assessment of executive functions has 
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previously relied on tasks that have been shown to be impaired in individuals with frontal lobe 
damage, for example, the Wisconsin Card Sorting Test (Anderson, Damasio, Jones, & Tranel, 
1991), the Tower of London Test (van den Heuvel et al., 2003), and verbal fluency tests such 
as Controlled Oral Word Association Test (Loonstra, Tarlow, & Sellers, 2001). However, more 
recently, it has been found that executive functions are not entirely dependent upon frontal lobe 
function and are regulated by neural networks involving different brain areas with co-ordinated 
complex functions to achieve a singular goal (Elliott, 2003). 
2.6.2.3 Learning and memory 
The main classifications of memory are working memory (also referred to as short-term 
memory) and long-term memory (Baddeley & Hitch, 1974). Working memory involves 
temporarily holding and manipulating limited amounts of information without thorough 
processing (in the current study tasks assessing working memory have been categorised under 
the domain ‘Executive Functions’). After initial acquisition of information, the next part of the 
memory process involves transferring encoded material to long-term memory, which is known 
as consolidation. Research suggests that the primary brain area responsible for memory 
consolidation is the hippocampus. Long-term memory is categorised into declarative memory 
(explicit memory) and procedural memory (implicit memory). Declarative memory consists of: 
i) semantic or factual memory, and ii) episodic memory or memory involving events and 
personal experiences (Lezak, 2004). Typically, learning and memory tests are further divided 
into verbal and visuospatial sub-categories. Some commonly used tasks to assess learning and 
memory are the Rey-Auditory Verbal Learning Test (M. Schmidt, 1996), the California Verbal 
Learning Test (Delis, Freeland, Kramer, & Kaplan, 1988), Verbal Paired Associates Test (Uttl, 
Graf, & Richter, 2002) and the Rey-Osterrieth Complex Figure Test (Shin, Park, Park, Seol, & 
Kwon, 2006). Learning and memory are complex processes that are coordinated by several 
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brain regions (e.g. the medial temporal lobe, frontal lobe, cerebellum, amygdala, neocortex and 
the striatum) (Lezak, 2004). 
2.6.2.4 Psychomotor speed 
Psychomotor speed is defined as the amount of time taken by an individual to detect and process 
a signal and to prepare and respond to a stimulus. Generally, tests assess reaction time 
(processing speed) and/or motor function, as motor function integrity affects speed on the 
cognitive task. Some examples include the Coin Rotation Test (Mendoza, Apostolos, 
Humphreys, B., & O'bryant, 2009), the Trail Making Test (Part A) (Bowie & Harvey, 2006) 
and the Digit Symbol Substitution Test (McLeod, Griffiths, Bigelow, & Yingling, 1982). 
2.6.3 Key areas impaired in depression  
Diminished concentration or indecisiveness is one of the main diagnostic items for MDD 
(DSM-5). In accordance with this finding, several systematic reviews examining cognitive 
deficits in depression have consistently found impairment in various cognitive domains, 
however, without consensus regarding impairment in specific domains (Austin, Mitchell, & 
Goodwin, 2001; Burt, Zembar, & Niederehe, 1995; Douglas et al., 2011; Marazziti, Consoli, 
Picchetti, Carlini, & Faravelli, 2010; Porter et al., 2015; Rock et al., 2013; H. Snyder, 2013; 
Thomas et al., 2009; Zalkanis et al., 1998).  
Overall, studies have shown significant cognitive deficits in attention and executive functioning 
(including inhibition, problem-solving and planning) (Fossati, Ergis, et al., 2002; Marazziti et 
al., 2010), verbal and visuospatial learning and memory (Austin et al., 2001; Douglas, Porter, 
Knight, & Alsop, 2013; Golinkoff & Sweeney, 1989; Marazziti et al., 2010; Sarosi et al., 2008; 
Thomas et al., 2009), in individuals with depression compared with healthy control participants. 
Since different cognitive domains may overlap, it may be that memory disturbance is related to 
attention deficits or executive function impairment without a specific deficit limited to a single 
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domain (Marazziti et al., 2010). Some studies suggest that cognitive impairment in specific 
domains (including episodic memory, executive function and psychomotor speed) is positively 
associated with symptoms of mood disturbance (Fossati, Coyette, Ergis, & Allilaire, 2002; 
McDermott & Ebmeier, 2009), however, methodological limitations in these studies limit the 
ability to draw meaningful conclusions related to differences in cognitive domains, as 
summarised in a review by Porter et al. (2015). 
In a study examining cognitive function in severe depression, widespread neuropsychological 
impairment was found in inpatients with depression compared with healthy control participants, 
with effect sizes ranging from moderate to large (Cohen’s d: 0.6 to 1.1) (Douglas et al., 2011). 
Studies in medication-free samples with mild-to-moderate depression have reported small to 
moderate effect size differences (most effect sizes were small-moderate ranging between 0.04-
0.61) (Bourke et al., 2012; Porter et al., 2003). In addition, a recent study by Douglas et al. 
(2018) found the prevalence of cognitive impairment to be the highest in inpatient samples with 
current symptoms of severe depression compared with outpatients in mild-moderate depressive 
episodes. Cognitive impairment has been found to have a similar magnitude in patients with 
bipolar disorder in comparison with patients with MDD (Bora, Yucel, & Pantelis, 2010).  
Inconsistent findings between cognitive studies of MDD in terms of the specific domains 
affected may be due to variability in study design, inclusion of depressed patients with different 
severity levels, lack of power, comorbid psychiatric disorders, depression rating scale selection 
and sensitivity of cognitive test batteries included (Castaneda, Tuulio-Henriksson, Marttunen, 
Suvisaari, & Lonnqvist, 2008). Additionally, cognitive function may be solely determined in 
terms of statistical significance, rather than a reflection of the actual difference in effect size. 
Studies have proposed that cognitive impairment is present in only a minority of patients with 
MDD while the remaining majority show normal cognitive functioning (Douglas et al., 2018; 
Grant, Thase, & Sweeney, 2001; Iverson, Brooks, Langenecker, & Young, 2011; Rohling, 
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Green, Allen, & Iverson, 2002), which has implications for interpretation of findings based on 
effect sizes or statistical significance (Burt et al., 1995; Iverson et al., 2011). 
To summarise, although deficits in executive function, learning and memory, and psychomotor 
speed have been more commonly reported in patients with MDD, overall, there is little 
consensus regarding findings related to impairment in specific domains. Evidence suggests that 
broad moderate deficits rather than domain-specific deficits across a range of domains are found 
in individuals with MDD (Porter et al., 2015). 
2.6.4 Cognitive impairment in depression: Longitudinal findings  
Evidence suggests that cognitive impairment may persist after recovery from depression in 
many individuals. Whilst individuals in an acute episode of depression have been found to show 
worse performance in most cognitive domains, compared with healthy individuals, many 
studies including reviews have also demonstrated that depression may have a detrimental and 
residual impact on cognitive function (Bora, Harrison, Yucel, & Pantelis, 2013; Castaneda et 
al., 2008; Douglas & Porter, 2009; Hasselbalch et al., 2011; Jaeger et al., 2006; Paelecke-
Habermann, Pohl, & Leplow, 2005; Reppermund, Ising, Lucae, & Zihl, 2009; Rock et al., 2013; 
Trivedi & Greer, 2014). However, an understanding of findings in reproductive-aged female 
populations is very limited, which is the focus of the current thesis. A review found that the risk 
for cognitive impairment is worsened with each depressive episode while the individual is in 
recovery (Porter et al., 2015), and that possible vascular and neurodegenerative factors may 
play a substantial role (Bora et al., 2013), however, more longitudinal prospective studies are 
required to ascertain this hypothesis (Hasselbalch et al., 2011). Rock et al. (2013) in a meta-
analytical systematic review (including 24 studies for the review and six studies for the meta-
analysis), found significant cognitive deficits in executive function and attention (including 
moderate effect sizes) and non-significant deficits (small effect sizes) in memory to persist in 
recovered patients with depression. The study, thus, concluded that impairment in at least in 
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some cognitive domains is a core feature of depression and is dissociable from symptoms of 
low mood in remission. Similarly, another study found no association between depression 
severity and any measures of cognitive function and suggested that depression and cognitive 
function are separable constructs (Reppermund et al., 2009). Thus, rather than being a 
secondary symptom of depression, cognitive function and mood may be independent features 
of the same disorder.  
There is, however, some evidence that certain aspects of cognitive function may improve 
following treatment of mood symptoms in MDD (Constant et al., 2005; Douglas & Porter, 
2009). Constant et al. (2005) found a beneficial effect of antidepressant treatment (Sertraline) 
over a period of seven weeks on psychomotor slowing associated with attentional bias and 
executive function in young individuals with MDD (n = 20) compared with healthy control 
participants (n = 26). Douglas et al. (2009), in a systematic review (including 30 studies), found 
improvement in mood to be associated with improvement in some cognitive domains and found 
age to play a crucial role. In younger adult populations, improvement in mood was significantly 
associated with better outcomes on measures of verbal fluency and verbal learning and memory, 
however, impairment in executive functions and attention were found to persist across 
treatment.  
In summary, pronounced cognitive deficits are evident in individuals suffering from current 
depression and those in remission; with evidence suggesting that some aspects of cognitive 
impairment appear to improve following the treatment of symptoms of depression, while other 
domains may remain impaired. Much of the literature has examined this relationship in elderly 
individuals, and since the focus on the current thesis is on premenopausal females, literature 
related to cognitive impairment in depressed females of reproductive age will be discussed in 




2.7 DEPRESSION AND EMOTION PROCESSING 
The terms ‘emotions’ and ‘moods’ are often used interchangeably, but differ in important ways. 
Moods are longer-lasting and can activate specific emotions (Ekman, 2007), therefore, it may 
be hypothesised that a low mood found in MDD may affect an individual’s experience and 
perception of emotions. The ability to detect and decode others’ facial emotional expressions is 
vital for social functioning and for promoting interpersonal relationships. Facial expressions 
communicate an individual’s mental state and related emotional cues; and may influence 
behavioural responses and regulate mood (M. Phillips, Drevets, Rauch, & Lane, 2003). Facial 
emotion processing involves empathy, which refers to sensitivity to, and understanding of, the 
mental states of others (Bourke, Douglas, & Porter, 2010; Leppänen, 2006; Stuhrmann, Suslow, 
& Dannlowski, 2011; Tarnowski, Kołodziej, Majkowski, & Rak, 2017). Similar to findings 
related to cognitive function in depression, short-term and long-term abnormalities (in 
recovered individuals) in emotion processing have also been found in individuals with MDD 
and in individuals with an increased risk of developing MDD (Leppänen, 2006; Leppänen, 
Milders, Bell, Terriere, & Hietanen, 2004; Surguladze et al., 2004) reviewed by (Bourke et al., 
2010). Specific findings related to facial emotion processing in MDD will be discussed in the 
following sections, followed by a discussion of neuroimaging findings related to cognitive 
impairment and impairment in emotion processing found in MDD.  
2.7.1 Measures of facial emotion processing 
A standardised set of stimuli including six universally-recognised emotional expressions forms 
the basis of measures most widely used to assess facial emotion processing (Ekman & Friesen, 
1971). Two main categories of tasks are used to assess facial emotion processing, namely, 
identification (emotional labelling) and discrimination (categorising) paradigms (Bourke et al., 
2010). Tasks often involve morphed face paradigms using computerised combinations of 
varying emotional content (from 0 to 100% in increments of 10%) presented in a random order 
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(Young et al., 1997). Accuracy, response speed and type of misclassification of ambiguous or 
neutral expressions are principal outcomes of facial emotion processing paradigms. 
2.7.2 Facial emotion recognition accuracy in depression 
Evidence from studies (Douglas & Porter, 2010; Gotlib, Krasnoperova, Yue, & Joormann, 
2004; Leppänen et al., 2004; Suslow, Dannlowski, Lalee-Mentzel, Donges, & Arolt, 2004) 
including reviews (Bediou, Saoud, Harmer, & Krolak-Salmon, 2009; Bourke et al., 2010; 
Leppänen, 2006; Stuhrmann et al., 2011) suggests that depression involves reduced accuracy 
and reduced reaction time in recognising emotions including sadness, happiness and disgust, 
however, many other studies have not found these effects.  
Accuracy in recognising some facial expressions of emotion has been found to be related to 
treatment outcome and recurrence of depressive illness in some studies (Douglas & Porter, 
2009; Harmer, Bhagwagar, et al., 2003; Joormann & Gotlib, 2006; LeMoult, Joormann, 
Sherdell, Wright, & Gotlib, 2009; Stuhrmann et al., 2011).  
Treatment response to antidepressant medication has been shown to significantly improve 
aspects of facial expression recognition. In 68 patients with severe depression, recognition of 
angry facial expressions significantly improved in antidepressant treatment responders 
compared with non-responders (Douglas et al., 2011). Mikhailova et al. (1996) found 
recognition accuracy of happy, sad and neutral faces to improve following antidepressant 
treatment in male patients with depression, although this study did not include a comparison 
group. Tranter et al. (2009) found significant increases in recognition accuracy of emotional 
expressions including disgust, happiness and surprise following two weeks of treatment 
(Citalopram and Reboxetine) in 59 patients with depression, which was not subject to further 
change at six weeks. Additionally, a significant association was observed between an increased 
accuracy in recognition of happy faces (at 2 weeks) and improvement in clinical state following 
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6 weeks of treatment in this study. A further study found impairment in recognition of happy 
facial expressions (measured by standard facial stimuli with varying intensities of happiness) 
in untreated patients with MDD (n = 19) compared with a healthy control group (n = 19); which 
was found to reverse following treatment (Fluoxetine) (Fu et al., 2007). Overall, these findings 
suggest that antidepressant treatment may benefit facial emotion recognition accuracy 
independent of the affective state of stimuli. 
2.7.3 Neutral misinterpretation bias in depression 
Misclassification of ambiguous or neutral facial expressions has been found in MDD (Bourke 
et al., 2010; Douglas & Porter, 2010). Individuals with MDD tend to misclassify neutral or 
ambiguous faces as negative or sad, and misinterpret happy faces as neutral (Elliott, Zahn, 
Deakin, & Anderson, 2010; Harmer, O’Sullivan, et al., 2009; Stuhrmann et al., 2011). These 
findings fit with the psychological theories of depression including negative cognitive biases 
(Beck, 1967). Cognitive theories posit that individuals with depression are likely to not only 
misinterpret ambiguous events as negative but also to show an enhanced memory for negative 
events, together with an ability to intensify negative material in memory tasks by filtering out 
of positive stimuli (Beck, 1979; Bouhuys, Geerts, & Gordijn, 1999; Elliott et al., 2010; Gotlib, 
Kasch, et al., 2004; Gotlib, Krasnoperova, et al., 2004; Leppänen et al., 2004; Surguladze et al., 
2004).  
In contrast to the cognitive theories of depression, neurobiological theories relate symptoms of 
depression to a chemical imbalance in neurotransmitters, therefore including pharmacotherapy 
as first-line treatment. Some evidence suggests that antidepressant treatment has immediate 
effects in the brain and improves a negative interpretation bias in individuals with MDD much 
earlier than its effects on mood (Harmer, O’Sullivan, et al., 2009). Studies have shown that a 
single administration of antidepressant medication increases processing of positively valenced 
material in healthy individuals (Harmer, Hill, Taylor, Cowen, & Goodwin, 2003) and improves 
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a negative interpretation bias in healthy individuals without MDD (Norbury et al., 2009), 
suggesting that antidepressants may reverse impairment in emotion processing found in MDD. 
Douglas et al. (2011) found a significant reduction in negative interpretation bias (following 
two weeks of treatment) in 68 individuals with MDD. Following two weeks of antidepressant 
treatment, non-responders were significantly less likely to misinterpret neutral faces as negative 
(sad) compared with treatment responders but not compared with healthy control participants. 
2.7.4 Attentional biases  
An attentional bias towards positive emotional faces (for example, happy facial expressions) or 
away from negative emotional faces (for example, sad facial expressions) has been reported in 
MDD (Bourke et al., 2010; Leppänen, 2006). Such an attentional bias may be one of the 
important factors involved in abnormal emotion processing which may adversely affect 
interpersonal relationships in the life of an individual with MDD. Joorman et al. (2007) in a 
dot-probe paradigm, found a selective avoidance of sad faces in currently and previously 
depressed individuals and found increased attention toward happy faces in healthy controls, 
which was not observed in individuals with MDD. On the other hand, in another study involving 
a dot- probe paradigm (Gotlib, Krasnoperova, et al., 2004), female patients with MDD showed 
an attentional bias towards sad facial expressions compared with happy, fearful and angry facial 
expressions. In another paradigm involving scanning several faces and discerning differences 
between them (Face-in-the-Crowd Task), Suslow et al. (2001) found no difference between 
individuals with depression (n = 15) and healthy controls (n = 15) on accuracy of detecting sad 
faces, however, individuals with depression were found to have a significantly slower response 
time to positive faces, suggesting a reduced attention to positive stimuli in depression. Overall, 
the existing literature suggests an attentional bias away from positive and toward negative facial 
emotional stimuli in individuals with MDD (Bourke et al., 2010). However, attentional bias 
studies have many different outcome variables (for example, reaction time, accuracy and bias) 
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and measure different emotional expressions, therefore, generalised conclusions beyond those 
made by individual papers are difficult to draw. 
2.7.5 Neuroimaging findings related to impairment in cognitive function and emotion 
processing in depression 
Neuroimaging studies have reported smaller hippocampal volumes in individuals with 
depression (Bremner et al., 2000), which has been related to impairment in memory also found 
in depression (van der Flier et al., 2004). Increased and sustained amygdala activity (Drevets, 
Bogers, & Raichle, 2002; Drevets et al., 1992; J. Hamilton & Gotlib, 2008; Siegle, Steinhauer, 
Thase, Stenger, & Carter, 2002) and volumetric amygdala abnormalities (increased volume in 
medicated depressed patients and decreased volume in unmedicated patients) have been found 
in individuals with depression (J. Hamilton, Siemer, & Gotlib, 2008). Dorsal prefrontal cortex 
and anterior cingulate abnormalities are reported in individuals with depression along with 
impaired cognitive function (Haldane & Frangou, 2014; Liotti & Mayberg, 2001), however, 
further studies are required to fully determine the functional changes associated with cognitive 
impairment in major depression. 
Structural and frontal abnormalities including abnormalities in key brain regions including 
increased activity in the amygdala, orbitofrontal cortex and the striatum (responsible for 
emotional identification and production) and decreased activity within the dorsolateral 
prefrontal cortex and the anterior cingulate cortex (involved in emotion regulation) have been 
associated with impairment in emotion processing (Haxby, Hoffman, & Gobbini, 2002; 
Stuhrmann et al., 2011). Studies have also implicated these brain regions in the aetiology of 
MDD (M. Phillips et al., 2003; M. Phillips, Ladouceur, & Drevets, 2008). Additionally, 
abnormalities in brain regions such as the hippocampus, prefrontal cortex, and the 
somatosensory cortex have been linked with impairment in emotion processing (Haxby et al., 
2002). Specific impairments in emotion processing such as mood-congruent processing bias 
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(hyperactivation toward negative facial stimuli and hypoactivation toward positive facial 
stimuli) have been related to abnormalities in the amygdala, ventral-striatum, anterior cingulate 
cortex, parahippocampal gyrus, insula, fusiform face area and putamen in individuals with 
major depression compared with healthy controls (Fusar-Poli et al., 2009; Leppänen, 2006; 
Stuhrmann et al., 2011). However, there are inconsistencies in findings related to prefrontal 
brain areas which have been speculated to be due to varying paradigms and heterogeneous 
patient samples (Stuhrmann et al., 2011).   
It has been suggested that antidepressant medication may modulate the neural networking 
involved in emotion processing (including an increased amygdala activity) which may help 
normalise a negative bias found in mood and anxiety disorders. Antidepressant treatment was 
found to significantly reduce amygdala activity in response to emotional faces, particularly 
related to negative emotional faces (Harmer, Mackay, Reid, Cowen, & Goodwin, 2006; 
Norbury et al., 2009; Sheline et al., 2001) and increase dorsolateral prefrontal cortex activity in 
response to unconsciously shown fearful faces (Fales et al., 2009) in patients with depression 
compared with healthy controls. 
Overall, neuroimaging evidence in facial emotion processing studies suggests that the abnormal 
neural activation may be responsible for impairment in emotion processing observed in patients 
with MDD, and that neural abnormalities may be reversed with antidepressant treatment, which 
may help normalise the negative bias found in MDD. 
 
2.8 ANXIETY – COMORBIDITY AND PREVALENCE OF ANXIETY IN 
DEPRESSED SAMPLES  
Anxiety symptoms are commonly observed in patients with depression, with more than 70% of 
individuals with MDD also diagnosed with a sub-type of anxiety disorder (Gorman, 1996; 
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Hirschfeld, 2001; Kessler, Merikangas, & Wang, 2007; Lamers et al., 2011; Wolitzky-Taylor 
et al., 2014). The US National Comorbidity Survey reported that 59.2% of individuals with 
MDD also experienced at least one type of an anxiety disorder (Kessler et al., 2003). These 
results were broadly consistent with the New Zealand Mental Health Survey (Te Rau 
Hinengaro) which reported that the most common mental health comorbidities occurred 
between symptoms of anxiety and depression, with approximately 49.6% of those individuals 
suffering from MDD also experiencing some symptoms of anxiety (Oakley-Browne et al., 
2006). Risk factors for both psychiatric conditions may include genetic and environmental 
factors or an interaction between the two, impacting on clinical and treatment outcomes 
(Pollack, 2005). 
Limited research has examined the impact of comorbid anxiety and depression on cognitive 
impairment, and with inconclusive results (Herrera-Guzmán et al., 2009; Nitschke & Heller, 
2005). Cognitive data from extant research indicates that anxiety is not a homogenous entity 
attempts to examine its neural circuitry should take into account comorbidity with other 
disorders (Nitschke & Heller, 2005). Some studies have found individuals with depression and 
comorbid anxiety to experience specific cognitive impairment. In a study examining the effect 
of comorbid anxiety on cognitive function in individuals with depression, it was found that 
memory was impaired, regardless of whether or not comorbid anxiety was present. However, 
specific deficits in executive function and psychomotor speed were found only in the depressed 
group with comorbid anxiety, compared with the depression only group and the healthy control 
group (Basso et al., 2007). In another study, cognitive impairment was found to be common in 
young adults with MDD and comorbid anxiety (Castaneda et al., 2008). The profile of cognitive 
impairment was found to be dependent on the type of anxiety. For example, executive function 
impairment was common in individuals with MDD only, however, in those individuals with 
MDD and comorbid obsessive-compulsive disorder, deficits in executive function and visual 
memory were found. With regard to changes in cognitive impairment following treatment of 
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depression with comorbid anxiety, one study found that individuals with MDD and comorbid 
anxiety showed less improvement in cognitive function than individuals with MDD only, 
following antidepressant treatment (Herrera-Guzmán et al., 2009). Thus, overall findings 
suggest that the occurrence of both anxiety and depression together may be associated with 
worse cognitive impairment compared with individuals with either diagnosis alone.  
 
2.9 TREATMENT STRATEGIES FOR DEPRESSION 
2.9.1 Pharmacological treatment 
Historically, depression was thought to be a disease of the brain or the mind, and hence, 
treatment was carried out in accordance with this aetiological understanding, involving either 
pharmacological intervention or psychological therapy. The former consists of medications that 
alter key neurotransmitter levels (for example, serotonin noradrenalin or dopamine) in patients 
(see Box 2.1), however, while antidepressants can treat the symptoms of depression they may 
not always address its causes. Therefore, antidepressant medication is often used 
simultaneously with psychotherapy to treat more severe depression. However, depressive 
disorders are challenging to treat. Current first-line treatments for MDD have limited efficacy 
(Arroll et al., 2009; Penn & Tracy, 2012; Sugarman, Loree, Baltes, Grekin, & Kirsch, 2014), 
with up to 40% of depressed patients failing to demonstrate a response to first-line 
antidepressant drug treatment, and many of those who do respond ultimately relapse (Arroll et 
al., 2009; Gaynes, 2009; Khan & Brown, 2015; Nemeroff, 2007). The effect size of current 
antidepressant treatment trials of patients with MDD is approximately 0.30 which is modest 
(Gibertini, Nations, & Whitaker, 2012; Khan & Brown, 2015). Furthermore, the compliance 
rate with antidepressants can be low, with up to 50% of patients discontinuing antidepressant 
treatment prematurely (Sansone & Sansone, 2012; Trivedi, Lin, & Katon, 2007). Additionally, 
antidepressants have unwanted side-effects (Arroll et al., 2009; Eyding et al., 2010), and do 
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little to improve cognitive impairment (Airaksinen et al., 2006; Porter et al., 2016; Shilyansky 
et al., 2016). The following section (see Box 2.1) will describe the main treatment agents 
involved in anti-depressant treatment for MDD. 
Box 2.1  
Different Pharmacological Strategies for Major Depressive Disorder 
Pharmacological treatment of depression 
All antidepressant medication agents increase serotonin, norepinephrine and/or dopamine 
levels via different mechanisms. First-generation antidepressants comprise of tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). The subsequent group 
of medication became known as second-generation agents, and are considered more 
sophisticated in terms of mode of action and safety (Amick et al., 2015; Williams et al., 
2000). These include selective serotonin reuptake inhibitors (SSRIs), serotonin 
noradrenaline reuptake inhibitors (SNRIs) and the noradrenaline-dopamine reuptake 
inhibitors (NDRIs) (Koenig & Thase, 2009).  
Tricyclic antidepressants: Tricyclic antidepressants block the reuptake of serotonin and 
noradrenaline transporters and the most common agents in this category include 
Clomipramine and Imipramine. Some side-effects include dry mouth, weight gain, and 
sexual dysfunction.  
Monoamine oxidase inhibitors: Monoamine oxidase inhibitors block the actions of 
monoamine oxidase enzymes that are responsible for the breaking down of neurotransmitters 
including serotonin, dopamine and noradrenaline. Decreased levels of these 
neurotransmitters are associated with MDD. Therefore, by inhibiting the effects of 
monoamine oxidase enzymes, MAOIs increase neurotransmitter levels which help improve 
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mood. Medications within this class include Phenelzine, Tranylcypromine and 
Isocarboxazid.  
Selective serotonin reuptake inhibitors – Selective serotonin reuptake inhibitors are 
considered first-line antidepressant treatment in New Zealand and include Citalopram, 
Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine and Sertraline. These medications 
selectively inhibit the reuptake of serotonin. Unlike TCAs, SSRIs can be started at a 
therapeutic dose and cause fewer side effects such as constipation, gastrointestinal issues, 
dry mouth and blurry vision (Koenig & Thase, 2009). However, other side effects include 
agitation or motor restlessness, and increased suicidality.  
Serotonin-noradrenaline reuptake inhibitors: These medications increase both serotonin and 
noradrenaline levels and include Venlafaxine, Desvenlafaxine and Duloxetine. Common 
side-effects include nausea, dizziness, headache and insomnia.  
Noradrenaline and dopamine reuptake inhibitors: These medications block noradrenaline 
and dopamine reuptake transporters, respectively. Bupropion is the most commonly used 
NDRI and combination therapy of Bupropion with other second-generation antidepressants 
has been shown to improve outcomes in patients for whom antidepressant monotherapy has 
failed to work (Moreira, 2011). There is an associated risk of epileptic seizures with the use 
of NDRIs (Penn & Tracy, 2012) and other side effects include anxiety, insomnia, loss of 
appetite and weight loss. 
 
2.9.2 Psychotherapy  
A recent update of current care guidelines for management of depression and treatment research 
suggests that combining antidepressant medication with psychotherapy is more effective that 
sole treatment with either (Cuijpers et al., 2013; Harmer, Goodwin, & Cowen, 2009; Isometsä 
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et al., 2015), however, other studies have not found similar results (Kocsis, Gelenberg, 
Rothbaum, & et al., 2009; von Wolff, Hölzel, Westphal, Härter, & Kriston, 2012). 
Antidepressants were deemed suitable for severe depressive symptoms, however, brief 
psychotherapies including cognitive, interpersonal, or problem-solving were thought to be more 
beneficial in mild-to-moderate depression. Cognitive Behavioural Therapy (CBT) has been 
found to be generally efficacious for the treatment of depression (Cuijpers et al., 2013) and aims 
to identify and modify dysfunctional thinking or behavioural patterns; substituting them with 
more functional and accurate thoughts and behaviours (Beck, 1979). Interpersonal therapy 
(IPT) helps individuals understand problematic interpersonal issues and learn healthy ways of 
expressing emotions and communicating needs (de Mello, de Jesus Mari, Bacaltchuk, Verdeli, 
& Neugebauer, 2005). The Australia and New Zealand Clinical Practice Guidelines (2004) for 
the treatment of depression report that all recognised antidepressant treatment should precede 
psychological treatment in severe cases of depression, however, in moderate-severe depression, 
CBT and IPT are equally effective as medication. 
 
2.10 KEY POINTS  
Major depressive disorder is a serious and pervasive mood disorder affecting twice as many 
females as males in adulthood. In at least some females, depression may have hormonal 
underpinnings. Cognitive impairment and deficits in facial emotion processing are well-
established findings in MDD. Whilst antidepressant treatment may offer short-term and long-
term benefits, it still has limited benefits for individuals with mild-moderate depression and 
does not always help improve cognitive deficits. It is, therefore, important to develop 
comprehensive treatment strategies that optimise overall function, particularly in patients 
whose symptoms of depression may be influenced by hormonal abnormalities, such as in 




ANDROGENS IN FEMALES 
 
 
3.1  INTRODUCTION 
Since the word ‘androgen’ has its origins in the Greek word ‘andros’ meaning man, this group 
of sex hormones is often mistakenly believed to exist only in males. However, androgens are 
important sex steroids in females as well as males. This class of hormones has important 
implications, mainly in sexual development, for maintaining sexual desire and in their 
conversion (via aromatisation) into oestrogen. Females secrete greater amounts of androgens 
than oestrogens (Burger, 2002). 
While the role of oestrogens (female sex hormones) in the female brain has received a great 
deal of research attention, knowledge of the effect of testosterone and other androgens on the 
female brain remains more limited. Increasing evidence suggests a role of androgens in mood 
and cognitive function (Beauchet, 2006; Cherrier, 2005; Davison & Davis, 2003; Gooren, 2007; 
Janowsky, 2006; Zitzmann, 2006). However, few studies have examined this relationship in 
reproductive-aged females. It has been established that reproductive-aged females have the 
greatest risk for developing depressive disorders compared with non-reproductive-aged females 
and males (Noble, 2005). Therefore, it is imperative to understand the main functions and 
mechanisms of androgens in reproductive-aged females to further current understanding of 
mood and associated cognitive impairment in females.  
For clarity in this thesis, sex hormones (also known as sex steroids, gonadocorticoids or gonadal 
steroids) refer to both testosterone and oestrogen. The main types of androgens, production 
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rates and functions, and effects of androgen-excess related disorders in females will be 
discussed in the following sections. 
 
3.2 NORMAL ANDROGEN FUNCTION IN HEALTHY FEMALES 
Women produce approximately 66% of the total androgens found in men (Burger, 2002). This 
group of hormones is synthesised in the endocrine tissues from cholesterol or via aromatisation 
from other androgens or androgen precursors, peripherally, including the liver, gonads and 
adrenal cortex in females (Hodgson & Braunstein, 2006). Androgens are vital for maintaining 
muscles and bones, maintaining positive protein balance, regulation of the reproductive tract 
and kidney function, and in stimulating sexual development (important during puberty for 
sebum production and hair growth) and sexual desire (Swerdloff, Wang, Hines, & Gorski, 
1992). An important function of androgens is that they are precursors to oestrogen, responsible 
for oestrogen synthesis (via conversion of testosterone or DHEA to oestrogen) (Burger, 2002). 
Major biological events in women including adrenarche, menarche, sexuality, fertility and 
menopause are mediated by androgens (Hodgson & Braunstein, 2006). Androgens also play a 
role in the organisational and activational aspects of brain function.  
 
3.3  TYPES AND SOURCES OF ANDROGENS 
The main androgens in women, in decreasing order of serum concentration, are 
dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione 
(A-dione), androstenediol (A-diol), testosterone (Total and Free), and dihydrotestosterone 
(DHT) (Burger, 2002; Davison & Davis, 2003). Testosterone and DHT are the only androgens 
that bind to the androgen receptor, whereas DHEA, DHEAS and A-dione are considered as pro-
androgens and require conversion to testosterone in order to have an androgenic effect on the 
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body (Burger, 2002). Androgens are produced in the adrenal glands (in the zona reticularis of 
the adrenal cortex) (25%), ovaries (in the ovarian stroma) (25%), fat cells and through 
peripheral conversion of precursor androgens (DHEA and A-dione) (50%) in females 
(Abraham, 1974; Davison, Bell, Donath, Montalto, & Davis, 2005; Endoh, Kristiansen, Casson, 
Buster, & Hornsby, 1996; Hamson, Roes, & Galea, 2016; Haning et al., 1991; O'Neill, 2012). 
Androgen precursors such as DHEA, DHEAS, A-dione, A-diol and 11 β- 
hydroxyandrostenedione (11OHA) (also known as C-19 steroids) have their sources mainly in 
the adrenal glands (Rege et al., 2013), whereas the main types of androgens including 
testosterone (Total, Free and DHT) are primarily produced in the ovaries. The next section will 
discuss the different types of androgens and pro-androgens. 
Box 3.1  
Forms of Testosterone 
 
At present, there is no consensus regarding a single, reliable measurement standard of androgen 
levels (Rosner, Auchus, Azziz, Sluss, & Raff, 2007). Direct assays of testosterone are 
Total Testosterone: 98 percent of testosterone is bound to Sex Hormone Binding Globulin 
(SHBG; See Section 3.3.4) and albumin in women and is referred to as Total Testosterone. 
Free Testosterone: The lesser fraction of testosterone (1 to 2 percent) is estimated to be 
biologically available or in an active form and is known as Free Testosterone. This measure 
is also referred to as Bioactive or Bioavailable Testosterone. 
Free Androgen Index: A ratio of Total Testosterone to SHBG is known as Free Androgen 
Index (FAI) and is considered a reliable way of calculating bioavailable testosterone in 
women (Total T/SHBG x 100= FAI). 
Dihydrotestosterone: Dihydrotestosterone (DHT) is primarily a peripheral product of 
testosterone conversion and circulates in low concentrations in serum. DHT is non-






considered unreliable and expensive, therefore assays are generally established after extraction 
and chromatography, or alternatively are derived through equations estimating Free or Total 
Testosterone levels (Al Kindi, Al Essry, Al Essry, & Mula-Abed, 2012; K. Miller et al., 2004; 
Sodergard, Backstrom, Shanbhag, & Carstensen, 1982; Vermeulen, Verdonck, & Kaufman, 
1999). 
3.3.1  Testosterone 
The most potent androgen, testosterone, is produced by the ovarian stroma (25%) and the 
adrenal cortex (25%) in women, while the remaining production results from peripheral 
conversion from several precursors including circulating A-dione, DHEA and DHEAS (Baird, 
Horton, Longcope, & Tait, 1968; Burger, 2002; Davison & Davis, 2003; Longcope, 1986). It 
is estimated that 98% of Total Testosterone is bound to SHBG and a lesser fraction, known as 
Free Testosterone, is biologically available and unbound. Total Testosterone levels are known 
to be weakly correlated with Free Testosterone levels. The metabolically active portion, Free 
Testosterone (also known as bioavailable or bioactive testosterone), provides a more predictive 
assay of androgenic status, particularly in women with endocrine disorders involving androgen 
excess (Huang, Brennan, & Azziz, 2010; Vermeulen et al., 1999). 
Free Androgen Index (see Box 3.1) is considered to be a reliable measure of Free Testosterone 
in women. Lower levels of SHBG are associated with higher FAI levels (Burger, Dudley, Cui, 
Dennerstein, & Hopper, 2000). Therefore, any factors affecting SHBG production also 
influence testosterone levels. These may include factors such as obesity, hyperinsulinemia, 
glucocorticoids, oral oestrogen, thyroxine, and menopause, which decrease SHBG levels, and 
in turn, may lead to elevated Free Testosterone levels (Burger et al., 2000; Davison & Davis, 
2003; Simó, Sáez-López, Barbosa-Desongles, Hernández, & Selva, 2015; Thijssen, 1988).  
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Testosterone has important physiological consequences either directly or via aromatisation 
(conversion via enzyme aromatase) to oestradiol in women (Davis & Wahlin-Jacobsen, 2015). 
Two major metabolites of testosterone that show significant physiological activity are DHT and 
oestrogen, therefore, testosterone can exert its effects through the androgen receptor or the 
oestrogen receptor.    
Testosterone can be converted to oestradiol in the brain by the aromatase enzyme, found in the 
hippocampus and amygdala (Janowsky, 2006) or in adipose tissue (Kim & Halter, 2014). DHT, 
another metabolite of testosterone (via the action of 5α-reductase), is considered to be a more 
potent androgen compared with testosterone, since it binds with greater affinity to androgen 
receptors (Hamson et al., 2016). It is a peripheral product of testosterone conversion and is 
found in low circulating serum concentrations (Abraham, 1974). However, unlike testosterone, 
DHT is non-aromatisable (does not convert to oestrogen). In women, testosterone varies with 
menstrual phases, with lowest concentrations seen early in the follicular phase of the menstrual 
cycle, then rising to a mid-cycle peak before lowering in the luteal phase (but still remaining 
higher than early follicular phase) (Abraham, 1974).   
3.3.2  Dehydroepiandrosterone and Dehydroepiandrosterone sulphate  
Both DHEA and DHEAS are abundant endogenous adrenal androgens produced by the adrenal 
cortex which contributes to 80% of DHEA production and more than 90% of DHEAS synthesis 
(Abraham, 1974; Geese & Blanchard Raftogianis, 2001; Luu-The, Dufort, Paquet, Reimnitz, & 
Labrie, 1995; Spark, 2002). DHEA is mainly secreted by the adrenal zona reticularis (50%), 
the ovarian theca (20%) and is also synthesised from circulating DHEAS (30%) (Labrie, Martel, 
& Balser, 2011; Longcope, 1986; Luu-The et al., 1995). Production is stimulated by ACTH, 
which is secreted by the pituitary gland (Ogino, Miyagawa, & Iguchi, 2016). Evidence suggests 
that DHEA is associated with age-related changes in immune function, mood and cognitive 
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function (Barrett‐Connor, Mühlen, Laughlin, & Kripke, 1999; Herbert, 2007; Wolkowitz et al., 
1999). 
The sulphated form of DHEA, DHEAS, is mainly secreted by the adrenal glands (zona 
reticularis) and to a small extent by the ovaries. DHEAS is known to be a biologically weak 
androgen (Endoh et al., 1996), however, is a crucial source of peripheral androgen production 
(Burger, 2002). Its secretion is regulated by ACTH and may be influenced by prolactin, Insulin 
Growth Factor-1 (IGF-1) and oestrogen. DHEA/testosterone and DHEAS/testosterone ratios, 
however, have been shown to be age-invariant (Zumoff, Strain, Miller, & Rosner, 1995). 
3.3.3 Androstenedione and Androstenediol 
A-dione is secreted by the adrenal glands (50%) and the ovarian stroma (50%) and is a precursor 
to testosterone (Horton & Tait, 1966). It is a metabolite of DHEA and can also be produced 
intracellularly from DHEAS via DHEA (Burger, 2002). A-diol is a major metabolite of the 
potent androgen DHEA, secreted by the adrenal glands. It is also an androgen precursor and is 
capable of activating both androgen and oestrogen target genes (Miyamoto, Yeh, Lardy, 
Messing, & Chang, 1998). 
3.3.4  Sex Hormone Binding Globulin  
Sex Hormone Binding Globulin is a circulating steroid-transporting protein, produced by the 
liver, and binds tightly to androgens (mostly testosterone) and oestrogen (O'Neill, 2012; Simó et 
al., 2015). It binds reversibly and with great affinity to testosterone and DHT, and to a certain 
extent, with oestrogen. In its bound state, SHBG transports these hormones in the blood as 
biologically inactive forms (C. Li, Ford, Li, Giles, & Liu, 2010). The main fraction of 
testosterone, Total Testosterone, is bound to SHBG, unlike the small fractions of biologically 
active sex hormones in plasma (Free Testosterone). Androgenicity (physiological effect of 
androgens), therefore, depends mainly on Free Testosterone due to the high affinity of SHBG to 
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Total Testosterone. In females, SHBG concentrations are twice as high as males, indirectly 
proportional to testosterone levels, which, in turn, are ten-fold lower in females compared with 
males. SHBG controls the amount of testosterone that the body tissues can use, and therefore, 
any abnormalities in SHBG levels indicate testosterone abnormalities in women. 
Table 3.1  
Androgen Production in Women 
Type of androgen Normal levels of androgens in women 
Total Testosterone 
0.1-1.2 ng/ml (0.3-2.7 nmol/L) 
1 ng/ml = 3.47 nmol/L   
Free Testosterone  
0.6-6.8 pg/ml (<50 pmol/L) 









Pregnancy 0.2-1.2 µg/ml 








0.5-2 ng/ml (2-8 nmol) 
 
SHBG 20-90 nmol/L 
18-114 
Source-(Canterbury Health laboratories), FAI- Free Androgen Index, DHEA-Dehydroepiandrosterone,. DHEAS- 






3.3.5  Sex hormones and the blood brain barrier 
The blood brain barrier (BBB) separates the central nervous system from peripheral tissues and 
is a protective barrier for neurons in the brain (Banks, 2012). Integrity of the BBB is crucial for 
protecting the brain from toxic substances entering through the blood stream, and is ensured  by 
multicellular systems including endothelial cells, astrocytes, pericytes among other systems 
(Almutairi, Gong, Xu, Chang, & Shi, 2016; Hampl, Bičíková, & Sosvorová, 2015). However, 
the BBB shows selective permeability toward sex hormones (Pardridge & Mietus, 1979). As 
sex hormones are small in size and are lipid-soluble, they are able to cross the BBB in both 
directions (Banks, 2012; Cornford, Braun, Oldendorf, & Hill, 1982; Pardridge, 1981). Current 
understanding is that concentration of androgens in the brain is limited to Free Testosterone but 
not Total Testosterone, as it is only Free Testosterone that is able to cross the BBB (Carruthers, 
2009; Pardridge, 1986).  
 
 
Figure 3.1- Steroidogenesis in the ovaries, adrenal glands and peripheral tissues of 
androgens in females.  
DHEAS-Dehydroepiandrosterone sulfate, DHEA-Dehydroepiandrosterone, A-Androstenedione, T- Testosterone, E2- 




3.3.6 Other Important Hormones 
Hormones apart from androgens in reproductive-aged healthy females will be discussed in the 
following section (see Box 3.2). 
 
Box 3.2  
Other Important Hormones 
Oestrogen 
Oestrogens are primary female sex hormones with widespread biological actions. This group of 
hormones consists of chemically similar hormones including oestrone, oestradiol and oestriol. 
Oestrogens play an essential role in the development of female sexual characteristics and in the 
regulation of menstrual cycle and the reproductive system. Oestrogenic hormones regulate the 
menstrual cycle by controlling the growth of uterine lining during the first part of the cycle.  
The main sources of production are the ovaries, adrenal glands and the fat tissues in females. 
Oestrogens can also be synthesised in non-reproductive tissues such as liver, heart, muscle, 
bone and the brain (R. Li, Cui, & Shen, 2014). The peripheral conversion of testosterone to 
oestrogen (via the enzyme aromatase) contributes to a small amount of total oestradiol, 
which is the most potent and prevalent oestrogenic hormone particularly during reproductive 
years (Arevalo, Azcoitia, & Garcia-Segura, 2015). Of the total oestradiol, 50% is protein 
bound and 3% is free (Kim & Halter, 2014). 
It has been suggested by both animal and human studies that oestradiol and progesterone are 
both highly lipophilic and easily pass through the BBB (see Section 3.3.5) and regulate BBB 
permeability (Alkayed et al., 2001; Maggioli et al., 2016; Naderi, Khaksari, Abbasi, & 
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Maghool, 2015). Oestradiol and progesterone receptors are vastly expressed in brain areas 
related to cognitive function and emotion processing (Brinton et al., 2008; Gruber, Tschugguel, 
Schneeberger, & Huber, 2002; McEwen, 2002), however, a recent review found no consistent 
evidence related to the relationship between menstrual phases involving high or low oestrogen 
levels and sexually dimorphic cognitive skills in females (Poromaa & Gingnell, 2014). 
Progesterone 
Progesterone is a female sex hormone vital for supporting pregnancy by maintaining the 
uterine lining to receive a fertilised egg in the uterus. This hormone is mainly secreted by 
the ovaries, and in smaller quantities by the adrenal glands and the placenta (which continues 
to produce large quantities of progesterone throughout pregnancy). Levels are generally low 
before ovulation and rise after the egg is released from the ovary. If pregnancy occurs, 
progesterone levels remain elevated, otherwise a drop in levels is seen prior to menstruation. 
Birth control pills or oral contraceptive pills use a progestin, a synthetic form of 
progesterone, which is structurally different to progesterone and works by preventing 
ovulation, thickening the mucus at the cervix to prevent sperm from entering and changing 
the womb lining to prevent pregnancy. Selman et al. (1997) reported that the administration 
of progestins in animal subjects resulted in suppression of the HPA axis. Progestins have 
been shown to act on the hypothalamus and the pituitary gland to prevent ovulation in healthy 
premenopausal females (Richter, Robinson, & Evans, 2002). Combination pills make use of 
both oestrogen and progestins for the same purpose (Duijkers et al., 2015). 
Anti-Mullerian Hormone 
Anti-Mullerian Hormone (AMH) is considered to be a quantitative marker for ovarian 
reserve indicating follicle depletion rates and ovarian ageing (Fiçicioǧlu, Kutlu, Baglam, & 
Bakacak, 2006; Gruijters, Visser, Durlinger, & Themmen, 2003; Kevenaar et al., 2006; 
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Smeenk et al., 2007; van Rooij et al., 2004), independent of the menstrual cycle (La Marca 
et al., 2006). It is crucial for sex differentiation during foetal development and postnatally, it 
is expressed in the ovaries in females. Anti-Mullerian Hormone levels are generally lowest 
at birth and increase in a stable manner until adulthood in females and decrease subsequently, 
marking reproductive decline (M. Lee et al., 1996). 
Studies suggest that AMH levels may be a more accurate marker of female reproductive 
status/fertility (particularly early menopause) compared with chronological age alone (van 
Disseldorp et al., 2008). Serum AMH levels have been found to be significantly higher in 
women with ovarian dysfunction (in women with endocrine disorders) (Dewailly et al., 
2010; Pellatt et al., 2007) indicating increased follicle count and poor ovarian reserve 
(Cook, Siow, Brenner, & Fallat, 2002; Fanchin et al., 2003; Laven et al., 2004). Some 
studies have associated AMH with reduced oestrogen levels (Josso, di Clemente, & 
Gouédard, 2001). A recent study found elevated prenatal AMH levels to reprogram the 
foetus and induce PCOS in adulthood (Tata et al., 2018).  
Cortisol 
Cortisol is one of the major glucocorticoid hormones synthesised in the adrenal cortex under 
the control of the HPA axis. The organisation of the HPA axis is regulated by sex hormones 
(Handa et al., 1994; Pasquali, 2012; Viau, 2002; M. Williamson, Bingham, & Viau, 2005). 
Hypercortisolism or abnormally high cortisol secretion is a well-known feature of MDD and 
has been related to a dysfunctional hyperactive HPA axis (Pariante & Miller, 2001). Cortisol 
has been shown to inhibit ACTH and corticotrophin releasing factor (CRF) synthesis and 
release from the pituitary and the hypothalamus respectively, ultimately resulting in a drop 
in cortisol levels (known as the negative feedback signal). Excess cortisol may lead to 
Cushing’s syndrome or amenorrhoea (absence of menstrual periods during reproductive 
years), whereas a deficiency in cortisol levels has been related to Addison’s disease. 
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Androgens and cortisol have been shown to be related, with an elevated Cortisol/DHEA ratio 
demonstrated in depression (A. Young, Gallagher, & Porter, 2002). 
 
3.4 NEUROBIOLOGY OF ANDROGENS 
3.4.1  Important brain areas in androgen metabolism 
The brain contains receptors for androgens and oestrogens (Adhya et al., 2018; Arevalo et al., 
2015; Handa, Reid, & Resko, 1986; Kruijver, Balesar, Espila, Unmehopa, & Swaab, 2003; 
Kruijver, Fernández-Guasti, Fodor, Kraan, & Swaab, 2001; Puy et al., 1995; Simerly, Swanson, 
Chang, & Muramatsu, 1990; Toran-Allerand, 2004; Zuloaga, Puts, Jordan, & Breedlove, 2008a) 
and is known to be efficient at producing and metabolising these sex hormones (Altman, 2004; 
Stoffel-Wagner, 2003). Brain areas crucial for learning and memory in humans such as the 
hippocampus, prefrontal cortex, amygdala and the hypothalamus have abundant androgen 
receptors (Beyenburg et al., 2000; Finley & Kritzer, 1999; Sarrieau et al., 1990). Studies have 
shown that some brain areas contain the enzyme aromatase and the androgen metabolite 5α-
reductase which are crucial for the conversion of testosterone to either DHT or oestrogen 
(Baulieu, 1998; Stoffel-Wagner, 2003). Research has increasingly demonstrated that androgens 
have neuromodulatory actions in the development of the brain (Do Rego et al., 2009; Janowsky, 
2006; McEwen, Alves, Bulloch, & Weiland, 1998), depending upon their binding to respective 
androgen or oestrogen receptors. Androgen deprivation has been shown to be associated with loss 
of hippocampal density in ovariectomised female rats, restored with androgen treatment (Leranth, 
Hajszan, & MacLusky, 2004). Some evidence suggests that testosterone may be neuroprotective 
in both older males and females (Kurth et al., 2014; Pike, Carroll, Rosario, & Barron, 2009). Pike 
(1999) demonstrated that testosterone neuroprotection was not reduced by an oestrogen receptor 
antagonist, suggesting that testosterone together with oestrogen provide a neuroprotective ability, 
however, through distinct mechanisms. The effects of androgens on the brain may be classified 
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into two fundamentally separate categories- organisational and activational effects (Arnold, 2009; 
Goel & Bale, 2008; Schulz, Molenda-Figueira, & Sisk, 2009). 
3.4.2  Organisational effects of androgens 
Testosterone has differential effects on the developing male and female brain, and this androgen 
continues to have an effect into adulthood (Baron-Cohen, Knickmeyer, & Belmonte, 2005; 
Filova, Ostatnikova, Celec, & Hodosy, 2013). Androgens play a crucial role in brain 
organisation during early development (Goel & Bale, 2008; Swerdloff et al., 1992), which is 
observed in sex-typical behaviours in childhood and later in adulthood (Berenbaum, 1999; 
Berenbaum, Bryk, & Beltz, 2012; Hines, 2010). In foetal and neonatal stages, androgens act on 
the brain, and are responsible for differentiation in neural structures and function (Baron-Cohen 
et al., 2005). Prenatal exposure to testosterone has been shown to have permanent effects on 
the organisation of the brain, affecting its morphology (Weiner, Primeau, & Ehrmann, 2004). 
The brain regions with greatest sexual dimorphism in adulthood also have the highest 
expression of sex hormone receptors during brain development (J. Goldstein et al., 2001).  
Animal studies also suggest that sex hormones play an important organisational role in the 
central nervous system, and may be associated with permanent changes in the morphology in 
the nervous system (Foecking, McDevitt, Acosta-Martínez, Horton, & Levine, 2008; D. Shi & 
Vine, 2012) . Prenatal sex hormones including androgens in animals have been linked to sex 
differences in cognitive function into adulthood (Isgor & Sengelaub, 1998; Karaismailoğlu & 
Erdem, 2013). Animal studies involving the development of a female reproductive system in a 
castrated (therefore testosterone deprived) male rabbit foetus and the development of a male 
reproductive system in female animals receiving testosterone implants demonstrate the effects 
of testosterone on sexual characteristics (Jost, 1947; Vom Saal & Bronson, 1980). Enlargement 
in brain regions responsible for mating behaviour (sexually dimorphic nucleus) has been shown 
to be related to testosterone administration (Dominique Toran-Allerand, 1976).  
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Apart from sexual differentiation, testosterone has also been related to neurodevelopmental 
disorders affecting the human brain. Increasing evidence suggests that prenatal exposure to high 
concentrations of testosterone may be related to autistic spectrum disorder (ASD) (Auyeung et 
al., 2009; Baron-Cohen et al., 2015; Manning, Baron-Cohen, Wheelwright, & Sanders, 2001). 
As reported by the American Psychiatric Association (2013), ASD is a neurodevelopmental 
disorder characterised by impaired verbal and non-verbal communication, repetitive 
behaviours, and unusually restricted or stereotyped interests. This includes difficulties in social-
emotional reciprocity and impairment in emotional processing. Other key symptoms involve 
delayed language development, reduced eye contact, and diminished ability to empathise. One 
biological theory to explain cognitive and emotional abnormalities in individuals with autism 
is the ‘Androgen Theory of Autism’ (Baron-Cohen et al., 2005).  
3.4.3  Androgen Theory of Autism  
The androgen theory of autism posits that autistic spectrum conditions may be associated with 
increased exposure to foetal or prenatal testosterone (measured in amniotic fluid) (Baron-Cohen 
et al., 2015; Baron-Cohen et al., 2011; Baron-Cohen & Wheelwright, 2004; Ingudomnukul, 
Baron-Cohen, Wheelwright, & Knickmeyer, 2007). Interestingly, high foetal testosterone 
levels have been found to negatively correlate with cognitive function and emotion processing 
(particularly empathy) in individuals with ASD (E. Chapman et al., 2006; Knickmeyer et al., 
2006; Knickmeyer, Baron‐Cohen, Raggatt, & Taylor, 2005). In children, higher levels of foetal 
testosterone have been found to negatively correlate with eye contact at 12 months of age, 
verbal ability (vocabulary) at 18 months and social relationships at 4 years of age (Knickmeyer 
et al., 2005; Lutchmaya, Baron-Cohen, & Raggatt, 2002a, 2002b). Regarding brain 
development, smaller corpus callosum, gyrus, lateral frontoparietal cortex and lower 
connectivity between hemispheres has been found to be significantly associated with higher 
foetal testosterone exposure (Auyeung et al., 2009). 
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There is a significant male bias in autistic spectrum conditions, with ratios as high as 4:1 (four 
affected males for every one affected female) in individuals with ASD (Baron-Cohen et al., 
2011; Gillberg, Cederlund, Lamberg, & Zeijlon, 2006; Werling & Geschwind, 2013), 
suggesting androgens may be involved in the development of this disorder. A typical male 
profile has been found in the neurodevelopment of autistic spectrum conditions and some 
studies have suggested hyper-masculinisation in parents of offspring with autism (Baron-Cohen 
et al., 2005). The consistent finding of a negative association between foetal testosterone and 
empathy and social functioning suggest significant organisational effects (Baron-Cohen et al., 
2011). Evidence shows positive associations between foetal testosterone and autistic traits in 
infancy and also in childhood (Auyeung, Taylor, Hackett, & Baron-Cohen, 2010). Impairment 
in facial emotion processing has been found in individuals with autism and together, with the 
male-bias of autism, evidence for this theory appears strong (Baron-Cohen et al., 2011). 
Females with abnormally elevated testosterone levels have been found to have a higher number 
of autistic traits compared with unaffected siblings (Knickmeyer et al., 2006). Additionally, 
studies have found a higher incidence of PCOS related symptoms including ovulatory 
dysfunction, hirsutism and cystic acne (related to excess androgens) (see Chapter Five for a 
detailed description of the syndrome) in women with autistic spectrum conditions 
(Ingudomnukul et al., 2007; Pohl, Cassidy, Auyeung, & Baron-Cohen, 2014). Therefore, the 
common risk factor, elevated testosterone levels, may be implicated in both autistic spectrum 
conditions and in conditions involving abnormalities in the androgen system into adulthood 
(Ingudomnukul et al., 2007).  
There are complications in investigating the organisational effects of sex hormones since 
measurements before birth (prior to brain organisation) and follow-up data are difficult to obtain 
and involve ethical considerations. However, a putative physical marker of foetal testosterone 
accessible to researchers is the digit length ratio, also known as the 2D:4D ratio. The 2D:4D 
finger ratio is an index of the length ratio between the 2nd and 4th digit (lower ratio indicates 
48 
 
high foetal testosterone) (Lutchmaya, Baron-Cohen, Raggatt, Knickmeyer, & Manning, 2004; 
Manning et al., 2001; Romero-Martínez et al., 2013). Foetal testosterone has been found to 
stimulate the growth of the fourth finger (starting from the thumb) whereas oestrogen has been 
found to promote the growth of the index finger. Males have a significantly lower 2D:4D ratio 
on their right hand (longer fourth finger), compared with females, which is negatively 
associated with prenatal testosterone (Breedlove, 2010; Hönekopp, Bartholdt, Beier, & Liebert, 
2007; Lutchmaya et al., 2004). Furthermore, a lower 2D:4D ratio (high foetal testosterone) has 
been found to be associated with lower scores on empathy measures in individuals with autistic 
spectrum disorders and their parents (Manning et al., 2001; Romero-Martínez, de Andrés-
García, Ruiz-Robledillo, González-Bono, & Moya-Albiol, 2014). 
One study found that a single administration of testosterone in sixteen healthy women was 
followed by significantly impaired cognitive function, and this effect was associated with the 
2D:4D ratio (van Honk et al., 2011). Moreover, the ratio predicted more than 50% variance in 
this effect, with a significant effect of testosterone observed in females with low ratios (higher 
prenatal exposure to testosterone). It has also been suggested that the digit ratio is sensitive to 
total androgen stimulation, related to the interaction between prenatal testosterone exposure and 
ambient androgen sensitivity (Breedlove, 2010), however, with mixed evidence (Hönekopp et 
al., 2007). 
3.4.4  Activational effects of testosterone  
Although the androgen theory of autism is related to the organisational effects of testosterone, 
research suggests that the activational effects of testosterone, observed in experimental studies 
involving testosterone administration, may also impact emotion processing in females (Bos, van 
Honk, Ramsey, Stein, & Hermans, 2013; Hermans et al., 2007; van Honk & Schutter, 2007; van 
Honk et al., 2011). Testosterone exposure in males including both the early brain formation period 
and puberty is important for the development of masculinisation of the neurocircuitry involved 
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in reproductive behaviour (Goel & Bale, 2008) and that similar effects have been found in female 
rats using a single administration of testosterone (Jacobson, Csernus, Shryne, & Gorski, 1981). 
Research suggests that adolescence and later adulthood may be a sensitive period for 
testosterone-dependent brain organisation. The hormonal milieu including elevated levels of 
sex hormones during puberty and adolescence (activational effects of testosterone), and the 
interaction between increased levels of hormones and the brain, may have significant effects on 
mood and cognitive and social function in individuals (Hermans, Putman, & Van Honk, 2006; 
Ingudomnukul et al., 2007; Sisk & Zehr, 2005; van Honk, 2009; van Honk & Schutter, 2007). 
Circulatory serum androgens may modulate brain function in later adulthood (Kimura & 
Hampson, 1994; van Wingen et al., 2009). Since mood disorders are more prevalent during the 
reproductive age in females, it has been hypothesised that sex hormones during this stage 
influence the neurotransmitter receptors in the brain leading to depressive symptoms 
(Janowsky, Halbreich, & Rausch, 1996). 
Although activational effects are not responsible for permanently changing brain morphology, 
they modulate neurotransmitter receptors in the brain, which in turn, may affect mood and 
associated cognitive function (Halbreich, Lemus, Lieberman, Parry, & Schiavi, 1990; J. 
Hamilton, Parry, & Blumenthal, 1988; Janowsky et al., 1996; Murray, 1991; Parry, 1989; 
Steiner, 1987), however, this needs further investigation. Experimental studies involving 
testosterone administration have shown decreased recognition of consciously shown emotional 
faces, decreased gaze avoidance and gaze aversion and worse performance on measures of 
emotion processing following testosterone administration in healthy females and in females 
with Social Anxiety Disorder (Hermans et al., 2007; Olsson, Kopsida, Sorjonen, & Savic, 2016; 
van Honk & Schutter, 2007; van Honk et al., 2011) (see Chapter 5 for a review of literature). 
Such interventional studies implicate the need for better understanding of the effect of excess 
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androgens on brain function in females since androgen abnormalities may play a role in 
depressive symptomatology and impaired cognitive function. 
3.5  ANDROGEN DISORDERS 
Abnormalities in the androgen system may lead to excess or deficient production of testosterone 
in females causing endocrine disorders. Many factors affect androgen production and 
metabolism in women of reproductive age. As discussed earlier, a decrease in SHBG levels is 
associated with increased testosterone levels. Decreased SHBG levels (therefore high 
testosterone levels) are seen in obese individuals, patients with PCOS, hypothyroidism, and 
Cushing syndrome. Increased SHBG levels and lower testosterone are found in liver disease, 
hyperthyroidism, and individuals using corticosteroids or hormonal replacement therapy and 
pregnant females. Androgen levels may also decrease due to ageing and menopause (Abraham, 
1974; Burger & Papalia, 2006; Davison et al., 2005; Labrie, Bélanger, Cusan, Gomez, & 
Candas, 1997). Androgen deficiency is seen in Turner’s syndrome (Gravholt, Svenstrup, 
Bennett, & Sandahl Christiansen, 1999), Addison’s disease (adrenal insufficiency of cortisol 
and androgen production) (Hunt et al., 2000), hypopituitarism (K. Miller et al., 2001) and 
cardiovascular disease (Kloner, Carson, Dobs, Kopecky, & Mohler, 2016). Androgen-excess 
related disorders are related to more frequently seen endocrine disorders in women of 
reproductive age. Hyperandrogenism can affect various tissues and organs manifesting into 
different clinical features such as acne, hirsutism, infertility, androgenic alopecia and 
virilisation (Homburg, 2009; Lizneva, Gavrilova-Jordan, Walker, & Azziz, 2016). 
The main disorders of androgen excess include: 
1) Congenital Adrenal Hyperplasia: Congenital Adrenal Hyperplasia (CAH) is a genetic 
disorder which involves adrenal abnormalities. In addition to testosterone excess, androgen 
precursors such as DHEAS and 17OH-Progesterone (17OHP) are significantly elevated 
(Berenbaum et al., 2012; Jacobs, Edelheit, Coleman, & Herzog, 1999; Little, 2013). CAH 
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can be classified according to the specific type of enzyme deficiency involved. In classic 
CAH, with a more severe form of enzyme deficiency, females who may be born with 
ambiguous genitalia experience virilisation due to excess androgen exposure (Mueller et 
al., 2014). Non-classic CAH is a milder variant with less severe enzyme deficiency and has 
a later-onset with mild hyperandrogenism similar to PCOS and is therefore considered as 
a differential diagnosis to PCOS (Solomon, 2007). 
2) Cushing Syndrome: High cortisol levels (overproduction by adrenal glands), and 
moderately high androgen levels (clinically observed as hirsutism and menstrual 
irregularities) are seen in individuals with Cushing syndrome (Barbetta et al., 2001; Haouat 
et al., 2012). 
3) Polycystic Ovarian Syndrome: The most common endocrine disorder in women of 
reproductive age is PCOS and will be discussed in the next chapter. 
 
3.6 KEY POINTS 
Androgens have important actions in women's physiology. Women of reproductive age have 
the greatest risk of developing mood and anxiety disorders, which in some cases, may be related 
to abnormal androgen function. The main types of androgens in women are testosterone (Total 
and Free) and precursors including DHEA, DHEAS and androstenedione. Androgen receptors 
in women are highly expressed in brain areas responsible for cognitive function and emotion 
processing. 
The androgen theory of autism posits that exposure to higher levels of testosterone in the foetal 
stage may cause autism, which involves social and emotional deficits in individuals, similar to 
deficits observed in MDD. Women with endocrine disorders such as PCOS (the most common 
endocrine disorder) have been reported to have a higher prevalence of symptoms of depression 
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and anxiety and impairments in cognitive function and emotion processing; suggesting 




POLYCYSTIC OVARIAN SYNDROME 
 
 
4.1 INTRODUCTION   
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in females of 
reproductive age (Azziz, Woods, et al., 2004; Bozdag, Mumusoglu, Zengin, Karabulut, & 
Yildiz, 2016; Farrell & Antoni, 2010; Franks, 1995; McGowan, 2011), affecting up to 5 to 22% 
of females depending upon the diagnostic criteria used (Azziz et al., 2016; Bozdag et al., 2016; 
Farquhar et al., 1994; Goodarzi & Azziz, 2006; Knochenhauer et al., 1998; Lizneva, Suturina, 
et al., 2016; March et al., 2010; Mueller et al., 2014; Nestler, 1998; Sirmans & Pate, 2014; 
Teede et al., 2010). Polycystic ovarian syndrome involves a wide variety of clinical features, 
and its aetiology still remains unclear (Azziz, 2004; J. Strauss, 2003; Tsilchorozidou, Overton, 
& Conway, 2004). Recent evidence suggests that PCOS might be a complex multigenic 
disorder with substantial epigenetic and environmental influences (Escobar-Morreale, 2018). 
Clinical and research understanding of PCOS has evolved, from the syndrome being perceived 
as purely a menstrual and cosmetic problem to a multi-faceted disorder involving metabolic 
and hormonal abnormalities (Fenton, 2005). However, the central biochemical abnormality of 
PCOS is androgen (testosterone) excess (Azziz et al., 2009; Franks, 1991; Homburg, 2009). 
Prevalence studies have consistently documented higher rates of mood and anxiety disorders in 
females with PCOS (Cooney & Dokras, 2017; Dokras et al., 2012; Teede et al., 2011).  
The current chapter will introduce the clinical features, epidemiology and risk factors involved 
in PCOS. The complexities involved in the assessment and treatment of PCOS will also be 
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discussed. The final part of the chapter will review findings related to studies examining the 
relationship between PCOS and mood and cognitive function. 
 
4.2  CLINICAL FEATURES  
4.2.1  Background 
First described in 1935 as ‘Stein-Leventhal’ syndrome, the exact definition of PCOS is still 
contested (I. Stein, 1959). Drs Stein and Leventhal’s findings involving seven patients with 
oligomenorrhea (irregular menses with fewer than nine menses per year) or amenorrhea (no 
menses) bilaterally polycystic ovaries, obesity and hirsutism constituted the first report of the 
syndrome (I. Stein & Leventhal, 1935). This heterogeneous disorder, now well-known as 
PCOS, consists of broad and variable clinical manifestations. Cardinal features include elevated 
androgen levels (hyperandrogenism), observed as physical symptoms of  cystic acne (Reingold 
& Rosenfield, 1987; Scholl, Wu, & Leyden, 1984; Slayden, Moran, Sams, Boots, & Azziz, 
2001; Vexiau et al., 1990), excessive and unwanted terminal hair growth on the body 
(hirsutism), particularly the face, back, chest and abdominal regions (Azziz, Carmina, Dewailly, 
Diamanti-Kandarakis, Escobar-Morreale, Futterweit, Janssen, Legro, Norman, Taylor, et al., 
2006; Diamanti-Kandarakis et al., 1999; Fauser et al., 2012; Sirmans & Pate, 2014; Spritzer, 
Barone, & Oliveira, 2016), androgenic alopecia (thinning scalp hair, male pattern baldness) 
(Cela et al., 2003), virilisation (Azziz, Sanchez, et al., 2004), chronic anovulation and ovulatory 
dysfunction (including menstrual disturbances) (Balen & Rutherford, 2007; Franks, 1995; Hull, 
1981), and polycystic ovarian morphology (PCOM) in the form of multiple ovarian cysts (Azziz 
et al., 2016). Other important features are infertility (Hart, 2008; Teede et al., 2010), insulin 
resistance and obesity (Dunaif, Segal, Futterweit, & Dobrjansky, 1989; Teede et al., 2010; 
Valenzuela & Stone, 2014). Clinical symptoms are often classified into three main categories, 
related to abnormalities in the reproductive, hormonal, and metabolic systems, respectively. 
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Currently, metabolic symptoms are not formally recognised in diagnostic classification 
systems, but are known to be strongly related to, and highly prevalent in PCOS. The metabolic 
features of PCOS are thus discussed in the Risk Factors section of this chapter (see page 64). 
4.2.2  Hormonal features 
The main hormonal abnormality involved in PCOS is hyperandrogenism (Azziz et al., 2016). 
This feature may be observed as either clinical hyperandrogenism including cosmetic features 
such as hirsutism, acne and alopecia, and/or biochemical hyperandrogenism including androgen 
excess. Elevated circulating androgen levels (mainly Free Testosterone) are commonly found 
in patients (Balen et al., 1995; Hahn et al., 2005; Huang et al., 2010; Lujan, Chizen, & Pierson, 
2008). The three main diagnostic criteria for PCOS (including Rotterdam, National Institutes 
of Health [NIH] and Androgen Excess and PCOS Society [AE-PCOS]: refer to page 59) include 
hyperandrogenaemia as a common diagnostic feature of PCOS compared with other features of 
PCOS (ovulatory dysfunction and ovarian cysts). High FAI levels are another important 
endocrine marker of symptoms involved related to ovarian function in PCOS (Imani et al., 
2000; Mathur, Moody, Landgrebe, & Williamson, 1981; Vermeulen et al., 1999). Sex Hormone 
Binding Globulin (SHBG) levels are often lower (therefore Free Testosterone levels are higher) 
in females with PCOS (Jayagopal, Kilpatrick, Jennings, Hepburn, & Atkin, 2003; Pugeat, 
Crave, Tourniaire, & Forest, 1996). Absolute levels of circulating Luteinising Hormone (LH), 
and the LH/Follicle Stimulating Hormone (LH/FSH) ratio, are also significantly higher in 
females with PCOS (Fauser et al., 1991; Ropelato et al., 1999; A. Taylor et al., 1997). Adrenal 
precursor androgens including DHEA, DHEAS (Azziz, Sanchez, et al., 2004; Brennan, Huang, 
& Azziz, 2009; Goodarzi, Carmina, & Azziz, 2015), and A-dione levels (O'reilly et al., 2014) 




4.2.3  Reproductive features 
Polycystic Ovarian Syndrome was originally understood as a condition characterised by 
multiple enlarged ovarian cysts observed at the time of surgery (I. Stein & Leventhal, 1935). It 
was thought that ovarian cysts uniquely characterised PCOS, however, in recent times, studies 
have concluded that PCOS is a complex syndrome, and may be present even in females with 
regular, ovulatory, menses  (without reproductive or ovulatory dysfunction), but showing signs 
of hyperandrogenism (Adams, Polson, & Franks, 1986; Carmina, Koyama, Chang, Stanczyk, 
& Lobo, 1992; Clayton et al., 1992; Farquhar et al., 1994; Polson, Wadsworth, Adams, & 
Franks, 1988; Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 
2004). Polycystic ovarian morphology (PCOM) is characterised by an excessive number of 
preantral follicles in the ovary; termed as multi-follicularity (Azziz et al., 2016). Ovarian cysts 
are clinically defined by the presence of more than 10 cysts measuring 2 to 8mm in diameter, 
distributed or scattered peripherally around a dense core of stroma (connective tissues of the 
ovary) (Adams et al., 1986), and are detected by ultrasound or other forms of pelvic imaging. 
The term ‘polycystic ovaries’ adds to the diagnostic confusion since polycystic ovaries are not 
the main criteria for diagnosis, and are less relevant than the volume of ovarian stroma, which 
is more closely related to serum testosterone levels (Fratantonio, Vicari, Pafumi, & Calogero, 
2005; Kyei-Mensah et al., 1996). In addition, multiple cysts on ultrasound have been detected 
in 20 to 30% of normal cycling non-hyperandrogenic females (Clayton et al., 1992; Farquhar 
et al., 1994; Michelmore, Balen, Dunger, & Vessey, 1999; Polson et al., 1988). Polycystic 
ovarian morphology (PCOM) is associated with normal oestrogen and progesterone levels but 
with high androgen and low SHBG levels, suggesting PCOM may be indicative of mild ovarian 
hyperandrogenism (Adams, Taylor, Crowley Jr, & Hall, 2004; Fratantonio et al., 2005). It has 
been recently suggested that PCOM may also be related to, and a significant predictor of, insulin 
resistance (refer to section 4.5.1), which is a key metabolic feature of PCOS (Hong et al., 2017). 
However, since clinical and biochemical features of hyperandrogenism and hyperinsulinemia 
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in PCOS may exist independently of ovarian cysts, there has been a shift from the original 
definition of PCOS to a broader, more inclusive understanding of the syndrome involving 
metabolic and hormonal abnormalities (Dumesic et al., 2015; Dunaif & Fauser, 2013). 
However, a recent study found that inclusion of ovarian morphology results in statistically 
significant higher prevalence estimates for PCOS (Skiba, Islam, Bell, & Davis, 2018). 
Other reproductive features may present in the form of anovulation or ovulatory dysfunction. 
About 70 to 80% of patients with PCOS have ovarian dysfunction, which manifests as oligo or 
amenorrhea (Ehrmann, 2005). Prolonged anovulation may lead to dysfunctional uterine 
bleeding which may mimic a more regular menstrual cycle (Teede et al., 2010). As many as 
85% of females with PCOS experience menstrual irregularities (Azziz et al., 2009), however, 
newer diagnostic criteria (see Section 4.3) consider females with regular menstrual cycles 
eligible for receiving diagnosis if they show hyperandrogenic or metabolic symptoms (Azziz, 
Carmina, Dewailly, Diamanti-Kandarakis, Escobar-Morreale, Futterweit, Janssen, Legro, 
Norman, Taylor, et al., 2006). 
Another common reproductive feature involved in PCOS symptomatology is infertility (Hull, 
1987; Nestler, 2008; Wild, Pierpoint, Jacobs, & McKeigue, 2000). The primary cause of 
infertility is considered to be anovulation (found in PCOS), accounting for more than 75% of 
cases of infertility (Gorry, White, & Franks, 2006; Joham, Teede, Ranasinha, Zoungas, & 




Table 4.1  
Common Symptoms of Polycystic Ovarian Syndrome 
REPRODUCTIVE HORMONAL METABOLIC 
 Multiple ovarian cysts 
 Infertility 
 Oligo/anovulation 
 Oligomenorrhea (menstrual irregularity) 
 Pelvic pain, uterine bleeding 
 Poly-cystic ovarian morphology/multi-
follicularity 
 Biochemical abnormalities including 
hyperandrogenism/ androgen excess (high 
testosterone levels) 
 Clinical hyperandrogenism: hirsutism, 
cystic acne, alopecia, skin tags, acanthosis 
nigricans (dark velvety patches in body 
folds and creases). 
 Insulin resistance and hyperinsulinemia 
 Obesity (particularly central obesity) and 
weight gain 
 Insulin resistance can lead to lipid 







4.3  DIAGNOSIS / CLASSIFICATION 
1) The National Institutes of Health (NIH) - National Institute of Child Health and Human 
Disease (NICHD) 1992  Criteria:  Using this 1990 US criteria, PCOS can be defined by i) 
presence of clinical and/or biochemical hyperandrogenism, ii) chronic anovulation, and iii) 
absence of other endocrine disorders. The NIH diagnostic criteria do not include the 
presence of polycystic ovaries on ultrasound (Zawadzki, 1992) (as cited by (Azziz, 2006)). 
2) The Rotterdam Criteria (proposed by the European Society for Human Reproduction and 
Embryology and the American Society for Reproductive Medicine  (ESHRE/ASRM) expert 
conference held in Rotterdam: The Rotterdam criteria (2004) requires two of the three 
following features: i) clinical and/or biochemical hyperandrogenism (elevated Free 
Testosterone and FAI levels, reduced SHBG levels, increased DHEAS levels, hirsutism) 
(Welt et al., 2006; Zawadzki, 1992); ii) oligo or anovulation, and iii) polycystic ovaries and 
exclusion of other endocrinopathies. Under this criteria, new phenotypes of PCOS emerge, 
for example, patients with polycystic ovaries and hyperandrogenism but with normal 
ovulation, or alternatively, patients with anovulation and cystic ovaries without clinical or 
biochemical androgen excess (Azziz, 2004). One of the main objectives of the Rotterdam 
criteria was to correct for the increasing evidence related to clinical and biochemical 
hormonal features in females with PCOS, making these criteria broader than the original 
NIH diagnostic criteria. An expert panel from the NIH Evidence-Based Methodology 
Workshop on PCOS recommended that clinicians use the Rotterdam diagnostic criteria for 
PCOS since it is more recent and relevant compared with the NIH criteria (Dumesic et al., 
2015; Lizneva, Suturina, et al., 2016). 
3) Androgen Excess and PCOS (AE-PCOS) Society  
The more recent AE-PCOS criteria (Azziz, Carmina, Dewailly, Diamanti-Kandarakis, 
Escobar-Morreale, Futterweit, Janssen, Legro, Norman, & Taylor, 2006) defines PCOS as 
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involving the presence of clinical or biochemical hyperandrogenism (including hirsutism 
and conditions related to hyperandrogenemia) and ovulatory dysfunction (oligo-
anovulation or polycystic ovaries) (Azziz et al., 2009), however, emphasising 
hyperandrogenism. Females with PCOM and oligo-anovulation (without androgen excess) 
do not meet the criteria for a diagnosis of PCOS based on AE-PCOS Society (Azziz, 
Carmina, Dewailly, Diamanti-Kandarakis, Escobar-Morreale, Futterweit, Janssen, Legro, 
Norman, Taylor, et al., 2006).  
Both the AE-PCOS and the Rotterdam Criteria definitions represent broad extensions of 
the original NIH criteria. Since the diagnosis of PCOS is based on exclusion, all three 
criteria ensure omission of differential diagnosis or other endocrinological conditions and 
ovulatory dysfunction which may resemble PCOS symptomatology. These include: 1) 
thyroid dysregulation, 2) hyperprolactinemia, 3)  pregnancy, 4) Cushing’s syndrome, 5) 
androgen-producing tumours, 6) drug-induced androgen excess and, 7) late-onset 
Congenital Adrenal Hyperplasia  (Azziz et al., 2009; Dumesic et al., 2015; Franks, 1995; 
Yildiz, Bozdag, Yapici, Esinler, & Yarali, 2012; Zawadzki, 1992). Diagnostic criteria for 




Table 4.2  
Diagnostic Criteria for Polycystic Ovarian Syndrome   
The National Institutes of Health (NIH) / 
National Institute of Child Health and 
Human Disease (NICHD 1992 US Criteria) 
The Rotterdam 2004 Criteria Androgen Excess and PCOS society  
(AE-PCOS) 
 Hyperandrogenaemia 
 Ovulatory dysfunction 
Two of the three following criteria: 
 Hyperandrogenaemia 
 Ovulatory dysfunction 
 Polycystic ovaries 
Both criteria to be satisfied: 
 Hyperandrogenaemia 





4.4  EPIDEMIOLOGY  
4.4.1 Background 
Worldwide prevalence of PCOS ranges from 5 to 22% depending upon the diagnostic criteria 
used (Azziz et al., 2016). Although the number of females diagnosed with PCOS is significantly 
increasing (Ganie & Kalra, 2011), the reported prevalence rate may still not be entirely accurate 
due to being diagnosed less frequently (simply attributed to obesity) or misdiagnosed in clinical 
practice (Christensen et al., 2013; Sirmans, Parish, Blake, & Wang, 2014). Additionally, it has 
been thought that although it is likely that PCOS affects females at all ages, symptoms of 
hyperandrogenism may be more visible and better able to be clinically evaluated during 
reproductive age. Therefore, symptoms of hyperandrogenism and ovulatory function may be 
only weakly visible at each end of the reproductive spectrum (Goodarzi et al., 2015). 
One retrospective study found that estimated prevalence rates changed along with different 
diagnostic criteria being used (which increased using the Rotterdam criteria) (March et al., 
2010). Regarding symptomatology involved in PCOS, approximately 85 to 90% of females 
with irregular menses may be diagnosed with PCOS, while 30 to 40% of females with 
amenorrhoea have been found to be at risk of developing PCOS (Hart, 2008; Sirmans & Pate, 
2014). Over 80 to 90% of normally menstruating females with cutaneous hyperandrogenic 
symptoms are routinely diagnosed with PCOS using ultrasound measures (Adams et al., 1986; 
Azziz, Sanchez, et al., 2004). 
4.4.2 Cross-Cultural Differences 
The overall prevalence rate (5 to 22%) of PCOS in females is largely derived from studies 
involving European females with the syndrome (Farquhar et al., 1994; K. Williamson, Gunn, 
Johnson, & Milsom, 2001). However, studies have shown that racial origin and ethnicity 
significantly influence PCOS symptomatology (Ehrmann et al., 2002; K. Williamson et al., 
63 
 
2001). One study in New Zealand found a strikingly high prevalence of PCOS (52%) in Indian 
subcontinent Asian females (Rodin, Bano, Bland, Taylor, & Nussey, 1998). Dunaif et al. (1993) 
found a higher prevalence of PCOS in Hispanic females compared with Caucasian females. 
Similarly, considerable differences in symptomatology related to ethnicity were found in one 
cross-sectional study involving European, Maori, Indian, Chinese, Asian and Pacific Island 
females found (K. Williamson et al., 2001). A higher incidence of hirsutism was observed in 
European and Maori females compared with other ethnic groups. Acne was rarely observed in 
Pacific Island females, however, infertility was commonly reported in this group along with 
Indian females compared with European females with PCOS. Furthermore, non-European 
females (Indian, Pacific Island and Maori females) had the greatest rate of obesity, insulin 
resistance and lipid abnormalities, possibly due to an influence of a western lifestyle involving 
diet and lifestyle factors (Hodge et al., 1994), which are implicated in PCOS. 
4.4.3  Cultural differences in prevalence related to obesity and metabolic features 
Carmina et al. (1992) found a comparable prevalence of ovarian cysts (68 to 80%), testosterone 
levels, DHEAS levels, and insulin resistance, between Japanese and Caucasian females with 
PCOS. However, Japanese females were found to have less hirsutism, lower obesity and insulin 
levels (but not insulin resistance). Authors concluded that obesity and hyperandrogenism are 
affected by dietary, environmental and ethnicity-related factors. Other studies have varied 
ethnic groups including  African-American, Indian, Mexican-American and South-Asian 
females with PCOS with comparable BMI, to have higher incidence of insulin resistance 
compared with Caucasian females with PCOS, with lower insulin resistance (Dunaif et al., 
1993; Ehrmann et al., 2002; Kauffman, Baker, DiMarino, Gimpel, & Castracane, 2002; 




4.5 RISK FACTORS 
PCOS involves multiple risk factors including obesity, environmental and lifestyle-related 
factors, which contribute to the complex presentation of the disorder (including the metabolic 
abnormalities observed) in the clinical picture and pose a diagnostic challenge. No single 
aetiological factor is sufficient to fully explain the varied range of symptoms in individuals with 
PCOS. Studies have shown genetic, metabolic, and environmental factors to play a synergistic 
role in the development of the syndrome (Dumesic et al., 2015).  
4.5.1  Metabolic risk factors: Insulin resistance  
Polycystic Ovarian Syndrome is associated with increased risk for metabolic disorders (G. 
Conway et al., 2014; Sirmans & Pate, 2014). Pathogenic metabolic factors such as insulin 
resistance with compensatory hyperinsulinemia are risk factors for PCOS and put individuals 
with PCOS at risk for lipid abnormalities, impaired glucose tolerance and Type 2 diabetes. 
(Apridonidze, Essah, Iuorno, & Nestler, 2005; Chang, Nakamura, Judd, & Kaplan, 1983; 
Ciaraldi et al., 1992; Diamanti-Kandarakis & Dunaif, 2012; Dunaif, 1997; Futterweit, 1999; 
Goudas & Dumesic, 1997; Tsilchorozidou et al., 2004). Hyperinsulinemia is, however, not 
formally recognised in current diagnostic classification systems, as noted in the first section of 
this chapter (Azziz, 2006). Insulin resistance or hyperinsulinemia is defined as a decreased 
ability of insulin to regulate the metabolic actions of glucose uptake, production or lipolysis, 
which further leads to elevated insulin levels relative to glucose levels (Bergman, Finegood, & 
Ader, 1985; Dunaif & Finegood, 1996; Dunaif et al., 1992; Hardy, Czech, & Corvera, 2012; 
Kahn, 1985; Ovalle & Azziz, 2002). Although not a diagnostic requirement, insulin resistance 
is present in most females with PCOS, to some degree (Balen & Michelmore, 2002; Barber, 
Wass, McCarthy, & Franks, 2007; Dokras et al., 2005; Dunaif, 1997; Dunaif et al., 1989; Farrell 
& Antoni, 2010; Legro, Kunselman, Dodson, & Dunaif, 1999). Although insulin resistance 
plays a crucial role in exacerbating obesity, some studies have shown insulin resistance to be 
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independent of obesity (Diamanti-Kandarakis & Dunaif, 2012; Dunaif et al., 1989; Stepto et 
al., 2013). Obesity is well-known as a significant risk factor for PCOS and associated disorders 
in females. 
Strong associations between PCOS and metabolic syndrome including central obesity and 
dyslipidaemia have been documented (Rubin, Glintborg, Nybo, Abrahamsen, & Andersen, 
2017; Sharpless, 2003). A significant proportion of females with PCOS have been shown to be 
overweight or obese (Álvarez-Blasco, Botella-Carretero, San Millán, & Escobar-Morreale, 
2006; Isikoglu, Berkkanoglu, Cemal, & Ozgur, 2007; S. Lim, Davies, Norman, & Moran, 2012; 
Moran, Hutchison, Norman, & Teede, 2011), which may further exacerbate associated 
metabolic and reproductive abnormalities such as infertility (Brassard, AinMelk, & 
Baillargeon, 2008). Weight gain is associated with worsening of symptoms while weight loss 
has been shown to help improve the metabolic and endocrinal profile and associated symptoms 
in females with PCOS (Teede et al., 2013). Further hormonal complications including 
suppressed SHBG levels (associated with increased testosterone levels) have been found in 
obese females with PCOS and hirsutism (Franks, 1989; Kiddy et al., 1990). In addition, 
metabolic abnormalities may further lead to increased risk of obstetric complications including 
pregnancy-induced hypertension, preeclampsia and gestational diabetes (Bjercke et al., 2002) 
(cited by (Azziz, Marin, Hoq, Badamgarav, & Song, 2005)). 
In summary, metabolic abnormalities associated with PCOS may lead to the development of 
Type 2 diabetes, glucose intolerance, hyperlipidaemia, and a risk of cardiovascular disease, 
hypertension and endometrial hyperplasia (Daniilidis & Dinas, 2009; Legro, 2003; Wild, 2002). 
Androgen excess has been thought to play a pivotal role in exacerbating these conditions 
(Apridonidze et al., 2005; Chen et al., 2007; Coviello, Legro, & Dunaif, 2006; Diamanti-
Kandarakis, Papavassiliou, Kandarakis, & Chrousos, 2007; Korhonen, Hippeläinen, Vanhala, 
Heinonen, & Niskanen, 2003), since correcting androgen abnormalities can help insulin 
66 
 
sensitivity and improve metabolic profile (Dahlgren, Landin, Krotkiewski, Holm, & Janson, 
1998). 
4.5.2  Genetic risk factors 
Genetic studies have attempted to identify genes that contribute substantially to the 
development of the PCOS phenotype, however, without compelling evidence (De Leo et al., 
2016; Diamanti-Kandarakis, Kandarakis, & Legro, 2006; Franks, Gharani, & McCarthy, 2001; 
Franks, McCarthy, & Hardy, 2006; Kosova & Urbanek, 2013; Mutharasan et al., 2013; Shen et 
al., 2013; Xu et al., 2011). Nevertheless, family history is a substantial risk factor for PCOS 
(Amato & Simpson, 2004; Battaglia et al., 2002; Crosignani & Nicolosi, 2001; Franks et al., 
1997; Franks et al., 2008; Givens, 1988; Hague, Reeders, Peto, & Jacobs, 1988; Kahsar-Miller, 
Nixon, Boots, Go, & Azziz, 2001; Legro, Bentley-Lewis, Driscoll, Wang, & Dunaif, 2002; 
Vink, Sadrzadeh, Lambalk, & Boomsma, 2006). Family studies have found sisters of females 
with PCOS to have higher than normal androgen levels (Hong et al., 1998; Legro, Driscoll, 
Strauss, Fox, & Dunaif, 1998) and monozygotic twins to be more affected with PCOS than 
dizygotic twins (Vink et al., 2006); suggesting genetic involvement in the syndrome. 
Animal studies have suggested that excess foetal androgen exposure in female non-human 
primates induces PCOS-like symptoms (Abbott, Dumesic, Eisner, Kemnitz, & Goy, 1997; 
Padmanabhan, Manikkam, Recabarren, & Foster, 2006) via alteration of the epigenome 
(chemical modifications to the DNA which alter gene expression)  (Z. Li & Huang, 2008; Xu 
et al., 2011). Hyperandrogenism has been found to induce the epigenetic alterations of genetic 
components in ovarian granulosa cells that are involved in the ovulatory dysfunction aspect of 
PCOS (Qu et al., 2012). However, there are mixed findings in the literature, and the single-gene 
aetiology hypothesis has been rejected by several genome-wide association studies (De Leo et 
al., 2016). However, these studies show evidence consistent with PCOS having a polygenic 
component (Dumesic et al., 2015) with significant novel loci (Chen et al., 2011; Hayes et al., 
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2015; Y. Shi et al., 2012), implicating gonadotropin and gonadotropin receptor variants to be 
associated with PCOS phenotypes (Azziz, 2016; Dumesic et al., 2015). Since the PCOS 
phenotype is varied and complex, is has been concluded that the diverse clinical presentation 
may result from its aetiological heterogeneity which needs to be further investigated. 
4.5.3 Environmental risk factors 
Environmental risk factors are increasingly being understood to play an important role in PCOS 
(Diamanti-Kandarakis, Piperi, et al., 2006). Symptoms usually appear around menarche 
(Franks, 2002), and may be precipitated by diet and lifestyle factors causing weight gain (Moran 
et al., 2011). Additionally, exposure to environmental toxins and endocrine disruptors may 
contribute to the development of symptoms (Kandaraki et al., 2011; Zhang et al., 2014). 
Environmental factors such as psychotropic medication, particularly sodium valproate (used to 
treat bipolar disorder and epilepsy) have been implicated in developing hyperandrogenism, 
obesity and ovulatory dysfunction (Franks et al., 2001; Franks et al., 1997; Isojarvi, 
Laatikainen, Pakarinen, Juntunen, & Myllyla, 1993; McIntyre, Mancini, McCann, Srinivasan, 
& Kennedy, 2003).  
 
4.6 BIOLOGICAL MECHANISMS 
Four main proposed hypotheses related to laboratory findings have attempted to explain the 
complex pathophysiological mechanism of the syndrome (Matalliotakis, Kourtis, Koukoura, 
& Panidis, 2006): 
1) The LH hypothesis - A primary neuroendocrine defect further leads to increased LH 
production (pulse frequency and amplitude), resulting in ovarian hyperandrogenism and 




2) The insulin hypothesis - Since most females with PCOS are resistant to insulin, 
irrespective of BMI, the pancreas compensates for insulin resistance by over-production 
and release of insulin (Nestler, 1998; Nestler et al., 1991; Pugeat & Ducluzeau, 1999; 
Weaver et al., 1990; Yki-Järvinen, Mäkimattila, Utriainen, & Rutanen, 1995), further 
stimulating testosterone production and decreasing SHBG levels (Adashi et al., 1981; 
Azziz et al., 2003; Chang et al., 1983; González, 2012; Kirschner et al., 1990; Legro, 
Gnatuk, Kunselman, & Dunaif, 2005; Panidis et al., 1998; Panidis, Skiadopoulos, Rousso, 
Ioannides, & Panidou, 1995; Song, Rhodes, Veldhuis, & Butler, 2003; Valenzuela & Stone, 
2014; Willis, Mason, Gilling-Smith, & Franks, 1996). In PCOS, insulin resistance is 
characterised by adrenal and ovarian tissue sensitivity (Diamanti-Kandarakis & 
Papavassiliou, 2006). Insulin resistance is the main cause of hyperinsulinemia in PCOS, 
which is characterised by excess levels of insulin relative to glucose (Tsilchorozidou et al., 
2004), however, hyperinsulinemia is further responsible for insulin resistance (Shanik et 
al., 2008). Hyperinsulinemia stimulates androgen production from sources including 
ovarian, adrenal and adipose tissue while suppressing SHBG secretion from the liver 
leading to excess androgen levels observed in PCOS, further associated with anovulation. 
3) The ovarian hypothesis - This hypothesis is linked to the LH hypothesis discussed above. 
An abnormal ovarian response to gonadotropin action may be secondary to androgen 
excess (Gilling-Smith, Willis, Beard, & Franks, 1994). A dysfunctional ovarian hyper-
responsiveness to gonadotropin action has been thought to be the main underlying fault of 
androgen excess (Rosenfield, 1999). Evidence for this hypothesis may also be observed in 
the form of follicular dysfunction (including the presence of small follicles) by pelvic 
ultrasound measures. Studies have indicated that follicular cells may also respond to FSH 
stimulation implying blocked FSH activity at the ovarian level (Loh, Wang, & Matthews, 
2002; Magoffin, 1989; Pang, Softness, Sweeney III, & New, 1987). Follicle Stimulating 
hormone levels have been linked to chronic anovulation in females with PCOS 
(Matalliotakis et al., 2006). 
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In summary, a comprehensive overview of all three hypotheses further leads to an 
understanding that hyperandrogenism and anovulation are the main outcomes of abnormalities 
involving increased LH production, increased insulin levels, increased androgen production, 
and decreased/blocked FSH activity (see Figure 4.2).  
Elevated circulating androgen levels are further associated with physical symptoms of PCOS 
mainly in the form of hirsutism and acne (Azziz, Carmina, Dewailly, Diamanti-Kandarakis, 
Escobar-Morreale, Futterweit, Janssen, Legro, Norman, & Taylor, 2006; Escobar-Morreale et 
al., 2011; Hatch, Rosenfield, Kim, & Tredway, 1981; Martin et al., 2008; Sachdeva, 2010). 
Testosterone and DHT together exert their effect on androgen receptors and hair follicles, which 
in turn leads to coarse terminal hair growth (Azziz et al., 2016) mainly on the face, back, chest 
and abdominal region.  
 
 
Figure 4.2  






In the early 1930s, the primary form of treating PCOS involved ovarian wedge resection to 
restore ovarian function and menstrual regularity (I. Stein, 1959, 1965; Wallach, Donesky, & 
Adashi, 1995). In later years, laparoscopic ovarian drilling was considered an alternative to 
ovarian surgery for treating ovulatory dysfunction (Al-Fadhli & Tulandi, 2004; Farquhar, 
Lilford, Marjoribanks, & Vandekerckhove, 2007; Hashim, Al-Inany, De Vos, & Tournaye, 
2013; Palomba, Zullo, Diamanti-Kandarakis, & Orio Jr, 2007  ). However, ovarian drilling may 
not be an optimal treatment for PCOS, since little research has shown the effect of ovarian 
drilling on suppressing androgen production. Since the main hormonal abnormality in PCOS is 
elevated testosterone levels, the focus now tends to be on lowering elevated levels of androgens.  
4.7.2  Investigations 
Currently, in clinical practice, routine investigations include: 
1. Hormonal measures of oligo-anovulation including LH, FSH, progesterone and 
oestradiol levels.  
2. Hirsutism and acne score. 
3. Main assays include serum testosterone levels (Total Testosterone, Free Testosterone 
and FAI levels) (Fenton, 2005; Hahn et al., 2007; Huang et al., 2010).  
4. Additional measures may include cortisol, thyroid function, and prolactin depending on 
the patient’s symptoms.  
5. Fasting glucose levels along with the oral glucose tolerance test are used to assess 
adiposity and obesity. 
6. Measures of A-dione and DHEAS in some cases are recommended. 
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7. Serum levels of AMH may be raised in patients with PCOS and may be an additional 
measure based on the clinician’s recommendation. 
4.7.2.1  Therapeutic targets 
1) Treating hyperandrogenemia - Symptoms of hyperandrogenism (hirsutism, acne, and 
alopecia) are usually self-treated by individuals by seeking cosmetic assistance, for 
example, shaving, waxing, bleaching and electrolysis (Legro et al., 2013; Moghetti & 
Toscano, 2006; Sanchez, Perez, & Azziz, 2002; Trüeb, 2002). Treatment for biochemical 
androgen excess may involve oral contraceptive pills (Sachdeva, 2010) or anti-androgen 
medication (Calaf et al., 2007).  
2) Improving insulin sensitivity and metabolic abnormalities - Treatment of metabolic 
abnormalities involved in PCOS aims to correct insulin resistance and associated 
symptoms of Type 2 diabetes and mainly consists of Metformin while monitoring glucose 
levels. Diet and lifestyle changes are most beneficial to achieve weight loss, to normalise 
hyperlipidaemia (Badawy, Aal, & Abulatta, 2009; Fenton, 2005; Jayasena & Franks, 2014; 
Markle, 2001; Sheehan, 2004) and to improve metabolic abnormalities, mood, fertility and 
ovulatory function, and thus, are often preferred as first-line treatment in PCOS (Kiddy et 
al., 1992; Moran et al., 2011; Teede et al., 2011; Thomson et al., 2010). Diet and lifestyle 
interventions are especially effective when used in conjunction with standard clinical 
treatment (Badawy & Elnashar, 2011; Hart, Hickey, & Franks, 2004). 
3) Correcting anovulation and reducing infertility - Treatment for ovulatory dysfunction aims 
to regularise the menstrual cycle and improve fertility, and consists of anti-oestrogen 
medication. Anovulation is associated with low FSH concentrations and is usually treated 
with medications such as Clomiphene citrate, Tamoxifen, aromatase inhibitors, Metformin, 
glucocorticoids or gonadotropins (Badawy et al., 2009; Carroll & Palmer, 2001; Harborne, 
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Sattar, Norman, & Fleming, 2005; Homburg, 2005; Messinis, 2005; Nugent, 
Vandekerckhove, Hughes, Arnot, & Lilford, 2000; Palomba et al., 2005; Sastre, Prat, 
Checa, & Carreras, 2009). First-line treatment for infertility in PCOS involves Clomiphene 
citrate, (a selective oestrogen receptor regulator), Letrozole (aromatase inhibitor) or 
Metformin (Legro et al., 2014).  
4.7.2.2  Pharmacological interventions 
Pharmacological agents are used in severe cases of metabolic, reproductive and 
hyperandrogenic abnormalities and when lifestyle modifications fail to treat these symptoms. 
These include oral contraceptive pills and anti-androgen medication. 
4.7.2.2.1 Oral contraceptive pills  
Oral contraceptives (OCPs) are often used as a first-line pharmacological treatment in females 
with no desire to conceive (Badawy & Elnashar, 2011; Givens, Andersen, Wiser, & Fish, 1974; 
Legro et al., 2013; Wild, Umstot, Andersen, & Givens, 1982). Oral contraceptive pills are 
effective in regulating menstrual cycles and reducing ovarian androgen production. They are 
generally used in the form of oestrogen-progestin combination therapy (consisting of both 
oestrogen and progesterone) (Ehrmann, 2005; Huber & Walch, 2006; Markle, 2001  ; Sirmans 
& Pate, 2014). Oestrogen in OCPs reduces hyperandrogenism by increasing direct negative 
feedback on LH secretion, stimulating SHBG production, decreasing ovarian androgen 
synthesis and adrenal androgen secretion (Azziz et al., 2016; Badawy & Elnashar, 2011). 
Progestins in OCPs inhibit the conversion of testosterone to DHT and binding of DHT to 




4.7.2.2.2 Anti-androgen medication 
If hyperandrogenism still persists after use of the OCP then anti-androgen treatment is 
prescribed (Dumesic et al., 2015; Martin et al., 2008). Anti-androgen medication aims to 
decrease androgen production or inhibit androgen-binding receptors (Escobar-Morreale et al., 
2011; Falsetti, Gambera, Platto, & Legrenzi, 2000; Koulouri & Conway, 2008; Swiglo et al., 
2008; Townsend & Marlowe, 2004; Van Zuuren & Fedorowicz, 2015; Venturoli et al., 1999; 
Yildiz, 2008). Anti-androgen agents include Cyproterone Acetate (CPA), Spironolactone, 
Flutamide or 5-α-reductase activity inhibitors such as Finasteride and are helpful with managing 
acne, hirsutism or alopecia. Combination therapy of anti-androgens and OCPs is used in 
females (particularly sexually active females) with severe hirsutism or if the OCP fails to 
achieve desired results. Additionally, anti-androgen medication used in combination with 
Metformin has beneficial effects on metabolic symptoms involved in PCOS (Fenton, 2005). 
4.7.2.2.3 Cyproterone Acetate 
Cyproterone Acetate (CPA) is an androgen blocker, and a progestogen with anti-androgenic 
properties, and is commonly used to treat hyperandrogenism (Azziz, Carmina, & Sawaya, 2000; 
Neumann et al., 1970). Cyproterone Acetate inhibits the binding of testosterone and its 
conversion product 5a-dihydrotestosterone to androgen receptors (Venturoli et al., 1999). This 
anti-androgen is usually prescribed in doses ranging from 50 to 100mg in conjunction with 
Ethinyl Estradiol 20 to 50μg as an oestrogen replacement (to regularise the menstrual cycle). It 
is generally well-tolerated, though it is not devoid of side effects including nausea, headaches, 
breast tenderness and weight again among others. However, it is considered beneficial to treat 





Flutamide is an anti-androgen with similar androgen-receptor blocking effects to CPA, 
however, without the progestogenic effect or the effect on hypothalamic activity shown by 
CPA. Generally prescribed in doses ranging from 125 to 500mg daily, it is a useful medication 
for treating hirsutism (Escobar-Morreale et al., 2011; Koulouri & Conway, 2008).  
4.7.2.2.5 Spironolactone 
Spironolactone is another commonly used anti-androgen and reduces hirsutism scores by 
approximately 40% (Badawy & Elnashar, 2011; Lobo, Shoupe, Serafini, Brinton, & Horton, 
1985; Lumachi & Rondinone, 2003; Moghetti, Tosi, et al., 2000). This anti-androgen works by 
being a competitive inhibitor of androgen receptor binding and suppresses LH and 5-α-
reductase activity (Swiglo et al., 2008; Van Zuuren & Fedorowicz, 2015). It is generally well-
tolerated in usual doses ranging from 100 to 200mg daily. Spironolactone is often used in 
conjunction with OCPs (Spritzer, Lisboa, Mattiello, & Lhullier, 2000), and has been found to 
be more effective compared with Metformin to reduce hirsutism and androgen levels (Alpanes, 
Alvarez-Blasco, Fernandez-Duran, Luque-Ramirez, & Escobar-Morreale, 2017). 
4.7.2.2.6  Metformin 
Metformin is used to reduce and manage the complications of insulin resistance involved in  
PCOS (Azziz et al., 2016). This medication improves peripheral insulin sensitivity (Moghetti, 
Castello, et al., 2000; Sam & Dunaif, 2003; Tang, Lord, Norman, Yasmin, & Balen, 2012) and 
in turn may decrease androgen levels (Badawy & Elnashar, 2011). Metformin has been shown 
to have optimal results when used in conjunction with lifestyle intervention (Naderpoor et al., 
2015). Metformin also improves hyperandrogenism; although to a small extent (Naka et al., 
2011) and is usually prescribed in doses ranging 1500 to 2000mg daily.  
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4.8 POLYCYSTIC OVARIAN SYNDROME AND MOOD 
4.8.1 Background 
A 2006 review stated that although more than 2,100 PubMed citations on PCOS appeared since 
2000, only three percent addressed psychological concerns in females with PCOS (Himelein & 
Thatcher, 2006b). However, in the past decade, more studies have addressed the psychological 
aspect of PCOS (Cooney & Dokras, 2017; Cooney et al., 2017; Dokras, 2012; Glowinska, 
Zielona-Jenek, Pawelczyk, & Banaszewska, 2016; Karjula et al., 2017; Teede et al., 2010). It 
is now well-known that PCOS is strongly linked to mood and anxiety disorders, with consistent 
evidence, including meta-analyses, showing depression and anxiety levels to be higher and 
more severe in females with PCOS compared with healthy controls, independent of obesity and 
other physical aspects of the syndrome (Barry, Kuczmierczyk, & Hardiman, 2011; Bruce-Jones, 
Zolese, & White, 1993; Cooney & Dokras, 2017; Cooney et al., 2017; Dag et al., 2017; Deeks, 
Gibson-Helm, & Teede, 2010; Dokras, 2012; Dokras et al., 2011, 2012; Elsenbruch et al., 2003; 
Farrell & Antoni, 2010; Kerchner, Lester, Stuart, & Dokras, 2009; Özenl et al., 2009; Veltman-
Verhulst, Boivin, Eijkemans, & Fauser, 2012) (findings from these studies will be discussed in 
detail in the section 4.8.2). Other psychiatric illnesses including bipolar disorder (Rasgon et al., 
2005; Wooderson, Gallagher, Watson, & Young, 2015), borderline personality disorder (BPD) 
(Roepke et al., 2010; Trisno, Worsley, & Kulkarni, 2016), body dissatisfaction and eating 
disorders (Bernadett & Szeman, 2016; Himelein & Thatcher, 2006a, 2006b), and poor health-
related Quality of Life (QoL) (Barnard, Ferriday, et al., 2007; Ching, Burke, & Stuckey, 2007; 
Coffey & Mason, 2003; Crete & Adamshick, 2011; Elsenbruch et al., 2003; Jones, Hall, Balen, 
& Ledger, 2008; McCook, Reame, & Thatcher, 2005) are also more frequently reported in 
individuals with PCOS compared with healthy females. There is an overall consensus that 
females with PCOS are at an increased risk of psychiatric disorders and distress, and in a recent 
review and meta-analysis, it was found that females with PCOS show a high prevalence of 
depression (OR: 3.78; 95% CI: 3.03-4.72), with a moderate-to-severe degree of severity (OR: 
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4.18. 95% CI: 2.68-6.52) (Cooney et al., 2017) (see Table 4.3). The higher prevalence of 
depression and anxiety is an important issue to address since a seven-fold increased risk, for 
suicide attempts was found in females with PCOS compared with controls (Mansson et al., 
2008), which warrants more attention to the mental health component related to the syndrome. 
Polycystic Ovarian Syndrome has been poetically described as a ‘thief of womanhood’ 
(Kitzinger & Willmott, 2002) because of its association with troublesome symptoms such as 
hirsutism, acne, alopecia, oiliness of the skin, seborrhoea (scaly and red patches on scalp) and 
infertility (Dumesic et al., 2015; Ferriman & Gallwey, 1961; Hahn et al., 2005; Himelein & 
Thatcher, 2006b; Jones et al., 2008; Mechanick & Dunaif, 1990). These symptoms may have a 
profound negative impact on the patient and may threaten her feminine identity, which may  
lead to body dissatisfaction (Himelein & Thatcher, 2006a) and may further lead to depression 
(Karjula et al., 2017). Studies have found associations between hyperandrogenic and metabolic 
aspects of the syndrome and depression and anxiety (Borghi et al., 2017; Deeks et al., 2010; 
Ekbäck, Lindberg, Benzein, & Årestedt, 2013; Farrell & Antoni, 2010; Naqvi et al., 2015; Scott 
et al., 2008). Hyperandrogenic symptoms of PCOS (for example hirsutism) have been shown 
to be associated with diminished QoL  (Kitzinger & Willmott, 2002; Z. Li et al., 2011; Pate, 
2016) and social anxiety (Sonino, Fava, Mani, Belluardo, & Boscaro, 1993).  In a systematic 
review and meta-analysis assessing QoL in females with PCOS, it was found that the PCOS 
group (n = 423) had lower scores on all Short-Form-36 (SF-36) dimensions related to health-
related QoL, compared with controls (n = 285), particularly in emotional role function (Z. Li 
et al., 2011).  However, there is mixed evidence, with some studies showing no significant 
relationship between hirsutism and mood (Barth, Catalan, Cherry, & Day, 1993; Rahiminejad 
et al., 2014; Shulman, DeRogatis, Spielvogel, Miller, & Rose, 1992), which suggests that other 
factors such as biochemical abnormalities and obesity may also be associated with 
psychological abnormalities in PCOS.  
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4.8.2 Findings from meta-analytical reviews and other studies 
Significantly increased prevalence and increased risk for symptoms of depression and anxiety 
has been found in females with PCOS compared with healthy females, and findings from these 
studies will be discussed in detail in the following section (Barry, Kuczmierczyk, et al., 2011; 
Blay, Aguiar, & Passos, 2016; Cooney & Dokras, 2017; Dokras, 2012; Dokras et al., 2011, 
2012; Farrell & Antoni, 2010; Veltman-Verhulst et al., 2012). 
A systematic review (including 17 studies) and meta-analysis (including 10 cross-sectional 
studies) reported a four-fold increased risk for abnormal depression scores in females with 
PCOS (4.03 [95% confidence interval [CI] 2.96–5.5, p < 0.01]) (n = 522) compared with 
healthy females (n = 475) across several countries, independent of BMI and the screening tool 
used (OR 4.09, 95% CI 2.62–6.41, p < 0.01) (Dokras et al., 2011). Another systematic review 
(n = 9 studies) and meta-analytical study (n = 4) by the same research group examined anxiety 
in females with PCOS. Prevalence of GAD and overall symptoms of anxiety were found to be 
significantly higher in females with PCOS (n = 450) compared with healthy control females (n 
= 377) (OR 6.88, 95% CI 2.5-18.9, p < 0.01) (Dokras et al., 2012). In a recent meta-analysis 
(six studies) (Blay et al., 2016) anxiety (OR =2.76; 95% CI 1.26 to 6.02; Log OR =1.013; p = 
0.011) and depression levels (OR =3.51; 95% CI 1.97 to 6.24; Log OR =1.255; p < 0.001) were 
found to be significantly higher in females with PCOS (unspecified number of females) 
compared with healthy control females. Despite including a stricter inclusion criterion, 
including studies only if they involved standardised interviews or screening tools for psychiatric 
evaluation and for diagnosis of PCOS (e.g., Rotterdam, NIH or AE-PCOS society criteria) 
symptoms of anxiety and depression were found to be higher in a sample with PCOS. Barry et 
al. (2011) found significantly higher depression (Z = 17.92, p < 0.00001; Hedges’ g = 0.82; 
95% CI 0.73–0.92) and anxiety levels (Z = 5.03, p < 0.00001; Hedges’ g = 0.54; 95% CI 0.33–
0.75) in their systematic review and meta-analysis, which included a total of twelve 
comparative studies, of which six assessed anxiety (208 PCOS, 169 healthy controls), whereas 
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all twelve assessed depression (910 PCOS, 1347 healthy controls). Body Mass Index was 
proposed to play an important role since studies controlling for BMI showed smaller differences 
on depression and anxiety scores in females with PCOS compared with healthy controls. 
However, levels of depression and anxiety were found to be only mildly elevated in females 
with PCOS. Similar levels of mild-moderate depression and anxiety were found in another 
comprehensive meta-analytical study (Veltman-Verhulst et al., 2012). Although twenty-six of 
twenty-eight studies found higher depression levels and seventeen studies found higher anxiety 
levels in females with PCOS compared with controls in this study (2012), females with PCOS 
(n = 2834) were found to show mild-moderate severity of depression, with half of the studies 
in the meta-analysis showing scores in the non-clinical range compared with healthy controls 
(n = 2705). Mood and anxiety symptoms were found to be similar in all phenotypes of PCOS, 
for example, obese females with infertility and hirsutism had similar depressive levels 
compared with lean fertile females.  
A recent systematic review (including 30 cross-sectional studies) and meta-analysis (18 studies 
assessing depression and 9 studies assessing anxiety) found females with PCOS (n = 3050) to 
have significantly increased odds of both moderate and severe mood and anxiety scores compared 
with healthy controls (n = 3858) (Cooney & Dokras, 2017). Females with PCOS had over three 
times the odds of moderate-severe symptoms of depression and over five times the odds of 
symptoms of anxiety compared with healthy controls. In the meta-regression analysis (based on 
15 studies separate from the systematic review), females with PCOS and depression had higher 
mean values of age, BMI, hirsutism and insulin resistance (but not testosterone levels) and 
females with PCOS and anxiety showed higher mean values of BMI, hirsutism and Free 
Testosterone levels. 
Overall, rates of depression and anxiety are higher in PCOS samples, however, associations 
between BMI and mood and/or anxiety in PCOS samples are more complex. A systematic review 
79 
 
and meta-analysis found an increased risk for low mood in females with PCOS compared with 
healthy females, independent of BMI (Dokras et al., 2011). This finding is consistent with later 
studies which did not report significant associations between BMI and mood in PCOS samples 
(Blay et al., 2016; Dokras, 2012). Furthermore, one study found mood and anxiety symptoms to 
be similar in all phenotypes of PCOS, including obese females with infertility and hirsutism, who 
showed similar levels of depression compared with lean and fertile females (Veltman-Verhulst et 
al., 2012). Although two systematic reviews found higher mean values of BMI, insulin resistance, 
and hirsutism in women with PCOS and depression and anxiety compared with healthy controls, 
there were considerable methodological issues in these studies including strict inclusion criteria 
(further discussed in Chapter Five, section 5.3.1.2). 
 
4.9  POLYCYSTIC OVARIAN SYNDROME AND COGNITIVE FUNCTION 
4.9.1 Background 
Gender differences in cognitive functioning have been well-documented (Halpern, 2000; 
Hampson & Kimura, 1992; Kimura, 1996; Kimura & Hampson, 1994; Schattmann & Sherwin, 
2007b). Organisational effects of sex hormones may help explain the superior performance by 
males on tasks assessing mathematical ability (Benbow, 1988), mental rotation and visuospatial 
ability (Driscoll, Hamilton, Yeo, Brooks, & Sutherland, 2005; D. Goldstein, Haldane, & Mitchell, 
1990; L. Harris, 1981; Linn & Petersen, 1985; Silverman, Kastuk, Choi, & Phillips, 1999; N. 
Watson & Kimura, 1991; Wittig & Petersen, 1979) and by females on tasks assessing verbal 
ability (Kimura, 1983; Kramer, Delis, & Daniel, 1988; E. Weiss, Kemmler, Deisenhammer, 
Fleischhacker, & Delazer, 2003), verbal fluency (Halpern, 2000), psychomotor speed and manual 




Table 4.3  
Meta-Analytical Findings Related to Depression and Anxiety in Females with Polycystic Ovarian Syndrome  
  
Study Main goal Number of 
participants 
Findings 
Barry et al. (2011)  
 
Systematic review and meta-analysis (12 
studies) examining symptoms of depression 
and anxiety in PCOS 
12 studies assessing 
depression: 910-PCOS, 
1347-HC; 
6 studies assessing 
anxiety: 208-PCOS,  
169-HC. 
Significantly higher levels of mild depression and anxiety in 
PCOS patients compared with healthy controls.  
Lower BMI was found to be associated with lower levels of 
depression and anxiety. 
Dokras et al. (2011) Systematic review (17 studies)  and meta-
analysis (10 studies) examining symptoms 
of depression in PCOS 
PCOS-522 
HC-475 
Four-fold increased risk for higher depression scores in PCOS 
females compared with healthy controls, independent of BMI 
or depression rating scales used. 
Dokras et al. (2011) 
 
 
Systematic review (9 studies) and meta-
analysis (4 studies) examining symptoms of 





Significantly higher prevalence of generalised anxiety 
symptoms in females with PCOS compared with healthy 
controls. 
Increased risk for symptoms of anxiety in females with PCOS. 
Anxiety disorders including social anxiety disorder, panic 




Table 4.3 Continued 
PCOS- Polycystic Ovarian Syndrome, HC- Healthy Controls, BMI- Body Mass Index, QoL- Quality of Index 
Study Main goal Number of participants Findings 
Veltman-Verhulst et 
al. (2012) 
Meta-analytical study including 28 studies 
examining depression and 17 studies 
examining anxiety in females with PCOS  
PCOS-2834 
HC-2705 
Majority of studies found higher levels of depression and 
anxiety in females with PCOS compared with healthy controls. 
Clinical hyperandrogenism did not account for emotional 
distress (QoL) in females with PCOS. 
BMI found to be unrelated to symptoms of depression in PCOS. 
Blay et al. (2016)  Meta-analysis (six studies) including 5 
studies examining symptoms of anxiety in 
PCOS and six examining symptoms of 
depression in PCOS 
PCOS-343 
HC-318 
Significantly higher anxiety and depression levels in females 
with PCOS compared with healthy controls.  
Cooney et al. (2017) 
 
Systematic review (30 studies) and meta-
analysis (18 studies assessing depression 




Significantly increased odds of any symptoms of depression 
and anxiety and of moderate/severe symptoms of depression 
and anxiety in females with PCOS compared with healthy 
controls, independent of BMI.  
Meta-regression analysis findings included higher mean 
values of age, BMI, hirsutism in PCOS females with 
depression but no relationship between mood and 
testosterone levels. Females with PCOS and concurrent 
anxiety showed higher mean BMI values, hirsutism score and 
Free Testosterone levels compared with the control group. 
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A unique opportunity lies in investigating the effect of testosterone on cognitive functioning in 
females with PCOS with high levels of testosterone, and to study differences in cognitive 
function before and after a pharmacological intervention. However, only a few studies until 
now have examined this relationship (Barnard, Balen, Ferriday, Tiplady, & Dye, 2007; Barry, 
Parekh, & Hardiman, 2013; Schattmann & Sherwin, 2007a, 2007b; Soleman et al., 2016). These 
studies will be discussed in the next section. 
4.9.2 Cognitive function in PCOS  
Cognitive function in females with PCOS is not an entirely well-studied area of research and 
of the few studies that have assessed cognitive function in females with PCOS, results are 
mixed. Overall, two studies suggested better spatial ability in females with PCOS  (Barnard, 
Balen, et al., 2007; Barry et al., 2013) and two other studies suggested better executive 
functioning in females with PCOS following anti-androgen treatment (Schattmann & Sherwin, 
2007a; Soleman et al., 2016). 
Barry et al. (2013) examined visuospatial ability (Mental Rotation Test [MRT] in females with 
PCOS (n = 69) and found significantly better spatial ability in this sample compared with 
healthy controls (n = 41). Additionally, a significant positive correlation was found between 
Free Testosterone levels and spatial ability within the PCOS group in this study, however, the 
same result was not found in the control group, which could be due to a small sample size of 
the study. Similarly, Barnard et al. (2007) found better performance (improved reaction time) 
on the spatial task in the PCOS group compared with the control group. In this internet-based 
study, 135 right-handed females with PCOS and healthy control females (n = 322) were 
stratified based on anti-androgen treatment and the presence of symptoms of depression (Zung 
Depression Rating Scale) (Zung, 1965). The PCOS group using anti-androgen medication (n = 
69-109) was found to have significantly faster reaction time on the spatial task compared with 
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untreated PCOS group (n = 66-110) suggesting that anti-androgen treatment may help improve 
reaction time on tasks assessing spatial ability. However, in this study, females with PCOS 
showed impaired performance in speed and accuracy on word recognition tasks (verbal learning 
and memory; considered to show a significant female-advantage). A similar impairment in 
performance on female-favouring tasks including verbal learning and memory, executive 
functions (verbal fluency, working memory) and psychomotor speed was observed in females 
with PCOS and hyperandrogenism (n = 29) compared with healthy females (n = 22) 
(Schattmann & Sherwin, 2007b). Compensatory performance on male-favouring cognitive 
tasks was not found in this study, which was, however, hampered by very low numbers. Another 
small randomised placebo-controlled trial investigated cognitive function in 19 females with 
PCOS before and after three months of anti-androgen (CPA) treatment (Schattmann & Sherwin, 
2007a) and found no significant change in visuospatial ability and perceptual speed following 
treatment. Executive function (verbal fluency; COWAT) was found to improve post-treatment. 
A more recent small interventional study involving anti-androgen treatment examined working 
memory (executive functions) in females with PCOS using functional magnetic resonance 
imaging (fMRI) measures (Soleman et al., 2016). Baseline results showed greater levels of 
activation in the right superior and inferior parietal lobe during the memory task in the PCOS 
group (n = 14) compared with the healthy control group (n = 20). No significant difference was 
found in working memory scores (N-back Task involving letters) (Kane, Conway, Miura, & 
Colflesh, 2007) between the two groups. Post-treatment fMRI results showed no difference in 
brain activity between groups, suggesting a normalisation by treatment, along with increased 
accuracy in one aspect of the working memory task in females with PCOS.  
Emotion processing has not been well-studied in females with PCOS. Only one neuroimaging 
study until now has examined emotion processing in females with PCOS (Marsh et al., 2013). 
In this small interventional study, females with insulin-resistant PCOS (n = 7) were found to 
have greater limbic activation during the emotion processing task as found by fMRI, compared 
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with healthy controls (n = 5), which reduced with treatment. Limbic areas including the 
prefrontal cortex, anterior cingulate, amygdala, and ventral basal ganglia/nucleus accumbens 
(known to be involved in the integration and evaluation of emotional information), have been 
implicated in depression. However, differences between groups in performance on tasks 
assessing emotion processing were unreported in this study. 
In summary, one study showed significant cognitive impairment in females with PCOS, two 
studies found better spatial ability in females with PCOS, while two remaining studies found 
better executive functioning in females with PCOS following anti-androgen treatment. Further 
investigation is required to examine cognitive functioning in females with PCOS and high 
androgen levels.  
 
4.10  CONCLUSION AND IMPLICATIONS 
The underlying reason for the association between PCOS, mood and anxiety disorders still 
remains unclear (Cooney & Dokras, 2017). Neurobiological theories have been used to explain 
increased mood and anxiety symptoms in studies (Belmaker & Agam, 2008). Methodological 
issues such as selection of studies (exclusion of studies with incomplete reports), recruitment 
of participants from varying clinical settings, non-standardised tools and self-report measures 
used to assess symptoms, influence of covariates such as BMI, obesity and medications 
involved, lack of sensitivity analyses, and not accounting for heterogeneity of the syndrome 
have all led to contrasting clinical recommendations and an incomplete understanding of the 
aetiology of  mood and anxiety disorders in PCOS (Blay et al., 2016; Dokras et al., 2011; 
Veltman-Verhulst et al., 2012). 
It was recently documented that although the majority of physicians (>85%) were aware of 
cardio-metabolic comorbidities, very few were well-informed about the psychiatric distress 
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(depression and anxiety) involved in the syndrome (Dokras et al., 2017). Given the consistent 
evidence supporting the high prevalence of depression and anxiety in females with PCOS, it is 
imperative to implement appropriate treatment strategies that address the psychological issues 
involved. Polycystic Ovarian Syndrome has a significantly negative impact on health-related 
QoL, however, there is still a gap in both research and clinical practice related to causal factors 
behind mood and anxiety disorders in PCOS. The association between the biochemical aspects 
of the syndrome and psychiatric comorbidities need to be elucidated, particularly the 
association between the principal hormonal abnormality characteristic of PCOS: androgen 
excess, which may be related to mood, and therefore, low mood in PCOS could be resolved by 
normalising androgen levels. It has taken considerable time for guidelines by health 
professionals to recommend routine screening for mood symptoms in patients with PCOS 
(Center for Research Excellence in PCOS, 2015). Polycystic Ovarian Syndrome is not only a 
personally challenging and distressing experience for females who suffer from it but also a 
diagnostic challenge for clinicians. Therefore, it is essential to effectively treat the hormonal 
and psychological aspects of PCOS in a holistic manner, by promoting a healthy collaboration 





ANDROGENS, DEPRESSION, ANXIETY, COGNITIVE FUNCTION 
AND EMOTION PROCESSING IN WOMEN:  




This chapter provides a systematic review of both cross-sectional and interventional studies that 
examined the association between androgen levels and mood, anxiety, cognitive function and 
emotion processing in females of reproductive age with and without PCOS.  
5.1.1 Background  
Depression is a serious and debilitating condition (see Chapter Two) and affects twice as many 
females as males in adulthood (Karger, 2014; Kessler, 2003; Kessler et al., 1994; Noble, 2005; 
Piccinelli & Wilkinson, 2000; Weissman et al., 1993; Weissman & Olfson, 1995). This 
difference in prevalence between genders, as well as increased prevalence of mood disorders in 
medical conditions associated with abnormal sex hormones, suggests that for at least some 
females, depression, and perhaps associated cognitive impairment, may have hormonal 
underpinnings. An example of an endocrine condition associated with an increased prevalence 
of mood disorders is PCOS. Polycystic Ovarian Syndrome is the most common 
endocrinological disorder in females of reproductive age (Azziz, Woods, et al., 2004; Bozdag 
et al., 2016; Farrell & Antoni, 2010; Franks, 1995; McGowan, 2011), affecting up to 5 to 22% 
of females, depending upon the diagnostic criteria (Azziz et al., 2016; Bozdag et al., 2016; 
Farquhar et al., 1994; Goodarzi & Azziz, 2006; Knochenhauer et al., 1998; Lizneva, Suturina, 
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et al., 2016; March et al., 2010; Mueller et al., 2014; Nestler, 1998; Sirmans & Pate, 2014; 
Teede et al., 2010). The high prevalence of depression and anxiety in females with PCOS is 
well-documented and associations between symptoms of depression and androgen excess have 
been indirectly implicated from prevalence and intervention studies in PCOS samples compared 
with healthy, age-matched females (Barry, Kuczmierczyk, et al., 2011; Bishop, Basch, & 
Futterweit, 2009; Blay et al., 2016; Cooney & Dokras, 2017; Cooney et al., 2017; Deeks et al., 
2010; Dokras, 2012; Dokras et al., 2011, 2012; Mansson et al., 2008; Veltman-Verhulst et al., 
2012) (see Chapter Four). However, there is limited understanding of the direct effect of 
androgens on the female brain and the clinical manifestations of this. Additionally, a slightly 
increased rate of depression is found in patients with PCOS and large numbers of other women 
who are treated with the OCP and similar hormonal agents aiming to reduce androgen levels 
(Skovlund, Morch, Kessing, & Lidegaard, 2016). It is important to consider whether the two 
are linked and to consider other possible cognitive/emotional aspects of lowered androgen 
levels. 
Data on testosterone levels in depression and during treatment is equivocal. Significant 
increases in testosterone levels in females have been reported following antidepressant 
treatment (Cohen, 1999; Giltay et al., 2012; Kumsar et al., 2014). However, these findings have 
not been consistently replicated, with other studies, including one longitudinal study, reporting 
significantly higher blood concentrations of Total Testosterone at baseline in untreated 
depressed females compared with healthy control females (Baischer et al., 1995) and decreased 
Free Testosterone levels in patients (12 males and eight females) treated with antidepressants 
compared with the placebo condition in a double-blind placebo controlled study (Cohen, 1999). 
These findings, and those in PCOS, suggest that testosterone (and perhaps other androgens) 
may play a role in the development of mood disorders for a subset of females. However, the 
exact nature of this relationship is unclear due to lack of direct measurement of androgen levels 
in relation to mood symptoms in PCOS samples.  
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There is a suggestion of worse cognitive function in the areas of memory, attention, and executive 
function in females with PCOS compared with healthy females (Barnard, Balen, et al., 2007; 
Schattmann & Sherwin, 2007b). Whether this worse performance is related to symptoms of 
depression or is an independent feature of androgen excess has not been examined yet. The 
finding of gender differences in cognitive function, with males generally outperforming females 
on tests of mathematical and visuospatial ability (Benbow, 1988; Driscoll et al., 2005; D. 
Goldstein et al., 1990; L. Harris, 1981; Linn & Petersen, 1985; N. Watson & Kimura, 1991; Wittig 
& Petersen, 1979) and females outperforming males in tests of  verbal memory, processing speed, 
and verbal fluency (Halpern, 2000) suggests an organisational effect of sex hormones (previously 
discussed in Chapter Three, section 3.4.2) and does not necessarily imply an effect of ambient 
androgen levels since, of course, other hormones vary between genders. Research suggests that 
females with PCOS, however, tend to show worse performance on tasks of verbal and spatial 
memory, processing speed and attention and executive function (verbal fluency) compared with 
healthy females (Barnard, Balen, et al., 2007; Schattmann & Sherwin, 2007b). Findings from 
neurobiological studies indicate a wide distribution of androgen receptors in brain regions 
fundamental for learning and memory, particularly the hippocampus (Beyenburg et al., 2000; 
Brännvall, Bogdanovic, Korhonen, & Lindholm, 2005; Hamson et al., 2013; Xiao & Jordan, 
2002), temporal cortex (Puy et al., 1995; Sarrieau et al., 1990), and the prefrontal cortex, which 
is not prominently involved in learning and memory function but plays a role (Finley & Kritzer, 
1999). However, recent studies have found that there may be other factors including epigenetic 
factors such as psychological, socio-cultural and environmental that may affect sex differences in 
cognitive function, which warrant further investigation (Levine, Foley, Lourenco, Ehrlich, & 
Ratliff, 2016; D. Miller & Halpern, 2014). 
Emotion processing is the ability to detect and decode facial emotional expressions and is 
required for successful interpersonal relationships. Research suggests significant emotion-
specific deficits in MDD (Bourke et al., 2010). Reviews have suggested that individuals with 
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depression show abnormal facial emotion processing observed in the form of impaired 
recognition accuracy, misinterpretation of neutral faces as sad, and attentional biases to sad 
faces (Bouhuys et al., 1999; Bourke et al., 2010; Stuhrmann et al., 2011). The amygdala, which 
is involved in processing emotional material (Kesler et al., 2001; Morris et al., 1998), has been 
well-documented to mediate gender differences in emotion processing (Hamann, 2005; Kret & 
De Gelder, 2012; Schienle, Schäfer, Stark, Walter, & Vaitl, 2005; S. Schneider et al., 2011), 
has a high density of androgen receptors (Abdelgadir, Roselli, Choate, & Resko, 1999; Sarrieau 
et al., 1990; Simerly et al., 1990; Zuloaga, Puts, Jordan, & Breedlove, 2008b), and its activity 
has been found to be influenced by sex hormones including testosterone (van Wingen, Mattern, 
Verkes, Buitelaar, & Fernández, 2010). 
Despite these indicative findings, relatively limited research has directly assessed the 
relationship between androgen abnormalities and symptoms of depression and anxiety in 
reproductive-aged females. Even less is known of the direct association between androgen 
levels and cognition and emotion processing. Importantly, knowledge of this association will 
help inform endocrinologists about the complexities of PCOS from a mental health perspective. 
For this purpose, existing literature was reviewed on the direct relationship between 
abnormalities in the androgen system in females and the psychological symptoms of depression 
and anxiety, together with associated features of brain function including cognitive function, 
and emotion processing. 
5.1.2 Aims 
This review aims to examine the role played by androgen excess in mood and anxiety, and 
related worse cognitive performance, in reproductive-aged females with and without PCOS. 
The current review was inclusive in sampling, in that it was inclusive of both cross-sectional 
and interventional studies relating mood, anxiety and cognitive function in reproductive-aged 
female samples with PCOS and without PCOS.  
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This review has two overarching aims: 1) to provide a clear understanding of the relationship 
between androgens, mood, anxiety, cognitive function and emotion processing in females of 
reproductive age, and 2) to identify methodological issues of research in this area. 
5.2 METHOD 
5.2.1 Search Strategy  
Electronic database searches were carried out for relevant papers using PubMed, Google Scholar 
and Web of Science up to January 2017. In the initial search, the following terms were used:  
 ‘androgen’ or ‘testosterone’ or ‘polycystic ovary syndrome’ or ‘polycystic ovarian 
disorder’, and  
 ‘major depressive disorder’ or ‘depression’, or ‘anxiety’, and  
 ‘cognitive function’ or ‘neuropsychological function’, or ‘spatial ability’ or ‘emotion 
processing’ or ‘facial expression recognition’.  
Reference lists for all relevant papers were checked and Web of Science was used to review the 
articles that had cited relevant articles found using these search strategies. 
5.2.2 Inclusion criteria 
Inclusion criteria were as follows: 
- Interventional or observational studies that involved an assessment of symptoms of 
depression/anxiety and/or cognitive function and/or emotion processing AND 
androgen levels,  
- Non-pregnant, pre-menopausal females aged between 16 and 45 years (PCOS or non-
PCOS, 




5.2.3 Exclusion criteria 
Studies were excluded for the following reasons: (i) inclusion of male and female participants 
without a separate analysis of results for the female sample, (ii) androgen levels not reported 
(often because androgen levels were used as a screening tool in PCOS studies), (iii) lacking 
analyses directly investigating associations between androgen levels and mood/cognitive 
function/emotion processing, and (iv) use of a non-standardised measure of mood or anxiety 
symptoms. 
 
5.3 RESULTS AND DISCUSSION 
A total of 73 studies met the inclusion criteria, by including a direct examination of the 
relationship between androgens and mood/anxiety/cognitive function/emotion processing in 
reproductive-aged females (see Tables 5.1, 5.2, 5.3, 5.4). Thirty-three studies specifically 
examined associations between androgen levels and symptoms of depression and anxiety 
symptoms, of which 21 studies included PCOS samples (see Table 5.1) and 12 included non-
PCOS samples (see Table 5.2). Of the remaining forty studies, 21 used an observational study 
design (see Table 5.3) and 19 used an experimental/interventional study design (see Table 5.4) 
to examine the relationship between androgen levels and cognitive function and emotion 
processing.  
Measures of Androgens 
A range of androgens were analysed including: Testosterone (Total Testosterone, Free 
Testosterone, generally used synonymously with Bioactive and Bioavailable Testosterone), 
Dihydrotestosterone (DHT), Dehydroepiandrosterone (DHEA), Dehydroepiandrosterone 
Sulfate (DHEA-S), Androstenedione (A-dione), Androstenediol (A-diol) and Free Androgen 
Index (FAI) (ratio of Total Testosterone to SHBG multiplied by a 100). Sex Hormone Binding 
Globulin (SHBG) was also assessed by several studies.  
93 
 
Free Testosterone appears to be a more useful measurement than Total Testosterone since only 
Free Testosterone is available to act at the receptors (Huang et al., 2010) (see Chapter 3, Section 
3.3.1). Therefore, studies investigating the relationship between Free Testosterone/FAI and 
psychological measures are likely to be more relevant than those which examine Total 
Testosterone levels (Vermeulen et al., 1999). Other androgens are similar to testosterone in their 
action, with the exception of DHEA, DHEA-S and A-dione, which are pro-androgens or 
precursors to testosterone (see Chapter Three). Given its somewhat different profile, it is worth 
considering the effects of DHEA-S quite separately from those of other androgens. However, the 
best androgen measures for the purpose of this review remains to be Free Testosterone or FAI.   
Another important methodological issue that was identified was a consideration of the variability 
of testosterone levels or the point in the range of testosterone levels at which a group is 
functioning. Some studies included PCOS patients (higher than normal testosterone levels) while 
others included anorexia nervosa and HIV patients (lower androgen levels) and transsexuals 
undergoing cross-sex hormone treatment (with varied androgen levels). Additionally, there are 
many other issues related to testosterone assessment or administration including diurnal/seasonal 
fluctuations and fluctuations related to menstrual phases. First, one study suggested that 24-hour 
mean plasma testosterone concentrations showed a steep decline at age 40 (age range included 
21-51 years) in non-obese females with regular menstrual cycles (Zumoff et al., 1995). 
Additionally, testosterone levels in females are subject to small but significant fluctuations in 
testosterone levels during different menstrual phases (Goebelsmann, Arce, Thorneycroft, & 
Mishell, 1974; Judd & Yen, 1973). Goebelsmann et al. (1974) found that Total Testosterone 
levels were highest around midcycle LH peak and higher during the follicular phase compared 
with the luteal phase of the cycle. Additionally, averages for individual participants varied 
significantly for the entire cycle. However, the study concluded that mean testosterone levels 
largely fell into a relatively narrow range. Free Testosterone levels were not assessed in the 
Goebelsmann et al. study. Although it has been suggested that sexually dimorphic cognitive skills 
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that show a significant male-advantage improve during menstrual phases involving low 
oestrogen, and cognitive tasks with a female-advantage improve in association with high 
oestrogen levels (Hampson, 1990; Hausmann, Slabbekoorn, Van Goozen, Cohen-Kettenis, & 
Güntürkün, 2000; Nyborg, 1983; S. Phillips & Sherwin, 1992), a recent review and meta-analysis 
did not find robust evidence related to the influence of menstrual cycle on cognitive function 
(Poromaa & Gingnell, 2014). This review, however, suggested an association between 
improvement in performance on tasks assessing verbal or spatial working memory and higher 
levels of oestradiol. There was limited evidence for this finding, however, and is not the main 
topic of interest for the current review. Additionally, in Poromaa et al’s study (2014), emotion-
processing related changes were more consistently found to be associated with progesterone, 
however, no significant findings related to testosterone levels were reported. 
Issues regarding testosterone administration include the type of administration, i.e., gel, patch or 
injection, and the determination of the most effective time period between exogenous 
administration and testing (Gordon, Corbin, & Lee, 1986; Postma et al., 2000). This may help 
clarify results, since in a small cross-sectional study involving collection of multiple samples of 
testosterone, van Honk et al. (1999) found a significant association between emotion processing 
of angry faces (attending away from threatening faces), mood (Profile of Mood States: POMS) 
and Free Testosterone samples collected six hours prior to testing (showing highest Free 
Testosterone levels of all samples taken), but not with testosterone samples taken at other time-
points in 16 healthy females.  However, this may likely be a chance finding due to multiple samples 
collected prior to the emotion processing assessment. Regarding interventional studies involving 
testosterone administration, studies have repeatedly shown that there is a tenfold increase in Total 
Testosterone following testosterone administration returning to baseline within 90 minutes, with 
no changes in SHBG. However, Free Testosterone levels have not been reported to increase in 
these studies (Bos et al., 2013; Hermans et al., 2007; Postma et al., 2000; Schutter & van Honk, 
2004; Tuiten et al., 2000; van Honk, Peper, & Schutter, 2005; van Honk et al., 2001).
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Table 5.1  
Studies Examining the Relationship between Androgen Levels, Mood and Anxiety in Females with Polycystic Ovarian Syndrome (21 studies) 
Study Study sample Mean age (yrs) Study design and key measures Key findings 
Rocco et al. (1991) 21 Polycystic Ovarian 
Syndrome females 
(PCOS) , 
10 healthy controls 
(HC) 
PCOS = 20.2  
HC = 21.7 
Cross-sectional study design 
Clinical measures: Minnesota Multiphasic Personality 
Inventory (MMPI), State-Trait Anxiety Inventory (STAI).  
Androgen measures:  Total testosterone (Total T), 
Androstenedione (A-dione), Dehydroepiandrosterone 
sulphate (DHEA-S). 
Depressed and non-depressed PCOS groups identified 
based on MMPI scores (>upper limit of 70) and STAI 
(>upper limit of 44, 48). 
Higher A-dione levels in depressed females with PCOS (n 
= 11) compared with non-depressed females with PCOS (n 
= 10). 
No significant correlation between androgen levels and 
anxiety. 
Ragson et al. 
(2003) 
32 PCOS Unstated* Cross-sectional study design 
Clinical measures: Centre for Epidemiological Studies- 
Depression Rating Scale (CES-D). 
Androgen measures: Bioavailable T (Free Testosterone: 
Free T). 
No significant correlation between depression (CES-D) and 
Free T levels. 
Weiner et al. 
(2004) 
27 PCOS and 27 HC PCOS = 28.2  
HC = 30 
Cross-sectional study design 
Clinical measures: Visual Analogue Scale (VAS: 6 
negative and 4 positive moods), STAI, State-Trait 
Depression Adjective Check List. 
Androgen measures: Total T, Free T. 
Significant positive correlation between Free T levels and 
anxiety (STAI) in HC group. 
Significant negative correlation between state anxiety and 
Free T levels in PCOS group. 
No significant relationship between mood and Free T levels 
in PCOS group. 
Curvilinear relationship between Free T levels and mood 
and anxiety with highest depression and anxiety levels at 
mid-range (10-26 pg/ml) of Free T levels (analysis included 
both groups) 
Hahn et al. (2005) 120 PCOS and 50 HC PCOS = 29  
HC = 30 
Cross-sectional study design 
Clinical measures: Symptom Checklist Survey 90 R 
(SCL-90-R) to measure of mood and anxiety. 
Androgen measures: Total T 





Table 5.1 Continued 
Study Study sample Mean age (yrs) Study design and key measures Key findings 
Hollinrake et al. 
(2007) 
103 PCOS and 103 
HC 
PCOS = 29.8  
HC = 30.7 
Cross-sectional study design 
Clinical measures: Primary Care Evaluation of Mental 
Disorders Patient Health Questionnaire (PRIME-MD 
PHQ) to measure anxiety and mood and Beck Depression 
Inventory (BDI) to measure depression. 
Androgen measures: Total T, Free T, DHEA-S. 
No significant difference in androgen levels between 
depressed (n = 36) and non-depressed (n = 67) PCOS 
females. 
No significant correlation between depression (BDI) and 
androgen levels or between anxiety and androgen levels. 
Soyupek et al. 
(2008) 
37 PCOS and 35 HC PCOS=24.10+6.13 
HC= 26.14+5.67 
Cross-sectional study design 
Clinical measures: BDI 
Cognitive measures: Psychomotor speed (Manual 
dexterity)measured by the Grooved Pegboard Test 
Androgen measures: Total T, DHEA-S. 
No significant correlations between mood and androgen 
levels. 
No significant correlations between manual dexterity and 
androgen levels. 
Adali et al. (2008) 42 PCOS and 42 HC PCOS=23.5  
HC= 24.4 
Cross-sectional study design 
Clinical measures: General Health Questionnaire (GHQ-
12) to measure psychiatric distress, BDI. 
Androgen measures: Total T, DHEA-S 
No significant correlation between mood (BDI) and 
androgen levels. 
Mansson et al 
(2008) 
 
49 PCOS and 49 HC Both groups-35.9 Cross-sectional study design 
Clinical measures: Mini International Neuropsychiatric 
Interview (MINI). 
Androgen measures: Total T, Free Androgen Index (FAI) 
(to estimate Free T). 
Total T and Free T levels not significantly correlated with 
Major Depressive Disorder (MDD) (including history of 
MDD) in PCOS group.  
FAI levels higher in PCOS group with a lifetime incidence 





117 PCOS (75 with 
depression, 42 
without depression) 
and 84 HC 
PCOS with depression- 
21.9 
Without depression- 21.1  
HC = 21-32 
Cross-sectional study design 
Clinical measures: PRIME-MD PHQ-9. 
Androgen measures: Total T. 
No significant difference in Total T levels between PCOS 




Table 5.1 Continued 
Study Study sample Mean age (yrs) Study design and key measures Key findings 
Jedel et al 
(2011) 
72 PCOS females: 35 
depressed and 37 
non-depressed 
28.5 Cross-sectional study design 
Clinical measures: Microneurography to measure 
sympathetic nerve activity (to measure affective 
symptoms), Comprehensive Psychopathological Rating 
Scale For Affective Syndrome to measure depression and 
anxiety, Montgomery-Asberg Depression Rating Scale 
(MADRS)-self rated for assessing mood and Brief Scale 
for Anxiety (BSA-A) 
Androgen measures: Total T, Free T, 
Dehydroepiandrosterone (DHEA), DHEA-S, A-dione, 
Androstenediol (A-Diol), Dihydrotestosterone (DHT). 
Lower Total T and Free T levels (and glucuronidated 
androgen metabolite -3G) (< 10 pg/ml) in PCOS females 
with higher scores on depression rating scale (MADRS-
S>11) (n = 35) compared with PCOS group with lower 
depression scale scores (n = 37). 
Binary logistic regression analyses showed significant 
negative correlation between Free T levels and depression 
(lower Free T and 3G levels associated with higher scores 
on MADRS-S(>11) 
No significant association between androgen levels and 
anxiety. 
Barry et al 
 (2011) 
76 PCOS and 49 
subfertile HC 
PCOS = 28.8  
HC = 35.1 
Cross-sectional study design 
Clinical measures: Hospital Anxiety and Depression 
Scale (HADS), and Polycystic Ovarian Syndrome 
Questionnaire (PCOS-Q) for assessing hyperandrogenic 
symptoms. 
Androgen measures: Total T 
No significant correlation between Total T levels and mood 
or anxiety in either group.  
 
Livadas et al 
(2011) 
130 females with 
PCOS ( 54 normal 
anxiety, 46 moderate 
anxiety 30 severe 
anxiety) 
Normal = 25.2  
Moderate = 25.9  
Severe = 2437 
Cross-sectional study design 
Clinical measures: STAI (Trait and State), BDI. 
Androgen measures: Total T, Free T, A-dione, DHEA-S, 
FAI. 
No significant correlation between mood (BDI) and 
androgen levels.  
Significant positive correlation between anxiety and FAI 
levels, higher STAI-S (not STAI-T) scores associated with 
higher FAI levels (significance value p < 0.05 between 
patients with normal and moderate anxiety). 
Pastore et al 
(2011) 
94 PCOS and 96 HC PCOS= 27.2  
HC= 30-34 
Cross-sectional study design 
Clinical measures: Quick Inventory of Depressive 
Symptomatology Self-Report (QIDS) 
Androgen measures: Total T, Free T, DHEA-S. 
Androgen levels not significantly correlated with 
depression in PCOS females. 






Cross-sectional study design 
Clinical measures: BDI, STAI, HADS, General Health 
Questionnaire (GHQ),  PCOS-Health Related Quality of 
Life (PCOS- HRQoL) (to assess emotions, hirsutism, 
weight, infertility and menstrual problems) 
Androgen measures: Total T, FAI. 
Significant positive correlation between FAI levels and 
mood (HADS not BDI) (higher FAI levels associated with 
higher score on depression sub-scale of HADS). 
Significant positive correlation between FAI levels and 
state anxiety (higher FAI levels associated with higher 




Table 5.1 Continued 
Study Study sample Mean age (yrs) Study design and key measures Key findings 
Moran et al. (2012) 54 PCOS females 
(National Institutes of 
Health (NIH) 
Criteria) N = 29 and 
non-NIH N = 25 
groups) and 27 HC 
NIH PCOS=32  
Non-NIH PCOS=33.4  
HC = 36.4  
 
Cross-sectional study design 
Clinical measures: Polycystic Ovarian Syndrome 
Questionnaire Health Related Quality of Life (PCOS-Q 
HRQoL) and HADS  
Androgen measures: Total T, FAI. 
Multivariate regression analyses showed FAI levels and 
age to significantly predict depression. 
No association between androgen levels and anxiety. 
Annagür et al.  
(2013) 
Total n = 73 
PCOS with: 
MDD (23), PCOS 
with Generalized 
Anxiety Disorder 
(GAD)(20) and PCOS 
with no psychiatric 
Diagnosis (ND)(30) 
MDD = 21.7  
GAD = 22.2  
ND = 21.9 
Cross-sectional study design 
Clinical measures: Structured Clinical Interview for 
DSM-IV (SCID-I)  
Androgen measures: Free T, DHEA-S. 
DHEA-S levels significantly higher in PCOS females with 
MDD and PCOS females with GAD group (no difference 
in androgen levels between these two psychiatric groups) 
compared with PCOS group with no psychiatric diagnosis. 
 
Milsom et al 
(2013) 
102 PCOS and 1349 
HC 
PCOS = 17  
HC = 14-19 
Cross-sectional study design (survey) 
Clinical measures: Reynolds Adolescent Depression 
Scale (RADS-2)  
Androgen measures: Total T 
No significant correlation between Total T levels and 




300 PCOS 26.56 yrs Cross-sectional study design 
Clinical measures:  HADS 
Androgen measures: Total T, FAI. 
Significantly higher FAI levels in depressed and anxious 
females with PCOS compared with PCOS females without 
symptoms of depression or anxiety. 
Rahiminejad et al. 
(2014) 
120 PCOS Mean age- 24 Cross-sectional study design  
Clinical measures: BDI 
Androgen measures: Total T 
No significant difference in Total T levels between 
depressed and non-depressed females with PCOS. 
No significant correlation between BDI and Total T levels. 
Klimczak et al 
(2015) 
60 PCOS divided into 
groups based on age 
(</> 27 years) and 
depression scores 
(PHQ9 and QIDS) 
(age-range 19-46) 
Median age- 27 
Cross-sectional study design 
Clinical measures: BDI, QIDS, PHQ9 
Androgen measures: DHEA-S, Total T, A-dione, FAI. 
 
No significant differences in androgen levels between 
depressed and non-depressed groups (QIDS and PHQ). 
 
Asik et al. (2015) 71 PCOS, 50 HC PCOS=22 
HC=24 
Cross-sectional study design 
Clinical measures: HADS 
Androgen measures: Total T, DHEA-S 
No significant correlations between mood and androgen 
levels in the entire sample 
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Table 5.1 Continued 
ABS- Affect Balance Scale, A-dione-Androstenedione, A-diol- Androstenediol ,BDI- Beck Depression Inventory, Bioactive T = Biologically Active Testosterone, BMI = Body Mass Index, BSA- Brief 
Scale for Anxiety , CES-D- Centre for Epidemiological Studies- Depression Rating Scale , COWAT- Controlled Oral Word Association Test , DHEA= Dehydroepiandrosterone, DHEA-
S=Dehydroepiandrosterone Sulfate, DSI- DeRogatis Symptom Inventory, FAI- Free Androgen Index, Free T- Free Testosterone, GHQ-12- General Health Questionnaire , HC = healthy controls,  HADS- 
Hospital Anxiety and Depression Scale,  HAM-A- Hamilton Rating scale for Anxiety, HAM-D- Hamilton Depression Rating Scale, ICD-10- International Classification of Diseases, MAACL- Multiple 
Affect Adjective Check List ,MADRS- Montgomery-Asberg Depression Rating Scale, MINI- Mini International Neuropsychiatric Interview, MMPI- Minnesota Multiphasic Personality Inventory,  
PRIME-MD PHQ- Primary Care Evaluation of Mental Disorders Patient Health Questionnaire, PCOS-Q- Polycystic Ovarian Syndrome Questionnaire, POMS- Profile Of Mood States, PCOS = 
Polycystic Ovarian Syndrome, , PL = placebo group, QIDS- Quick Inventory of Depressive Symptomatology, SCL-90-R- Symptom Checklist Survey 90 R, SCID-I- Structured Clinical Interview for 
DSM-IV, STAI- State-Trait Anxiety Inventory, Total T = Total Testosterone, VAS- Visual Analogue Scale, ZARS- Zung Anxiety Rating Scale. 
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Table 5.2  
Studies Examining the Relationship between Androgen Levels, Mood and Anxiety in Reproductive-aged Females without Polycystic Ovarian 
Syndrome (12 studies) 
Study Sample Mean age (yrs) Measure of Interest Key findings 
Shulman et al 
(1992) 
 
20 females with facial 
hirsutism 
27.5 Cross-sectional study design 
Clinical measures: DeRogatis Symptom Inventory (DSI) 
for general mental health symptoms and Affect Balance 
Scale (ABS) (with 4 negative and 4 positive mood states)  
Androgen measures: Total T, Free T, Bioactive 
Testosterone (Bioactive T), DHEA, DHEA-S, A-dione. 
Significant positive correlation between depression (DSI 
score) and Free T levels (higher Free T levels associated 
with higher depression scores).  
Significant correlations between Bioactive T levels and 
depression (ABS), with a negative correlation between 
Bioactive T and positive affect (ABS) and positive 
correlation between Bioactive T and negative affect. 
No significant association between androgens and anxiety 
levels. 
De Rogatis et al. 
(1993) 
20 females with 
idiopathic hirsutism 
27.5 Cross-sectional study design 
Clinical measures: DSI, ABS 
Androgen measures: Total T, Free T, Bioactive T, 
DHEA, DHEA-S, A-dione. 
Significant positive correlation between Free T and 
Bioactive T levels, depression (DSI and ABS) and phobic 
anxiety (DSI) (higher Free T levels associated with higher 
scores on depression rating scale and phobic anxiety sub-
scale). 
Significant negative correlation between Free T and 
Bioactive T levels and total positive affect score (ABS). 
No significant association between Total T, DHEA, 
DHEA-S and A-dione levels and mood or anxiety. 
Landen et al 
(2004) 
216 females with (n = 
31) and without (n = 
185) social anxiety 
Age range- 
41-42 
Cross-sectional study design 
Clinical measures: DSM-IV based self-report 
questionnaire to measure social anxiety and related 
psychiatric conditions including depressed mood, anxiety 
attacks, bulimia nervosa, obsessive-compulsive disorder 
and premenstrual dysphoric disorder. 
Androgen measures: Total T, Free T, DHEA-S. 
Total T levels significantly lower in social anxiety group 
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Miller et al.  
(2007) 
 
43 Females with 




26.3 Cross-sectional study design 
Clinical measures: Hamilton Depression Rating Scale  
(HAM-D), Hamilton Rating scale for Anxiety (HAM-A) 
Androgen measures: Total T and Free T 
Significant negative correlation between Total and Free T 
levels, and mood and anxiety severity in anorexic females, 
(lower levels of Total and Free T associated with higher 
anxiety (HAM-A>18) and higher depression scores (HAM-
D>12) compared with anorexic females without depression 
and anxiety.  
Step-wise regression analysis showed Free T levels to 
significantly predict depression and anxiety severity. 





(PCOS-7, non PCOS- 
16) and 30 HC 




Cross-sectional study design 
Clinical measures:  Structured Clinical Interview for 
DSM-IV TR (SCID II), MINI, Zanarini Rating Scale to 
assess BPD, HAM-D 
Androgen measures: Total T, FAI, DHEA-S, A-dione. 
Multiple regression analyses showed a significant positive 
correlation between symptoms of low mood (HAM-D) and 
FAI levels in BPD group (higher scores on HAM-D 
associated with higher levels of FAI), not significant after 
controlling for BMI. 
Total T, FAI and A-dione levels significantly elevated in 
BPD group. 
Zheleznova et al 
(2012) 
101 females with 
epilepsy and anxiety 
and/or depression   
29.43 Cross-sectional study design 
Clinical measures:  International Classification of 
Diseases (ICD-10), HADS, BDI to assess mood, Zung 
Anxiety Rating Scale (ZARS) to assess and anxiety and 
Symptom Checklist (SCL-90) Scale to measure 
psychopathological symptoms. 
Androgen measures: Testosterone (exact measure unspecified)* 
Significant negative correlation between T levels and 
depression and anxiety (higher T levels associated with 
lower scores on depression scale (HADS and SCL-90) and 
anxiety (HADS) in epileptic patients with mild depressive 
disorder (n = 58). 
Schutter et al 
(2017) 
76 healthy females 17.4 Cross-sectional study design 
Clinical measures- NEO-PI-R (self-report personality 
inventory to measure traits related to depression and anxiety). 
Androgen measures: Free T 
No significant correlation between T levels and anxiety and 
depression in females. 
Baischer et al 
(1995) 
 
20 depressed females 
and 10 HC 
32.5 Interventional study (T levels measured before and during 
clomipramine treatment for 4 weeks) 
Clinical measures: HAM-D 
Androgen measures: Total T 
At baseline, significantly elevated Total T levels in untreated 
depressed patients (HAM-D >14) compared with HC. 
Antidepressant treatment followed by decreased T levels in 
depressed patients. 
No significant differences in T levels between HC group 
and patient group post clomipramine treatment. 
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Wolkowitz et al 
(1999) 
10 females with MDD 
(5 in DHEA group, 5 





44 Double-blind placebo-controlled study design involving 
30 mg DHEA treatment for 6 weeks 
Clinical measures: HAM-D 
DHEA group showed significantly greater decrease in 
depression (HAM-D scores) compared with placebo group. 
Schutter et al 
(2005) 
14 healthy females 21.6 Randomised double-blind placebo-controlled crossover 
study design involving 0.5 mg T administration (with two 
testing sessions separated by 48 hours) 
Clinical measures: Profile Of Mood States (POMS: VAS 
version) to measure depression and anxiety following 
three hours of T administration. 
No significant differences in self-reported mood or anxiety 
following T administration compared with placebo 
condition. 
Dolan Looby et al 
(2009) 
25 HIV-infected 
females (with Free T 
levels below normal 
range), 13 under 
treatment and 12 in 
placebo group 
Treatment = 13 
Placebo = 12 
Randomised placebo-controlled trial  (involving active 
transdermal T administration (300 mcg twice weekly) 
over 18 months) 
Clinical measures: BDI 
Androgen measures: Total T, Free T. 
Significant improvement in mood (BDI indices) following 
18 months of T administration compared with placebo. 
Kumsar et al 
(2014) 
Females with (n = 52) 
and without (n = 30) 
major depression 
Depressed group- 31.3 
HC-33.1 
Interventional study involving SSRI anti-depressant 
treatment (50 mg Sertraline) for six weeks. 
Clinical measures: SCID-I, HAM-D. 
Androgen measures: Total T, Bioavailable (FAI). 
Pre-treatment Total T and FAI levels significantly lower in 
depressed group compared with HC. 
Significant increases in Total T and FAI levels following 
antidepressant treatment. 
No significant difference in post-treatment androgen levels 
between the two groups. 
ABS- Affect Balance Scale, A-dione-Androstenedione, A-diol- Androstenediol, BDI- Beck Depression Inventory, Bioactive T = Biologically Active Testosterone, BMI = Body Mass Index, BSA- 
Brief Scale for Anxiety , CES-D- Centre for Epidemiological Studies- Depression Rating Scale , DHEA= Dehydroepiandrosterone, DHEA-S=Dehydroepiandrosterone Sulfate, DSI- DeRogatis 
Symptom Inventory, FAI- Free Androgen Index, Free T- Free Testosterone, GHQ-12- General Health Questionnaire , HC = healthy controls, HRM = hormone group, HADS- Hospital Anxiety and 
Depression Scale,  HAM-A- Hamilton Rating scale for Anxiety, HAM-D- Hamilton Depression Rating Scale, ICD-10- International Classification of Diseases, MAACL- Multiple Affect Adjective 
Check List ,MADRS- Montgomery-Asberg Depression Rating Scale, MINI- Mini International Neuropsychiatric Interview, MMPI- Minnesota Multiphasic Personality Inventory, PRIME-MD PHQ- 
Primary Care Evaluation of Mental Disorders Patient Health Questionnaire, PCOS-Q- Polycystic Ovarian Syndrome Questionnaire, POMS- Profile Of Mood States, PCOS = Polycystic Ovarian 
Syndrome, , PL = placebo group, QIDS- Quick Inventory of Depressive Symptomatology, SCL-90-R- Symptom Checklist Survey 90 R, SCID-I- Structured Clinical Interview for DSM-IV, STAI- 
State-Trait Anxiety Inventory, Total T = Total Testosterone, VAS- Visual Analogue Scale, ZARS- Zung Anxiety Rating Scale,  *= Insufficient information about the study sample provided by the 
authors – contact with corresponding author of the study was attempted at least twice, with no response. 
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Table 5.3  
Cross-sectional Studies Examining the Relationship between Androgen Levels, Cognitive Function and Emotion Processing in Reproductive-
aged Females with and without Polycystic Ovarian Syndrome (21 studies) 
Study Study sample Mean age (yrs) Measures of Interest Main Findings 
Shute et al 
(1983) (Study 1 
and 2) 
Study 1: 
48 healthy females 
Study 2: 
12 females with 
highest and lowest 
androgen levels (n = 6 
each) (selected from a 







Cross-sectional study design 
Cognitive measures:  
Visuospatial ability: Six timed-tests from the French 
Reference Kit for Cognitive Factors (including 2 tests 
each from 3 factors namely flexibility of closure, spatial 
orientation and visualization)  
Androgen measures: Free T 
Study 2: 
Cross-sectional study design 
Cognitive measures: Visuospatial ability: Minnesota 
Paper Form Board Test (MPFB), Primary Mental 
Abilities Test (PMA) and Comprehensive Ability Battery 
Space Test (CAB-S) to measure Mental Rotation. 
Androgen measures: Free T 
Study 1: 
Regression analyses showed no significant correlation 
between Free T levels and spatial ability in females. 
Study 2: 
Significant difference between two groups in spatial 
performance with high-androgen group performing 
significantly better compared with low-androgen group on 
spatial visualisation (MFPB scores). 
 
McKeever et al 
(1987) 
19 left-handed and 23 
right-handed healthy 
females 
*Unspecified Cross-sectional study design 
Cognitive measures: Visuospatial ability- Stafford 
Identical Blocks Test, MPFB Test. 
Verbal Ability- Shipley Hartford Vocabulary Test 
Executive Function-Verbal Fluency Test. 
Androgen measures: Total T 
No significant correlation between spatial or verbal ability 
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46 females divided 
into high and low T 
groups. 
 
21.5 Cross-sectional study design with two test sessions (only 
baseline scores used) 
Cognitive measures:  
Visuospatial ability- Paper Folding, Mental Rotations 
Test (MRT) (Vandenberg & Kuse). 
Verbal ability- verbal articulation (Tongue-Twister Task) 
Psychomotor speed- Finding A’s Test and Identical 
Pictures Test (both from ETS kit of Factor-Referenced 
Cognitive Tests) 
Mathematical ability- Mathematics Aptitude Test 
General intelligence- Advanced Vocabulary Test 
Androgen measures: Free T 
Significantly better visuospatial ability performance (Paper 
Folding scores) in high T group compared with low T 
group. 
Multiple regression analysis found no significant 
correlations between T levels and cognitive performance.  
 
Hassler et al 
(1992) 
25 healthy females 18.77 Cross-sectional study design 
Cognitive measures: Visuospatial ability-Spatial 
Relations Test, Hidden Pattern Test, and Witelson’s 
Dichaptic Stimulation Test. 
Executive function- verbal fluency measured by German 
version of Primary Mental Abilities Test. 
Androgen measures: Total T 
Total T levels not significantly correlated with cognitive 
function. 
 
Phillips et al 
(1992) 
25 healthy females 24 Repeated-measures study (females tested in menstrual 
and luteal phase in a counterbalanced manner)  
Clinical Measures: Multiple Affect Adjective Check List 
(MAACL) to measure anxiety and mood  
Cognitive tests: 
Verbal Memory- Wechsler Memory Scale including four 
sub-scales-Logical memory/Paragraph Recall, Visual 
Reproduction, Associate Learning  
Executive function- Digit Span. 
Androgen Measure: Free T. 
Free T levels significantly negatively correlated with verbal 
memory (lower levels of Free T within luteal phase 
associated with better performance) in delayed recall of 
paragraphs. 
No significant correlation between mood (MAACL scores) 
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23 Cross-sectional study design 
Cognitive measures: 
Visuospatial ability: Paper Folding Test (PFT) and MRT 
Executive Function: verbal fluency measured by 
Controlled Associations Test and Controlled Oral Word 
Association Test (COWAT) 
Androgen measures: Free T 
Free T levels significantly positively correlated with spatial 
ability (Spatial Composite: MRT and PFT composite score) 
in females (only in right-handed females). 
Janowsky et al 
(1998) 
30 healthy females 29.8 Longitudinal study design with two test sessions during 
mid-luteal phase  
(with a gap of four weeks) 
Clinical measures: Geriatric Depression Scale  
Cognitive measures: 
General intelligence- Vocabulary subtest of Wechsler 
Adult Intelligence Scale (WAIS) 
Spatial ability- Block Design test (WAIS-R), Card 
Rotation task. 
Verbal and visuospatial memory- Toy Task  
Executive function- verbal fluency measured by Letter 
Fluency and Category Fluency Task. 
Psychomotor speed-Grooved Pegboard Test to assess fine 
motor dexterity and speed and Dart Throwing to assess 
visual-motor skills.  
Androgen measures: Free T. 
No significant correlations between Free T levels and 
visuospatial or verbal ability across both sessions. 
Psychomotor speed (Dart-throwing performance) 
significantly positively correlated with Free T levels in 
females using their dominant hand (significantly negatively 
correlated with use of non-dominant hand). 
 
Neave et al 
(1999) 




Cross-sectional study design 
Cognitive measures:  
Visuospatial ability- MRT, Water-Level Test. 
Executive function- Verbal Fluency Test, Verbal 
Associations Test.  
Androgen measures: Free T 
No significant association between Free T levels and 
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Hausmann et al 
(2000) 
12 healthy females 29.1 Longitudinal study design with counterbalanced blood 
samples collected over 3-day intervals over 6 weeks) 
Cognitive measures:  
Visuospatial ability- Revised Vandenberg and Kuse’s 
MRT (I and II), Mirrors Pictures Test (2D MRT), Hidden 
Figures Test. 
Androgen measures- T (unstated) 
Stepwise multiple regression and partial correlation showed 
significant positive correlations between T levels and 
spatial ability (MRT) for both sessions.  
 
Halari et al 
(2005) 
42 healthy females 27.7 Cross-sectional study design 
Cognitive measures:  
General intelligence-Verbal Ability -Vocabulary subtest 
of WAIS-R  
Verbal learning and memory and ability- Working 
Memory Task. 
Visuospatial ability- Mental Rotations Test, 
Computerized Benton Judgement of Line Orientation 
Task. 
Executive function- Phonological Fluency, Category 
Fluency. 
Inhibition Task (with five forward and backward 
conditions)  
Androgen measures: Total T, FAI, Free T (estimated 
from FAI). 
No significant correlations (partial and curvilinear) between 
Total T or Free T levels and cognitive function. 
Falter et al 
(2006) 
22 healthy females and 
disembedding data of 
12 females from 
another testing set 
24.12 Cross-sectional study design 
Cognitive measures: 
Visuospatial ability: Shepard and Metzler’s MRT, Figure-
disembedding Task (to measure the ability to find a 
smaller simpler form of a larger complex picture), 
Targeting Task (to measure speed of object-localisation) 
and Perceptual Discrimination Tasks (control) to measure 
object recognition ability. 
Androgen measures: Free T 
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Burkitt et al 
(2007) 
40 healthy females 
divided into high T 
(n = 19) and low T 
(n = 18) groups 
 
19.85 Cross-sectional study design (with T levels measured before and 
after counterbalanced cognitive testing) 
Cognitive measures:  
Visuospatial ability: Vandenberg and Kuse’s MRT, Virtual Water 
Maze Task (vWM)  
Androgen measures: Free T 
Low Free T group performed significantly worse on 
Block 2 of Virtual Water Maze Task (average of 






28 PCOS and 20 
HC 
PCOS = 27.7  
HC = 26 
Cross-sectional study design 
Clinical measures: POMS-Bipolar Form to measure mood. 
Cognitive measures: 
General intelligence -Vocabulary subtest of WAIS-III 
Visuospatial ability- Vandenberg and Kuse’s MRT, Paper Folding 
Test, Water Level Test (Spatial perception) 
Visuospatial Learning and Memory: Block-Tapping  Task(forward 
and backward span) 
Verbal learning and memory- RAVLT, Logical Memory, Paired 
Associates Test 
Executive function- COWAT, Category Fluency, Digit Span 
(forwards and backwards),  
Psychomotor speed- Finding A’s, Purdue Pegboard to measure 
perceptual speed and manual dexterity 
Androgen measures: 
Total T, Free T (estimated by FAI value), FAI. 
FAI levels significantly negatively correlated with 
psychomotor speed (total scores on Purdue Pegboard) 
No other significant correlations between androgen 
levels and mood or cognitive function in PCOS and 
HC groups.  
 
Gomez-Gil et al 
(2009) 
33 FM transsexuals 
 
Longitudinal- 27.4  
Cross-sectional- 
Off T treatment-23.7  
On T treatment- 27.7 
Longitudinal (with a 6 month gap involving T treatment between 
testing sessions, n = 14) and cross-sectional study design (with 
patients on(n = 9) and off (n = 10) T treatment for at least 6 
months)  
Cognitive measures:  
Verbal memory- Logical memory Test (Wechsler Memory Scale-
Revised) 
Visuospatial memory- Visual Paired Associates Test (Wechsler 
Memory-Scale) and Rey-Osterrieth Complex Figure Test (ROCF). 
Androgen measures: Total T, Free T 
Significant improvement in one aspect of visuospatial 
memory (Visual Paired Associates 1-immediate 
recall) following androgen treatment over 6 months 
but no significant differences on another measure of 
spatial memory(ROCF performance) or verbal 
memory (Logical Memory Test). 
In cross-sectional aspect of study, significantly better 
scores on visuospatial memory (Visual Paired 
Associates 1-immediate recall and ROCF: copy and 
delayed recall) in T group but no significant 
differences between groups on verbal memory. 
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Puts et al 
(2010) 
160 healthy females 20.43 Cross-sectional study with a within-subjects design (involving 2 
testing sessions) 
Cognitive measures:  
Visuospatial ability- Vandenberg and Kuse’s 3-D MRT 
Androgen measures: 
 Free T 
Free T levels not significantly correlated with within-
sex variation in spatial performance. 
Regression analyses showed Free T levels did not 
significantly predict spatial ability performance 
(MRT scores). 
Between-session improvement in MRT scores 
unrelated to Free T levels. 
Durdiakova et al 
(2012) 
 
9 healthy females 25.6 Cross-sectional study design (examining effect of cognitive task on 
T levels with 2 samples of T before and after MRT)  
Cognitive measures: 
Visuospatial ability: MRT 3-D Tetris game  
Androgen measures: Total T 
No correlation between baseline T levels and spatial 
ability (MRT total score) 
T levels significantly decreased following spatial task 
(MRT) in 8 of 9 females. 
Barry et al 
(2013) 





and 41 HC with 
comparable 
subfertility 
PCOS- 29  
HC-35 
Cross-sectional study design  
Cognitive measures: 
General intelligence-Vocabulary task  
Visuospatial Ability: 3-D MRT   
Androgen measures: Total T 
Significant positive correlation between Total T 
levels and visuospatial ability (3-D MRT) in PCOS 




24 Mothers of children 
with ASD (caregivers) 
and 22 non-caregivers 
(mothers of normal 
children) (HC) 
45 Cross-sectional study design 
Clinical measures: STAI-S and POMS. 
Cognitive measure: Verbal learning and memory: RAVLT 
Androgen measure: Free T (measured pre-and post RAVLT) 
Curvilinear relationship between Free T levels and 
verbal memory (RAVLT) in caregivers with increases 
in T levels significantly correlated with better verbal 
memory, up to a certain point followed by decreased 
performance with increasing T levels.  
In caregivers, high baseline Free T levels correlated 
with larger number of words remembered (better verbal 
memory performance) in List A Trial III.  
No significant associations found between Free T levels 
and other RAVLT measures. 
No correlation between Free T levels and cognitive 
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Hussain et al.  
(2016) 
45 healthy females 30.31 Cross-sectional study design 
Cognitive measures: 
General intelligence- Test for Non-Verbal Intelligence-3 
Verbal memory- RAVLT 
Visuospatial ability- Virtual Navigation Task 
Androgen measures: Total T 
Total T levels not significant correlated with spatial or 
verbal memory. 
Van Honk et al 
(1999) 
 
16 healthy females 22 Cross-sectional study design with multiple salivary 
measurements of T preceding mood and cognitive assessment. 
Clinical measures: POMS, VAS  
Emotion Processing measure: Emotional Stroop task to measure 
attention (Pictures of Facial Affect including neutral and angry 
faces). 
Androgen measure: Free T 
T sample collected six hours before assessment 
significantly positively correlated with facilitation 
interference (attending away from anger faces on the 
Emotional Stroop task).  
No significant association between T samples at other 
time points and emotion processing. No significant 
correlation between T levels (sampled at all three time 
points) and scores on depression rating scale (POMS). 
Stanton et al 
(2009) 
14 healthy females 20.96 Cross-sectional study design 
Clinical measures: fMRI to measure amygdala and ventromedial 
prefrontal cortex BOLD responses to anger faces  
Emotion Processing measure: Face Stimulus Test: Facial 
expressions including task 1 with passive viewing of emotional 
faces and task 2 involving an oddball task while viewing anger 
and neutral faces.  
Androgen measure: Free T 
Regression analyses showed no significant correlation 
between Free T levels and amygdala or ventromedial 
prefrontal cortex BOLD response involved in emotion 
processing. 
ABS- Affect Balance Scale, A-dione-Androstenedione, A-diol- Androstenediol ,BDI- Beck Depression Inventory, Bioactive T = Biologically Active Testosterone, BMI = Body Mass Index, BSA- Brief 
Scale for Anxiety , CAB-S- Comprehensive Ability Battery Space Test, CES-D- Centre for Epidemiological Studies- Depression Rating Scale , COWAT- Controlled Oral Word Association Test , DEFT- 
Dynamic Facial Expression Task, DHEA= Dehydroepiandrosterone, DHEA-S=Dehydroepiandrosterone Sulfate, DSI- DeRogatis Symptom Inventory, FAI- Free Androgen Index, Free T- Free 
Testosterone, GHQ-12- General Health Questionnaire , HC = healthy controls, HRM = hormone group, HADS- Hospital Anxiety and Depression Scale,  HAM-A- Hamilton Rating scale for Anxiety, 
HAM-D- Hamilton Depression Rating Scale, ICD-10- International Classification of Diseases, MAACL- Multiple Affect Adjective Check List , MADRS- Montgomery-Asberg Depression Rating Scale, 
MINI- Mini International Neuropsychiatric Interview, MMPI- Minnesota Multiphasic Personality Inventory, MRT–Mental Rotations Test, PRIME-MD PHQ- Primary Care Evaluation of Mental 
Disorders Patient Health Questionnaire, PCOS-Q- Polycystic Ovarian Syndrome Questionnaire, POMS- Profile Of Mood States, PCOS = Polycystic Ovarian Syndrome, , PL = placebo group, PMA- 
Primary Mental Abilities Test, QIDS- Quick Inventory of Depressive Symptomatology, ROCF-Rey-Osterrieth Complex Figure Test, RMET- Reading the Mind in the Eyes Task, , SCL-90-R- Symptom 
Checklist Survey 90 R, SCID-I- Structured Clinical Interview for DSM-IV, STAI- State-Trait Anxiety Inventory, Total T = Total Testosterone, VAS- Visual Analogue Scale, vWm- Virtual Water Maze 
Task, WAIS- Vocabulary subtest of Wechsler Adult Intelligence Scale, , ZARS- Zung Anxiety Rating Scale,  *= Insufficient information about the study sample provided by the authors – contact with 
corresponding author of the study was attempted at least twice, with no response.
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Table 5.4  
Interventional Studies Examining the Relationship between Androgen Levels, Mood, Anxiety, Cognitive Function and Emotion Processing in 
Reproductive-Aged Females with and without Polycystic Ovarian Syndrome (19 studies) 
Study Study sample Mean Age (yrs) Interventional studies: Measures of interest and 
study design 
Key findings 




25.7 Longitudinal study design with cross sex hormone 
treatment involving T administration for 3 months  
Cognitive measures: 
General Intelligence (verbal ability) measured by 
Verbal Reasoning Test  
Visuospatial ability- Rotated Figures Test,  
Executive function -Verbal Fluency measured by 
Word Production and Sentence Production Test. 
Significant improvement in visuospatial ability (Rotated 
Figures Test), worse executive function (verbal fluency) and 
no significant change in verbal ability following T 
administration. 
 
Van Goozen et al 
(1995) 
35 FM ,15 male-to 
female (MF) 
transsexuals, 20 HC 





Longitudinal study design involving cross sex 
hormone treatment (T or oestrogen administration)  
with two test sessions separated by 12 weeks 
Clinical measures: Diary for measuring mood 
Cognitive measures: 
General Intelligence (verbal ability) measured by 
Verbal Reasoning Test.  
Visuospatial Ability-Card Rotation Task  
Executive Function- verbal fluency- Word 
Production and Sentence Production Test 
Significantly better visuospatial ability (Card Rotation) and 
worse executive function (verbal fluency-Word Production) 
performance following T administration in FM group. 
Significantly decreased spatial ability performance and 
improved verbal fluency (Sentence production) in MF 
transsexuals following anti-androgen treatment. 
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study design 
Key findings 
Slabbekoorn et al 
(1999)  
25 FM transsexuals 
and 20 MF 
MF- 29.1 
FM- 26 
Longitudinal study design involving cross-sex 
hormone treatment (androgen and antiandrogen 
(Cyproterone Acetate CPA)) with oestrogen 
treatment with testing sessions separated by baseline, 
3, 12, and 18 months. 
Cognitive measures: 
General Intelligence (verbal ability) measured by 
Verbal Reasoning Test  
Visuospatial ability – Rotated Figures (2-D and 3-D), 
Hidden Figures Task.  
Executive Function- verbal fluency-  Words (VF-W) 
Task (adapted from Gordon et al., 1986) ,Sentences( 
FV-S) Task 
Psychomotor speed- Fine Motor Movement Task to 
measure manual dexterity and Perceptual Speed (Test 
D2) Task. 
T administration (after a gap of 18 months) followed by 
improved spatial ability (3-D Rotated Figures and Hidden 
Figures task), no deteriorating effect of T administration on 
verbal fluency or psychomotor speed in FM transsexuals. 
Anti-androgen treatment followed by no significant changes 




15 healthy females 
divided into two 
groups: placebo - T 
administration (n = 8) 
and T-placebo(n = 7) 
23.6 Double-blind  placebo-controlled counterbalanced 
cross-over study design involving 0.5 mg T 
administration separated by four weeks  
Cognitive measures: 
 Visuospatial learning and memory- Spatial Memory 
Stimulus with 3 conditions: Object-Location Memory 
(three conditions to measure selective aspects of 
memory: Positional Reconstruction, Object-to-
position assignment, and Combined Condition 
Tasks). 
In the first two conditions (Object-to-position and the 
Positional Reconstruction condition), the effect of T 
administration, delay of recall and interaction effect between 
T and delay of recall not significant.  
Significantly better performance in combined condition (after 
three-minute delay in recall) following T administration 
compared with placebo  
Separate t-tests for immediate and delayed recall scores 
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study design 
Key findings 
Van Goozen et al 
(2002) 
 
19 FM, 22 MF, 23 HC 
females, 20 HC males 
FM- 26.2 
MF- 31.4 
Longitudinal study design involving cross-sex 
hormone treatment with androgen or antiandrogen 
(CPA with Estradiol) treatment (over a span of 14 
weeks) 
Cognitive measures: 
General intelligence (verbal ability) measured by 
Verbal Reasoning Test  
Visuospatial ability- Line Orientation Test, Rotated 
Figures (RF) (2-D and 3-D), Targeted Throwing 
(spatial-motor) Task. 
No change in visuospatial ability following androgen or anti-
androgen treatment in either group. 
 
Aleman et al 
(2004) 
26 healthy females: T-
placebo (n = 14) and 
placebo-T (N = 12) 
administration 
Age range- 20- 32  
 
Double-blind placebo-controlled cross-over study 
design with 0.5 mg T administration  
Cognitive measures: Visuospatial ability -
Vandenberg and Kuse’s 3-D MRT (including four 
test drawings, where subjects are asked to identify 
two of the four test drawings depicted the target 
drawing in rotated positions). 
Significantly improvement in visuospatial ability (MRT) 
following single T administration compared with placebo 
condition. 
Significant difference between T and placebo condition with 
better MRT scores for placebo-T but not T-placebo condition. 
Miller et al 
(2005) 
33 anorexic females 
with relative T 
deficiency divided into 
two groups- 
T (n = 24) and 
placebo (n = 9) 
T - 25 
Placebo-22 
 
Randomized double-blind placebo-controlled trial 
with T administration (0.15 mg or 0.3 mg daily) for 3 
weeks. 
Clinical measures: BDI 
Cognitive measures: Visuospatial ability- 
Vandenberg and Kuse’s 3-D MRT  
Androgen measures: Total T, Free T, DHEA-S. 
At baseline, significant negative correlation between Free T 
levels and depression (BDI) and significant positive 
correlation between Free T levels and spatial ability (3-D 
MRT). 
Significant improvement in visuospatial ability following T 
administration compared with placebo condition.  
Significant improvement in mood in T group following 3 
weeks of T administration compared with placebo which 
showed no change. 
Forward stepwise regression analysis showed T and placebo 
condition to be the only significant factors to predict change 
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19 hirsute females 
with PCOS randomly 
assigned to receive 
anti- androgen 
treatment (AA) (n = 8) 
and  placebo(n = 11) 
Placebo-26.8 
Treatment-26.6 
Randomised double-blind placebo-controlled study 
design involving anti-androgen administration (50 
mg Cyproterone acetate (CPA) and oestrogen for 3 
months 
Clinical measures: POMS-Bipolar Form 
Cognitive measures: 
Visuospatial ability- Mental Rotations, Paper Folding 
(spatial visualisation), Water Level (spatial 
perception) Test 
Verbal ability- Vocabulary subtest of WAIS-III  
Verbal learning and memory- Rey Auditory Verbal 
Learning Test (RAVLT), Logical Memory Test, 
Paired Associates Test 
Executive function- verbal fluency measured by 
COWAT, Category Fluency Test, Digit Span 
(forwards and backwards), Block-Tapping (forward 
and backward span) Test 
Psychomotor speed- Finding A’s, Purdue Pegboard 
Androgen measures: Total T, Free T, FAI. 
Significant improvement in verbal fluency (COWAT) 
performance following anti-androgen treatment in PCOS 
females, however, follow-up (lower) FAI levels unrelated to 
COWAT performance. 
No significant change in visuospatial ability, executive 
function (Block Tapping) verbal memory, psychomotor speed 
(manual dexterity and speed) following anti-androgen 
treatment.  
Post-treatment FAI levels significantly negatively correlated 
with spatial visualisation (Paper Folding test) and verbal 
learning and memory (Paired Associates test). 
No significant differences in mood between groups or across 
testing times. 
Pintzka et al 
(2016) 
42 healthy females 




Randomised  double-blind placebo-controlled study 
design with 0.5 mg of T administration  
Cognitive measures:  
Visuospatial learning and memory -Virtual 
Environment (VE) Learning and Navigating Task, 
Sense of Direction Questionnaire Short-Form to 
measure navigational strategies 
Visuospatial ability-Vandenberg and Kuse’s MRT, 
fMRI stimuli with a self-paced Block Design Task. 
Androgen measures: Total T, A-dione, DHEA-S. 
T group performed significantly better on spatial ability 
(MRT) and showed significantly better visuospatial learning 
(representation of direction (VE)) compared with placebo, 
however, no change following T administration on navigation 




Table 5.4 Continued 
Study Study sample Mean Age (yrs) Interventional studies: Measures of interest and 
study design 
Key findings 
van Honk et al 
(2005) 
16 healthy females Age-range- 
19- 26 
Randomised double-blind  placebo-controlled cross-
over study design with 0.5 mg T administration (two 
days apart) 
Clinical Measures: STAI, POMS, Carver and 
White’s Behavioural Inhibition Scale (BIS) to 
measure short-term changes in anxiety  
Emotion processing measure: Masked Emotional 
Stroop Task (Pictures of Facial Affect) to measure 
unconscious emotional response to fearful faces. 
Vigilant emotional response to masked fearful faces observed 
in placebo condition. 
Significant decrease in attentional bias for unconsciously seen 
(masked) fearful facial expressions following T 
administration compared with placebo condition.  
No change in response to happy faces.  
No significant difference in self-reported anxiety (STAI) and 
mood (POMS) between placebo and T conditions. 
Van Honk et al. 
(2007)  
16 healthy females  Age range- 19-26 Double-blind within-subjects placebo-controlled 
cross-over study design with 0.5 mg T administration 
or placebo 
Clinical Measures: POMS 
Emotion Processing measure: Emotion-Recognition 
Task 
 
Testosterone administration followed by reduced sensitivity 
to consciously recognising anger faces compared with 
placebo.  
No significant effect of testosterone on faces of fear or 
disgust. 
No significant difference between testosterone and placebo 
conditions on mood. 
Hermans et al 
(2007) 
20 healthy females Age-range-18-23 Randomised double-blind placebo-controlled mixed-
factorial cross-over study design with 0.5 mg T 
administration  
Clinical measures: 
STAI (Trait) and the computerised version of POMS 
(for measuring mood and anxiety) and VAS of the 
Self-Assessment Manikins (to measure subjective 
experience of the stimuli such as valence and 
arousal), skin conductance and cardiac responses. 
Emotion processing measure: International Affective 
Picture System photoset with emotional content 
(including three valence categories: negative, neutral 
and positive) 
Lower skin conductance responses and reduced affective 
startle response to negative valence pictures in high-trait 
anxiety participants following T administration. 




Table 5.4 Continued 
Study Study sample Mean Age (yrs) Interventional studies: Measures of interest and 
study design 
Key findings 
van Wingen et al 
(2009) 
42 healthy females 




females with lower 





Experimental  group = 
42  
HC = 23 
Double-blind placebo controlled  cross-over study 
design involving 0.9 mg T administration (in middle-
aged females) with two test sessions 
Clinical measures: fMRI to measure amygdala response 
during facial emotional face matching task, Mood Rating 
Scale and STAI to assess mood and anxiety. 
Emotion processing measure: Blocked Design Task 
including an emotional and visuo-motor control 
condition. 
Androgen measures: Total T, DHEA-S, DHT. 
Increased amygdala reactivity following T administration in 
experimental group during emotional condition compared 
with visuo-motor control condition of behavioural task. 
No significant effect on accuracy of responses or reaction 
time on emotion processing (behavioural task) following T 
administration. 
T levels not correlated with mood, anxiety or cognitive 
function. 
Van Honk et al 
(2011) 
16 healthy females 21 Double blind placebo-controlled within-subjects  
cross-over study design with 0.5 mg T administration 
(or placebo with a 48 hr gap) 
Clinical measures- POMS 
Emotion processing measure: Reading the Mind in 
the Eyes Test (RMET (computerised adaptation) to 
assess facial emotion processing 
Androgen measures: Free T 
T administration followed by significant decrease in facial 
emotion processing (RMET) compared with placebo. 
Significant negative correlation between Free T levels and R-
MET in placebo condition. 
T levels unrelated to self-reported mood. 
Terburg et al 
(2012) 
20 healthy females Age-range 
20-25 
Longitudinal placebo-controlled counterbalanced 
study design with 0.5mg T administration for one week. 
Clinical measures: POMS (VAS version) 
Emotion processing measure: Social dominance task 
including 30 stimuli including angry, happy and 
neutral facial expressions 
Significant reduction in gaze aversion (slower gaze aversion/ 
higher attendance) related to unconsciously shown anger 
faces following T administration compared with placebo 
condition.  
No effect of T administration on self-reported mood states. 
Bos et al.  
(2013) 
12 healthy females 20.4 Double-blind placebo-controlled counterbalanced  
cross-over design with T administration (0.5mg)   
Clinical measures- fMRI to measure response to 
emotional expressions, STAI. 
Emotion processing measure: Dynamic Facial 
Expression Task (DEFT), with fear (experimental 
condition) and happy (control condition) faces. 
Increased and equal amygdala response to both fear and 
happy (control) faces (no selective effect on fear response) 
following T administration compared with placebo. 
No association between baseline testosterone levels and 
amygdala response to fear faces. 
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Androgen measures: Free T 
Table 5.4 Continued 
Study Study sample Mean Age (yrs) Interventional studies: Measures of interest and 
study design 
Key findings 
Enter et al 
(2015) 
18 females with Social 
Anxiety Disorder 
(SAD) and 19 HC. 
SAD- 23.1 
HC- 25.2 
Randomised double-blind placebo-controlled cross-
over study design with 0.5 mg T administration on 
two separate days) 
Clinical measures: MINI (screening), BDI and the 
Liebowitz Social Anxiety Scale, Gaze avoidance 
indexed by relative reduction of initial gaze fixations 
on the eye-region measured by eye-tracker 
Emotion processing measure: Face stimuli (NimStim 
set of facial expressions) including angry, happy and 
neutral facial expressions. 
Lower baseline T levels in SAD group compared with HC. 
Significant increase in first fixations towards the eye-region 
of facial stimuli (reduced gaze avoidance, initially observed 
in placebo condition) in SAD group, not in HC following T 
administration. 
Significant effect of T on angry faces; not on other emotional 
expressions in the SAD group. 
No significant changes in emotion processing following either 
T or placebo condition in HC group. 
Bos  et al. (2016) 16 healthy females 20.8 Randomised double-blind placebo- controlled 
counterbalanced cross-over study design with 0.5 mg 
T administration  
Clinical and Emotion processing measures: fMRI, 
Empathy Quotient Test, Systemizing Quotient 
Revised, POMS, RMET  
Androgen measures: Free T 
Significant reduction in connectivity between the left inferior 
frontal gyrus (IFG) (activated during RMET) and the anterior 
cingulate cortex and the supplementary motor area following 
T administration during the facial emotion processing task (R-
MET) compared with placebo. 
No change in emotion processing (RMET) or self-reported 
mood (POMS) following T administration. 
Olsson et al 
2016 
33 healthy females 26.9 Randomised double-blind placebo controlled study 
design with T administration 
Emotion processing measure: RMET 
Decreased accuracy in inferring emotional states (RMET) 
following T administration compared with placebo condition. 
ABS- Affect Balance Scale, A-dione-Androstenedione, A-diol- Androstenediol ,BDI- Beck Depression Inventory, Bioactive T = Biologically Active Testosterone, BMI = Body Mass Index, 
BSA- Brief Scale for Anxiety , CES-D- Centre for Epidemiological Studies- Depression Rating Scale , COWAT- Controlled Oral Word Association Test , DEFT- Dynamic Facial Expression 
Task, DHEA= Dehydroepiandrosterone, DHEA-S=Dehydroepiandrosterone Sulfate, DSI- DeRogatis Symptom Inventory, FAI- Free Androgen Index, Free T- Free Testosterone, GHQ-12- 
General Health Questionnaire , HC = healthy controls, HRM = hormone group, HADS- Hospital Anxiety and Depression Scale,  HAM-A- Hamilton Rating scale for Anxiety, HAM-D- Hamilton 
Depression Rating Scale, ICD-10- International Classification of Diseases, MAACL- Multiple Affect Adjective Check List ,MADRS- Montgomery-Asberg Depression Rating Scale, MINI- 
Mini International Neuropsychiatric Interview, MMPI- Minnesota Multiphasic Personality Inventory, MRT–Mental Rotations Test, PRIME-MD PHQ- Primary Care Evaluation of Mental 
Disorders Patient Health Questionnaire, PCOS-Q- Polycystic Ovarian Syndrome Questionnaire, POMS- Profile Of Mood States, PCOS = Polycystic Ovarian Syndrome, , PL = placebo group, 
QIDS- Quick Inventory of Depressive Symptomatology, ROCF-Rey-Osterrieth Complex Figure Test, RMET- Reading the Mind in the Eyes Task, , SCL-90-R- Symptom Checklist Survey 90 
R, SCID-I- Structured Clinical Interview for DSM-IV, STAI- State-Trait Anxiety Inventory, Total T = Total Testosterone, VAS- Visual Analogue Scale, vWm- Virtual Water Maze Task, 
WAIS- Vocabulary subtest of Wechsler Adult Intelligence Scale, , ZARS- Zung Anxiety Rating Scale. 
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5.3.1 Cross-sectional Studies Relating Mood/Anxiety to Androgen Levels in PCOS 
Samples  
5.3.1.1  Study and patient characteristics 
Twenty-one studies were identified. All studies examined mood in PCOS samples, and 14 of 
21 studies included a healthy control group. Ten of 21 studies measured anxiety as well as 
symptoms of depression. Most studies with a control group reported higher levels of depression 
and/or anxiety in their PCOS group compared with healthy control participants, with the 
exception of two studies (Milsom, Nair, Ogilvie, Stewart, & Merry, 2013; Pastore, Patrie, 
Morris, Dalal, & Bray, 2011). All 21 studies used a cross-sectional design. 
5.3.1.2 Symptoms of depression and androgen levels 
Free Testosterone and Free Androgen Index (FAI): Free Testosterone and FAI levels were 
measured in 12 out of 21 studies.  
Five studies found a significant association between FAI or Free Testosterone levels and mood 
(Bazarganipour et al., 2013; Cinar et al., 2011; Jedel et al., 2011; Moran, Deeks, Gibson-Helm, 
& Teede, 2012; Weiner et al., 2004). Three studies found an association between higher 
androgen (FAI) levels and higher symptoms of depression (n = 580), two others found a 
negative (n = 35) and curvilinear (n = 27) association respectively, while the remaining seven 
studies found no significant relationship between mood and androgen levels (n = 541). 
Three studies (two using correlational analyses and one using comparative analysis) found a 
significant positive association between FAI levels and symptoms of depression. A large study 
including 226 females found that higher FAI levels were associated with greater depression 
severity measured by the Hospital Anxiety and Depression Scale (HADS) (r = 0.321, p < 0.05) 
but not with the Beck Depression Inventory (BDI) (n = 226) (Cinar et al., 2011). Similarly, 
Moran et al. (2012) found higher FAI levels (and age) to be significantly associated with greater 
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depression severity (HADS) (multivariate regression showed log-transformed FAI levels (r = 
0.38, p = 0.003) to significantly predict depression levels) in a sample of 54 females with PCOS. 
In another large study (Bazarganipour et al., 2013) significantly higher FAI levels were 
observed in females with PCOS with symptoms of depression (HADS) (13.15 ± 46.99) 
compared with females with PCOS but without symptoms of depression (9.47 ± 30.60) (p < 
0.05) (total n = 300).  
In contrast, Jedel et al. (2011) found significantly lower Free Testosterone levels in PCOS 
females with higher depression rating-scale scores (Montgomery-Asberg Depression Rating 
Scale; MADRS > 11) (n = 35) compared with non-depressed PCOS females (p = 0.025) (n = 
37). Regression analysis showed a significant negative correlation between Free Testosterone 
levels and mood (lower Free Testosterone levels associated with higher scores on MADRS). 
Although Weiner et al. (2004) did not find a significant correlation between mood (State-Trait 
Depression Adjective Check List) and Free Testosterone levels in their PCOS group, a 
curvilinear relationship was found between mood and Free Testosterone levels across the entire 
sample including PCOS (n = 27) and healthy control females (n = 27). Highest mood symptom 
scores were found at mid-range of testosterone levels in this study.  
Seven remaining studies (n = 541) did not find a significant relationship between Free 
Testosterone or FAI levels and mood (scales used comprised of the Structured Clinical 
Interview for DSM-IV (SCID-I), BDI, QIDS, PHQ9, MINI, CES-D) (Annagür et al., 2013; 
Hollinrake, Abreu, Maifeld, Van Voorhis, & Dokras, 2007; Klimczak, Szlendak-Sauer, & 
Radowicki, 2015; Livadas et al., 2011; Mansson et al., 2008; Pastore et al., 2011; Rasgon et al., 
2003). This is in accord with a meta-analysis, which in a meta-regression, showed no 
relationship between depression in PCOS and Free Testosterone or FAI levels characteristic of 
PCOS (Cooney et al., 2017). In this analysis, no evidence was found that Free Testosterone/FAI 
levels were higher in women with PCOS and concurrent depression. However, this analysis did 
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not include all of the studies reviewed above since it excluded studies without a control group 
among other exclusion criteria which included: 1) studies that used self-report measures for 
PCOS symptoms, 2) studies which recruited adolescents with PCOS (included in the current 
review (Milsom et al., 2013)), 3) studies that did not report mean BMI in both groups, or, 4) 
studies that did not report prevalence of depression or anxiety but reported mean scores.  
Total Testosterone: Total Testosterone was assessed by 19 out of 21 studies in this section, 
with only one study finding a significant association between Total Testosterone and symptoms 
of depression. Jedel et al. (2011) found lower Total Testosterone levels to be associated with 
greater depression severity (MADRS) in PCOS females with depression compared with PCOS 
females with lower MADRS scores (n = 37).  
DHEA/DHEA-S: DHEA/DHEA-S levels were measured in 10 studies (Adali et al., 2008; 
Annagür et al., 2013; Asik et al., 2015; Hollinrake et al., 2007; Jedel et al., 2011; Klimczak et 
al., 2015; Livadas et al., 2011; Pastore et al., 2011; Rocco et al., 1991; Soyupek et al., 2008). 
Only one study found a significant association between mood and DHEA-S, with DHEA-S 
levels being significantly higher in PCOS females with MDD (n = 23) compared with non-
depressed PCOS females (n = 30) (Annagür et al., 2013).  
A-dione: Four studies measured A-dione levels (Jedel et al., 2011; Klimczak et al., 2015; 
Livadas et al., 2011; Rocco et al., 1991), and only Rocco et al. (1991) found a significant 
association between A-dione levels and mood. In this small study, higher A-dione levels were 
found in females with PCOS and depression (assessed by the Minnesota Multiphasic 
Personality Inventory; MMPI) (n = 11) compared with non-depressed PCOS females (n = 10) 
(Rocco et al., 1991). 
In summary there is no consistent evidence of a direct relationship between androgen levels, 
particularly the key measures of Free Testosterone and/or FAI levels and mood in PCOS. Of 
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the twelve studies that measured Free Testosterone and FAI levels in association with mood, 
three large studies (of which two used correlational analyses, and one used comparative group 
(depressed vs non-depressed analysis) found a positive association (higher testosterone levels 
associated with higher symptoms of depression), two studies (one using comparative group and 
correlational analysis, the other using only correlational analysis) found a negative and a 
curvilinear relationship, however, seven others (with a mixture of comparative and correlational 
analyses) failed to find any significant results. It is to be noted that the sample size was 
approximately equal in the positive and negative (no significant findings) studies. Interestingly, 
studies that found a positive relationship used the HADS to assess symptoms of depression 
while the negative studies did not. The HADS was primarily developed to assess symptoms of 
depression in a medical sample such as PCOS, and it excludes items relating physical symptoms 
involved in medical conditions including appetite, tiredness/fatigue, and sleep disturbances 
which other depression rating scales such as the BDI include. Therefore, the HADS may be 
more likely to demonstrate a clear relationship between the psychological symptoms of 
depression and androgen levels in PCOS.  
There is no strong evidence for significant associations between mood and Total Testosterone, 
which is expected since Total Testosterone is not a reliable measure of overall androgen levels, 
as compared with Free Testosterone or FAI levels. No convincing evidence exists regarding the 
relationship between mood and levels of precursor androgens including DHEA/ DHEA-S or A-
dione. Only one study each including a PCOS sample found an association between DHEA-S 
and A-dione and mood respectively (Annagür et al., 2013; Rocco et al., 1991). 
5.3.1.3  Androgen levels and anxiety symptoms in PCOS samples in cross-sectional studies 
Twelve studies assessed anxiety in PCOS samples (Annagür et al., 2013; Barry, Kuczmierczyk, 
et al., 2011; Bazarganipour et al., 2013; Cinar et al., 2011; Hahn et al., 2005; Hollinrake et al., 
2007; Jedel et al., 2011; Livadas et al., 2011; Mansson et al., 2008; Moran et al., 2012; Rocco 
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et al., 1991; Weiner et al., 2004). Six (n = 805) of 12 studies found significant associations 
between androgen levels and anxiety levels (scales included the SCID-I, HADS, STAI, and 
MINI, with the most common scale being the STAI) (Annagür et al., 2013; Bazarganipour et 
al., 2013; Cinar et al., 2011; Livadas et al., 2011; Mansson et al., 2008; Weiner et al., 2004). 
Four large studies found a significant positive association between state anxiety and FAI levels 
(n = 705) (Bazarganipour et al., 2013; Cinar et al., 2011; Livadas et al., 2011; Mansson et al., 
2008), one small study found a negative correlation between state anxiety and FAI levels (n = 
27) (Weiner et al., 2004), one small study found a positive association between GAD and 
DHEAS levels (n = 20) (Annagür et al., 2013) and six remaining studies (n = 409) found no 
significant association (Barry, Kuczmierczyk, et al., 2011; Hahn et al., 2005; Hollinrake et al., 
2007; Jedel et al., 2011; Moran et al., 2012; Rocco et al., 1991). 
An increased prevalence of anxiety disorders, particularly GAD and SAD, has been reported in 
females with PCOS ([OR] 6.88 95% CI 2.5–18.9, 4 studies, (Dokras et al., 2012), p = 0.04, 
(Laggari et al., 2009)). A high incidence of social anxiety in women with PCOS may be 
expected considering clinical features of acne, hirsutism, and weight gain which are involved 
in the syndrome and which may contribute to poor self-esteem, and sensitivity to social scrutiny 
(Barnard, Ferriday, et al., 2007; Hahn et al., 2005; Kitzinger & Willmott, 2002). Furthermore, 
anxiety and mood disorders are frequently comorbid conditions (Brawman-Mintzer, 
Emmanuel, Jarrell, & Ballenger, 1993), which may help explain increased anxiety prevalence 
in depressed females with PCOS. Further studies are needed to understand whether testosterone 
plays a role in directly influencing anxiety levels in females with PCOS. 
Overall, Free Testosterone and/or FAI levels have been examined in relation to anxiety by six 
studies, of which four found significant positive associations, one found a negative association 
while the one remaining study found no significant association. In this study, although PCOS 
females with GAD (n = 20) were found to have significantly higher DHEA-S levels compared 
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with PCOS females without GAD (p = 0.001) (n = 30) (Annagür et al., 2013), no significant 
association was found between Free Testosterone levels and anxiety levels. In a large study (n 
= 300 females with PCOS), significantly higher FAI levels were found in females with PCOS 
and symptoms of anxiety (HADS) (p < 0.001) (n = 96) compared with females with PCOS 
without symptoms of anxiety (n = 204) (Bazarganipour et al., 2013). Livadas et al. (2011) found 
higher FAI levels to correlate significantly with more severe state anxiety (STAI-S) in 130 
females with PCOS with varying levels of anxiety. This positive correlation between FAI levels 
and state anxiety (STAI-S) was replicated in another large sample (n = 226) of females with 
PCOS (Cinar et al., 2011). In contrast, Weiner et al. (2004) reported a significant negative 
correlation between Free Testosterone levels and state anxiety (STAI-S) in females with PCOS 
(n = 27). In their healthy group, however, a positive correlation between Free Testosterone 
levels and state anxiety was reported (n = 27). One study examining FAI levels in relation to 
SAD found higher FAI levels in PCOS females with SAD (n = 49) compared with PCOS 
females without SAD (n = 49) (Mansson et al., 2008). 
The remaining six studies that measured anxiety in relation to Total and Free Testosterone 
levels found no significant association between anxiety and testosterone levels (total n = 446) 
(Barry, Kuczmierczyk, et al., 2011; Hahn et al., 2005; Hollinrake et al., 2007; Jedel et al., 2011; 
Moran et al., 2012; Rocco et al., 1991). It is to be noted that three of six studies finding no 
association between anxiety and testosterone levels assessed only Total Testosterone levels 
(Barry, Kuczmierczyk, et al., 2011; Hahn et al., 2005; Rocco et al., 1991). Anxiety rating scales 
used by the negative studies included the HADS (Zigmond & Snaith, 1983), SCL-90-R 
(Derogatis & Fitzpatrick, 2004), PRIME-MD PHQ (Spitzer, Kroenke, & Williams, 1999), the 
Comprehensive Psychopathological Rating Scale for Affective Syndrome (Svanborg & Åsberg, 
1994), and the STAI (Spielberger, 2010). The STAI was used by only one negative study, 
however, the positive studies that found an association between anxiety and androgen levels 
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tended to commonly use the STAI together with the HADS to assess symptoms of anxiety and 
tended to assess FAI levels.  
Overall, studies that did find a significant positive association were larger (total n = 705) 
compared with studies that did not find an association (total n = 446). SAD is of interest given 
emotional processing data, which will be discussed in Section 5.4. 
5.3.1.4  Overall summary 
There is no consistent evidence of a direct relationship between androgen levels and mood 
and/or anxiety in PCOS. Overall, studies that found a positive association between higher FAI 
levels and greater symptoms of depression used the HADS as the primary depression rating 
scale, whereas the studies that found a negative association or found no significant association 
used other depression rating scales. Since the HADS is more appropriate to assess symptoms 
of mood and anxiety in medical samples, such as PCOS, and is a recognised and well-validated 
measure, findings of positive associations between testosterone levels and higher symptoms of 
mood in studies using the HADS could be considered as more reliable.   A meta-analytic review 
of a smaller number of studies (Cooney et al., 2017) which measured mood and anxiety in 
PCOS and measured Free Testosterone or FAI levels and had a control group demonstrated 
higher Free Testosterone/FAI levels in females with PCOS and concurrent anxiety (p < 0.05), 
but no relationship between testosterone levels and mood was reported. However, in Cooney et 
al’s (2017) study, only 13 studies assessed androgen levels in relation to symptoms of mood 
and/or anxiety, which were included in the current study. Apart from these 13 studies (Annagür 
et al., 2013; Asik et al., 2015; Bazarganipour et al., 2013; Bhattacharya & Jha, 2010; Cinar et 
al., 2011; Hollinrake et al., 2007; Jedel et al., 2010; Klimczak et al., 2015; Livadas et al., 2011; 
Mansson et al., 2008; Moran et al., 2012; Rahiminejad et al., 2014; Soyupek et al., 2008), the 
current review  included eight additional cross-sectional studies including PCOS samples 
(Adali et al., 2008; Barry, Kuczmierczyk, et al., 2011; Hahn et al., 2005; Milsom et al., 2013; 
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Pastore et al., 2011; Rasgon et al., 2003; Rocco et al., 1991; Weiner et al., 2004) which led to 
somewhat different results from Cooney et al’s (2017) review regarding the specific 
relationship between mood, anxiety and androgen levels. As noted previously (see page 118), 
Cooney et al. (2017) had a different exclusion criteria from the current review. Therefore, in 
the current review, different findings related to the association between Free Testosterone levels 
and mood/anxiety may have emerged due to broader inclusion criteria. In the current study, a 
meta-analysis was not carried out since most studies included in the current review did not have 
equivalent measures and used different methodological procedures. Therefore, a systematic 
review was considered more appropriate. 
5.3.2 Studies relating mood/anxiety to androgen levels in non-PCOS samples (Cross-
sectional and interventional findings) 
Twelve studies assessed the association between androgen levels and symptoms of depression 
and/or anxiety in females without PCOS (see Table 5.2). The five experimental/interventional 
studies included in this section involved: antidepressant treatment (sertraline, clomipramine) 
(Baischer et al., 1995; Kumsar et al., 2014), DHEA treatment (Wolkowitz et al., 1999), 
testosterone administration in HIV-infected patients (Dolan Looby, Collins, Lee, & Grinspoon, 
2009), and testosterone administration in healthy females (Schutter, Peper, Koppeschaar, Kahn, 
& van Honk, 2005), to examine the effects on mood and anxiety. 
5.3.2.1  Depression and androgen levels in non-PCOS females (Cross-sectional findings) 
Free Testosterone and FAI (including Bioactive Testosterone and Bioavailable 
Testosterone): Free Testosterone and/or FAI levels were assessed in seven out of 12 studies, 
with three cross-sectional studies (total n = 71) (including females with hirsutism and females 
with Borderline Personality Disorder) finding a significant positive correlation between Free 
Testosterone and FAI levels and  greater symptoms of depression) (Derogatis, Rose, Shulman, 
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& Lazarus, 1993; Roepke et al., 2010; Shulman et al., 1992), two studies (total n = 95) (one 
including Sertraline treatment, the other cross-sectional study including females with anorexia 
nervosa) finding a negative association (higher Free Testosterone and/or FAI levels associated 
with less severe symptoms of depression) (Kumsar et al., 2014; K. Miller, Wexler, et al., 2007) 
while the remaining two (including one experimental study with HIV females and the other 
cross-sectional study including healthy females) (total n = 101) (Dolan Looby et al., 2009; 
Schutter, Meuwese, Bos, Crone, & Peper, 2017) found no significant association between Free 
Testosterone/FAI levels and mood. 
Roepke et al. (2010) found a significant positive correlation between symptoms of depression 
(HAM-D) and FAI levels in females with BPD (n = 31). However, this correlation was not 
significant after controlling for BMI. The two other studies recruiting females with hirsutism 
showed more severe symptoms of depression (DeRogatis Symptoms Inventory and Affect 
Balance Scale) to be significantly correlated with higher Free Testosterone levels (total n = 40). 
Significant positive correlations between worse mood (lower positive affect) and higher Free 
Testosterone and Bioactive Testosterone were also found in both studies (r =  0.60, p <0.01 for 
both studies) (Derogatis et al., 1993; Shulman et al., 1992). 
In contrast, two out of seven studies found lower Free Testosterone levels to be associated with 
more severe symptoms of depression (Kumsar et al., 2014; K. Miller, Wexler, et al., 2007). In 
a sample of 43 females with anorexia and depression, a significant negative correlation was 
found between Free Testosterone levels and depression severity (lower Free Testosterone levels 
associated with higher HAM-D scores) (K. Miller, Wexler, et al., 2007). Multivariate regression 
analysis found Free Testosterone levels to be positively correlated with depression severity. 
However, a group with anorexia nervosa would be likely to show significant variation in overall 
hormone levels. In Kumsar et al’s (2014) interventional study involving antidepressant 
treatment (Sertraline) over a six-week period, baseline FAI levels were found to be significantly 
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lower in females with depression (n = 52) compared with healthy control participants (p < 
0.001) (n = 30). A significant increase in testosterone levels was noted following the six-week 
antidepressant treatment in the patient group, and post-treatment levels were not significantly 
different between the two groups. 
The remaining two studies including female patients with HIV (n = 25) (Dolan Looby et al., 
2009) and healthy females (n = 76) (Schutter et al., 2017) found no significant correlation 
between Free Testosterone or FAI levels and mood. Dolan Looby et al’s (2009) study included 
females with HIV who showed lower testosterone levels at baseline compared with healthy 
females, however, this study found no significant association between testosterone levels and 
mood. 
To summarise, of the seven studies that measured Free Testosterone levels and FAI levels in 
non-PCOS samples, three found higher Free Testosterone or FAI levels to be associated with 
greater depression severity, two found lower Free Testosterone and FAI levels to be associated 
with greater depression severity, and the remaining two found no significant relationship 
between Free Testosterone and depression severity. It is to be noted, however, that two of the 
three studies that found a positive association between testosterone levels and mood in non-
PCOS samples used tests not specifically designed to measure current severity of symptoms of 
depression (DeRogatis Symptoms Inventory and Affect Balance Scale), which may be 
relatively insensitive to clinically significant symptoms of depression. Overall, the results are 
inconsistent.   
Total Testosterone: Total Testosterone levels were measured in seven out of 12 studies. Two 
studies reported a negative association between Total Testosterone and depression severity. 
Miller et al. (2007) found Total Testosterone levels to be significantly negatively correlated 
with depression (lower Total Testosterone associated with higher depression scores) in females 
with anorexia (n = 43). Kumsar et al. (2014) found lower Total Testosterone levels in an 
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untreated depressed group (n = 52) compared with a non-depressed group (n = 30). One study 
out of seven reported a significant positive association between Total Testosterone and mood, 
with higher Total Testosterone levels found in a sample of 20 untreated females with 
depression, compared with a healthy control group (n = 10) (Baischer et al., 1995). The 
remaining four studies found no significant relationship between Total Testosterone levels and 
mood in varying groups (see Table 5.2) (Derogatis et al., 1993; Dolan Looby et al., 2009; 
Roepke et al., 2010; Shulman et al., 1992). 
DHEA, DHEA-S and A-dione: DHEA and DHEA-S levels were measured in four cross-
sectional studies. No significant relationship between DHEA or DHEA-S and mood was found 
in any of these studies (Derogatis et al., 1993; Landén et al., 2004; Roepke et al., 2010; Shulman 
et al., 1992). A-dione was measured in two cross-sectional studies, however, no significant 
relationship with mood was reported (Roepke et al., 2010; Shulman et al., 1992). 
5.3.2.2  Depression and androgen levels in non-PCOS females :( Interventional findings) 
Three small interventional studies examined the effect of androgen administration on mood; 
one in a sample of healthy females (Schutter et al., 2005), one in a sample of depressed females 
(Wolkowitz et al., 1999) and one in females with HIV (Dolan Looby et al., 2009). It is important 
to understand that results from experimental studies involving testosterone administration are 
quite different from results from studies involving anti-androgen medication, since the latter 
comprise of a completely different methodology in a medical sample with hormonal 
abnormalities. Additionally, it is not reasonable to suggest that testosterone administration 
studies are likely to have the opposite results of anti-androgen administration. The former is 
often short-term and testosterone levels increase for only a short period of time. It is clearly not 
just the opposite of treatment for PCOS. However, these studies can provide useful data 
regarding the effects of androgens in the brain. 
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A randomised placebo-controlled trial showed significant improvement in mood symptoms 
(BDI) in a sample of females with HIV and with lower baseline testosterone levels (n = 13) 
following testosterone administration over 18 months, compared with the placebo condition       
(−6.8±2.2 vs. −1.9±3.1; p =0.02), (n = 12) (Dolan Looby et al., 2009). Similarly, in another 
small randomised, placebo-controlled study involving DHEA-S treatment for females with 
depression (Wolkowitz et al., 1999), a significant decrease in HAM-D scores (improvement in 
mood) was found in depressed females (n = 5) compared with placebo (n = 5) following 
DHEAS treatment over six weeks (group-by-time interaction: F = 5.21, df = 1, 20, p < 0.04). 
This result may be more likely related to the anti-glucocorticoid effects of DHEA (Gallagher et 
al., 2008; Kalimi, Shafagoj, Loria, Padgett, & Regelson, 1994) which is in line with research 
showing that cortisol suppression helps to improve low mood (Murphy, 1991) (see Chapter 2). 
However, in another small randomised double-blind placebo-controlled crossover study (n = 
14), testosterone administration was not associated with significant change in self-reported 
mood or anxiety (POMS) compared with the placebo condition (Schutter et al., 2005). It is 
important to note that the POMS is not a depression rating scale and is suitable for assessing 
six different dimensions of mood swings over a short period of time, therefore, the results may 
not accurately reflect symptoms of depression. 
Two other interventional studies involved antidepressant treatment and found contrasting 
results despite using similar antidepressant agents (Clomipramine and Sertraline). At baseline, 
a positive association was found in one study, with significantly elevated Total Testosterone 
levels found in untreated depressed patients (n = 20) compared with controls (n = 10) (Baischer 
et al., 1995). Following Clomipramine treatment (four weeks), Total Testosterone levels were 
found to reduce significantly in the patient group, to the point that they were not significantly 
different from healthy controls. In contrast, in a larger sample, Kumsar et al. (2014) found lower 
pre-treatment Total Testosterone and FAI levels in depressed patients (n = 52) compared with 
healthy females (n = 30). A significant increase in androgen levels was found following 
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antidepressant treatment (Sertraline over a course of six weeks) in females with depression. No 
significant differences were observed between the two groups post-treatment. 
5.3.2.3  Overall summary  
To summarise, the association between Free Testosterone or FAI levels and mood in non-PCOS 
samples remains unclear, with studies showing mixed findings in disparate groups. Total 
Testosterone does not seem to be correlated with symptoms of depression in non-PCOS samples 
with anorexia nervosa and depression, with only one study finding a positive association in 
untreated patients with depression while the remaining studies failed to find an association. 
There is no evidence of a significant relationship between DHEA/DHEA-S and A-dione levels 
and mood in non-PCOS samples. 
5.3.2.4  Anxiety and androgen levels in non-PCOS samples 
Of the seven studies that measured anxiety in non-PCOS samples, three found no significant 
relationship between androgen levels and anxiety (n = 110) (Schutter et al., 2017; Schutter et 
al., 2005; Shulman et al., 1992). The remaining four studies found significant relationships 
between anxiety levels and androgens, with three finding a negative association (n = 175) and 
one a positive association (n = 20).  
Two studies (total n = 144) including females with anorexia nervosa and females with epilepsy 
and anxiety, respectively, reported a negative association with lower androgen levels  
significantly related to greater symptoms of anxiety (HAM-A, HADS, Zung Anxiety Rating 
Scale (ZARS) (K. Miller, Wexler, et al., 2007; Zheleznova et al., 2013). In the study of females 
with epilepsy and anxiety, however, the type of testosterone measured was not specified (e.g., 
Total or Free) (Zheleznova et al., 2013). Additionally, Derogatis et al. (1993) found Free 
Testosterone and Bioactive Testosterone levels to be significantly associated with greater 
phobic anxiety (De Rogatis Symptom Inventory [DSI]) in 20 hirsute patients. One study found 
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lower Total Testosterone levels in individuals with SAD (assessed by DSM-IV based self-
report questionnaire) (n = 31) compared with healthy controls (n = 185) (Landén et al., 2004).  
As with depression studies, measures of anxiety including HAM-A, Zung Anxiety Rating Scale 
(ZARS), a DSM-IV based self-report questionnaire  and the DSI were variable in terms of their 
sensitivity in detecting anxiety symptoms at mild and severe ends of the spectrum. The DSM-
IV based self-report questionnaire used in Landén et al’s (2004) was not specifically an anxiety 
rating scale and covered an assessment of social anxiety disorder and five additional psychiatric 
conditions including mood, panic attacks, obsessive compulsive disorder, and premenstrual 
dysphoric disorder. The DSI is an 89-item self-report inventory and was designed to measure 
overall psychiatric distress over several dimensions, including panic anxiety, interpersonal 
sensitivity, depression, and phobic anxiety. The ZARS is designed to measure anxiety levels 
within the normal range extending up to levels of extreme anxiety. However, one study found 
that females showed higher scores on the ZARS (and the STAI) compared with males and that 
scores were inversely correlated with age (Knight, Waal‐Manning, & Spears, 1983). The HAM-
A is a suitable measure for detecting the severity of symptoms of anxiety and their change over 
time. However, the study that assessed anxiety in samples with epilepsy using the HAM-A did 
not assess the type of testosterone measured, thus likely to affect results (Zheleznova et al., 
2013). This result including non-significant associations between anxiety and testosterone 
levels in non-PCOS samples are in contrast to findings in PCOS samples involving positive 
associations between FAI levels and symptoms of anxiety. It is worth considering the range of 
testosterone levels that individuals show at baseline (for example significantly elevated in 
PCOS vs low in females with anorexia or HIV) (Dolan Looby et al., 2009; K. Miller, Lawson, 
et al., 2007) in relation to symptoms of anxiety. Overall, these results do not suggest a strong 
association between testosterone levels and symptoms of anxiety. 
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5.3.2.5  Methodological issues in studies examining the association between symptoms of 
mood and androgen levels in PCOS and non-PCOS samples 
5.3.2.5.1 Sampling bias 
An explanation for an increased rate of symptoms of depression in the PCOS samples may 
simply relate to a sampling bias. Patients with PCOS displaying physical/visible symptoms 
(including hair and skin abnormalities and/or infertility) are more likely to experience 
psychiatric symptoms as a result of the physical symptoms of PCOS, compared with females 
without physical symptoms of PCOS (Asik et al., 2015; Deeks et al., 2010; Dunaif, 1997; 
Elsenbruch et al., 2006; Ferriman & Gallwey, 1961; Kitzinger & Willmott, 2002; Mechanick 
& Dunaif, 1990; Moran, Gibson-Helm, Teede, & Deeks, 2010; Polson et al., 1988; Sonino et 
al., 1993). Since females with PCOS and physical symptoms may be more likely to present to 
an endocrinological clinic, compared with females with PCOS and biochemical abnormalities 
(including high Free Testosterone levels) but without physical symptoms, the syndrome may 
go undetected in this population thereby excluding a large group of females with PCOS, which 
may affect overall results. Additionally, results would apply only to this subsection of the 
population at large which may not be a representative group. This may, in turn, obscure results 
to some extent. However, the question still remains whether symptoms of low mood are a direct 
consequence of biochemical abnormalities such as increased testosterone levels, or are present 
due to the physical symptoms of PCOS. Some studies have found no association between the 
physical symptoms of PCOS and mood or anxiety (Barth et al., 1993; Hollinrake et al., 2007; 
Karjula et al., 2017; Shulman et al., 1992). Shulman et al. (1992) found an increased incidence 
of depression in facially hirsute females which correlated with serum levels of Free 
Testosterone but not with the extent of facial hirsutism.  
5.3.2.5.2  Correlational versus categorical analyses 
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Overall, studies including both PCOS and non-PCOS samples used two main methods to 
determine the relationship between androgens and symptoms of depression. The first was a 
correlation between levels of depression and levels of key androgens, which was subject to 
difficulties related to the type of scale used. Second, some studies split the PCOS group into 
those with depression and those without (Annagür et al., 2013; Bazarganipour et al., 2013; 
Bhattacharya & Jha, 2010; Hollinrake et al., 2007; Jedel et al., 2011; Klimczak et al., 2015; 
Rahiminejad et al., 2014; Rocco et al., 1991), or into groups within the diagnosis of PCOS 
based on specific criteria (NIH and non-NIH) (Moran et al., 2012), and then examined between-
group differences in testosterone levels. In this situation, in most cases, a scale with a 
predetermined cut-off to diagnose depression was used, which may not be as useful as a clinical 
interview (see next section). Regardless of the method of determining the relationship and the 
scales used, the data does not strongly support a direct relationship between testosterone and 
depression.  
5.3.2.5.3  Depression rating scales 
Depression rating scales, as opposed to diagnostic interviews, measure differences in severity 
of depression symptoms, or changes in depressive symptoms over time. There are, however, 
many different depression rating scales that serve different purposes. Inconsistencies in findings 
may be explained, in part, by the use of particular depression rating scales. Rating scales are 
usually designed to either: 1) measure change in depression during treatment trials, in which 
case they are designed for people with significant clinical depression and may not detect 
correlations at lower levels of depressive symptoms, such as those found in PCOS (mild-
moderate severity), 3) scales that are used to measure low levels of mood variability in normal 
populations, for example, the POMS 2) screen for depression and are, therefore, developed in 
order to have a cut-off but not to be sensitive to differences in levels of depression at a higher 
severity. With regards to PCOS samples, the preference would be to use depression rating scales 
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that detect low levels of depression symptoms, however, most studies examining mood in 
PCOS samples have used scales that are designed to assess more severe depressive symptoms. 
The former is of particular relevance, as despite findings of more depression and anxiety in 
females with PCOS, the severity of depression in PCOS remains to be that of moderate severity 
(Barry, Kuczmierczyk, et al., 2011), and therefore, there needs to be a depression measure with 
appropriate sensitivity to pick up associations relevant to lower symptoms of depression. 
Additionally, many studies used self-report questionnaires such as the HADS, BDI, and QIDS 
(Barry, Kuczmierczyk, et al., 2011; Bazarganipour et al., 2013; Hollinrake et al., 2007; Livadas 
et al., 2011; Moran et al., 2012; Pastore et al., 2011; Rasgon et al., 2003). The most commonly 
used depression rating scale to assess mood in PCOS samples was the BDI (Adali et al., 2008; 
Cinar et al., 2011; Hollinrake et al., 2007; Klimczak et al., 2015; Livadas et al., 2011). Overall, 
in the current review, studies that reported significant positive associations tended to measure 
Free Testosterone or FAI levels. These studies finding an association between FAI levels and 
mood tended to be larger compared with studies which found associations in contrasting 
directions and studies which found non-significant relationships. Additionally, the three studies 
that found a positive association used the HADS including Cinar et al’s study (2011) which 
included the BDI together with the HADS to assess symptoms of depression. As noted earlier 
(section 5.3.1.4), the HADS was developed to examine symptoms of anxiety and depression in 
medical populations (for example, females with PCOS). It does not focus on the somatic 
symptoms of depression, such as loss of energy, sleeping patterns, appetite and tiredness or 
fatigue, which could be related to the medical condition experienced by an individual rather 
than a reflection of low mood. The BDI, however, includes somatic symptoms of depression, 
and therefore, is a more suitable instrument to use in psychiatric populations whereas the HADS 
may be better suited for medical populations such as PCOS, providing a more accurate estimate 
of symptoms of depression in these populations and may operate at the correct part of the 
spectrum of symptoms of depression. 
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Other measures used to assess depression in the reviewed studies were not designed specifically 
to measure current severity or levels of depression and may be less sensitive to subtle 
differences in mood state, therefore, less likely to show correlations with factors which impact 
mood states such as testosterone levels, for example, the Minnesota Multiphasic Personality 
Inventory (Rocco et al., 1991), the Mini International Neuropsychiatric Interview (MINI) 
(Mansson et al., 2008), the Neuroticism-Extraversion-Openness Personality Inventory (NEO-
PI-R), the Affect Balance Scale, the Multiple Affect Adjective Check List, Health-Related 
Quality of Life, and the Symptom Checklist Survey (Derogatis et al., 1993; Hahn et al., 2005; 
S. Phillips & Sherwin, 1992; Rocco et al., 1991; Schutter et al., 2017; Shulman et al., 1992). 
Only two small studies (n = 58) used a clinician-administered measure of depression rather 
than a self-report depression rating scale to determine presence or absence of clinically 
significant depression and found a significant association between androgen levels and 
depression and anxiety in patients with PCOS, however, in opposite directions. Annagur et al. 
(2013) in a small study found significantly higher androgen (DHEAS) levels in females with 
PCOS and MDD (n = 23) (Structured Clinical Interview for DSM-IV; SCID-I) compared with 
females with PCOS without MDD (n = 30) (p = 0.001), whereas Jedel et al. (2011) (n = 35) 
found lower androgen levels ) (Total and Free T levels, p = 002) in females with PCOS with 
higher symptoms of depression (MADRS) compared with females with PCOS with lower 
symptoms (n = 37). However, these studies measured different forms of androgens, are very 
small and potentially underpowered to show significant results.  
5.3.3 Androgen levels and cognitive function in observational studies  
Nineteen studies with an observational design assessed the relationship between androgen 




5.3.3.1 Verbal learning and memory 
Seven cross-sectional studies measured verbal learning and memory in relation to androgen 
levels (Gómez-Gil et al., 2009; Halari et al., 2005; Hussain, Hanafi, Konishi, Brake, & Bohbot, 
2016; Janowsky, Chavez, Zamboni, & Orwoll, 1998; S. Phillips & Sherwin, 1992; Romero-
Martínez, González-Bono, Salvador, & Moya-Albiol, 2015; Schattmann & Sherwin, 2007b). 
Five of seven studies found no significant relationship (n = 178) while the remaining two (n = 
49) reported inconsistent findings (S. Phillips & Sherwin, 1992; Romero-Martínez et al., 2015). 
In a sample of 25 healthy females (S. Phillips & Sherwin, 1992), lower Free Testosterone levels 
were associated with better verbal memory performance (Wechsler Memory Scale). Romero-
Martínez et al. (2015) found a curvilinear relationship between Free Testosterone and verbal 
memory in a sample of 24 mothers of children with autism spectrum disorder on an isolated 
aspect of the RAVLT, with no specific correlation between Free Testosterone and verbal 
memory found in the control group with mothers of healthy children (n = 22).  
Overall, these results suggest minimal evidence of a relationship between androgen levels and 
verbal learning and memory. 
5.3.3.2 Verbal ability 
Three studies assessed verbal ability (Gouchie & Kimura, 1991; Halari et al., 2005; McKeever, 
Rich, Deyo, & Conner, 1987) (Tongue Twister Task, Vocabulary Sub-test of WAIS-R, Shiplet 
Hartford Vocabulary Test) and found no significant correlations between verbal ability and 
androgen levels. 
5.3.3.3 Visuospatial learning and memory 
There was no significant association between androgen levels and spatial learning and memory 
in three of four studies (Halari et al., 2005; Janowsky et al., 1998; Schattmann & Sherwin, 
2007b). The remaining small study found significantly better visual memory performance 
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(Visual Paired Associates) in a testosterone-treated group (n = 9) compared with the no-
treatment group (n = 10) in 33 female-to-male transsexuals (Gómez-Gil et al., 2009). There 
were no significant differences in verbal memory between groups in this study.  
5.3.3.4 Visuospatial ability 
Six of 16 studies (n = 170) found a significant relationship between spatial ability and androgen 
levels (Barry et al., 2013; Burkitt, Widman, & Saucier, 2007; Gouchie & Kimura, 1991; 
Hausmann et al., 2000; Moffat & Hampson, 1996; Shute, Pellegrino, Hubert, & Reynolds, 
1983). Moffat et al. (1996) found a significant positive correlation between spatial ability 
(Mental Rotations Task [MRT] and Paper Folding Test) and Free Testosterone levels, however, 
this finding was limited to right-handed females only (n = 19). Gouchie and Kimura (1991) did 
not find a significant correlation between Free Testosterone levels and spatial ability (Paper 
Folding) but found significantly better performance in a high testosterone group compared with 
low testosterone group (p < 0.03) (n = 46) on this task. Burkitt et al. (2007) found significantly 
worse spatial ability in females with low androgen levels (n = 18) compared with females with 
high androgen levels (n = 19) on an aspect of a Virtual Water Maze Task (females with low 
testosterone levels needed significantly longer time to complete the task (M = 96.769 ± 66.395 
SD) compared with females with higher testosterone levels (M = 47.481 ± 41.023 SD, p < 0.05). 
In a small study (n = 12), females were divided into high and low testosterone groups (n = 6 in 
each group), and females with higher Free Testosterone levels performed significantly better 
on a Spatial Visualisation Task compared with females with lower Free Testosterone levels 
(Shute et al., 1983). However, in the first part of the same study (Shute et al., 1983), 
correlational analyses showed no significant association between Free Testosterone levels and 
spatial ability (n = 48 healthy females). A small longitudinal, observational study (n = 12) 
found a significant positive correlation between testosterone (unspecified) levels and spatial 
ability (Vandenberg and Kuse’s MRT) in healthy females (Hausmann et al., 2000). In a PCOS 
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sample (n = 69), Barry et al. (2013) found a significant positive correlation between Total 
Testosterone levels and spatial ability (3-D MRT) (r = 0.376, n = 56, p < 0.002) compared with 
41 sub-fertile healthy females. 
The 10 remaining studies (n = 394), including one with females with PCOS (Schattmann & 
Sherwin, 2007b), found no significant association between androgen levels and visuospatial 
ability (Stafford Identical Blocks Test, Minnesota Paper Form Board Test, Spatial Relations 
Test) (Durdiaková, Hodosy, Kubranská, Ostatníková, & Celec, 2012; Falter, Arroyo, & Davis, 
2006; Halari et al., 2005; Hassler, Gupta, & Wollmann, 1992; Hussain et al., 2016; Janowsky 
et al., 1998; McKeever et al., 1987; Neave, Menaged, & Weightman, 1999; Puts et al., 2010). 
5.3.3.5 Psychomotor speed 
Two of three studies including one with a PCOS sample examining psychomotor speed found 
a significant relationship between this domain and androgen levels. FAI levels significantly 
negatively correlated with motor speed in a sample of 28 females with PCOS (higher FAI levels 
associated with slower performance on the Purdue Pegboard Task) (Schattmann & Sherwin, 
2007b). In contrast, another study found psychomotor speed (Dart-Throwing Task) to be 
significantly positively correlated with Free Testosterone levels (higher Free Testosterone 
levels associated with faster performance) (Janowsky et al., 1998). In this study, the significant 
correlation was found in females using their dominant hand, however, a significant negative 
correlation was found in females using their non-dominant hand (total n = 30). The finding is, 
therefore, somewhat mixed. One study found no significant association between psychomotor 
speed (Finding A’s and Identical Pictures Test) and Free Testosterone levels (n = 46) (Gouchie 




5.3.3.6 Executive function 
No evidence was found regarding a relationship between executive function and androgen 
levels in five studies including healthy females (total n = 149) (Halari et al., 2005; Hassler et 
al., 1992; McKeever et al., 1987; Moffat & Hampson, 1996; Neave et al., 1999) and one with 
28 females with PCOS  (Schattmann & Sherwin, 2007b). 
5.3.3.7  Summary of findings  
Overall, no strong evidence of a relationship between androgen levels and verbal learning and 
memory or verbal ability was found in five observational studies. Only two studies found 
significant yet mixed results with one associating lower Free Testosterone levels with better 
verbal memory (S. Phillips & Sherwin, 1992) while the other finding a curvilinear relationship 
between Free Testosterone levels and verbal memory (one aspect of the RAVLT) (Romero-
Martínez et al., 2015). No strong evidence regarding the relationship between androgen levels 
and attention and executive function was found. Only one small study out of four studies 
examining visuospatial memory in relation to testosterone levels found better visual memory in 
a testosterone-treated group (Gómez-Gil et al., 2009). There was mixed evidence regarding the 
association between Free Testosterone/FAI levels and psychomotor speed with three studies 
examining this relationship and finding a positive (Janowsky et al., 1998), negative 
(Schattmann & Sherwin, 2007b) and no association (Gouchie & Kimura, 1991).  
Until now, a well-studied cognitive domain in relation to testosterone levels seems to be 
visuospatial ability. Although 10 studies (n = 394) found no significant association between 
spatial ability and androgen levels, six studies found a significant and consistent positive 
relationship (n = 170). Females with relatively higher levels of testosterone were found to show 
better performance on spatial ability tasks compared with females with lower testosterone 
levels. Studies have shown gender differences in spatial abilities with males outperforming 
females (Choi & Silverman, 2002; Halpern, 2000; Linn & Petersen, 1985; Maccoby & Jacklin, 
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1978; Masters & Sanders, 1993), which may, however, relate to the organisational effect of 
testosterone. Findings related to activational effects of testosterone, i.e., change in visuospatial 
ability following testosterone administration will be discussed in the following section. 
5.3.4 Androgen levels and cognitive functioning in interventional/experimental 
studies 
Nine studies with an interventional study design investigated the relationship between androgen 
levels and cognitive function in females of reproductive age. Only one study included patients 
with PCOS (Schattmann & Sherwin, 2007a).  
5.3.4.1 Verbal learning and memory 
Only one study measured verbal learning and memory and found no significant changes 
following anti-androgen treatment in females with PCOS (n = 8) on the RAVLT, Logical 
Memory Test, and the Paired Associates Test (Schattmann & Sherwin, 2007a). 
5.3.4.2  Verbal ability 
Verbal ability was measured using the Verbal Reasoning Test in four studies (Slabbekoorn, 
Van Goozen, Megens, Gooren, & Cohen-Kettenis, 1999; Van Goozen, Cohen-Kettenis, 
Gooren, Frijda, & Van de Poll, 1994, 1995; Van Goozen, Slabbekoorn, Gooren, Sanders, & 
Cohen-Kettenis, 2002) including transsexual participants, and the Vocabulary sub-test of 
Wechsler Adult Intelligence Scale-III in one study including participants with PCOS 
(Schattmann & Sherwin, 2007a). None of the five studies involving testosterone or anti-
androgen administration in transsexual or PCOS participants found a significant association 




5.3.4.3 Visuospatial learning and memory 
Two interventional studies included a measure of visuospatial learning and memory (Pintzka, 
Evensmoen, Lehn, & Haberg, 2016; Postma et al., 2000). On the Object-Location Memory 
Task, Postma et al. (2000) found no effect of testosterone administration on the first two task 
conditions (Positional Reconstruction and Object-to-Position Assignment) but found better 
performance on the third (combined) condition (assessing immediate and delayed recall) 
following testosterone administration (n = 8), compared with the placebo condition (n = 7) in 
healthy females. Pintzka et al. (2016) found better visuospatial learning (representation of 
direction on the Virtual Environment Learning and Navigating Task) in the testosterone group 
(n = 21) compared with the placebo group (n = 21) (corrected p < 0.02).  
5.3.4.4 Visuospatial ability 
Significant improvement in spatial ability was found in six of eight studies following 
testosterone administration (Aleman, Bronk, Kessels, Koppeschaar, & van Honk, 2004; K. 
Miller, Grieco, & Klibanski, 2005; Pintzka et al., 2016; Slabbekoorn et al., 1999; Van Goozen, 
Cohen-Kettenis, et al., 1994; Van Goozen et al., 1995). Two studies found significant 
improvement in visuospatial ability (Rotated Figures Test, Card Rotation Task) in female-to-
male transsexual samples (total n = 57) following testosterone administration over a period of 
three months (Van Goozen, Cohen-Kettenis, et al., 1994; Van Goozen et al., 1995). 
Slabbekoorn et al. (1999) found a significant improvement in spatial ability scores (Rotated 
Figures 2 and 3-Dimensional and Hidden Figures Task) following testosterone administration 
over 1.5 years in a sample of 20 female-to-male transsexuals. Similarly, Miller et al. (2005) 
found baseline Free Testosterone levels to be significantly positively correlated with spatial 
ability (3-D Mental Rotation score) in a clinical sample of 33 females with anorexia. 
Testosterone administration (n = 24) for three weeks was followed by significant improvement 
in visuospatial ability compared with the placebo condition (n = 9). 
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In single-dose administration studies, Aleman et al. (2004) found a significant improvement in 
spatial ability (Mental Rotation score) in 26 healthy females following testosterone 
administration (n = 14) compared with a placebo condition (n = 12). Similarly, Pintzka et al. 
(2016) found that a single dose of testosterone in healthy females (n = 21) was associated with 
significantly better performance on one spatial ability measure (Mental Rotations Test) 
compared with placebo condition (n = 21); however, in this study, no differences were found 
in the other measure of spatial ability (fMRI stimuli with a self-paced Block Design Task).  
Two studies found no significant change in visuospatial ability following testosterone 
administration and anti-androgen treatment, respectively, in females with and without PCOS 
(Schattmann & Sherwin, 2007a; Van Goozen et al., 2002). In the Van Goozen et al. study 
(2002) no effect of testosterone treatment over a span of 14 weeks was observed on spatial 
ability (Line Orientation Test, Rotated Figures (2-D and 3-D), Targeted Throwing Task) in 
female-to-male transsexuals (n = 19) in comparison with healthy females who did not receive 
treatment over the course of 14 weeks (n = 22). This result may be explained by the fact that 
the male and female brain are fundamentally different in many ways and may react differently 
to testosterone. Therefore, an increase in testosterone levels in a female brain (involving 
testosterone treatment) does not necessarily change its function to a more male pattern. Given 
that the administration of testosterone induces large changes in testosterone levels, this may be 
more likely to show a change in cognitive function but may have less relevance to the usual 
physiology of the female/male brain. It is important to note, however, that while some studies 
suggest that sex differences in the brain are significantly widespread (Cahill, 2006), other 
studies postulate that these findings are not entirely accurate (Eliot, 2011; Rippon, Jordan-
Young, Kaiser, & Fine, 2014), reviewed by McCarthy (2016). The other study including PCOS 
samples involved anti-androgen treatment (CPA) over a course of three months and found no 
significant changes in spatial ability (MRT, Paper Folding, Water Level Test) post-treatment 
(Schattmann & Sherwin, 2007a). However, in this sample of 19 hirsute PCOS females, post-
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treatment FAI levels were significantly negatively correlated with spatial visualisation scores 
(Paper Folding), suggesting that lower levels of FAI were associated with better spatial 
performance, which is in contrast to findings from other studies.  
Overall, results suggest a positive association between testosterone and visuospatial ability with 
higher levels of testosterone related to improvements in visuospatial ability. 
5.3.4.5 Psychomotor Speed 
Two treatment studies measured psychomotor speed, however, neither found a significant effect 
of administration of testosterone on this domain (Schattmann & Sherwin, 2007a; Slabbekoorn 
et al., 1999).  
5.3.4.6 Executive function 
Executive function (verbal fluency) was assessed by four interventional studies involving both 
androgen and anti-androgen treatment.  In 19 hirsute females (Schattmann & Sherwin, 2007a), 
verbal fluency (COWAT) significantly improved following anti-androgen treatment (n = 8) 
compared with placebo (n = 11). However, post-treatment androgen levels (FAI) were not 
significantly correlated with improved verbal fluency. Reduced verbal fluency (Word and 
Sentence Production) was found following androgen treatment in both longitudinal studies 
involving female-to-male transsexual samples (Van Goozen, Cohen-Kettenis, et al., 1994; Van 
Goozen et al., 1995). Another study found no significant change in verbal fluency (Word and 
Sentence Task) following testosterone treatment in a sample of 25 female-to-male transsexuals 
(Slabbekoorn et al., 1999). Overall, results tend to indicate that androgen treatment results in 





5.3.4.7  Summary of findings 
Previous research has focused on the organisational effects of testosterone involving an 
examination of gender differences in specific cognitive abilities. Verbal fluency is recognised to 
be a female-superior cognitive domain (Halpern, 2000) while males generally have an advantage 
in visuospatial function (Choi & Silverman, 2002; Linn & Petersen, 1985; Maccoby & Jacklin, 
1978; Masters & Sanders, 1993). In the current review, although no significant findings related 
to organisational effects of testosterone were obtained from cross-sectional studies regarding the 
relationship between androgen levels and verbal fluency, interventional studies found androgen 
treatment to be associated with decreased verbal fluency performance (Van Goozen, Cohen-
Kettenis, et al., 1994; Van Goozen et al., 1995) whereas anti-androgen treatment appeared to 
benefit verbal fluency (Schattmann & Sherwin, 2007a). Since females with PCOS have elevated 
testosterone levels, it would be expected that they may show an advantage over healthy females 
on tasks assessing spatial ability, which also have a significant male-advantage. However, the 
current review found no significant association between testosterone levels and spatial ability in 
females with PCOS (Barry et al., 2013; Schattmann & Sherwin, 2007b). Some studies including 
both cross-sectional and double-blind placebo controlled trials found improved performance on 
tasks assessing spatial visualisation and mental rotation ability following testosterone 
administration compared with the placebo condition in healthy females  (Aleman et al., 2004; 
Burkitt et al., 2007; Gouchie & Kimura, 1991; Hausmann et al., 2000; K. Miller et al., 2005; 
Moffat & Hampson, 1996; Pintzka et al., 2016; Shute et al., 1983; Slabbekoorn et al., 1999; Van 
Goozen, Cohen-Kettenis, et al., 1994; Van Goozen et al., 1995), however, many other studies 
examining this association did not find significant results related to this domain (Durdiaková et 
al., 2012; Falter et al., 2006; Halari et al., 2005; Hassler et al., 1992; Hussain et al., 2016; 
Janowsky et al., 1998; McKeever et al., 1987; Neave et al., 1999; Puts et al., 2010). These findings 
are, of course, different from those in PCOS samples with naturally and abnormally elevated 
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testosterone levels. Overall, in PCOS samples, there seems to be no significant association 
between testosterone levels and spatial ability. 
5.4 ANDROGEN LEVELS AND EMOTION PROCESSING  
The relationship between androgen levels and emotion processing was examined by two cross-
sectional studies and ten interventional studies.  
5.4.1  Cross-sectional studies 
Two small cross-sectional studies (Stanton, Wirth, Waugh, & Schultheiss, 2009; van Honk et 
al., 1999) investigated the association between androgen levels and emotion processing in 
females, with one finding a relationship between attending away from angry faces and higher 
testosterone levels, while the other found no significant association. In 16 healthy females, 
higher Free Testosterone levels were significantly associated with attending away from angry 
faces (Emotional Stroop Task - Pictures of Facial Affect) (van Honk et al., 1999). However, 
this finding was limited only to testosterone samples taken 6 hours prior to testing (reflecting 
the highest levels of testosterone), testosterone samples collected at other times were not 
significantly correlated, which may be a chance finding due to multiple testing. Stanton et al. 
(2009) found no significant correlation (regression analysis) between emotion processing (Face 
Stimulus Test) and Free Testosterone levels (n = 14). Additionally, no significant correlation 
was found between brain activity (amygdala and ventromedial prefrontal cortex) and Free 
Testosterone levels during the emotion processing task in this study.  
5.4.2 Interventional studies 
Ten interventional studies assessed varied aspects of emotion processing in relation to 
testosterone levels (Bos et al., 2016; Bos et al., 2013; Enter, Terburg, Harrewijn, Spinhoven, & 
Roelofs, 2015; Hermans et al., 2007; Olsson et al., 2016; Terburg, Aarts, & van Honk, 2012; 
van Honk et al., 2005; van Honk & Schutter, 2007; van Honk et al., 2011; van Wingen et al., 
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2009). Four of ten studies examining the relationship between testosterone and facial emotion 
processing suggested that testosterone administration reduced aspects of the response to 
threatening facial stimuli, including faces expressing fear or anger (Hermans et al., 2007; 
Terburg et al., 2012; van Honk et al., 2005; van Honk & Schutter, 2007). van Honk et al. (2005), 
in a sample of 16 healthy females, found that the vigilant emotional response to masked fearful 
faces (Masked Emotional Stroop Task) observed in the placebo condition significantly reduced 
following testosterone administration. In another study, testosterone administration was 
followed by a reduced sensitivity in recognising angry faces compared with the placebo 
condition in 16 healthy females (van Honk & Schutter, 2007). However, in this study, no effect 
of testosterone was observed for faces expressing fear or disgust. Similarly, a significant delay 
in gaze aversion (gaze or attendance away from/endurance of attendance to threatening faces) 
from masked angry faces was found in another study including 20 healthy females following 
testosterone administration compared with a placebo condition (Social Dominance Task) 
(Terburg et al., 2012). Greater tolerability or a greater delay in gaze aversion further indicate 
reduced sensitivity toward threatening angry faces.  In the final study, Hermans et al. (2007) 
found a reduced anxiety response (lower skin conductance and reduced affective startle 
response) to negative-valence pictures in 20 high trait-anxiety participants (STAI) following 
testosterone administration.  
In a test of “social intelligence”, van Honk et al. (2011) found a significant decrease in the score 
on the Reading the Mind in the Eyes Test (RMET) following testosterone administration 
compared with the placebo condition (n = 16). In the same study, a significant negative 
correlation was found between endogenous Free Testosterone levels and RMET scores in the 
placebo condition. Another randomised double-blind study (Olsson et al., 2016) showed similar 
results with significantly reduced scores on the RMET following testosterone administration. 
Female participants (n = 33) performed less accurately on the task compared with the placebo 
condition (Olsson et al., 2016). In these studies, however, no significant effect of testosterone 
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administration was found on self-reported anxiety and/or mood (STAI, POMS) (Olsson et al., 
2016; van Honk et al., 2011). However, as discussed earlier, the POMS may not be an accurate 
reflection of symptoms of low mood as found in depression. To summarise, results indicate that 
increasing testosterone levels in females may be related to a decreased vigilant emotional and 
startle response, delay in gaze aversion, and decreased facial emotion processing which may all 
relate to social anxiety, and also to aspects of reduced “social intelligence”.  
Four brain-imaging studies found a significant association between brain activity during 
emotion processing tasks and testosterone administration (Bos et al., 2016; Bos et al., 2013; 
Enter et al., 2015; van Wingen et al., 2009), however, only one found a significant direct effect 
of testosterone administration on performance on the emotion processing task (Enter et al., 
2015). In a sample of 18 females with Social Anxiety Disorder (SAD), a significant decrease 
in gaze avoidance for angry faces was observed following testosterone administration (Enter et 
al., 2015). Gaze avoidance is understood to be a characteristic feature of SAD (Moukheiber et 
al., 2010; M. Stein & Stein, 2008) and individuals with SAD have been generally found to show 
low levels of testosterone compared with healthy individuals (Giltay et al., 2012). Studies have 
also demonstrated avoidance of the eye-region of angry faces in individuals with SAD (Horley, 
Williams, Gonsalvez, & Gordon, 2004). Enter et al.’s (2015) study showed a significant effect 
of a single administration of testosterone on gaze avoidance toward angry faces (reduced gaze 
avoidance) in females with SAD (n = 18) but not in healthy controls (n = 19). However, no 
significant change was found in performance on the task assessing facial emotion processing 
(NimStim task involving angry, happy and neutral facial expressions) following testosterone 
administration in this study. Three remaining studies (n = 53) found significant changes in brain 
activity in areas crucial for emotion processing (including increased amygdala activity, reduced 
connectivity between left inferior frontal gyrus, anterior cingulate cortex and supplementary 
motor area, reduced neural response to emotional faces in the precuneus) following testosterone 
administration compared with the placebo condition (Bos et al., 2016; Bos et al., 2013; van 
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Wingen et al., 2009). However, no direct effect of testosterone administration on measures of 
emotion processing (emotion condition of the Blocked Design Task, Dynamic Facial 
Expression Task, adaptation of the RMET) was detected in any of the studies (Bos et al., 2016; 
Bos et al., 2013; van Wingen et al., 2009). In addition, androgen levels were not found to be 
significantly correlated with self-reported mood (Mood Rating Scale and POMS) or anxiety 
(STAI) in these studies. 
Overall, these results suggest that testosterone administration reduces sensitivity of response to 
threatening facial stimuli, particularly faces expressing anger and fear, and reduces anxiety 
response by altering physiological skin and affective startle response (Hermans et al., 2007; 
Terburg et al., 2012; van Honk et al., 2005; van Honk & Schutter, 2007). Testosterone 
administration was found to be associated with decreased social anxiety (Enter et al., 2015; 
Terburg et al., 2012) observed through reduced gaze avoidance (and increased fixation toward 
the eye region), reduced physiological anxiety response, and attentional bias, which seems to 
be a consistent finding. Data suggests that testosterone administration reduces attention towards 
threat stimuli while reducing gaze avoidance (a socially anxious pattern) and reduces startle 
response and skin conductance, both in healthy volunteers, and in high trait anxiety and social 
anxiety (Hermans et al., 2007). 
5.4.3  Overall summary 
Observational studies were less likely to find significant positive results, perhaps due to issues 
of relatively compressed ranges of testosterone levels, normal fluctuation in androgen levels, 
and heterogeneous groups. Studies tended to find worse performance on tests assessing “social 
intelligence” (RMET) following testosterone administration (Olsson et al., 2016; van Honk et 
al., 2011). Van Honk et al. (2011) also found a significant negative correlation between baseline 
Free Testosterone levels and scores on a computerised adaptation of the RMET (higher 
testosterone levels associated with worse empathy). This is consistent with findings showing 
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testosterone’s capacity to alter the processing of facial threat, particularly facial indicators of 
fear and anger which promote sociality through an empathic understanding of other people’s 
emotions. (Baron-Cohen, 2002; J. Harris, Rushton, Hampson, & Jackson, 1996; Hermans et al., 
2006; van Honk & Schutter, 2007). Studies have shown a negative association between 
empathy, crucial for understanding or inferring the emotional states of others and important for 
healthy social functioning, and testosterone levels (Olsson et al., 2016; van Honk et al., 2011).  
There was strong evidence for an association between emotion processing and changes in brain 
activity following testosterone administration in neuroimaging studies (Bos et al., 2016; Bos et 
al., 2013; Enter et al., 2015; van Wingen et al., 2009). Although data consistently shows reduced 
sensitivity toward fearful and threatening emotional faces (observed through reduced gaze 
aversion and avoidance and reduced recognition accuracy of dominant angry faces) 
neuroimaging studies involving testosterone administration in humans have consistently shown 
increased amygdala reactivity (Bos et al., 2013; van Wingen et al., 2009). The amygdala is 
strongly linked to neural networks involved in fear responses and is sensitive to emotional facial 
expressions (Phelps & LeDoux, 2005). Patients with mood and anxiety disorders have been 
found to show exaggerated amygdalar responses to emotional faces compared with controls 
(Bos et al., 2013; Drevets, 2003; Monk et al., 2008). Additionally, androgen receptors are 
present in the amygdalar region and so this region is, therefore, a crucial target for testosterone 
(Sarkey, Azcoitia, Garcia-Segura, Garcia-Ovejero, & DonCarlos, 2008). However, one study 
found that testosterone administration appears to selectively increase activation of the 
superficial amygdala and to a lesser extent the basolateral amygdala, and an increased activation 
of these sub regions of the amygdala is consistent with a fear-reducing effect of testosterone 
(Bos et al., 2013). One brain imaging study found a significant reduction in connectivity 
between the left inferior frontal gyrus (IFG) and the anterior cingulate cortex (ACC) and 
supplementary motor area (SMA) crucial for the emotion processing task (RMET) compared 
with the placebo condition (Bos et al., 2016). Results suggest that these brain regions are crucial 
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for optimal performance on the emotion processing test. The above mentioned brain regions 
are involved in integrating sensory information and for planning behaviour during emotion 
processing. Studies have demonstrated worse performance following testosterone 
administration on the RMET which involves inferring emotions or mental states based on 
pictures of the eye-region (Olsson et al., 2016; van Honk et al., 2011). However, studies 
investigating changes in brain activity in relation to testosterone did not find a direct association 
between testosterone administration and performance on emotion processing measures.  
 
5.5 CONCLUSION   
This chapter investigated the relationship between androgen levels and symptoms of depression 
and anxiety, cognitive function, and emotion processing performance in females of 
reproductive age. The main reasons for conducting this systematic review were:  
1) There is a clear link between PCOS, characterised by androgen excess, and depression.  
The relationship of low mood to high levels of androgens in this condition is not, however, 
as clear (Cooney et al., 2017) and neither is the effect of anti-androgen treatment on 
depression. Additionally, there is limited evidence related to cognitive function and 
emotion processing in females with PCOS. It is, therefore, useful to examine the evidence 
regarding the direct association between androgen levels, and mood, cognitive and emotion 
processing performance in females with PCOS. 
2) Literature suggests that testosterone levels are positively correlated with male-favouring 
cognitive domains such as visuospatial ability and visuospatial learning and memory and 
negatively correlated with female-favouring cognitive domains including verbal learning 
and memory, psychomotor speed and verbal fluency (Halpern, 2000). However, this 
association is not clearly understood in females of reproductive age, particularly in samples 
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with PCOS showing abnormally elevated levels of Free Testosterone and FAI levels. 
Therefore, one of the aims of the current review was to investigate whether there was an 
association between androgen levels and cognitive function and emotion processing in 
females of reproductive age with and without PCOS. 
3) Until now only one small neuroimaging study has evaluated emotion processing in females 
with PCOS, however, the primary outcome of interest in this study was neuronal activation 
using fMRI during an emotion processing task. The aim of the current review was to 
examine testosterone levels in relation to emotion processing in both observational and 
experimental studies (involving testosterone administration). Experimental studies suggest 
that testosterone administration reduced sensitivity of response demonstrated through 
reduced gaze aversion and gaze avoidance, decreased physiological startle response, and 
decreased selective attention to threatening (anger and fear) faces following testosterone 
administration. Decreased social cognition (empathic response) was observed following 
testosterone administration. 
4) Studies that found a positive association between greater depressive symptomatology and 
higher levels of Free Testosterone and/or FAI used the HADS as the primary depression 
rating scale compared with studies that did not find any significant associations. 
5) Regarding cognitive function, no significant association was found between executive 
function (verbal fluency) in cross-sectional studies but interventional studies found 
androgen treatment to be associated with decreased verbal fluency performance whereas 
anti-androgen treatment appeared to benefit verbal fluency. No significant association was 
found between testosterone levels and spatial ability in females with PCOS. There was 
mixed evidence regarding the relationship between testosterone levels and visuospatial 
ability in interventional studies. Overall the relationship between cognitive function and 








The methods and materials for the current study will be described in this chapter. The rationale 
for the selection of tests used will also be provided. 
 
6.2  MAIN STUDY DESIGN 
The study was approved by the University of Otago Human Ethics Committee (Health) (see 
Appendix E). Participants gave written informed consent prior to study inclusion (see 
Appendices A and B for information sheets and consent forms). 
The study was a longitudinal, parallel-group study. Testing sessions were conducted at two 
time-points (baseline and 12 weeks after) for both patient and control groups. At each time-
point, measures of mood, cognitive functioning, emotion processing, and physical symptoms 
were collected. The study was naturalistic, in that the nature and choice of treatment for the 
patient group was the responsibility of the endocrinologist who worked at Christchurch 
Women’s Hospital and at a private clinic. All included patients had abnormalities in the 
androgen system and were treated with standard hormonal medication. The dosage/type of 
medicine depended on a variety of clinical factors. Non-PCOS control participants completed 





6.3.1  PCOS patients 
There were two pathways for recruitment of the clinical sample: 
1) females referred to gynaecological endocrine clinics at Christchurch Women’s Hospital 
(public hospital) and the Women’s Health Clinic at Southern Cross Hospital (private 
hospital) in Christchurch, or, 
2) females responding to advertisements in local newspapers (The Christchurch Star 
Newspaper and The Metropol) seeking volunteers with untreated symptoms of PCOS.  
Regardless of the pathway for recruitment, all patients were treated by the same 
Gynaecological-Endocrinologist, who assessed their hormonal profile and put a treatment plan 
in place depending on their condition.  
Inclusion criteria were as follows:  
1. females aged between 16 and 40 years,  
2. diagnosis of PCOS by the Gynaecological-Endocrinologist  
3. pre-menopausal, and 
4. able to provide informed consent. 
Reasons for exclusion included: 
1. taking exogenous hormones prior to the study, 
2. neurological conditions (e.g., multiple sclerosis), major psychiatric conditions (e.g., bipolar 
disorder or schizophrenia), or major chronic medical illnesses (e.g., cancer or HIV), 
3. current serious alcohol and/or substance dependence, 




6. previous head injury resulting in loss of consciousness for more than an hour, 
7. other endocrinological abnormality apart from excess androgen levels,  
8. infertility treatment (the current study involved androgen-lowering medication, including 
agents such as oral contraceptive pills, which are considered appropriate first-line treatment 
in females with no desire to conceive), 
9. insufficient visual or auditory functioning for completion of cognitive tests, and 
10. non-fluency in English. 
Once patients expressed interest in participation, they were provided with an information sheet 
(see Appendix A) and were then contacted by the PhD student to discuss further details of study 
participation and to complete preliminary screening. Opportunity was given to ask questions, 
and to call friends or family/whānau for advice or support, before deciding whether to consent 
to taking part in the study. After providing consent (see Appendix B for the consent form), 
baseline assessment was organised and completed before treatment began. Baseline assessment 
involved a more thorough screening of major neurological, psychiatric, or medical conditions. 
6.3.2 Control participants (Non-Polycystic Ovarian Syndrome) 
Control participants were eligible for inclusion provided they were pre-menopausal females 
aged between 16 and 40 years and showed normal androgen levels along with no physical 
symptoms of PCOS, such as hirsutism, severe acne, or ovarian cysts. Control participants were 
recruited over the same period as patients, using flyers posted in public places around 
Christchurch, including shopping malls, health centres, gymnasiums, university campuses (see 
Appendix C), and online resources (http://www.subjectswanted.co.nz/). Once a potential 
control participant had expressed interest, the study information sheet was mailed to them and 
any questions were answered over email or phone. Screening questions were conducted over 
the phone, before recruitment and assessment began. The control group had the same exclusion 
criteria as patients. Please see a flowchart (Figure 6.6) for an overview of study design, which 
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describes the relationship between Study 1 (baseline) and Study 2 (following treatment), and 
the nature of the two groups involved in these studies .  
6.3.3  Matching of control participants to PCOS patients 
Patients and control participants were matched in a pair-wise manner for age (within five years 
of age). An attempt was made to match the two groups for estimated premorbid IQ at a group 
level by advertising in places in which a representative sample of the population would be 
present, including malls, gyms, universities and libraries.  
The method of obtaining menstrual status and premorbid IQ is described below. 
6.3.3.1 Menstrual status  
Only reproductive-aged/pre-menopausal females were included in the current study. Control 
participants were classified as being in either the follicular or the luteal phase of their menstrual 
cycle, determined by recording the date the last menstrual period started, and the usual length 
of the menstrual cycle. The follicular phase (and consequently the menstrual cycle) varies 
widely, but the luteal phase is a known number of days. Control participants were typically 
tested at the same phase of their menstrual cycle at baseline and follow-up testing. Since females 
with PCOS often have highly irregular menstrual cycles or experience amenorrhea, this degree 
of consistency in menstrual cycle phases between baseline and follow-up was not possible to 
record in this group.  
6.3.3.2  Estimated Premorbid IQ  
Premorbid verbal IQ was estimated using the National Adult Reading Test (NART) (Nelson & 
Willison, 1991). It comprises of 50 words printed in order of increasing difficulty and is 
considered to be a reliable measure of premorbid verbal IQ in clinical use (Spreen & Strauss, 
1998). The value of the test lies in its ability to produce an accurate estimate of premorbid IQ 
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through word reading, since word reading tends to be preserved in abnormal aging and other 
neurological disorders (Crawford, Deary, Starr, & Whalley, 2001). Phonetically irregular and 
relatively short words are used (e.g., ‘ache’, ‘naïve’, ‘thyme’), as well as generally unfamiliar 
words (e.g., ‘assignate’, ‘demense’, ‘campanile’). Reading of an unfamiliar word depends on 
the individual’s ability to phonetically decode the constitutional elements of the word rather 
than reliance on prior familiarity with the word (Nelson & Willison, 1991). Participants read 
the list of words aloud and the number of errors were recorded by the interviewer. 
The NART produces a predicted verbal IQ score, as calculated by the total number of 
mispronunciation errors. United Kingdom norms for the NART were used in this study, due to 
limited availability of New Zealand norms at the time of study development. Correct 
pronunciation of NART words was determined from the pronunciation guide for Australian and 
New Zealanders provided by Macquarie University of Australia. The number of incorrect 
pronunciations were scored and converted to predict Wechsler Adult Intelligence Scale-
Revised Verbal IQ scores using the NART manual conversion table (see Appendix G).  
 
6.4  SCREENING INSTRUMENTS AND CLINICAL RATING SCALES 
6.4.1 Mini International Neuropsychiatric Interview: Version 5.0.0  
The Mini International Neuropsychiatric Interview (MINI) is a brief, structured diagnostic 
interview of psychiatric disorders in line with the Diagnostic and Statistical Manual of Mental 
Disorders: Version Four (DSM-IV) (Sheehan et al., 1998). The MINI has become a reference 
worldwide and has been translated into 65 languages, and demonstrates good concurrent 
validity. The initial questionnaire contains yes/no questions about psychiatric conditions. If any 
of these questions are answered yes, a more in-depth interview follows to determine whether a 
diagnosis can be made (see Appendix I). 
156 
 
The MINI was used in the current study to screen PCOS patients and control participants to 
ensure that they had not experienced current or past severe psychiatric conditions including 
bipolar or psychotic disorders. It took approximately 15-20 minutes to administer. Since 
psychotic disorders were part of exclusion criteria, they were screened over the phone before 
the participant arrived for baseline assessment.  
6.4.2 Depression rating scales 
Some of the more commonly used depression rating scales in research settings include the 
HAM-D (M. Hamilton, 1960), MADRS (Montgomery & Asberg, 1979), versions of the BDI 
(Beck, Steer, & Carbin, 1988), and the Patient Health Questionnaire-9 (PHQ-9) (Kroenke, 
Spitzer, & Williams, 2001). Since the current study involved a medical sample with 
endocrinological abnormalities, the HADS was used (see Section 6.4.2.2 for a description). It 
has been suggested that self-report and clinician-rated scales uniquely contribute to the 
prediction of treatment outcome (Uher et al., 2012), and thus, both clinician-rated (QIDS-
Clinician Rated Scale) and self-report (HADS) scales for depression were included in the 
current study (see Appendix J). 
6.4.2.1  Quick Inventory of Depressive Symptomatology - Clinician Rated 
The Quick Inventory of Depressive Symptomatology - Clinician-Rated (QIDS-C) was used in 
the present study to assess depression symptom severity in both groups. The QIDS is a relatively 
new and a more time-efficient measure of depressive symptom severity derived from the 30-
item Inventory of Depressive Symptomatology (IDS) (Rush, Carmody, & Reimitz, 2000; Rush 
et al., 2003). The QIDS is sensitive to small changes in mood symptoms related to medications 
or medical treatments (Rush et al., 2003), making it useful for research purposes. It was 
originally developed to improve on the available depression rating scales by 1) providing equal 
weightings (0-3) for each symptom item; 2) providing clearly stated anchors 
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(duration/frequency numbers) estimating frequency and severity of each item (e.g. 0, 1, 2, or 
3), and 3) including DSM-IV criterion items required to diagnose major depression. The usual 
time-frame for assessing symptom severity is the seven-day period prior to the interview.  
The QIDS has good psychometric properties in clinical populations. It shows strong concurrent 
validity with established depression rating scales (Rush, Bernstein, et al., 2006; Rush, Carmody, 
et al., 2006), with robust correlations between QIDS-C and the Inventory of Depressive 
Symptomatology (IDS-C30) for outpatients with MDD (r = 0.82) and bipolar disorder (r = 
0.81). Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) and QIDS-C 
have identical items and are highly correlated (Bernstein et al., 2009). High internal consistency 
(r = 0.85) has been demonstrated for QIDS-C (Trivedi et al., 2004). The QIDS-C has been 
found to be correlate strongly with the HAM-D (r = .61 to .83). An evaluation of QIDS-C in 
comparison with the MADRS and the QIDS-SR revealed nearly equal Cronbach α reliability (r 
= 0.85-0.89) (n = 229) (Doraiswamy et al., 2010). 
The QIDS has been used in a variety of research and clinical settings including inpatient and 
outpatient psychiatric clinics and primary care settings. It has been used in study samples 
including depressed pre-menopausal and post-menopausal females with and without depression 
(Kornstein et al., 2013; E. Young et al., 2007), females with PCOS (Klimczak et al., 2015; Pastore 
et al., 2011) , depressed post-menopausal females (Kripke et al., 2006), females with varied 
hormonal status and mood disorders (S. Weiss et al., 2016), and inpatients (70 to 79% females) 
with MDD and bipolar disorder (Bernstein et al., 2009). The rationale behind using the QIDS in 
the current study was its sensitivity to small changes in depressive symptomatology over time 
(Rush et al., 2003), which was relevant for the current study involving anti-androgen treatment. 
The scoring system for the QIDS converts responses to 16 separate items into the nine DSM-
IV symptom criterion domains, which are used to characterise a major depressive episode. 
These nine domains include: 1) depressed mood; 2) concentration; 3) self-criticism; 4) suicidal 
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ideation; 5) interest in social activities; 6) energy/fatigue; 7) sleep disturbance (initial, middle, 
and late insomnia or hypersomnia); 8) decreased or increased in appetite/weight; and 9) 
psychomotor agitation or retardation. The total score ranges from 0 to 27 and is obtained by 
adding the scores of each of the nine symptom domains of the DSM-IV criteria (Rush et al., 
2003). Four items are allocated to sleep disturbance (early, middle and late insomnia and 
hypersomnia), two items to psychomotor agitation and retardation, respectively, four items to 
appetite and weight disturbance, and one item for the following six domains: depressed mood, 
decreased interest, decreased energy, worthlessness and guilt, concentration and decision 
making and suicidal ideation. Each item is rated from 0 to 3 and for symptom domains with 
more than one item, the highest score obtained on the relevant item for each domain was 
considered. For example, if early insomnia is 2, middle insomnia is 1, late insomnia is 3 and 
hypersomnia is 2, the sleep disturbance domain is scored 3. (See Appendix J). The participant 
was asked to rate the severity and frequency of specific symptoms present over the last seven 
days. Higher scores reflected more severe depressive symptoms. 
6.4.2.2  Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) was developed as a self-report scale to 
assess, clearly define, and differentiate between depression and anxiety states (Zigmond & 
Snaith, 1983). It is considered a reliable instrument with valid measures of depressive 
symptoms and anxiety (Herrmann, 1997), and is sensitive to changes in response to 
psychological and pharmacological interventions (Cusin, Yang, Yeung, & Fava, 2010).  The 
HADS has been shown to efficiently assess severity of anxiety and depressive symptomatology 
in both medical and psychiatric conditions (Bjelland, Dahl, Haug, & Neckelmann, 2002; 
Herrmann, 1997) and shows sensitivity to small changes in symptoms over time in medical 
conditions (Hinz, Zweynert, Kittel, Igl, & Schwarz, 2009). Assessment of depression in medical 
populations is complicated due to an overlap between physical symptoms of depression and 
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symptoms of medical illness or side effects of medications to treat illnesses (e.g., disturbances 
in sleep and appetite). The HADS does not include items related to the physical symptoms of 
depression (Cusin et al., 2010; Zigmond & Snaith, 1983), which is why it was selected for 
inclusion in the present study. 
The HADS shows good Cronbach’s α reliability for anxiety (r = 0.85) and depression (r = 0.83) 
subscales (Golden, Conroy, & O'Dwyer, 2007). Test-retest reliability of the total scales and 
subscales is strong, with r = 0.89, 0.86 and 0.91 (p < 0.001) for anxiety, depression, and total 
scale scores, respectively (Spinhoven et al., 1997). Overall, the HADS has been found to have 
strong concurrent validity as shown in a comprehensive review (Bjelland et al., 2002) with 
comparable sensitivity and specificity of scales such as the General Health Questionnaire, 
Symptom Checklist-90 (anxiety scale) and the STAI. 
The HADS has been used in several studies examining psychological features in females with 
PCOS and in heathy females (Barry, Kuczmierczyk, et al., 2011; Bazarganipour et al., 2013; 
Cinar et al., 2011; G. Conway et al., 2014; Dag et al., 2017; Moran et al., 2012; Moran et al., 
2010; Moran, Teede, & Vincent, 2015; Zheleznova et al., 2013). Since the current study involved 
examining and comparing depression and anxiety in females with PCOS and controls, along with 
assessing change in symptoms within the PCOS group over the course of treatment, the HADS 
was selected as the self-report measure of psychological symptoms (see Chapter Five).  
The HADS determines clinical categories of disorder including no disorder, mild, moderate and 
severe anxiety/depression. It consists of 14 items with scores ranging from 0 (no symptoms) to 
3 (maximum severity) and takes two to five minutes to administer (Snaith, 2003). Results are 
assessed on each subscale: depression and anxiety, with total scores for each subscale ranging 
from 0 to 21 and total scores ranging from 0 to 42 points. For both anxiety and depression 
scales, scores of less than seven indicate non-cases. A score of 8-10 is considered mild, 11-14 
is moderate and a score of 15-21 is severe.  
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An example of an item from the anxiety scale is ‘I get a sort of frightened feeling as if something 
awful is about to happen’: 0) Not at all, 1) From time to time, occasionally, 2) A lot of the time, 
3) Most of the time/very definitely. An example item from the depression scale is ‘I can laugh 
and see the funny side of things’: 0) As much as I always could, 1) Not quite so much now, 2) 
Definitely not so much now, 3) Not at all.  
 
6.5 QUESTIONNAIRES FOR ADDITIONAL INFORMATION FROM 
PARTICIPANTS 
6.5.1 Demographic Questionnaire 
Different forms of the Demographic Questionnaire were completed by patients with PCOS and 
control participants at both time-points of the study (see Appendix H). Baseline items covered 
demographic characteristics such as age, gender, ethnicity, marital status, relationship history, 
and education. In addition, factors such as current physical illnesses, prescribed medications, 
current and history of mental illness, history of head injury, menstrual phase, length of 
menstrual cycle, hearing or sight difficulties, smoking behaviour, alcohol use, substance use 
and handedness were noted.  
At follow-up, the Demographic Questionnaire was a shorter version of the baseline version, as 
many of the demographic and clinical details did not need to be obtained more than once. The 
follow-up version included current physical illnesses, medications, phase of menstrual cycle 





6.6.  COGNITIVE ASSESSMENT 
6.6.1 Controlling for factors that may affect cognitive function 
Cognitive function is affected by many factors and it is important that consideration is given to 
these factors during study design and data analysis.  
Some of these factors include age, gender, medications, serious psychiatric or neurological 
illness, menstrual phase, substance consumption and abuse, and state anxiety. In the current 
study, these factors were taken into account by 1) only including female participants, 2) only 
including participants aged between 16 and 40 years to avoid hormonal and cognitive effects 
of menopause and menarche symptoms and to limit the effects of age-related cognitive decline, 
3) excluding females with severe neurological and psychiatric illnesses (e.g., multiple sclerosis 
and bipolar disorder) due to their effects on cognitive function and also since treatment involved 
(particularly Valproate) stimulates excess androgen production (Isojarvi et al., 1993; McIntyre 
et al., 2003; Nelson-DeGrave et al., 2004), 4) noting any alcohol/drugs taken by control 
participants or patients and excluding them if they reported taking any substances prior to 
testing, and 5) excluding females with other hormonal complications or females who were 
pregnant. The effects of state anxiety were measured using a Visual Analogue Scale in order to 
be able to control for state anxiety if significant group differences are found.  
6.6.1.1 State anxiety  
State anxiety may influence cognitive functioning. Studies have showed an impairment in 
verbal and spatial processes following induced anxiety (Eysenck & Calvo, 1992; Eysenck & 
Derakshan, 1998; Vytal, Cornwell, Arkin, & Grillon, 2012). To control for such an effect, a 
measure of state anxiety was included at both baseline and follow-up cognitive assessments for 
all participants. State anxiety was measured using a Visual Analogue Scale (VAS), which was 
completed at three predetermined time-points over the course of cognitive assessment (see 
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Appendix L). Participants were instructed to rate their current levels of anxiety by drawing a 
line perpendicularly along the scale from 0cm to 10cm, with 0cm reflecting lowest anxiety (“not 
at all anxious”) and 10cm reflecting highest possible anxiety (“worst anxiety ever”) (see Figure 
6.1). This scale was scored by measuring the number of centimetres between the left-hand end 
and the participant’s mark (e.g., a mark 5.6cm along the line would equate to a score of 5.6; see 
Figure 6.1). On the VAS, the interviewer noted the time when the three ratings of anxiety were 
made. Since this scale is subjectively marked, it is of most value when looking at change within 
individuals over a certain time period, which is why it was included in the current study.  
1.  Please rate the way you feel in terms of the dimension given below 
2.  Regard the line as representing the full range of the dimension 
3.  Rate your feelings as they are at the moment 
4.  Mark clearly and perpendicularly across each line 
 
Example:    
 
Not at all anxious           Worst anxiety ever 
Figure 6.1 Visual Analogue Scale used to measure state anxiety at three time-points 
during the cognitive testing 
 
6.6.1.2  Psychoactive substances 
Psychoactive substances have been shown to affect cognitive function. Nicotine has been 
related to improved performance on cognitive tests, particularly on tasks involving various 
aspects of attention, working memory and recognition memory (Kumari & Gray, 2003). In 
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contrast, alcohol and cannabis have a depressogenic effect on the central nervous system which 
slows reaction time and affects performance on cognitive tasks (Lyvers & Maltzman, 1991; 
Weissenborn & Duka, 2003). To account for the effects of nicotine, cannabis and alcohol on 
cognitive test performance in the present study, participants were instructed not to consume 
alcohol or cannabis within 12 hours prior to the testing session and were asked to report their 
smoking status, current alcohol and cannabis use and history as a part of the Demographic 
Questionnaire (see Appendix H). 
6.6.1.3  Visual and hearing acuity 
Visual and hearing acuity may influence performance on cognitive tests, as most involve 
presentation of visual or verbal stimuli. Prior to baseline assessment, participants were asked if they 
had visual or hearing impairments. Most participants who reported visual impairment had their 
vision corrected either with glasses or contact lenses and wore these during the testing sessions.  
6.6.1.4  Practice effects 
The term practice effect refers to enhanced performance on cognitive tasks due to prior 
experience on the same or a very similar task. Better performance occurs due to previous 
experience of the task rather than actual improvement of the skills being assessed. Practice 
effects in the present study were minimised in two ways.  First, where possible, alternate forms 
of most tasks were used for the follow-up session. The same version of the RMET, FER and 
the TMT were used for both test sessions. Overall performance may have improved as a result 
of participants being familiar with the task, although this is unlikely to occur for the emotion 
processing tasks since participants did not receive feedback about their baseline performance 
accuracy. Second, the matched control group completed both testing sessions in order to control 




6.6.2  Cognitive task selection 
Cognitive tasks administered in the current study were selected for inclusion because of their 
ability to measure cognitive functions shown to be impaired in depression, with the addition of 
tasks shown to be related to PCOS and high androgen levels (refer to Chapter 2, 3 and 4). Several 
cross-sectional and interventional studies assessing cognitive function in females with PCOS and 
females with high levels of androgens, or healthy females have focused on verbal and visuospatial 
learning and memory, verbal fluency, and psychomotor speed since these domains have been 
shown to be affected by gender differences and hormonal changes in females (Barry et al., 2013; 
K. Miller et al., 2005; Schattmann & Sherwin, 2007a, 2007b; Shute et al., 1983; Slabbekoorn et 
al., 1999; Van Goozen, Cohen-Kettenis, et al., 1994; Van Goozen et al., 1995) (Refer to Chapter 
2, Section 4.9.1 for a description of gender differences in cognitive function). Testosterone 
administration in females has been positively associated with better performance on tests 
measuring visuospatial ability and mental rotation (Aleman et al., 2004; Gouchie & Kimura, 
1991; Hausmann et al., 2000; Moffat & Hampson, 1996; Postma et al., 2000; Shute et al., 1983) 
(see Chapter Five) and negatively associated with verbal memory and fluency (Krug, Mölle, 
Dodt, Fehm, & Born, 2003; Thilers, MacDonald, & Herlitz, 2006). Additionally, testosterone has 
been shown to be related to emotion processing (van Honk et al., 2005; van Honk & Schutter, 
2007; van Wingen et al., 2009). Experimental studies suggest that testosterone administration 
decreases gaze avoidance and an anxiety response (see Chapter Five), however, little is known 
about emotion processing and testosterone levels in PCOS samples. Additionally, research 
suggests significant emotion-specific deficits in MDD (Bourke et al., 2010) and reviews have 
suggested that individuals with depression show abnormal facial emotion processing (Bouhuys 
et al., 1999; Bourke et al., 2010; Roiser & Sahakian, 2013; Stuhrmann et al., 2011). On the basis 
of such findings, psychomotor speed, verbal fluency, verbal learning and memory, visuospatial 
learning and memory and tasks assessing emotion processing were selected as the focus of 
cognitive assessment in the current study. The final five broad domains comprised of:  
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 verbal learning and memory  
 visuospatial learning and memory 
 attention / executive functioning  
 psychomotor speed 
 emotion processing 
The rationale for using particular cognitive tasks within these domains is discussed in section 6.7.  
6.6.3 Order of administration of cognitive tests    
All cognitive tests were administered to both groups in the same order for baseline and follow-up 
(see Table 6.1). This raises the possibility of a systematic bias from test order. Counterbalancing 
the order of the tests was an option to reduce this bias, however, this was difficult because of the 
delayed component required in some of the tasks. In addition, during the timed delay of the 
Consonant Vowel Consonant (CVC) Task, intervening tasks with minimal verbal content were 
administered to reduce the risk of interference of nonsense word recall on the CVC Task. In the 
current study, the TMT and the FER Task were administered as intervening tasks after CVC 
Trials 1-5 and before the CVC direct recall and recognition task was carried out. 
As mentioned previously, for some of the cognitive tasks, alternate forms were available for re-
testing. Such tasks are indicated by an asterisk in Table 6.1. 
6.6.4 Cognitive testing software 
The cognitive testing battery was designed to test a broad range of cognitive domains (see Table 
6.1). Pen-and-paper tasks were administered according to standardised instructions (Lezak, 2004) 
and computerised tests according to their manual protocols (CogState and E-Prime manuals). All 




Table 6.1  
Order of Test Administration in the Cognitive Testing Battery 
Order Cognitive Test Cognitive domain 
1 
Consonant Vowel Consonant Test (CVC) - 
Immediate recall trials* (1-5) 
Verbal learning and memory 
2 Trail-making Test (TMT)(Part A and B) Psychomotor speed  
3 Facial Expression Recognition (FER) Task Emotion processing 
4 CVC delayed recall and recognition trials* Verbal learning and memory 
5 Timed-Chase Test (TCT)* Psychomotor speed 
6 
Groton Maze Learning Test (GMLT) - 
immediate recall trials* 
Visuospatial learning and memory 
7 
Controlled Oral Word Association Task 
(COWAT)* 
Executive function / attention 
8 
Groton Maze Learning Test (GMLT) - 
delayed recall trial* 
Visuospatial learning and memory 
9 Digit Span Test*   Executive function / attention 
10 Reading the Mind in the Eyes Test (RMET) Emotion processing 
* Indicates cognitive tests with parallel forms for retesting 
 
6.6.4.1 CogState  
CogState® Research Software (CogState, 2006) comprises a customisable range of brief 
computerised cognitive tasks that have been used in a variety of different clinical populations. 
CogState software (version 5.0.0) was used to present the GMLT and the TCT (© 1999-2006 
CogState Ltd.). A computer mouse was used for responses in these tasks. Data were generated 
and collected automatically as the task was performed and uploaded immediately afterward 
from the online tool, DataPoint®. CogState has strong construct validity and correlations with 
standard cognitive tests (Mielke et al., 2014) and has been shown to control for practice effects 
by administering the tests at short-intervals (Fredrickson et al., 2010; Y. Lim et al., 2013; 





E-Prime (W. Schneider, Eschman, & Zuccolotto, 2002) is a widely-used software in 
behavioural research and has customisable computerised experiment requirements. The FER 
Task and the CVC Verbal Task were programmed using the E-Prime 2.0 professional software 
package. E-studio was used to run these tasks and generated data was saved automatically on 
the testing computer. 
 
6.7  DESCRIPTION OF TASKS IN THE COGNITIVE TESTING BATTERY 
6.7.1 Verbal learning and memory 
6.7.1.1 Consonant Vowel Consonant non-word verbal learning Task 
The Rey Auditory-Verbal Learning Task (RAVLT) (Rey, 1964) and the California Verbal 
Learning Task (CVLT) (Delis, Kramer, Kaplan, & Ober, 2000) are two of the most widely used 
measures of declarative verbal learning and memory. The RAVLT in conjunction with age has 
been shown to be useful in predicting psychological outcome after trauma to the brain (Ross, 
Millis, & Rosenthal, 1997) and is a good discriminator between patients with neurological 
disorders and healthy control samples (Schoenberg et al., 2006). The CVLT can usefully 
differentiate between patients with mild cognitive dysfunction and healthy control participants 
(Rabin et al., 2009).  
In the current study, the CVC Task was used to assess cognitive function. The CVC Task 
(Bourke et al., 2012) is a verbal learning and memory task which is designed to be more 
sensitive in detecting mood-related changes in cognitive function compared with the RAVLT 
and the CVLT. It is identical in format, administration and scoring to the recall and recognition 
trials of the RAVLT. The only difference is that in the CVC Task, nonsense words or ‘non-
words’ are presented, instead of words with semantic meaning, which lowers the risk of ceiling 
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effects (Vierck, Porter, Spittlehouse, & Joyce, 2015) and creates greater sensitivity in revealing 
subtle verbal learning or declarative memory deficits. The CVC Task provides less opportunity 
compared with traditional verbal memory tasks to access learning and mnemonic strategies 
(Bourke et al., 2012), thereby providing a mechanism to assess verbal learning and memory 
while controlling for effects of semantic meaning.  
Depressed participants have been shown to score significantly lower on the CVC Task 
compared with non-depressed healthy participants (Vierck et al., 2015). In another study of 
depressed outpatients, effect sizes for immediate recall performance on the CVC Task were 
larger than for the RAVLT, indicating a greater sensitivity to detect deficits in verbal learning 
(Bourke et al., 2012). Non-words in the CVC Task were selected from the Australian Research 
Council (ARC) Non-Word Database (Rastle, Harrington, & Coltheart, 2002) and were all 
monosyllabic in nature, with no semantic meaning in the English language. Each non-word 
comprised of three letters (e.g., vev, fol, wat) beginning and ending with consonants and with 
a vowel as the middle letter. Two different lists were used for baseline and follow-up, with a 
list of 15 words for each testing session (List A and B). Each list consisted of five vowels and 
a mix of consonants. The vowels in each list appeared three times per list in the same order on 
List A and B. Pre-recorded lists were played to participants through the laptop, so that 
participants could see the non-words appear on the screen and could hear them at the same time, 
with a gap of two seconds. This ensured consistent administration. The first five trials of the 
CVC Task took approximately 15 minutes and the recognition part of the task about one minute 
to complete. The number of non-words recalled on each of the learning and memory trials was 
recorded manually (see Appendix K for recording sheets).  
The recognition task was set up to play all 30 List A and List B non-words, and an additional 
15 new non-words, which were presented in random order on the computer screen one after the 
other for up to five seconds. These could be terminated sooner by the participant’s response. 
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The “Z” key was labelled with a “Y” indicating a non-word from the original list and the “/” 
key was labelled with an “N” indicating a new non-word. All outcome measures for both the 
CVC Task recall and recognition tasks were the same as those for the RAVLT. The scores for 
the recognition task were recorded by the computer. 
6.7.2 Visuospatial learning and memory 
6.7.2.1 Groton Maze Learning Test   
A measure of visuospatial learning and memory was important to include in the cognitive 
testing battery due to impairment in this domain in depression (Douglas et al., 2011). 
Visuospatial learning and memory was assessed using the computerised GMLT (CogState, 
2006) (Pietrzak et al., 2008; P. Snyder, Bednar, Cromer, & Maruff, 2005; P. Snyder, Werth, et 
al., 2005). Originally developed by Barker et al. (1931), and modified based on the Hidden 
Maze Task developed by Milner et al. (1965), the GMLT provides a valid measure of 
visuospatial processing speed and some aspects of executive function (Pietrzak, Cohen, & 
Snyder, 2007). The GMLT has been used in studies examining cognitive function in MDD 
(Douglas et al., 2011), psychotic disorders (P. Snyder et al., 2008), attention deficit 
hyperactivity disorder (Mollica, Maruff, & Vance, 2004), and mild cognitive impairment 
(Darby, Maruff, Collie, & McStephen, 2002). Further, the GMLT has been used in 
interventional studies involving testosterone administration in healthy post-menopausal 
females (Davison et al., 2011) and pregnant females with anxiety and depression (Kataja et al., 
2017), however, this task has not been previously used in studies including females with PCOS. 
Since the current study involves an examination of the effect of anti-androgen treatment in 
patients with PCOS, it was imperative that the visuospatial learning and memory measure be 






List A and List B of Nonsense Syllables Included in the Consonant- Vowel-Consonant Task 
at Baseline and Follow-up to Assess Verbal Learning and Memory 
LIST A 
 



































































The GMLT consisted of a 10 by 10 grid of square tiles, presented on a computer screen, in which 
a 28-step pathway was hidden (see Figure 6.2). The tiles at the start and finish were shown in 
locations at the top left and bottom right of the screen. Participants were instructed to find their 
way through the hidden pathway, moving one tile at a time. While moving through the hidden 
maze, participants were required to follow two rules; first, they could not move diagonally and 
second, they could only move one square at a time. The ability to use standard rules is imperative 
for optimal learning of the maze (P. Snyder et al., 2008). The computer indicated visual and 
auditory feedback after each move. If the move was correct the participant was prompted to “go 
on” by the tone created by making that move along with a green tick mark that appeared under 
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the tile. If the move was incorrect (displayed by a different tone and a red cross), the participant 
was required to go back and touch the last correct tile and then choose a different direction to 
advance forward. The GMLT began with three practice trials in a smaller, 5 by 5 grid of squares. 
This was followed by the main task (10 by 10 grid) which involved finding the hidden pathway 
over five successive learning trials. During these learning trials, participants were required to 
construct and hold a spatial representation of the pathway in their working memory.  
On each learning trial, the efficiency (number of correct moves per second) was automatically 
recorded. These scores were automatically saved on the Cogstate software on the laptop, and 
then transferred to the online data set on Cogstate. Twenty well-matched alternate forms of this 
test were available which were chosen by the software for each assessment in pseudo-random 
order to ensure that no participant completed the same hidden path more than once over the 




Groton Maze Learning Test initial screen (GMLT, CogState, 2006) 
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6.7.3  Attention and Executive Functioning 
6.7.3.1 Trail Making Test 
The Trail Making Test (TMT) is a commonly used cognitive test which assesses psychomotor 
speed, attention, and executive function. Under these broad domains, several cognitive 
functions such as visual search, sequencing, divided attention, cognitive flexibility and 
conceptual tracking are assessed (Battery, 1944; Mahurin et al., 2006; Partington & Leiter, 
1949; SÁNchez-Cubillo et al., 2009). 
The TMT consists of two parts (A and B). Part A of the TMT measures visual scanning, number 
recognition, numeric sequencing, and motor speed. Part B assesses the same cognitive functions 
as Part A, as well as additional functions of cognitive flexibility and divided attention. Trail 
Making Test (TMT Part A and B) have been found to have high construct validity (SÁNchez-
Cubillo et al., 2009). High inter-rater and alternate forms of reliability have been shown for this 
test (r = 0.78 to 0.92) (Bowie & Harvey, 2006; Charter, Adkins, Alekoumbides, & Seacat, 
1987; Franzen, 1996). The TMT is often used to examine cognitive decline, brain damage (Boll 
& Reitan, 1973; Giovagnoli et al., 1996; Reitan, 1992) and neurological diseases (Lezak, 
Howieson, & Loring, 1995; Reitan & Wolfson, 1993; Spreen & Strauss, 1998). 
The TMT has been previously used to examine cognitive function in patients with Alzheimer’s 
Disease (Reitan & Wolfson, 2004), schizophrenia and depression (Mahurin et al., 2006), and 
obsessive-compulsive disorder (Moritz et al., 2002). State anxiety and gender do not appear to 
affect performance on the TMT (Chavez, Trautt, Brandon, & Steyaert, 1983). A few studies 
examining cognitive function in post-menopausal females have included the TMT (Barrett-
Connor & Goodman-Gruen, 1999; Kugaya et al., 2003), however, no known studies involving 
pre-menopausal females with any endocrinological conditions have used this task prior to the 
current study.  
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In the current study, Part A and B of the TMT were administered to all participants during both 
testing sessions. Part A required participants to connect a series of encircled numbers, which 
were unevenly distributed on the paper, in ascending order. Participants were instructed to join 
the circles starting from 1-2-3 (to number 25) without lifting their pen/pencil up ‘as quickly as 
they could’. TMT Part B required participants to connect a series of encircled numbers and 
letters in an ascending manner, alternating between the two sequences (1-A, 2-B, 3-C to 13-L) 
(see Appendix M). Most studies use completion time as the only outcome measure for Part A 
and B because the assessor monitors the performance of the participant and intervenes to correct 
mistakes at the time of performance, therefore affecting total time taken to complete the task 
(Hays, 1995; Mahurin et al., 2006; Reitan, 1992; Reynolds, 2002).  
Time taken to complete Part A and B of the TMT were recorded and used as outcome variables 
for this task.  
6.7.3.2 Controlled Oral Word Association Test  
The Controlled Oral Word Association Test (COWAT) is a measure of verbal fluency and 
assesses the ability to spontaneously generate words beginning with a given letter within a set 
time limit. Verbal fluency is a cognitive function that facilitates information retrieval from 
memory, the success of which requires executive control over processes such as selective 
attention, self-monitoring and mental set shifting (Lezak, 2004). Evidence suggests that verbal 
fluency is impaired in MDD (Lezak et al., 1995; Okada, Okamoto, Morinobu, Yamawaki, & 
Yokota, 2003; Takamura et al., 2016).The COWAT has previously been used in some studies 
including depressed individuals (Oral et al., 2012; Pu et al., 2015; Roca et al., 2015; 
Smitherman, Huerkamp, Miller, Houle, & O'Jile, 2007), and in samples with mild cognitive 
impairment (Petersen et al., 1999). It has been used to detect verbal communication deficits 
following brain injuries, to measure an individual’s ability to verbally express themselves in 
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daily life, and to monitor developmental delays related to language in children (Loonstra et al., 
2001; E. Strauss, Sherman, & Spreen, 2006).  
Some research has shown the COWAT to have a greater female-advantage (Bolla, Lindgren, 
Bonaccorsy, & Bleecker, 1990; Rodriguez-Aranda & Martinussen, 2006), however, other studies 
have found mixed results (Lezak et al., 1995; Tombaugh, Kozak, & Rees, 1999). High androgen 
levels have been shown to be negatively related to COWAT performance in two studies involving 
females with PCOS (Schattmann & Sherwin, 2007a, 2007b), suggesting a detrimental effect of 
androgens on verbal fluency. The sensitivity of the COWAT in detecting changes in relation to 
depression and excess androgens formed the basis for its inclusion in the current study.  
The original version of the COWAT included the letters F-A-S which were chosen in a way that 
was statistically random and no parallel version was produced at the time this test was 
developed. The newer version, developed as part of Benton and Hamsher’s Multilingual 
Aphasia Examination (Benton, Hamsher, & Sivan, 1989), provided norms for two sets of letters, 
C-F-L and P-R-W. These letters were selected based on the frequency of English words 
beginning with these letters. In these sets, the first letter has a relatively high frequency in the 
English language, the second has a lower frequency, and the third the lowest frequency of the 
three. In the current study, C-F-L and P-R-W letter sequences were used at baseline and follow-
up respectively. The two forms of the COWAT have good test-retest reliability (r = 0.83) (Ruff, 
Light, Parker, & Levin, 1996). 
Additional instructions for the COWAT included not using proper nouns (for example, countries 
and people’s names), numbers, or the same word with a different ending (for example, eats and 
eating). Most researchers allow 60 seconds for each of the three word-naming trials in the 
COWAT, however, in the current study, 90 seconds were allowed to assess verbal slowing. We 
chose to use the 90 second time-limit in order to be able to compare the current findings with 
findings from previous studies in more severely depressed samples. Each word was recorded on 
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a scoring sheet, including mistakes and repetitions. The outcome measure was the total number 
of words generated for the three trials (see Appendix O for the COWAT recording sheets). 
6.7.3.3 Digit Span Test 
The Digit Span Test in the Wechsler batteries (intelligence and memory scales) is a widely-
used measure of verbal working memory (Lezak, 2004; Wechsler, 1958, 1997). More 
specifically, it assesses attention and short-term retention capacity (short-term memory) (Lezak 
et al., 1995) and examines the specific process of temporary storage (Digit Span Forward) and 
manipulation of information (Digit Span Backward). The Digit Span has been shown to have a 
high test-retest reliability (r = 0.83) (Wechsler & De Lemos, 1981).  
The Digit Span Test has been used by several studies examining cognitive function in depressed 
individuals (Klojčnik, Kavcic, & Vukman; Srisurapanont, Suttajit, Eurviriyanukul, & Varnado, 
2017; E. Warren & Groome, 1984) and has been found to be a reliable measure of central 
executive function in clinically depressed samples compared with healthy participants after 
controlling for medication status (Channon, Baker, & Robertson, 2009). Since sex hormones 
have been shown to affect working memory (Janowsky, Chavez, & Orwoll, 2000), assessment 
of immediate working memory was important to include in the current study.  
The Digit Span Test involves two parts (Digits Forward and Digit Backward) requiring 
attention and short term memory, with a working memory component in the latter test (Lezak, 
2004). Participants were instructed to remember up to seven pairs of number sequences and 
repeat them back to the interviewer in exactly the same way.  In Part A, the participant listened 
to a series of digits, one digit per second, and was asked to repeat it in the same way (Forwards). 
The first pair of number sequences included three digits, the following pair included one more 
digit, and so on until the last pair included nine digits (e.g.: 123, 1234, 12345). In the second 
part of the task (Backwards), the participant was asked to repeat the digits they heard in the 
176 
 
reverse order. This task started with number sequences of two numbers, followed by the next 
sequence with an additional digit, and so on until the last pair of number sequences included 
eight digits. Participants advanced when they had correctly recalled either of the sequences of 
numbers in the seven pairs. The sequences increased in length until a pair of sequences was 
failed or until the task was completed correctly. Scores on Forward Span as well as Backward 
Span were added to produce a Total Digit Span score, reflecting total number of digit sequences 
correctly recalled (maximum 14). Higher scores reflected greater accuracy. Span length 
(greatest number of digits recalled for Forward and Backward, separately) was also an outcome 
measure (see Appendix N).  
6.7.4  Psychomotor Speed 
6.7.4.1 Timed Chase Test 
The Timed Chase Test (TCT) was included in the current study to assess visuomotor processing 
speed (CogState, 2006). This test is generally used as a control task for the motor speed aspect 
of the GMLT. In this test, the participant was instructed to move as quickly and accurately as 
possible while following a coloured moving tile, one tile at a time, through the same 10 by 10 
grid of grey tiles as presented in the GMLT. The first part of the task contained an untimed 
practice session to familiarise the participant to the rules of the task. After the practice session, 
the main trial began, and lasted for 30 seconds. Participants were requested to make as many 
correct moves as possible within the time period. The number of correct moves made per second 
during the main timed trial was recorded automatically by Cogstate software and used as the 
main outcome measure for this test.  
6.7.5  Facial Emotion Processing Tasks 
The FER Task and the RMET were included in the current study as measures of emotion 
processing. Emotion processing involves the ability to ‘read the mind’ of individuals by 
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interpreting social cues and understanding mental states (see Chapter 2). Facial emotion 
processing is central to human social interactions and is influenced by emotional state (Bourke 
et al., 2010; Hale, 1998).  
Emotion processing is of interest to studies examining mood, since facial expression 
recognition has been found to be sensitive to pharmacological intervention in depressed 
individuals (Harmer, O’Sullivan, et al., 2009) and in healthy participants (Harmer, Bhagwagar, 
et al., 2003; Harmer, Rogers, Tunbridge, Cowen, & Goodwin, 2003). Studies, including 
reviews, investigating emotion processing in depressed individuals have found impaired facial 
expression recognition in depressed individuals (Douglas et al., 2011), consistent negative 
interpretation bias, and an attentional bias towards sad facial expressions and away from happy 
expressions (Beck, 1979; Bourke et al., 2010; Elliott, Zahn, Deakin, & Anderson, 2011; Mandal 
& Palchoudhury, 1985). Studies and reviews have shown consistent negative biases for 
ambiguous or neutral facial expressions in individuals with depression so that positive or neutral 
faces are likely to be evaluated as more sad or less happy compared with healthy control groups 
(Bouhuys et al., 1999; Bourke et al., 2010; Douglas & Porter, 2010; Gur et al., 1992; Hale, 
1998; Leppänen et al., 2004), which fits with the cognitive theories of depression (Beck, 1979; 
Fu et al., 2008; M. Warren, Pringle, & Harmer, 2015). This finding is consistent with studies 
including other stimuli such as negative words or ambiguous sentences in individuals with 
depression (Hindash & Amir, 2012).  
One neuroimaging study has examined facial expression recognition in females with PCOS and 
found significant changes in brain activity including greater limbic activation during the 
emotion processing task as found by fMRI in females with PCOS compared with healthy 
controls (see Chapter Five, section 4.9.2) (Marsh et al., 2013). Other studies have examined 
facial emotion recognition in relation to hormonal changes during the menstrual cycle in 
reproductive-aged females without PCOS (C. Conway et al., 2007; Derntl, Kryspin-Exner, 
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Fernbach, Moser, & Habel, 2008; Poromaa & Gingnell, 2014). Evidence suggests that 
testosterone administration in healthy females is associated with a reduced fear response (van 
Honk et al., 2005), reduced gaze aversion from angry faces (Terburg et al., 2012). Studies have 
also shown reduced gaze avoidance in females with Social Anxiety Disorder (Enter et al., 
2015), and worsened performance on tests of “social intelligence” assessing emotion processing 
(Olsson et al., 2016; van Honk et al., 2011) following testosterone administration.  
6.7.5.1 Facial Expression Recognition Task  
The FER Task developed by Harmer and colleagues at Oxford University, United Kingdom 
(Harmer, Bhagwagar, et al., 2003), was selected for inclusion in the current study to measure 
facial emotion processing (Harmer, Bhagwagar, et al., 2003; Harmer, Rogers, et al., 2003). This 
task has been widely used in studies involving depressed individuals (Douglas & Porter, 2010; 
Harmer, Hill, et al., 2003; Harmer, O’Sullivan, et al., 2009) and in studies involving 
antidepressant administration in healthy controls (Browning, Reid, Cowen, Goodwin, & 
Harmer, 2007).  
Cognitive models of depression suggest that depression is characterised by impaired facial 
emotion processing, with studies showing depressed participants to be biased in interpreting 
neutral faces as negative compared with healthy controls (see Chapter 2) (Douglas & Porter, 
2010; Gollan, Pane, McCloskey, & Coccaro, 2008; Gur et al., 1992; Leppänen et al., 2004; 
Stuhrmann et al., 2011). In order to more thoroughly assess the negative interpretation bias in 
the current medical sample with PCOS (and with possible symptoms of mild-moderate 
depression) a greater number of neutral faces were included in the FER Task.  
The FER Task features six basic facial emotions; anger, happiness, sadness, fear, surprise and 
disgust, as well as neutral expressions. These emotions are depicted through images of 
individual characters’ facial expressions taken from the Pictures of Affect Series (Ekman & 
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Freisen, 1976). Each facial emotion is morphed between the prototype (full emotion) and 
neutral by taking a variable percentage of the shape and texture differences between the two 
standard images 0% (neutral) and 100% (full emotion) in 10% steps (Bhagwagar, Cowen, 
Goodwin, & Harmer, 2004; A. Young et al., 1997). In the current study, forty-nine instead of 
thirty neutral facial expressions were included, and facial expressions of surprise (19 faces) 
were excluded as they were deemed to be least relevant to depressive symptomatology. 
Furthermore, expression intensities from 50% of each emotion (half way between the full 
emotion and neutral) to 100% of each emotion were included (see Figure 6.3 for examples of 
faces presented). 
  
Figure 6.3  
Six basic facial emotions; anger, disgust, fear, happiness, sadness and a neutral expression 
(Harmer, Bhagwagar, et al., 2003) 
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During the FER task, faces displaying five basic emotions were presented successively, one 
after another, on a computer screen for 500ms, followed immediately by a blank screen. A total 
of 144 facial presentations were presented (49 neutral, and 19 each of angry, happy, sad, fearful 
and disgusted). Participants were instructed to press one of six labelled buttons on the response 
pad (NEUTRAL, ANGRY, HAPPY, SAD, FEARFUL and DISGUSTED) as quickly and as 
accurately as possible. The accuracy and reaction time for each facial emotion was generated 
and recorded using E-Prime software. This task took approximately 10 minutes for participants 
to complete. 
6.7.5.2 Reading the Mind in the Eyes Test  
The Reading the Mind in the Eyes Test (RMET) was used as a measure of emotion processing 
in the current study (see Appendix P). The RMET (Baron-Cohen, Wheelwright, Hill, Raste, & 
Plumb, 2001; Baron‐Cohen, Jolliffe, Mortimore, & Robertson, 1997) was originally developed 
to assess emotion processing in individuals with autism spectrum disorders (Baron-Cohen et 
al., 2001). Adults with autism spectrum disorders have been shown to perform significantly 
worse on emotion processing tasks compared with sex-matched controls, and the Autism 
Spectrum Quotient (a widely used scale to assess autistic traits in adults) has been found to be 
inversely correlated with scores on the RMET, suggesting an impairment of emotion processing 
in autism (Baron-Cohen et al., 2001; Wing, 1988). The androgen theory of autism (see Chapter 
Three, section 3.4.3) (Baron-Cohen, 2002; Baron-Cohen et al., 2005; Baron-Cohen et al., 2011; 
Baron-Cohen et al., 2001; E. Chapman et al., 2006) provides evidence for a relationship 
between abnormal levels of androgen and impaired social function due to abnormalities in 
emotion processing and empathy (Hergüner, Harmancı, Hergüner, & Toy, 2012; Ingudomnukul 
et al., 2007; Knickmeyer et al., 2006; B. Lee et al., 2017; Ruta, Ingudomnukul, Taylor, 
Chakrabarti, & Baron-Cohen, 2011; Samson, 2009; Tordjman, Ferrari, Sulmont, Duyme, & 
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Roubertoux, 1997). This suggests that testosterone may play an important role in emotion 
processing.   
The RMET has been found to have acceptable test-retest reliability (Fernández-Abascal, 
Cabello, Fernández-Berrocal, & Baron-Cohen, 2013) and has been widely used across different 
cultures. One study in Italy (Vellante et al., 2013) showed a reliability value of 0.83 and an 
internal consistency (Cronbach’ alpha) to be 0.60, another study showed a reliability value of 
0.81 in a Turkish population for the RMET (Yildrim, Kasar, & Guduk, 2011). 
The RMET has previously been used in psychiatric samples including patients with anorexia 
(Harrison, Tchanturia, & Treasure, 2010), schizophrenia (Kettle, O'Brien-Simpson, & Allen, 
2008), borderline personality disorder (Schilling et al., 2012), and in healthy samples (Sapienza, 
Zingales, & Maestripieri, 2009; Voracek & Dressler, 2006). Furthermore, this test has been 
used in interventional studies involving testosterone administration in healthy females (Olsson 
et al., 2016; van Honk et al., 2011). 
The RMET includes 36 still pictures of the eye regions of Caucasian individuals, and one 
practice picture (Autism Research Center, University of Cambridge, Cambridge, United 
Kingdom) (Baron-Cohen et al., 2001; Baron‐Cohen et al., 1997). The main task requires 
participants to choose one of four adjectives (e.g., “jealous”, “panicked”, “arrogant”, “hateful”) 
which best described what the person in the picture may have thought or felt (see Figure 6.4 for 
an example picture) (see Figure 6.4). There was no time limit to complete the task, however, 
participants were asked to answer as quickly and accurately as they could.  
Scoring of the RMET involves a total score resulting from the sum of answers on all 36 items 
completed by the participant. Previous studies have reported no practice effect (Hallerbäck, 
Lugnegård, Hjärthag, & Gillberg, 2009; Handford, Lemon, Grimm, & Vollmer-Conna, 2013), 




Figure 6.4  
An example item from the Reading the Mind in the Eyes Test (Baron-Cohen et al., 2001) 
 
6.8  ENDOCRINOLOGICAL/PHYSICAL ASSESSMENT 
6.8.1  Physical measures 
6.8.1.1 Polycystic Ovarian Syndrome Questionnaire  
The Polycystic Ovarian Syndrome Questionnaire (PCOS-Q) was developed for this study by 
the PhD student and study investigators as a screening tool for volunteers who were responding 
to publicly posted flyers and newspaper advertisements. This non-standardised measure was 
used to assess common symptoms related to PCOS. Nine items were included which covered 
domains related to cosmetic, metabolic, and hormonal irregularities. They were as follows: 
 acne,  
 excess hair growth on face, back, chest or abdominal region, 
 irregular periods/menstrual disturbances,  
 weight management problems or weight gain issues,  
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 male pattern baldness/acute hair loss, 
 presence or absence of ovarian cysts,  
 history of miscarriages or problems with inferility, 
 skin thickening or discoloration (as signs of insulin resistance), and 
 family history of PCOS.  
The participant’s responses to these questions were the basis of screening for inclusion. If more 
than three symptoms were marked as ‘yes’ then further participation involved meeting the 
endocrinologist for accurate diagnosis and appropriate treatment. However, since hirsutism 
(excess hair growth) is an important and more specific marker of androgen excess, this 
symptom was given a greater weighting than the other less specific markers of androgen excess, 
such as weight and acne issues. Additionally, studies have shown that a proportion of females 
with hirsutism may experience psychological difficulties (Barth et al., 1993; Karjula et al., 
2017; Khomami, Tehrani, Hashemi, Farahmand, & Azizi, 2015; Sonino et al., 1993); thus it 
was considered important to use a specific measure of hirsutism, in order to account for the 
independent effect that hirsutism may have on mood. The Ferriman-Gallwey score (FG score) 
was used to evaluate and quantify hirsutism in females with PCOS. This score involved rating 
the presence of excessive hair from 0 to a maximum of 36 in body areas such as the upper lip, 
chin, neck, side burns, periareolar area, sternum, and the midline of the lower abdomen. Such 
criteria used by experts in the field is strict and hence reproducible. Thus, if a participant listed 
hirsutism without mentioning other issues, they were still considered eligible to meet with the 
endocrinologist (see Appendix D for the PCOS-Q). 
Additionally, for the patients recruited directly through the gynaecological endocrine clinics at 
Christchurch Women’s Hospital (public hospital) and the Women’s Health Clinic at Southern 
Cross Hospital (private hospital) in Christchurch, androgen-excess-related symptoms were 
assessed by the endocrinologist, including:  
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 visual quantification of hirsutism (FG score)  
 acne (mild, moderate, severe)  
 BMI 
 waist circumference 
 body fat percentage 
 alopecia (mild, moderate, severe) 
 acanthosis nigricans (mild, moderate, severe) 
 skin tags (mild, moderate, severe) 
 skin thickening (mild, moderate, severe) 
 sleep apnea (mild, moderate, severe) 
 relevant hormonal levels obtained from routine clinical tests (see Section 6.8.5) 
The primary hallmarks of PCOS are hyperandrogenism and anovulation, not ovarian cysts 
(Dunaif & Thomas, 2001; Sheehan, 2004); thus, ultrasound records of ovarian cysts were 
obtained only for some patients (at baseline) when deemed necessary.  
6.8.2 Androgen measures 
Androgen and other hormone levels, as well as symptoms of hyperandrogenism, were collected 
as part of usual clinical care and was provided by the endocrinologist at baseline. Blood samples 
were collected from patients to assess androgen measures including Total Testosterone (nmol), 
Free Testosterone (pmol), and FAI levels. Reference ranges for different types of assays were 
as follows:1) Free Testosterone (0.6-6.8 pg/ml [<50 pmol/L]), 2)Total Testosterone (0.1-1.2 
ng/ml  or  0.3-2.7 nmol/L). In some cases, when Free Testosterone measures were not collected 
for some patients, FAI levels were used for diagnosis. Blood samples were also collected from 
patients to assess androgen measures such as DHEA, DHEAS, and other hormonal measures 
including SHBG, LH, FSH, Estradiol, Progesterone, and AMH were recorded for some patients 
as deemed appropriate by the endocrinologist. 
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Blood samples were collected from the control participants by the research nurse at the 
Department of Psychological Medicine, University of Otago, Christchurch, and were 
immediately centrifuged and frozen. Samples were then assayed at the Christchurch Health 
Laboratories and reports were posted to the Department of Psychological Medicine (see 
Appendix Q). These indicated androgen levels and other hormonal levels including SHBG, LH 
and FSH, however, other hormonal levels were not the primary hormonal measures of interest. 
6.8.3 Treatment 
The clinical manifestation of PCOS varies from mild presentation of symptoms such as 
menstrual irregularities and cosmetic issues to more severe conditions involving reproductive 
and metabolic abnormalities. In the current study, a treatment plan was put in place by the 
endocrinologist, based on the individual patient’s symptom profile. Symptoms included:  
1) androgen-related symptoms - hirsutism, acne, alopecia, high testosterone levels 
2)  metabolic symptoms - weight gain issues and insulin resistance 
3) reproductive symptoms - irregularities in menstrual cycle  
Standard clinical treatment aimed to either decrease and/or block excess androgen levels and 
involved anti-androgen medication (Badawy & Elnashar, 2011; Falsetti et al., 2000) (see Chapter 
4). This included pharmacological agents such as the OCP, CPA, Flutamide, and Spironolactone. 
The OCP is effective in regulating the menstrual cycle and in controlling acne by decreasing 
androgen secretion, decreasing availability of DHT, and increasing SHBG levels (Badawy & 
Elnashar, 2011; Fenton, 2005; Nader & Diamanti-Kandarakis, 2006). Symptoms of 
hyperandrogenism varied in nature and severity in the current sample of patients, and were 
treated by CPA, Spironolactone and Flutamide. The OCP and Spironolactone were used in 
conjunction in some cases. Daily dosage ranged from 100-200mg for Spironolactone, 25-
100mg for CPA (in conjunction with oestradiol) and 250mg for Flutamide. Additionally, 
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Metformin was used to treat metabolic abnormalities involved in the syndrome, in the form of 
insulin resistance, and was often used in conjunction with anti-androgen medication (Badawy 
& Elnashar, 2011; Sam & Dunaif, 2003). In the current study, varied dose regimens of 
Metformin were used depending on the treatment goal, ranging from 1500-2000mg. In some 
cases, medication was modified in terms of drug or dosage during the initial 12 week treatment 
phase, and was noted during the follow-up session.  
 
6.9  PROCEDURE 
An overview of the study timeline is presented in Figure 6.5. All participants completed cognitive 
assessment at the Department of Psychological Medicine, University of Otago, Christchurch, 
New Zealand. The baseline assessment was conducted between 9am and 5pm on weekdays, and 
some weekends. For all participants, the baseline assessment began with the demographic 
questionnaire, followed by the PCOS-Q. Participants in both groups were then administered the 
MINI, the HADS and the QIDS. The cognitive assessment commenced following the 
administration of the mood rating scales, and took approximately 90 minutes to complete (see 
Appendix R for the order of cognitive tests). 
Approximately ten weeks after the baseline assessment, participants were contacted by 
telephone or were e-mailed to arrange a time for the 12-week follow-up assessment. Those 
patients who were unable to be contacted by telephone or email to organise the twelve-week 
assessment were posted a letter by six weeks to remind them of the follow-up assessment. At 
the follow-up assessment, the same procedure was repeated for the cognitive assessment and 
depression-rating scales, with the exception of the PCOS-Q, the MINI and the NART. No 
endocrinological assessment was required at this time-point. Therefore, each participant in the 
PCOS and non-PCOS control groups completed two testing sessions, one at baseline and one 
approximately 12 weeks after baseline, which added up to 214 assessments in all.  On average, 
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each participant’s follow-up occurred after a mean time of 13.4 (+2) weeks for the PCOS group, 
and 14.7 (+3) weeks for the control group after their baseline assessment. For both the PCOS 
and non-PCOS groups, baseline and follow-up interviews were conducted over a period of 
approximately four years. Participants were financially compensated for travel expenses with 
$40 petrol vouchers for baseline and follow-up sessions (see Appendix F). 
 
6.10  DATA MANAGEMENT 
6.10.1 Assessment of distribution of variables 
All continuous variables were plotted using normal residual plots to ensure that they were 
normally distributed, as assumed in the application of parametric analysis. Variables were found 
to be normally distributed. 
6.10.2 Power calculation and sample size 
In the current study, 50 patients with PCOS and 53 control participants provided adequate 
power (80%) to detect effect sizes of approximately 0.6 (or above) as statistically significant 
(two-tailed α=0.05).   
6.10.3 Computer software 
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Figure 6.5  
Timeline of Study Procedure  
PCOS-Q = Polycystic Ovary Syndrome Questionnaire, MINI Screening= Mini International Neuropsychiatric Interview, 
QIDS = Quick Inventory of Depressive symptoms, HADS = Hospital Anxiety and Depression scale, NART = National Adult 
Reading Test, CVC = Consonant Vowel Consonant Task, GMLT = Groton Maze Learning Test, COWAT = Controlled Oral 


















Figure 6.6  
Overview of the Study Design 
 
 
6.11  STATISTICAL ANALYSIS 
General statistical methods are described below. Details relevant to particular outcome 
measures are outlined in the appropriate sections of Chapters 7 and 8. 
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6.11.1 Approach to analyses 
6.11.1.1 Multiple comparisons 
Multiple statistical comparisons were conducted due to multiple outcome measures, thus 
increasing the risk of Type 1 error. The use of a correction, such as Bonferroni’s correction was 
considered. However, it was decided to address the risk of Type I errors by: 1) analysing data 
according to a priori hypotheses related to the cognitive domain that each task tested, 2) 
including both significant and non-significant results in text, tables and figures to ensure clarity 
in the number of comparisons, 3) acknowledge that significant results would need confirmation 
with further research, and 4) using patterns of evidence to facilitate better interpretation of 
results rather than isolated significant p-values. An alpha significance level set at the 
conventional two-tailed level of <0.05 was used throughout to indicate statistical significance. 
6.11.2  Cognitive data  
6.11.2.1 Baseline analysis 
Primary analyses 
Specific correlations between NART and the following cognitive variables (all p <0.01) were 
found: between  the CVC Trial 5, CVC Total Learning, CVC Delayed Recall, GMLT total 
errors on Trial 5, GMLT total errors on Trials 1-5, time taken on TMT (Part A and B), COWAT 
total score, Digit Span Total Forwards and Total Backward Span, and RMET. Body Mass Index 
(BMI) was also found to be significantly correlated with most cognitive variables, however, 
since high BMI is a consequence of PCOS, this factor was not controlled for in final analyses.  
At baseline, partial correlation coefficients, controlling for the effect of estimated premorbid 
verbal IQ (assessed by NART) were calculated to determine whether androgen variables were 
associated with mood, anxiety and cognitive variables across the whole sample. NART was 
controlled for in the primary analyses and the results with NART are included in Chapter Seven, 
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while the values in tables and figures without controlling for the effect of NART (raw scores) 
are presented in the Appendices (see Appendix S). Partial correlation coefficients investigating 
the associations between androgen variables and emotion processing variables were conducted 
controlling for mood (HADS-D), as HADS-D was found to be significantly correlated with 
emotion processing variables. Additionally, analysis also included an examination of the 
association between mood and cognitive variables, and for this purpose, bivariate correlational 
analysis was conducted.  
Secondary analyses 
Baseline differences on mood, anxiety and cognitive and emotion processing measures between 
the PCOS and control groups were analysed using univariate ANCOVA. The effect of estimated 
premorbid verbal IQ (assessed by NART) was controlled for in these analyses as this differed 
significantly between the two groups. In univariate ANCOVA (or ANOVA for emotion 
processing), group (PCOS or control) was a between-participants factor. Regarding emotion 
processing variables, univariate ANOVA (without NART as a covariate) was conducted as 
NART was not found to be correlated with facial emotion processing variables.  
Effect sizes were calculated for baseline cognitive and emotion processing comparisons 
between the PCOS and control groups. Estimates of effect size (ES) were calculated using the 
formula ( PCOS group - control group)/Spooled. 
Multivariate regression analysis was performed on cognitive and emotion processing data for 
further analysis. Multivariate regression analysis is a technique useful for exploring the 
relationship between one continuous dependent variable and a number of independent variables 
or predictors (usually continuous), allowing a sophisticated investigation of the inter-
relationship among a set of variables. The current study involved comparative and correlational 
analyses, and therefore, there was a sound and theoretical reason for conducting more 
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sophisticated multivariate regression analysis to predict which factors most affect cognitive and 
emotion processing data. The main focus was to determine whether the association between 
androgen variables (Free Testosterone and FAI levels) and cognitive variables was independent 
of factors including BMI, NART, age and HADS score. Analysis included cognitive variables 
that were found to be significantly correlated with androgen variables in partial correlational 
analyses, further discussed in Chapter Seven. Analysis comprised of two sets of results, with 
the inclusion and exclusion of BMI as an independent variable, to clearly elucidate the effect 
of other independent variables on cognitive variables. 
6.11.2.2  Follow-up analysis 
Primary analyses 
For follow-up analyses, the primary analysis consisted of bivariate correlations examining the 
association between change in mood and anxiety variables, and change in cognitive and 
emotion processing variables in the PCOS group. The control group was excluded from this 
analysis since they were not exposed to any treatment over the period of the study, and 
therefore, changes would not directly reflect systematic consequences of the treatment. Change 
in mood and cognitive variables over anti-androgen treatment was calculated by subtracting 
baseline scores from follow-up scores for each cognitive and mood variable. This change in 
score was further used in correlational analyses to examine the association between variables. 
Pearson’s correlation (two-tailed) was used for correlational analyses. 
Secondary analyses 
Differences between the two groups in change in symptoms of depression, anxiety, cognitive 
function and emotion processing were assessed using an independent samples t-test. Changes 




CHAPTER 7  
STUDY 1: ASSOCIATIONS BETWEEN ANDROGEN LEVELS AND 
MOOD, ANXIETY, COGNITIVE FUNCTION AND EMOTION 




Chapters Two to Five provided a background for the current study by 1) describing major 
depression and the core features of cognitive impairment and impairment in emotion 
processing, 2) providing a description of androgens in the context of PCOS, a condition 
associated with abnormally elevated androgen levels, and 3) a systematic review of studies 
investigating associations between androgen levels, symptoms of depression and anxiety, 
cognitive function and emotion processing in females of reproductive age.  
7.1.1 Aims 
The aims of the current chapter are: 
 To determine whether correlations exist between testosterone levels and symptoms of 
depression and anxiety, across both PCOS and non-PCOS control groups, 
 To determine whether correlations are present between testosterone levels and performance 
on measures of cognitive functioning and emotion processing across PCOS and non-PCOS 
control groups,  
 To determine whether symptoms of depression and anxiety correlate with aspects of 
cognitive function and emotion processing, and, 
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 To describe differences between a group of patients with PCOS and a non-PCOS control 
group on measures of mood, anxiety, cognitive function and emotion processing. 
7.1.2 General hypotheses 
Hypotheses for this chapter are as follows: 
 Free Testosterone and/or FAI levels in females with PCOS will be positively correlated 
with symptoms of depression. 
 Testosterone levels will be negatively correlated with cognitive function, suggesting worse 
cognitive performance on domains including visuospatial learning and memory, verbal 
learning and memory, verbal fluency (executive function) and psychomotor speed. 
 The PCOS group will show more symptoms of depression compared with the control 
group. 
 The PCOS group will perform less well on tasks assessing specific aspects of cognitive 
function and emotion processing, which may be related to greater depressive 
symptomatology, higher androgen levels, or both of these factors. 
7.1.3 Chapter outline 
The first part of this chapter will present data on recruitment and demographic variables. 
Following this, data from measures of androgens, mood ratings, and cognitive assessment will 
be presented as comparisons between the PCOS and non-PCOS control (which will be referred 
to as simply the ‘control group’ for the remainder of the thesis) groups. Cognitive tasks will be 
categorised into four main domains: verbal learning and memory, visuospatial learning and 
memory, attention and executive functioning, and psychomotor speed. Emotion processing 
findings and social cognition will be presented separately. Finally, results from correlational 




7.2 RECRUITMENT STATISTICS 
Patients in the PCOS group consisted of: 
a) Females who were referred to gynaecological endocrine clinics at Christchurch Women’s 
Hospital (public hospital) and the Women’s Health Clinic at Southern Cross Hospital 
(private hospital) in Christchurch, New Zealand (n = 32). All patients who received 
information about the study from the treating Gynaecological-Endocrinologist and were 
considered eligible for inclusion consented to participate in the current study.  
b) Females (n = 22) who were respondents to advertisements in local newspapers (The 
Christchurch Star Newspaper (http://www.starmedia.kiwi/) and The Metropol 
(https://www.metropol.co.nz/) seeking volunteers with untreated symptoms of PCOS.  
Over the three-year recruitment period, data were collected from 107 participants, including 54 
females with PCOS and 53 control females. The control group consisted of females who were 
respondents to flyers advertised online (http://www.subjectswanted.co.nz/) and in public places 
including the University of Otago (Christchurch campus), gyms and sports centres and 
shopping malls (see Chapter Six, section 6.3.2).  Four females in the PCOS group were 
excluded from the final analysis, as after a more detailed examination by the endocrinologist, 
their primary diagnosis was found to be CAH and not PCOS. 
 
7.3 PARTICIPANTS 
Fifty patients with PCOS and 53 control females were included in the baseline analyses.  
Inclusion criteria for the PCOS group was females between the ages of 16 to 40 years, with a 
diagnosis of PCOS by the treating Gynaecological-Endocrinologist. Regarding the control 
group, inclusion criteria consisted of reproductive-aged females who showed normal androgen 
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levels along with no physical symptoms of PCOS such as hirsutism, severe acne or ovarian 
cysts. Exclusion criteria for both groups was: taking exogenous hormones prior to study, 
neurological conditions or major chronic medical illnesses (e.g., multiple sclerosis or HIV), 
current serious alcohol or substance misuse, menopause, pregnancy, previous head injury (loss 
of consciousness for more than one hour), other endocrinological conditions except for PCOS, 
current treatment for infertility, insufficient visual or auditory functioning for completion of 
cognitive tests, and non-fluency in English (see Chapter 6).  
Independent-samples t-tests were conducted to compare age (years), BMI, total education and 
estimated verbal IQ (NART) between the PCOS and control groups (see Table 7.1). There was 
no significant difference in age (t = 0.78, p = 0.43), however, significant differences were found 
between groups on BMI (t = 3.12, p = 0.002), total education (t = -2.38, p = 0.019) and estimated 
verbal IQ (t = -3.44, p = 0.001). Since higher BMI is a key diagnostic feature for PCOS and not 
a separate symptom from the syndrome as such, it was not controlled for in the final analyses. 
Although attempts were made to match for IQ and education as the groups were recruited, we 
failed to recruit sufficient number of control participants in a lower IQ and education range. 
Therefore, in the final analysis, there was a significant difference in the NART score, which 
was also found to be highly correlated with cognitive variables (see Chapter 6, Section 
6.11.2.1), and thus, was treated as a covariate by using analysis of covariance (ANCOVA) in 
the final analyses. 
Distribution of handedness between the two groups did not differ (χ² = 1.33, p = 0.51). The 
New Zealand Census ethnicity categories were used as an outline for determining ethnicity in 
the sample. PCOS and control groups did not differ significantly in their ethnicity distributions 
(χ² = 8.66, p = 0.123). The majority of both groups identified themselves as ‘European’ which 
included New Zealand European, English, Dutch, Spanish, and German females. All other 
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females were categorised as either ‘Maori’, ‘Indian’, ‘Chinese’,’ or Samoan’, and all were 
fluent in English.   
Table 7.1 
Means (SD) or Percentages for Demographic Characteristics in Polycystic Ovarian 
Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS  Control   
 Mean/% SD Mean/% SD t / χ2 p 
Demographic Characteristics 
Age (years)^ 28.96 6.83 27.85 7.57 0.78 0.43 
BMI^ 27.80 8.04 23.89 4.18 3.12 0.002 
Total education 
(years)^ 
8.14 2.52 9.45 3.02 -2.38 0.019 
Verbal IQ (NART) ^ 105.30 8.35 111.04 8.56 -3.44 0.001 
Handedness 
(% right-handed)* 
(n = 48) 
96.00 
- 
(n = 50) 
96.22 
- 1.33 0.51 
Ethnicity Data       
European  42 (84)   40 (75.48)  8.66 0.123 
Maori  4 (8)   2 (3.8)    
Chinese  2 (2)   5 (9.4)    
Samoan  0 (0)   2 (3.8)    
Indian   2 (4)   4 (7.5)    
^ Independent samples t-test, *Pearson Chi-square, PCOS- Polycystic Ovarian Syndrome, BMI- Body Mass Index, NART- 
National Adult Reading Test. 
 
7.4 CLINICAL CHARACTERISTICS OF THE POLYCYSTIC OVARIAN      
SYNDROME GROUP 
7.4.1 Androgen levels 
Comorbid endocrine disorders in the PCOS group included endometriosis (n = 4) and 
premenstrual dysphoria (n = 1). Androgen levels including Total Testosterone, Free 
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Testosterone, FAI and LH levels were significantly higher in the PCOS group compared with 
the control group (see Table 7.2). Specific androgen measures were obtained for patients based 
on their clinical assessment by the treating Gynaecological-Endocrinologist, thus, not all 
androgen values were obtained for all patients with PCOS. For example, for the patients for 
whom Free Testosterone levels were not collected (n = 44), FAI values were derived from the 
measurement of Total Testosterone (see Chapter Three, Box 3.1).  
Table 7.2 
Means (SD) of Raw Scores of Androgen Levels and Other Hormonal Levels in the 
Polycystic Ovarian Syndrome and Control Groups 
 PCOS Control  
 N Mean SD N Mean SD t p 
LH 43 10.27 7.16 48 6.51 4.65 3.00 0.005 
FSH 46 5.97 6.95 50 4.66  2.96 1.22 0.22 
Total T  48 2.04 0.63 50 1.57 0.37 4.43 <0.001 
Free T 44 30.40  14.65 42 18.95  8.49 4.40 <0.001 
FAI^ 45 54.35  39.47 42 28.97  17.88 3.81** <0.001 
DHEA 31 7.58  3.35 - - - - - 
SHBG 47 60.93  55.91 42 82.54  73.20 -1.57 0.18 
The t-value for DHEA could not be computed as this androgen measure was only obtained for some PCOS patients but not 
for the control group, Raw values for hormone levels are presented in this table, LH-Luteinising Hormone, FSH- Follicle 
Stimulating Hormone, Total T- Total Testosterone (ng/ml), Free T- Free Testosterone (pg/ml), FAI- Free Androgen Index, 
DHEA- Dehydroepiandrosterone, PCOS- polycystic Ovarian Syndrome, SHBG- Sex Hormone Binding Globulin, ** - 
comparison of log transformed values was conducted due to outliers for statistical comparison, ^- Although the PCOS group 
was found to show high FAI levels, there was considerable variation in and considerable overlap in FAI levels between the 
PCOS group and the control group. See Appendix V for a boxplot graph. 
 
7.4.2 Mood and anxiety comparisons 
Table 7.3 presents scores on the depression and anxiety rating scales in the PCOS and control 
groups. The mean HADS depression subscale (HADS-D) score was significantly greater in the 
PCOS group (mean score represented ‘moderate depression’) compared with the control group 
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(mean score represented ‘mild depression’; 4.88 vs 2.66; t = 3.23, p = 0.002). Scores on the 
anxiety subscale of the HADS (HADS-A) were not significantly different between groups (t = 
1.38, p = 0.171).The mean QIDS score was significantly higher in the PCOS group compared 
with the control group (5.88 vs 3.92; t = 2.51, p = 0.014). QIDS scores for the PCOS group 
indicated ‘mild’ severity of depression whereas for the control group, scores indicated no 
depression (categorised as ‘none’ according to QIDS scoring) (Rush et al., 2003; Trivedi et al., 
2004). 
Table 7.3 
Means (SD) and Ranges for Clinical Characteristics in the Polycystic Ovarian Syndrome (n 
= 50) and Control (n = 53) Groups 
 PCOS  Control   
 Mean SD Mean SD t p 
HADS total score 12.76 7.09 9.49 5.95 2.54 0.013 
HADS anxiety score 7.88 4.02 6.83 3.66 1.38 0.171 
HADS depression score 4.88 3.83 2.66 3.10 3.23 0.002 
QIDS total score 5.88 4.48 3.92 3.37 2.51 0.014 
HADS = Hospital Anxiety and Depression Rating Scale, QIDS = Quick Inventory of Depression Symptoms. 
 
7.4.3 Axis I Diagnoses  
The MINI (Sheehan et al., 1998) was used to assess the presence of Axis I mental disorders in 
the PCOS and control groups (see Table 7.4). Initial screening ensured that females with 
schizophrenia, bipolar disorder with psychotic features, and/or substance dependence disorders 
were not included in the sample. Current psychiatric diagnoses endorsed by PCOS patients 
included MDD (n = 2), impulse control disorder (n = 1), SAD (n = 4), panic disorder (n = 2) 
and post-traumatic stress disorder (n = 1). In the control group, MDD (n = 6), GAD (n = 4), 
SAD (n = 1), and panic disorder (n = 2) were endorsed. Only one patient with PCOS and three 
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non-PCOS control participants reported using substances (alcohol), however, none met the 
criteria for a substance dependence disorder. Past psychiatric diagnoses endorsed by PCOS 
patients included panic disorder (n = 2) and MDD (n = 4). In the control group, MDD (n = 2), 
panic disorder with agoraphobia (n = 1) and SAD (n = 2) were endorsed. 
Table 7.4 
Presence of Current Axis I Disorders in the Polycystic Ovarian Syndrome (n = 50) and 
Control (n = 53) Groups 
Axis I Disorders N (%) PCOS    N (%) Control  χ2 
Mood disorders     
Major Depressive Disorder  9 (18)  6 (11.32) 0.92 
Bipolar Disorder I  3 (6)  1 (1.88) 0 
Anxiety disorders     
Generalised Anxiety Disorder  12 (24)  7 (13.20) 1.99 
Social Anxiety Disorder  10 (20)  4 (7.54) 3.39 
Panic Disorder with Agoraphobia  0  3 (5.66) 0 
Panic Disorder without Agoraphobia  2 (4)  2 (3.77) 0 
Agoraphobia  1 (2)  0 0 
Post-Traumatic Stress Disorder  3 (6)  0 0 
Substance Use Disorders    
Current alcohol use  1 (2)  3 (5.66) 0 
Eating disorders    
Bulimia nervosa  0   1 (1.88) 0 
No diagnosis  25 (50)  35 (66) 2.72 





7.4.4 Psychotropic medication 
At baseline, six control participants reported being on antidepressant medication (SSRIs, n = 
4; SNRIs, n = 2). Two control participants reported taking Lorazepam (anxiolytic). One control 
participant was taking Quetiapine (antipsychotic) for improving mood and sleep. Only one 
female with PCOS was on antidepressant medication (SSRI) at baseline. 
7.4.5 Anti-androgen medication 
At baseline, 23 patients and nine control participants reported taking the OCP or the COCP (see 
Table 7.5). After the Gynaecological-Endocrinologist assessed the symptom profile of patients, 
changes were made in medication type or dosage, and in some cases, included anti-androgen 
medication. Anti-androgen medication and hormonal agents included CPA, Spironolactone, 
Metformin, and Thyroxine, which will be discussed in further detail in Chapter Eight. Two 
control participants were taking Minoxidil (antihypertensive vasodilator used to treat 
androgenic alopecia) and Spironolactone, respectively, for dermatological/cosmetic purposes. 
Table 7.5 
Anti-androgen and Other Hormonal Medication used by the Polycystic Ovarian Syndrome 
(n = 50) and Control (n = 53) Groups at the Baseline Assessment 
Hormonal medication PCOS (n = 50) Control (n = 53) 
  N (%)  N (%) 
CPA  1 (2)  0 (0) 
Spironolactone  1 (2)  1 (1.89) 
Metformin   5 (10)  0 (0) 
OCP or COCP (Yasmin, Ginette, Brevinor)  23 (46)  9 (16.98) 
IUD (Mirena, Jadelle, Implanon)  4 (8)  5 (9.43) 
Thyroxine  2 (4)  1 (1.89) 
OCP = oral contraceptive pill, CPA= Cyproterone Acetate, COCP = combined oral contraceptive pill, IUD = Intra uterine 




7.4.6  General medication 
A minority of PCOS patients and controls were taking additional medications for conditions 
such as asthma, eczema, pain, insomnia, hay fever and hypertension. These included pain killers 
(codeine, ibuprofen, paracetamol, tramadol) (PCOS=4, controls=5), salbutamol inhaler 
(PCOS=2, controls=1), sleeping medication (melatonin and zopiclone) (PCOS=3, control=0), 
antibiotics (flucloxacillin, doxycycline) (PCOS=1, controls=2), antihistamines (cetirizine) 
(PCOS=4, controls=3). 
 
7.5 FACTORS THAT MAY INFLUENCE COGNITIVE FUNCTION  
7.5.1 State anxiety  
There were no significant differences between groups in reported state anxiety, and the slight 
reduction in state anxiety observed over time was not significant (see Table 7.6).  
Table 7.6 
State Anxiety in Polycystic Ovarian Syndrome Group (n = 50) Compared with the Control 
(n = 53) Group at the Baseline Assessment 
 PCOS Control  
 Mean SD Mean SD F p 
VAS Baseline 2.11 1.87 1.62 1.61 2.03 0.157 
VAS mid-assessment  
(change score) 
-0.13 1.64 -1.67 1.23 0.02 0.899 
VAS end of assessment 
(change score) 
-0.55 1.66 -0.66 1.32 0.13 0.72 
Note: mid- and end-assessment VAS scores reflect change from baseline, with negative scores representing reduced anxiety, 





7.5.2 Psychoactive substances 
Nicotine: The proportion of smokers did not differ significantly between groups (χ² (1) = 0.24 
p = 0.62). Within the PCOS group, there were four smokers (8%), and in the control group, two 
individuals were recorded as smokers (3.8%). 
Alcohol and cannabis consumption: Of all participants, only one participant reported 
consuming cannabis immediately prior to assessment, and was thus, excluded from analysis. 
Other participants did not report consuming either alcohol or cannabis pre-assessment.  
 
7.6 ANALYSIS OF COGNITIVE DATA 
PCOS patients (n = 50) and controls (n = 53) were compared on baseline cognitive tasks using 
univariate ANCOVA. Group status (PCOS or control) was the between-participants factor. 
Analyses included verbal IQ (NART score) as a covariate because of the significant difference 
found between PCOS and control groups (see Table 7.1), and significant correlations found 
between NART and some cognitive measures, with the exception of FER Task which showed 
no suggestion of being correlated with NART (see Chapter Six, Section 6.11.2.1). BMI was 
correlated with some cognitive variables (see Chapter Six), however, since BMI is a core 
clinical feature of PCOS, it was decided to not include this variable as a covariate in final 
analyses.  
Estimated marginal means (adjusted means and standard deviations) for all cognitive data are 
presented in the next sections, generated from ANCOVA (with NART as a covariate). In 




7.6.1 Distribution of cognitive variables 
Mood, cognitive and emotion processing outcome variables were normally distributed across 
the entire sample, allowing the use of parametric statistical analysis. 
7.7 VERBAL LEARNING AND MEMORY FINDINGS  
7.7.1 Consonant-Vowel-Consonant Test: immediate and delayed recall 
Univariate ANCOVA was conducted comparing the PCOS group and the control group on Trial 
1, Trial 5, Total Learning (Trials 1-5), Delayed Recall and recognition parts of the CVC Test 
(see Figure 7.1). 
No significant differences were found between the PCOS and the control groups after covarying 
for NART (see Table 7.7). 
Table 7.7  
Adjusted Means (SD) and Effect Sizes on the Consonant-Vowel-Consonant Task in the 
Polycystic Ovarian Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS Control  
 Mean SD Mean SD F p d 
CVC Trial 1 3.70 1.69 3.57 1.67 0.14 0.707 0.07 
CVC Trial 5  8.26 3.18 8.73 3.20 0.54 0.463 0.15 
CVC Total Learning  31.51 11.59 32.19 11.57 0.81 0.776 0.05 
Delayed Recall   6.68 3.39 6.82 3.42 0.04 0.842 0.03 
Recognition accuracy List A  13.90 1.13 14.34 1.16 3.39 0.069 0.37 
Adjusted means are presented using NART as a covariate with univariate ANCOVA, F = Univariate ANCOVA, d = Cohen’s 





7.8 VISUOSPATIAL LEARNING AND MEMORY FINDINGS 
7.8.1 Groton Maze Learning Test (GMLT) – visuospatial learning 
Univariate ANCOVA was conducted comparing the PCOS and the control groups on Trials 1-
5 and delayed trials of the GMLT, including NART as a covariate (see Table 7.8). No significant 
group differences were found on any GMLT variables after controlling for NART. 
 
Figure 7.1.  
Mean (+SD) number of words recalled on the five learning trials and delayed recall trial 
of the Consonant-Vowel-Consonant Task in the Polycystic Ovarian Syndrome (n = 50) 
and Control (n = 53) Groups 
7.8.2 Groton Maze Learning Test (GMLT) (delayed trial) – visuospatial memory 
The PCOS and control groups did not differ in the number of errors made on the delayed trial 
of the GMLT (see Table 7.8, F = 0.67, p = 0.413) indicating no specific deficit in visuospatial 






































Table 7.8  
Adjusted Mean Total Errors (SD) and Effect Sizes for the Groton Maze Learning Test in 
Polycystic Ovarian Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS Control    
 Mean SD Mean SD F p d 
GMLT Trial 1 15.41 2.96 15.73 2.98 0.28 0.597 0.10 
GMLT Trial 5  5.69 3.53 4.73 3.56 1.78 0.185 0.28 
GMLT Trials 1-5  44.90 11.94 42.70 11.93 0.83 0.363 0.19 
GMLT Delayed 
Trial /Trial 6  
5.12 3.39 4.56 3.34 0.68 0.412 0.17 
Adjusted means after covarying for NART, F = Univariate ANCOVA, d = Cohen’s d effect size, GMLT - Groton Maze 
Learning Test, PCOS - Polycystic Ovarian Syndrome 
 
 
Figure 7.2 Mean (± SD) Total number of errors on the Groton Maze Learning Test 
(GMLT) over the five learning trials (1-5) and the delay trial in in Polycystic Ovarian 





























7.9 PSYCHOMOTOR SPEED FINDINGS 
7.9.1 Timed Chase Test 
Univariate ANCOVA showed a significant group difference on the number of correct moves 
on the TCT (see Table 7.9, F = 13.42, p < 0.001) with a moderate effect size (0.76), after 
covarying for NART (see Table 7.9). The PCOS group performed significantly worse than the 
control group.  
7.9.2 Trail Making Test (Part A) 
Univariate ANCOVA showed no significant group differences after covarying for NART on 
the time taken (F = 0.361, p = 0.549) on the TMT (Part A). 
Table 7.9 
Means (SD) and Effect Sizes for Psychomotor Speed Measures in the Polycystic Ovarian 
Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS Control    
 Mean SD Mean SD F p d 
TCT  (no. of correct moves)  43.37 7.84 49.18 7.78 13.42 <0.001 0.76 
TCT total errors  0.62 1.27 0.66 1.23 0.03 0.866 0.03 
Trail Making Time Part A (seconds)  20.92 6.36 21.69 6.33 0.361 0.549 0.12 
Adjusted means using NART as a covariate in univariate ANCOVA, F = Univariate ANCOVA, d = Cohen’s d effect size, 
TCT - Timed Chase Test, PCOS - Polycystic Ovarian Syndrome 
 
7.10 ATTENTION AND EXECUTIVE FUNCTION FINDINGS 
7.10.1 Trail Making Test (Part B) 
Univariate ANCOVA showed no significant differences between groups on the time taken on 
the TMT (Part B) after covarying for NART (F = 0.01, p = 0.92) (see Table 7.10). 
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7.10.2 Controlled Oral Word Association Test 
Univariate ANCOVA showed no significant group differences after covarying for NART on 
the total COWAT score (F = 3.17, p = 0.07) (see Table 7.10). 
7.10.3 Digit Span  
No significant group differences were found in Univariate ANCOVA analysis after covarying for 
NART on Digit Span variables (Total Forward- F = 0.33, p = 0.56), (Forward Span- F = 0.25, p 
= 0.62), (Total Backward- F = 1.02, p = 0.31), (Backward Span- F = 0.27, p = 0.60) (see Table 
7.10). 
Table 7.10 
Means (SD and SEM) and Effect Sizes on Attention and Executive Function Variables in 
the Polycystic Ovarian Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS Control    
 Mean SD Mean SD F p d 
TMT List B (seconds)  44.48 17.81 44.09 17.76 0.01 0.915 0.02 
COWAT Total Score  49.53 13.99 54.59 13.97 3.17 0.078 0.37 
Digit Span Total Forward  8.79 2.19 9.04 2.18 0.33 0.567 0.11 
Digit Span Forward Span 6.94 1.20 7.06 1.23 0.25 0.621 0.10 
Digit Span Total Backward  6.87 2.12 7.31 2.11 1.02 0.315 0.20 
Digit Span Backward Span 5.00 1.20 5.13 1.16 0.27 0.607 0.10 
Adjusted means after covarying for NART, F = Univariate ANCOVA, d = Cohen’s d effect size, COWAT- Controlled Oral 
Word Association Test, TMT - Trail Making Test, TCT - Timed Chase Test, PCOS - Polycystic Ovarian Syndrome 
 
7.11 EMOTION PROCESSING FINDINGS 
7.11.1 Facial Expression Recognition Task: recognition accuracy  
Since NART was not found to be significantly correlated with the FER Task (see Chapter 6, 
Section 6.11.2.1), it was not included as a covariate in the final analysis. Univariate ANOVA 
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found the PCOS group to show significantly worse performance (worse accuracy) in 
recognising facial expressions of fear (F = 1.93, p = 0.04) and sadness (F = 5.97, p = 0.004) 
compared with the control group (see Table 7.11). 
7.11.2. Facial Expression Recognition Task: Neutral Misinterpretation Bias 
The percentage of neutral faces misinterpreted as one of the five emotions was compared 
between the PCOS (n = 50) and control (n = 53) groups.  
No significant between-group effects relating to neutral misinterpretation bias were found in 
univariate ANOVA. Effect sizes of all comparisons on each misinterpreted emotion were small 
(all ES < 0.35) (see Table 7.11). 
 
 
Figure 7.3  
Mean (+SD) Recognition accuracy for the five facial expressions of emotional and 
neutral expressions on the Facial Expression Recognition Task in the Polycystic Ovarian 






















Mean (SD) of Facial Expression Recognition (Accuracy and Neutral Misinterpretation) Scores, and Effect Sizes in the Polycystic Ovarian 
Syndrome (n = 50) and Control (n = 53) Groups 
 PCOS Control    
 Mean SD Mean SD F p d 
Recognition Accuracy         
Anger (%) 58.60 17.52 60.09 15.55 1.70 0.64 0.08 
Disgust (%) 67.10 21.54 71.32 21.08 0.05 0.31 0.19 
Fear (%) 86.00 11.99 90.28 9.06 1.93 0.04 0.40 
Happiness (%) 90.30 8.77 90.66 9.75 2.01 0.84 0.03 
Neutral (%) 77.20 16.51 73.32 12.84 1.08 0.18 0.26 
Sadness (%) 61.50 20.28 71.79 14.48 5.97 0.004 0.58 
FER Total Accuracy (%) 74.20 8.70 75.66 7.49 0.35 0.36 0.17 
FER Total Reaction Time (%) 1729.70 261.14 1762.09 363.96 2.98 0.607 0.10 
Neutral Misinterpretation Bias        
Neutral faces misinterpreted as angry 61.96 25.58 53.42 25.08 0.51 0.092 0.33 
Neutral faces misinterpreted as happy  9.00 13.60 6.24 11.35 2.12 0.265 0.22 
Neutral faces misinterpreted as sad 17.43 18.76 23.45 21.16 0.39 0.131 0.30 
Neutral faces misinterpreted as fearful 5.26 9.23 6.73 11.87 0.82 0.486 0.13 
Neutral faces misinterpreted as disgust 6.33 11.09 10.14 13.80 1.00 0.127 0.30 




Figure 7.4: Mean (+SD) Misinterpretation of neutral faces for the five facial expressions 
of emotion on the Facial Expression Recognition Task in the Polycystic Ovarian 
Syndrome (n = 50) and Control (n = 53) Groups 
7.11.3 Reading the Mind in the Eyes Test 
After co-varying for NART, group differences remained significant on the RMET, with the 
PCOS group performing significantly worse compared with the control group (F = 8.14, p = 
0.005) (raw score means: 26.78+0.47 vs 28.10 + 0.46; ES = 0.41, total possible score = 36) on 
RMET. 
 
7.12 CORRELATIONS BETWEEN TESTOSTERONE LEVELS, MOOD 
RATINGS, COGNITIVE VARIABLES AND EMOTION PROCESSING 
Partial correlational analysis was used to explore the relationship between testosterone 
variables (Total, Free and FAI), mood, and cognitive variables, while controlling for NART 
across the entire sample (n = 103) (since NART was found to be significantly different between 


































analysis was also used to explore the relationship between testosterone levels and emotion 
processing, however, without controlling for NART, since NART was not found to be 
significantly correlated with the FER Task. The results with raw scores (before controlling for 
NART) will be included in Appendix S, and only the adjusted results after covarying for NART 
will be presented in the following sections.  
7.12.1 Correlation between testosterone variables and mood 
Free Testosterone – Before controlling for NART, significant positive correlations were found 
between Free Testosterone and both depression measures used in the current study: the 
depression subscale of the HADS (rp = 0.33, p = 0.002), HADS total score (rp = 0.23, p = 0.028) 
and QIDS total score (rp = 0.24, p = 0.028) (see Appendix S). No significant correlation was 
found between the anxiety subscale of the HADS and Free Testosterone levels.  
After controlling for NART, no significant correlations were found between mood or anxiety 
subscales and Free Testosterone levels. 
Free Androgen Index- Before controlling for NART, significant positive correlations were 
found between FAI and the depression subscale of the HADS (rp = 0.37, p < 0.0001), HADS 
total score (rp = 0.27, p = 0.011) and QIDS total score (r = 0.31, p = 0.004), but not between 
FAI levels and anxiety (HADS-A). 
After controlling for NART, significant positive correlations remained between FAI levels and 
the depression subscale of the HADS (rp = 0.32, p = 0.002), HADS total score (rp = 0.21, p = 
0.05) and QIDS total score (rp = 0.26, p = 0.01), but not anxiety (HADS-A) (rp = 0.15, p = 0.604). 
Total Testosterone - No significant correlations were found between any depression or anxiety 
measures and Total Testosterone levels before or after controlling for NART.  
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To summarise, after controlling for NART, significant positive correlations were found 
between higher FAI levels and greater depressive symptomatology in the entire sample 
including females with and without PCOS (n = 103). 
Table 7.12 
Correlations between Testosterone Variables and Depression and Anxiety Variables across 
the Entire Sample (n = 103) after Controlling for Verbal IQ (NART) 
 HADS-D HADS-A HADS total score QIDS Total score 
Total T 
(ng/ml) 
-0.01 -0.02 -0.02 -0.01 
Free T  
(pg/ml) 
0.282.9. 0.04 0.18 0.18 
FAI 0.32** 0.05 0.21* 0.26** 
Table includes adjusted means using NART as a covariate.,* = p < 0.05, ** = p < 0.01, Positive correlational values indicate 
an association between higher levels of testosterone and higher symptoms of depression (worse mood, as assessed by the 
HADS and QIDS),HADS = Hospital Anxiety and Depression Scale, HADS-A = Hospital Anxiety and Depression Scale 
(Anxiety sub-scale), HADS-D = Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS = Quick inventory of 
Depressive Symptomatology, FAI = Free Androgen Index, Free T = Free Testosterone (pg/ml), Total T = Total 
Testosterone (ng/ml). 
 
7.12.2 Correlation between testosterone levels and cognitive variables 
Partial correlational analysis was used to study the relationship between testosterone levels and 
cognitive function while controlling for NART.  
7.12.2.1 Verbal learning and memory  
After controlling for NART, significant negative correlations were found between Free 
Testosterone and CVC recognition accuracy (rp = -0.23, p = 0.032) and FAI levels and CVC 





Correlations between Testosterone Variables and the Consonant Vowel Consonant Task 













0.00 -0.06 -0.02 0.00 -0.19 
Free T  
(pg/ml) 
-0.03 -0.07 -0.03 0.00 -0.23* 
FAI -0.06 -0.07 -0.04 0.00 -0.20* 
Table includes adjusted means using NART as a covariate. Positive correlational values indicate an association between higher 
levels of testosterone and better performance on the CVC Task assessing verbal learning and memory. *= p < 0.05, ** p < 
0.01,CVC - Consonant Vowel Consonant, FAI - Free Androgen Index, Free T - Free Testosterone (pg/ml), Total T - Total 
Testosterone (ng/ml). 
 
7.12.2.2  Visuospatial learning and memory 
After covarying for NART, significant negative correlations were found between Free 
Testosterone levels and performance on the GMLT (total errors on GMLT Trial 5, rp = -0.246, 
p = 0.023; total errors on GMLT Trials 1-5, rp = -0.228, p = 0.036) suggesting that higher 
testosterone levels were associated with worse performance (more errors) on the cognitive task. 
All other correlations were non-significant (see Table 7.14). 
7.12.2.3  Psychomotor speed 
After controlling for NART, significant negative correlations were found between Free 
Testosterone (rp = -0.310, p = 0.004) and FAI levels (rp = -0.262, p = 0.015) and performance 
on the TCT (number of correct moves). No significant correlations were found between 





Correlations between Testosterone Variables and Groton Maze Learning Test Variables 












0.00  -0.16 -0.10 -0.01 
Free T  
(pg/ml) 
-0.15  -0.25* -0.23* -0.07 
FAI -0.16  -0.16 -0.16 -0.01 
Note: Table includes adjusted means using NART as a covariate, positive correlational values indicate an association 
between higher levels of testosterone and better performance on the GMLT. * = p < 0.05, ** = p < 0.01,GMLT- Groton 
Maze Learning Test, FAI- Free Androgen Index, Free T- Free Testosterone, Total T- Total Testosterone.  
 
Table 7.15 
Correlations between Testosterone Variables and Psychomotor Speed Variables across the 
Entire Sample (n = 103) after Controlling for Verbal IQ (NART) 
 TCT (no of correct 
moves) 
TCT (total errors) TMT Part A (time) 
Total T 
(ng/ml) 
-0.13 -0.09 -0.10 
Free T  
(pg/ml) 
-0.31* -0.01 -0.14 
FAI -0.26** -0.01 -0.15 
Note: Table includes adjusted means using NART as a covariate, positive correlational values indicate an association 
between higher levels of testosterone and better performance on the TCT and TMT, *= p < 0.05, ** = p < 0.01,TCT- Timed 
Chase Test, TMT- Trail Making Test, FAI- Free Androgen Index, Free T- Free Testosterone (pg/ml), Total T- Total 
Testosterone (ng/ml).  
 
7.12.2.4. Attention and executive function 
After covarying for NART, no significant correlations were found between testosterone 




Correlations between Testosterone Variables and Attention and Executive Function Variables across the Entire Sample (n = 103) after 
Controlling for Verbal IQ (NART) 
 














-0.19 -0.13 0.00 -0.03 -0.03 -0.03 
Free T 
(pg/ml) 
-0.10 -0.16 -0.14 -0.18 -0.03 -0.01 
FAI 
-0.05 -0.11 -0.10 -0.11 -0.03 -0.00 
Note: Table includes adjusted means using NART as a covariate, positive correlational values suggest an association between higher levels of testosterone and better performance on attention and 
executive function variables, *= p < 0.05, **p = < 0.01, COWAT-Controlled Oral Word Association Test, TMT- Trail Making Test (Part B), FAI- Free Androgen Index, Free T- Free Testosterone 




7.12.2.5  Correlations between testosterone variables and facial expression recognition and 
emotion processing task variables  
The association between testosterone variables and FER Task and RMET variables was 
analysed using mood (HADS-D) as a covariate. Univariate analyses showed mood to be 
strongly correlated with FER variables and with testosterone levels, so it was important to 
control for this potentially confounding factor. 
7.12.2.5.1 Recognition accuracy  
After controlling for mood (HADS-D), a negative correlation remained significant between FAI 
levels and recognition accuracy of fearful faces (rp = -0.27, p < 0.05) on the FER Task 
suggesting that higher FAI levels were associated with worse recognition accuracy of faces 
depicting fear (see Table 7.17). 
7.12.2.5.2 Reaction time 
No significant correlations were found between reaction time on the FER Task and testosterone 
variables, irrespective of whether mood (HADS-D) as added as a covariate (see Table 7.18). 
7.12.2.5.3 Neutral misinterpretation bias 
No significant correlations between misinterpretation of neutral faces and testosterone variables 
were observed before or after controlling for mood (HADS-D) (see Table 7.19). 
7.12.2.5.4 Reading the Mind in the Eyes Test  
The RMET total score was not found to be significantly correlated with any measures of 





Correlations between Testosterone Variables and Facial Expression Recognition Variables (Recognition Accuracy) using Mood (Hospital Anxiety 
Depression Rating Scale- Depression Subscale) as a Covariate across the Entire Sample (n = 103) 





















































Note: Correlations include raw and adjusted scores for mood (HADS-D); positive correlational values suggest an association between higher levels of testosterone and better performance on the FER Task 





Correlations between Testosterone Variables and Facial Expression Recognition Variables (Reaction Time) using Mood (Hospital Anxiety and 
Depression Rating Scale- Depression Subscale) as a Covariate across the Entire Sample (n = 103) 
























































Note: Correlations include adjusted scores for mood (HADS-D); positive correlational values suggest an association between higher testosterone levels and faster performance on the FER Task (reaction 






Correlations between Testosterone Variables and Facial Expression Recognition Variables (Neutral Misinterpretation Bias) using Mood  
(Hospital Anxiety and Depression Rating Scale- Depression Subscale) as a Covariate across the Entire Sample (n = 103) 










































Note: Correlations include adjusted scores for mood (HADS-D), positive correlational values suggest an association between higher testosterone levels and worse performance on the FER Task  
(neutral misinterpretation bias), indicating more bias in misinterpreting neutral faces. 





7.12.3 Correlations between mood variables and cognitive variables  
The association between mood and anxiety variables and cognitive variables at baseline was 
assessed by conducting correlational analysis. Findings from these analyses are presented in the 
following sections. 
7.12.3.1 Verbal learning and memory 
A significant negative correlation was found between performance on CVC Trial 1 and scores 
on the HADS-D (r =-0.208, p = 0.03), suggesting that higher symptoms of depression were 
associated with worse performance on the CVC Task. No other correlations were found to be 
significant (see Table 7.20). 
 
Table 7.20 
Correlations between Mood and Anxiety Variables and Consonant-Vowel-Consonant Task 
Variables across the Entire Sample (n = 103) 








HADS -0.16 -0.13 -0.13 -0.10 -0.09 
HADS-D -0.20* -0.12 -0.15 -0.09 -0.16 
HADS-A -0.08 -0.10 -0.08 -0.08 -0.00 
QIDS -0.16 -0.08 -0.08 -0.07 -0.15 
Note: Positive correlational values suggest an association between higher symptoms of depression and better performance on 
the CVC Task, ** = p < 0.01, *= p < 0.05. 
CVC- Consonant Vowel Consonant Task, HADS- Hospital Anxiety and Depression Rating Scale, HADS-A - anxiety 





7.12.3.2 Visuospatial learning and memory 
A significant negative correlation was found between symptoms of anxiety (HADS-A) and 
GMLT performance (GMLT Trial 5) (r = 0.189, p = 0.05) indicating that higher symptoms of 
anxiety were associated with worse performance (more errors made) on the GMLT Trial 5. No 
other correlations were found to be significant (see Table 7.21). 
 
Table 7.21  
Correlations between Mood and Anxiety Variables and Groton Maze Learning Test 
Variables across the Entire Sample (n = 103) 





HADS 0.15 -0.13 -0.06 -0.02 
HADS-D 0.12 -0.03 0.04 -0.09 
HADS-A 0.14 -0.18* -0.11 -0.05 
QIDS 0.15 -0.12 -0.06 -0.07 
Note: Positive correlational values suggest an association between higher levels of depression and anxiety and better GMLT 
performance, **= p < 0.01,*= p < 0.05. 
GMLT- Groton Maze Learning Test, HADS- Hospital Anxiety and Depression Rating Scale, HADS-A - anxiety subscale of 
the HADS, HADS-D - depression subscale of the HADS, QIDS- Quick Inventory of Depressive Symptomatology.  
 
7.12.3.3  Psychomotor speed  
No significant correlations were found when comparing mood and anxiety variables with 
psychomotor speed variables (TCT and TMT – Part A) (see Table 7.22). 
7.12.3.4  Attention and executive function 
The relationship between mood and anxiety variables and attention and executive function 
variables (TMT-Part B, COWAT, and Digit Span Test) was examined using correlational 
analysis. Significant negative correlations were found between symptoms of depression 
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(HADS-D) and performance on Digit Span Total Forward (r = -0.202, p = 0.04) and Digit Span 
Forward Span (r = -0.263, p = 0.008). 
 
Table 7.22 
Correlations between Mood and Anxiety Variables and Psychomotor Variables across the 
Entire Sample (n = 103) 
 
TCT (no of Correct 
Moves) 
TMT Part A (time) TMT Part A (errors) 
HADS -0.12 -0.03 -0.02 
HADS-D -0.15 -0.02 -0.03 
HADS-A -0.06 -0.03 -0.01 
QIDS -0.04 -0.14 -0.07 
Note: positive correlational values suggest an association between higher symptoms of depression and anxiety and better 
performance on psychomotor speed variables. 
HADS- Hospital Anxiety and Depression Rating Scale, HADS-A (anxiety subscale of the HADS), HADS-D (depression 
subscale of the HADS), QIDS- Quick Inventory of Depressive Symptomatology, TCT-Timed Chase Test, TMT-Trail Making 
Task. 
 
7.13  MULTIVARIATE REGRESSION ANALYSIS 
Four variables were associated with cognitive measures on univariate analysis - BMI, NART, 
age and HADS total score. Therefore, a multivariate regression analysis was conducted to 
determine whether the association between testosterone variables (Free Testosterone and FAI 
levels) and cognitive variables was independent of these factors. The inclusion of BMI in this 
analysis was complex since BMI is part of the syndrome (high androgen levels may also imply 
high BMI levels in PCOS) and not a separate factor in this context. Therefore, analyses were 




Table 7.23  
Correlations between Mood and Anxiety Variables and Attention and Executive Function Variables across the Entire Sample (n = 103) 
 












HADS  0.08 -0.16 -0.20* -0.18 -0.08 -0.11 
HADS-D 0.08 -0.15 -0.25 -0.26** -0.10 -0.12 
HADS-A 0.06 -0.14 -0.11 -0.06 -0.04 -0.07 
QIDS 0.14 -0.12 -0.08 -0.08 -0.01 -0.01 
Note: Positive correlational values suggest an association between higher levels of depression and better performance on TMT-List B and Digit Span variables, **= p < 0.01, *= p < 0.05. 
COWAT- Controlled Oral Word Association Test, HADS- Hospital Anxiety and Depression Rating Scale, HADS-A- (anxiety subscale of the HADS), HADS-D- (depression subscale of the HADS), 




When multivariate regression analysis included Free Testosterone levels, BMI, NART, Age 
and HADS-D score, no significant associations were found between Free Testosterone levels 
and CVC Recognition accuracy, GMLT Total Errors on Trial 5, GMLT Total Errors on Trials 
1-5, TCT (number of correct moves), COWAT Total Score and Digit Span Variables (Total 
Forward and Forward Span).  
When analysis included Free Testosterone levels, NART, Age and HADS-D score (excluding 
BMI), multivariate regression analysis showed a significant negative association between Free 
Testosterone levels and the TCT (number of correct moves) (p = 0.03). All other correlations 
were not significant. 
Multivariate regression analyses including FAI levels, BMI, NART, Age and HADS-D score 
as independent variables found no significant associations between FAI levels and CVC 
Recognition Accuracy, GMLT Total Errors Trials 1-5 and the TCT (number of correct moves). 
Associations between FAI levels, NART, Age and HADS-D score and cognitive variables 
(excluding BMI) from the multivariate regression analysis showed no significant associations.  
 
7.14 DISCUSSION 
The aims of this chapter were: 
 To determine whether testosterone levels were associated with mood, anxiety, 
cognitive function and emotion processing across the whole sample (n = 103). 
 To determine whether PCOS and control groups differed on measures of mood, 
anxiety, cognitive function and emotion processing. 
 To determine whether the difference between groups on tasks assessing specific 
aspects of cognitive function and emotion processing was related to greater depressive 
symptomatology, higher androgen levels, or both of these factors. 
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The remainder of the current chapter will discuss the main findings in relation to these aims. 
7.14.1 Main findings  
The main results related to correlations between testosterone levels and mood, cognitive 
function, and emotion processing variables, after controlling for NART, were as follows:  
 Higher testosterone levels (Free Testosterone, FAI) were significantly related to poorer 
performance on the recognition trial on the CVC Task.  
 Higher Free Testosterone levels were significantly associated with worse performance 
on GMLT Trial 5 and GMLT Trials 1-5. 
 Higher testosterone levels (Free Testosterone, FAI) were significantly associated with 
slower performance on the TCT (number of correct moves).  
 After controlling for mood (HADS-D), a significant association remained between 
higher FAI and worse recognition accuracy of fearful faces on the FER Task.  
 Higher FAI levels were significantly associated with worse mood, as assessed by the 
QIDS and HADS. 
In summary, higher Free Testosterone and/or FAI levels were associated with worse 
performance on several cognitive domains including verbal learning and memory (CVC 
recognition accuracy), visuospatial learning and memory (GMLT errors), psychomotor speed 
(number of correct moves on the TCT) and emotion processing (recognition accuracy of fearful 
faces). Higher FAI levels but not Free Testosterone levels were associated with greater 
symptoms of depression (see Table 7.24 for an overall summary of findings). 
Multivariate analysis was conducted to further determine whether the association between Free 
Testosterone and FAI levels and cognitive variables was independent of other factors including 
BMI, NART, age and HADS-D score. Free Testosterone levels were found to be significantly 
associated with the TCT (number of correct moves) (p = 0.03) when BMI was excluded from 
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analysis. However, other correlations found in multivariate regression analysis were found to 
be non-significant.  
Comparative analyses showed greater symptoms of depression in the PCOS group compared 
with the control group. No significant differences were found between groups on symptoms of 
anxiety. Significant differences were found between the PCOS and control groups on some 
cognitive measures, including worse performance by the PCOS group on psychomotor speed 
(TCT), worse (lower) recognition accuracy on fearful faces and worse RMET (social 
intelligence/ empathy) total score. 
Analysis examining correlations between mood and cognitive variables showed: 
 More severe symptoms of depression (HADS-D) were significantly associated with 
worse performance on CVC Trial 1.  
 Higher anxiety levels (HADS-A) were significantly related to worse performance on 
the GMLT Trial 5. 
 More severe symptoms of depression (HADS) were significantly associated with 
poorer performance on three Digit Span variables (Digit Span Total Forwards, Digit 
Span Forward Span, Digit Span Total Score).  
Although significant negative correlations were found between Free Testosterone levels and 
mood variables (HADS, QIDS), correlations were found to be non-significant (at the trend 
level, p < 0.10) after controlling for estimated premorbid IQ (NART). However, FAI levels 
were found to significantly negatively correlate with mood (higher symptoms of depression 
(HADS, QIDS)) after controlling for NART. Pertaining to the current study, since high BMI 
levels are a key symptom of PCOS, we decided not to control for this variable in the final 
analysis. The inclusion of BMI as a covariate would be problematic since high BMI is a 
diagnostic marker of PCOS (higher androgen levels may also imply high BMI levels in PCOS) 
and not a separate factor in this context. However, to further clarify the association between 
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BMI and HADS depression sub-scale, and keeping in mind the differences in BMI levels 
between groups, a scatterplot diagram was included to illustrate any potential association (see 
Appendix T where this scatterplot is presented which shows that the relationship between BMI 
and HADS is broadly consistent across both groups). Overall, there was a significant 
association between BMI and HADS (r = 0.23, p < 0.05) across groups. Regarding hirsutism 
scores, studies have found associations between hirsutism scores and poor QoL and social 
anxiety, but not mood (see Section 4.8.1). Since high testosterone levels are reflective of the 
condition of hirsutism and since the FG score is a relatively insensitive instrument to examine 
hyperandrogenism compared with direct assays of testosterone levels (see section 6.8.1.1), we 
chose not to include FG score in the final analysis. Only just over half of the PCOS sample had 
an FG score recorded (n = 27; 54%), which made it less likely that a significant correlation 
would be found, and indeed we did not see evidence of this (see Appendix U). It would be 
beneficial for future studies with larger samples to investigate this relationship by including 
sub-group analyses examining mild, moderate and high levels of excessive hair and/or BMI in 
PCOS groups in relation to mood. 





7.14.1.1 Associations between mood and anxiety and androgen levels  
7.14.1.1.1 Associations between androgen levels and mood 
Correlational analyses showed significant positive associations between higher Free 
Testosterone and FAI levels and greater symptoms of depression (HADS-D, HADS Total Score 
and QIDS), before covarying for NART. After covarying for NART, significant positive 
correlations between FAI levels and symptoms of depression remained, however, only an 
indication of a weak association (trend) was found between Free Testosterone levels and 
symptoms of low mood.  
The relationship between low mood and high levels of Free Testosterone in PCOS is a complex 
issue (Cooney & Dokras, 2017; Kische et al., 2017). To date, studies examining depression in 
females with and without PCOS have yielded inconsistent results, including no statistically-
significant results, and positive, negative and curvilinear associations between androgen levels, 
particularly Free Testosterone levels, and symptoms of depression (Adali et al., 2008; Barry, 
Hardiman, Saxby, & Kuczmierczyk, 2011; Hahn et al., 2005; Hollinrake et al., 2007; Rocco et 
al., 1991; Weiner et al., 2004). There may be many reasons to explain such variability in results. 
These may include the presence of unwanted physical symptoms in PCOS including excessive 
facial hair, cystic acne, higher BMI values, centralised obesity and other skin and hair disorders. 
Such visible symptoms may have a negative psychological impact on the patient which needs 
to be taken into account while examining mood symptoms in patients with PCOS (Bishop et 
al., 2009; Himelein & Thatcher, 2006a, 2006b; Karjula et al., 2017; Kitzinger & Willmott, 
2002; Sonino et al., 1993). However, there is mixed evidence regarding mood symptoms in 
PCOS as some studies have found no association between the physical aspects of the syndrome 
and symptoms of low mood and anxiety (Barry, Kuczmierczyk, et al., 2011; Barth et al., 1993; 
Cesta et al., 2016; Shulman et al., 1992). Furthermore, some studies suggest that BMI is 
associated with low mood in PCOS (Milsom et al., 2013; Pastore et al., 2011) and some of these 
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results could be explained by the presupposition that the association between Free Testosterone 
levels and mood may be mediated by BMI, which may be a consequence of PCOS, rather than 
an independent factor that influences the relationship between androgen levels and mood. 
Overall, data suggests mixed evidence regarding the association between Free Testosterone or 
FAI levels and mood.  
In the review conducted in the current thesis (see Chapter Five), mixed evidence was found 
related to the association between mood and testosterone levels. Out of five total studies 
examining this relationship in non-PCOS females (Bazarganipour et al., 2013; Cinar et al., 
2011; Jedel et al., 2011; Moran et al., 2012; Weiner et al., 2004), three studies found a positive 
association between Free Testosterone/FAI levels and higher symptoms of depression (n = 
580), two others found a negative (n = 35) and curvilinear (n = 27) association respectively, 
while the remaining seven studies found no significant relationship between mood and 
androgen levels (n = 541) (Annagür et al., 2013; Hollinrake et al., 2007; Klimczak et al., 2015; 
Livadas et al., 2011; Mansson et al., 2008; Pastore et al., 2011; Rasgon et al., 2003).  Overall, 
studies that found a positive association, similar to the current study, included the HADS, which 
is more suitable for assessing symptoms of depression in a medical sample and may have helped 
to assess symptoms of depression more accurately in samples with high androgen levels (as 
noted in Chapter Five). A meta-analysis showed no relationship between depression in PCOS 
and elevated Free Testosterone or FAI levels characteristic of PCOS (Cooney et al., 2017). 
However, this analysis had a strict exclusion criteria (see Chapter Five, section 5.3.1.2). In 
summary, the finding related to a significant positive association between Free Testosterone 
and FAI levels and symptoms of depression in the current study may be explained by the 
inclusion of an adequate sample size and the use of HADS to assess symptoms of depression 




7.14.1.1.2  Group differences in mood and anxiety and methodological issues 
Symptoms of depression were found to be significantly greater in the PCOS group compared 
with control participants, which is consistent with previous studies (Cooney et al., 2017; 
Dokras, 2012; Hollinrake et al., 2007; Weiner et al., 2004). Overall, there is an agreement 
concerning the higher prevalence of symptoms of depression in females with PCOS, and a 
recent review found moderate-severe symptoms of depression in females with PCOS compared 
with healthy females (Cooney et al., 2017). Using the HADS, which is more suitable for a 
medical sample such as PCOS, together with the QIDS, the current study found mild-to-
moderate severity levels in the PCOS group, in agreement with other studies (Barry, 
Kuczmierczyk, et al., 2011; Veltman-Verhulst et al., 2012) , however, these findings are 
inconsistent with Cooney et al’s (2017) review. Additionally, Axis I disorders (MINI, see Table 
7.4) were found to be more prevalent in females with PCOS, particularly mood disorders (MDD 
and bipolar disorder), and anxiety disorders (particularly GAD and SAD). Current symptoms 
of anxiety (HADS-A) in the current study were not found to be significantly different between 
the two groups, which is in contrast to studies documenting higher rates of symptoms of anxiety 
in females with PCOS (Cooney & Dokras, 2017; Dokras et al., 2012). The control group in the 
current study was, however, not randomly selected, and this limitation will be discussed in 
detail in the final section (see Section 7.15.1.3) of the current chapter. 
Inconsistent findings may also be a result of including measures designed to detect different 
symptom severity levels. For example, in a large study (226 females) (Cinar et al., 2011), higher 
FAI levels were found to be associated with greater depression severity as measured by the 
HADS. The HADS was primarily designed to determine the severity of depression, not to 
determine whether caseness is met. The HADS together with the QIDS was considered suitable 
for assessing mood and anxiety in the current medical sample (see Chapter 6, Section 6.4.2 for 
the rationale behind choosing these rating scales). The HADS was designed to assess depressive 
symptoms in patients with medical illnesses. The QIDS was designed to detect more severe 
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symptoms of depression, and in the current study was used a) as an interviewer rated scale, 
which may be less subject to the influence of physical symptoms, and b) in case depressive 
symptoms were in the more severe range. Previous studies have found no association between 
mood and androgen levels using the QIDS (Klimczak et al., 2015; Pastore et al., 2011) which 
could be due to lesser severity of symptoms involved in PCOS compared with psychiatric 
samples. Some previous negative studies have extrapolated depression severity from scales 
which are not designed to measure clinical levels of depression. For example, studies have used 
Quality of Life measures and have found higher levels of depression, anxiety and emotion 
distress in patients with PCOS compared with controls (Hahn et al., 2005; Veltman-Verhulst et 
al., 2012).  
To summarise, in the current study, symptoms of depression but not anxiety were found to be 
higher in the PCOS group compared with the control group. Additionally, higher levels of Free 
Testosterone and FAI levels, characteristic of PCOS, were found to be significantly positively 
correlated with symptoms of depression across the entire sample. The current study, therefore, 
provides evidence that higher symptoms of depression are associated with raised testosterone 
levels in females, independent of the presence of PCOS.  
7.14.1.2 Associations between cognitive function and androgen levels: Group comparisons 
and correlation analyses  
7.14.1.2.1 Verbal learning and memory 
Free Testosterone and FAI levels were significantly negatively correlated with recognition 
accuracy on the CVC Task, after controlling for NART, suggesting that higher Free 
Testosterone and FAI levels were associated with worse performance on the recognition trial 
of the CVC Task. No significant differences on CVC variables were observed between the two 
groups before or after co-varying for NART.  
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Seven cross-sectional studies have examined verbal learning and memory in relation to 
androgen levels in healthy females, females with PCOS and female-to-male transsexuals 
(Gómez-Gil et al., 2009; Halari et al., 2005; Hussain et al., 2016; Janowsky et al., 1998; S. 
Phillips & Sherwin, 1992; Romero-Martínez et al., 2015; Schattmann & Sherwin, 2007b). One 
study including females with PCOS found a significant difference between PCOS and the 
healthy control groups on verbal learning and memory measures (Schattmann & Sherwin, 
2007b). Schattmann and Sherwin (2007b) reported that their PCOS group (n = 28) performed 
significantly worse than their healthy control group (n = 20) on one measure of verbal memory 
(Paired Associates Test and Logical Memory) but not the other (RAVLT). However, in this 
study, no significant correlations were found between androgen levels and verbal learning and 
memory measures. Two further studies have shown significant yet varied results (S. Phillips & 
Sherwin, 1992; Romero-Martínez et al., 2015). Phillips and Sherwin (1992) in 25 females, 
found a significant negative correlation between Free Testosterone levels and one sub-test of 
verbal memory (Delayed Paragraph Recall; but not Logical Memory, Visual Reproduction, and 
Associate Learning). In another small study (Romero-Martínez et al., 2015), a curvilinear 
relationship was found between Free Testosterone levels and verbal memory (RAVLT) in 
caregiving mothers of children with autism. Increases in testosterone levels significantly 
correlated with better verbal memory, up-to a certain point, followed by reduced performance 
with increasing testosterone levels only in the group with caregivers (n = 24) but not the control 
group, comprising of 22 caregiving mothers of children without autism.  
Other cross-sectional studies examining verbal learning and memory in relation to testosterone 
levels have found non-significant results (Gómez-Gil et al., 2009; Halari et al., 2005; Hussain 
et al., 2016; Janowsky et al., 1998). It is to be noted that one study with non-significant findings 
measured Total Testosterone levels and not Free Testosterone levels (Hussain et al., 2016). 
Baseline results from one interventional study failed to find a significant correlation between 
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Free Testosterone and FAI levels and verbal learning and memory (Paired Associates Test, 
Logical Memory and RAVLT) (Schattmann & Sherwin, 2007a).  
In the current study, only one aspect of verbal learning and memory was found to be associated 
with testosterone levels. Thus, although it is likely that this may be a chance finding, it could 
be that a specific impairment in recognition memory (and not recall) may be associated with 
testosterone levels. Little research in has examined the specific association between recognition 
memory and testosterone levels. Furthermore, the CVC Task is challenging as it provides less 
opportunity compared with traditional verbal memory tasks to access learning and mnemonic 
strategies (Bourke et al., 2012) and, therefore, may be more sensitive to show small and 
significant results.  
7.14.1.2.2 Visuospatial learning and memory  
The GMLT was used as a measure of visuospatial learning and memory. Correlational analyses 
showed that Free Testosterone was associated with worse performance (more errors) on some 
variables from the GMLT (total errors on Trial 5 and Trials 1-5, but not the Delayed Trial), 
which remained significant after controlling for the NART. No significant group differences 
were found on any GMLT variables (total errors for Trial 1, Trial 5, Trials 1-5 or Delayed 
Recall) before or after controlling for NART. 
There is very little data available regarding the relationship between visuospatial learning and 
memory in females with PCOS, particularly in relation to testosterone levels. On the other hand, 
visuospatial ability has been examined by numerous studies. Mental rotation ability has been 
found to be positively associated with testosterone levels in interventional studies involving 
testosterone administration (Aleman et al., 2004; K. Miller et al., 2005; Pintzka et al., 2016; 
Slabbekoorn et al., 1999; Van Goozen, Cohen-Kettenis, et al., 1994; Van Goozen et al., 1995) 
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(see Chapter Five). However, visuospatial ability is a separate function from spatial learning 
and memory, and only the latter was assessed in the current study.  
Only three studies so far have examined visuospatial learning and memory in relation to 
testosterone levels in females, with inconsistent results (Gómez-Gil et al., 2009; Janowsky et 
al., 1998; Schattmann & Sherwin, 2007b). One cross-sectional study, including 33 female-to-
male transsexuals (Gómez-Gil et al., 2009), found significantly better scores on visuospatial 
memory (Visual Paired Associates Test) in the testosterone group (n = 9) compared with the 
control group (n = 10). Janowsky et al. (1998) in a longitudinal observational study found no 
significant association between visuospatial memory (Toy Task) and Free Testosterone levels 
in 30 healthy females. In another cross-sectional study (Schattmann & Sherwin, 2007b) 
including a sample of 28 females with PCOS and 20 healthy controls, no significant correlations 
were obtained between testosterone levels and spatial memory (Block-Tapping Task). Post-hoc 
analyses showed significant group differences on only one component of the Block-Tapping 
Task (the Backward component of immediate memory, but not the Forward component), with 
the PCOS group showing significantly worse performance compared with the healthy control 
group. The Block Tapping Task is best suited to examine short-term visuospatial memory in 
individuals (Kessels, van Zandvoort, Postma, Kappelle, & de Haan, 2000) and is similar to the 
early learning trials involved in the GMLT, however, is unlike the remainder of the task, which 
may help explain the difference in results between Schattmann & Sherwin’s (2007b) study and 
the current findings including a significant negative association between Free Testosterone 




7.14.1.2.3 Psychomotor speed 
Free Testosterone and FAI levels were found to be significantly negatively correlated with 
performance on the TCT (number of correct moves) after controlling for NART, suggesting 
that higher testosterone levels were associated with worse performance (fewer correct moves) 
made on the TCT. Additionally, multivariate regression analysis found Free Testosterone levels 
to be significantly associated with the TCT (number of correct moves) (p = 0.03) when BMI 
was excluded from analysis, and this was the only task which was found to be significantly 
associated with testosterone levels. The PCOS group showed significantly worse performance 
on the TCT (fewer number of correct moves) after controlling for NART, with a large effect 
size (0.76). No significant correlations were found between testosterone levels and performance 
on the TMT– Part A (time). No significant group differences were found between the two 
groups on the remaining psychomotor speed variables after controlling for NART.  
In explaining this finding, it could be that that higher Free Testosterone and FAI levels 
characteristic of PCOS have a negative effect on psychomotor speed, which is considered a 
female-superior cognitive domain. Indeed, previous studies have found a significant female-
advantage in tasks assessing psychomotor speed (Gouchie & Kimura, 1991; Halpern, 2000) and 
it may be that abnormally elevated androgen levels negatively affect performance suggesting 
an organisational effect of testosterone. However, most studies examining psychomotor speed 
in reproductive-aged females with and without PCOS do not suggest consistent results 
(Gouchie & Kimura, 1991; Janowsky et al., 1998), except for one robust, cross-sectional study 
which found significant group differences and a significant negative correlation between FAI 
levels and psychomotor speed (Schattmann & Sherwin, 2007b). Schattman and Sherwin 
(2007b) reported that their PCOS group with high FAI levels (n = 29) performed significantly 
more slowly than their healthy control group (n = 22) on one measure of motor speed, manual 
dexterity (Purdue Pegboard), but not the other measure of perceptual speed (Finding A’s). 
Additionally, FAI levels were found to be negatively correlated with performance on the 
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manual dexterity task. However, in this study, similar to the current study, multiple cognitive 
tests were included which is a methodological limitation. Another study (Gouchie & Kimura, 
1991) examining psychomotor speed (Finding A’s Test) found no significant differences 
between two groups including females with high and low Free Testosterone levels and found 
no significant correlations between androgen levels and cognitive performance in these groups. 
Janowsky et al. (1998) found a significant positive correlation between Free Testosterone levels 
and the Dart Throwing Task which assessed visuo-motor speed, however, only in females using 
their dominant hand, which is likely to be a chance finding.  
The results of the current study are similar to those of Schattman and Sherwin’s study (2007b), 
possibly due to the inclusion of the motor task involved but also due to the inclusion of females 
with PCOS with high FAI levels in contrast to the other studies including only healthy females. 
Testosterone levels in these study samples may not be as elevated compared with females with 
PCOS, which may limit the spread of androgen levels and the chance of finding significant 
associations.  
In the current study, the TCT was used as a measure of motor speed, while the TMT-A was 
used to assess the additional perceptual processing component. In contrast to the TCT, no 
significant difference in performance was observed on the TMT-A in the PCOS group 
compared with the control group. Although these findings may seem contradictory, it may be 
that these two tests have a subtle difference in their requirement of different strategies and 
cognitive processes. 
In summary, current findings included significant negative correlations between Free 
Testosterone and FAI levels and TCT performance (number of correct moves) and significantly 
worse performance by the PCOS group compared with the control group. This suggests that 
high testosterone levels may be negatively associated with motor speed performance. It may be 
that testosterone levels are negatively associated with the motor speed aspect of psychomotor 
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speed rather than the perceptual speed component which previous studies have failed to find 
(Gouchie & Kimura, 1991; Schattmann & Sherwin, 2007b).  
7.14.1.2.4 Attention and executive function 
No significant correlations were found between testosterone levels and attention and executive 
function variables after controlling for NART. The PCOS group did not show significantly 
different performance to the control group on measures of attention and executive function 
(TMT - Part B, COWAT, and Digit Span) after controlling for NART.  
Relatively little information is available regarding the relationship between attention and 
executive function and testosterone levels in females. However, available data suggest that 
higher testosterone levels may be associated with worse verbal fluency (executive function) 
(Krug et al., 2003; Thilers et al., 2006).  Only one cross-sectional study found a significant 
relationship between executive function and testosterone levels in females. In a cross-sectional 
study examining verbal fluency in reproductive-aged females with and without PCOS 
(Schattmann & Sherwin, 2007b), females with PCOS and high Free Testosterone levels (n = 
29) demonstrated significantly worse performance on verbal fluency (COWAT) compared with 
healthy females (n = 22). Furthermore, FAI levels were negatively correlated with COWAT 
scores suggesting high testosterone levels may dampen executive functioning, which the 
current study did not find. Other cross-sectional studies have found no significant association 
between executive function measures and androgen levels in healthy females (Halari et al., 
2005; Hassler et al., 1992; Janowsky et al., 1998; McKeever et al., 1987; Moffat & Hampson, 
1996; Neave et al., 1999).  
To summarise, no significant correlations were found between attention and executive function 
performance and testosterone levels in the current study. Additionally, no significant group 
differences were found between groups on these measures.  
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7.14.1.3 Associations between emotion processing and androgen levels  
7.14.1.3.1 Facial Expression Recognition - Recognition accuracy and neutral misinterpretation 
Significant negative correlations were found between Free Testosterone and FAI levels and 
recognition accuracy of neutral and sad facial expressions, as well as total accuracy on the FER 
Task. However, after controlling for mood HADS-D, only the negative correlation between 
FAI levels and recognition accuracy of fearful faces remained significant. That is, higher FAI 
levels were associated with worse recognition accuracy of fearful faces. Correlational analyses 
showed no significant relationship between misinterpretation bias of neutral faces and 
testosterone levels. The PCOS group (n = 50) showed poorer recognition accuracy of fearful 
faces (ES = 0.40) and sad faces (ES = 0.58) compared with the control group (n = 53).  
Sex hormones can influence emotional states and their expression in individuals. Testosterone 
has been mainly associated with emotions of anger, and related behaviours such as aggression 
and social dominance (van Wingen, Ossewaarde, Bäckström, Hermans, & Fernández, 2011), 
however, this has been studied mostly in males (Archer, 2006; Mazur & Booth, 1998). Until 
now, the focus of most research on emotional processing in relation to sex hormones in females 
has focused on menstrual fluctuations in oestrogen and progesterone, and the effect of these 
fluctuations on mood (Poromaa & Gingnell, 2014) and on the perception of sexual or 
reproductive stimuli involved in emotion processing (Krug, Plihal, Fehm, & Born, 2000; 
Macrae, Alnwick, Milne, & Schloerscheidt, 2002). The majority of studies examining emotion 
processing in females with PCOS and in healthy control samples have used an interventional 
study design involving testosterone administration (Bos et al., 2016; Bos et al., 2013; Enter et 
al., 2015; Hermans et al., 2007; Olsson et al., 2016; Terburg et al., 2012; van Honk et al., 2005; 
van Wingen et al., 2011; van Wingen et al., 2009). Findings pertaining to these studies will be 
discussed in the following chapter (Chapter Eight) focusing on the longitudinal (post-treatment) 
results of the current study.  
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Only two cross-sectional studies until now have investigated the relationship between 
testosterone levels in reproductive-aged females and facial emotion processing performance 
(Stanton et al., 2009; van Honk et al., 1999). Stanton et al. (2009) used fMRI to measure blood-
oxygen-level dependent (BOLD) responses to angry faces (Face Stimulus Test) in the amygdala 
and ventromedial prefrontal cortex, as a function of endogenous testosterone in 14 healthy 
females. Free Testosterone levels were not associated with BOLD responses during the emotion 
processing task in this study. van Honk et al. (1999) in their observational study involving 
multiple time-coursed samples of salivary Free Testosterone obtained from 16 healthy females 
found significant associations between Free Testosterone levels taken six-hours prior to testing 
(higher levels of testosterone compared with the samples at other time points thereafter) and 
higher selective attention to angry faces (Emotional Stroop Task) and between the same time-
lag in testosterone samples and mood (POMS subscales including anger and tension). While 
these results may be due to chance, findings suggest that high levels of testosterone in females 
are associated with a reduction in sensitivity and higher selective attention to angry faces. One 
small neuroimaging study examining emotional processing in twelve females with and without 
PCOS with insulin resistance found greater limbic activation (including the prefrontal cortex, 
anterior cingulate, amygdala, and ventral basal ganglia/nucleus accumbens) in the PCOS group 
(n = 7) during an emotion processing task compared with non-insulin resistant controls (n = 5) 
(Marsh et al., 2013). However, this study did not report differences between groups in 
performance on tasks assessing emotion processing.  
Literature suggests an association between testosterone and aggression and studies have shown 
high testosterone levels to be positively associated with aggression (J. Harris et al., 1996). This 
may be due to a possible activating effect on the limbic region, particularly on the amygdala, 
observed through increased neural activity (Derntl et al., 2009; van Wingen et al., 2010; van 
Wingen et al., 2009), or through metabolisation into neuroactive steroids (Aikey, Nyby, 
Anmuth, & James, 2002) or aromatisation to oestrogen in presynaptic terminals (Hermans, 
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Ramsey, & van Honk, 2008; van Wingen et al., 2010), which may also have an effect on 
amygdala or limbic activation, thought to be important in fear perception (Adolphs, 2008). In 
contrast to findings related to greater amygdala activation associated with testosterone levels, 
studies have found testosterone to be associated with a reduced central fear and stress responses 
(Hermans et al., 2006; van Honk et al., 2005) and to selectively reduce sensitivity toward 
threatening emotional expressions, observed through reduced conscious recognition of facial 
threat, including emotions of fear, anger and disgust (van Honk & Schutter, 2007; Wirth & 
Schultheiss, 2007). Furthermore, some animal and human studies have shown that testosterone 
down-regulates the stress response (Aikey et al., 2002; Bitran, Kellogg, & Hilvers, 1993)  with 
the involvement of the amygdala (De Kloet, Joëls, & Holsboer, 2005). Testosterone has also 
been linked with worse empathy (Olsson et al., 2016; van Honk et al., 2011), which is a crucial 
function for understanding or inferring the emotional states of others, important for healthy 
social functioning. It has been postulated that testosterone, being predominantly a male 
hormone, may be associated with diminished or impaired empathic responses observed in 
individuals with autism, mostly occurring in males (Baron-Cohen et al., 2011; Manning et al., 
2001) which suggests an organisational effect of this androgen. In the current study, the PCOS 
group was found to show worse performance in accurately recognising negative emotional 
expressions of fear and sadness compared with the control group, which may be explained by 
the finding of a correlation between high testosterone levels and poorer recognition accuracy 
of fearful faces. Detecting emotional cues and processing negative facial emotional expressions, 
such as fear and sadness, reflect an empathic response and emotional sensitivity, which may be 
negatively affected by high testosterone levels in the PCOS group. This may explain reduced 
accuracy in recognising threatening emotional expressions including fear, consistent with the 
findings of the current study, however, this does not justify findings related to decreased 
accuracy in recognising sad (non-threatening) facial expressions in the PCOS group.  
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To summarise, in the current study, the PCOS group showed worse recognition accuracy related 
to fearful and sad faces compared with the control group. Correlational analysis after controlling 
for mood showed a significant negative correlation only between FAI levels and recognition 
accuracy of fearful faces suggesting that higher FAI levels were associated with reduced 
sensitivity toward threatening faces which may be observed through worse recognition 
accuracy of fearful faces in the entire sample with varying levels of testosterone. It is possible 
that since the PCOS group experienced more symptoms of depression compared with the 
control group, these symptoms mediated the relationship between worse performance on 
measures of emotion processing and testosterone levels. Facial emotion processing deficits 
have been demonstrated in depression, including reduced accuracy of in recognising facial 
emotions of sadness, happiness and disgust in individuals with depression (Bediou et al., 2012; 
Bediou et al., 2009; Bourke et al., 2010; Douglas & Porter, 2010; Gotlib, Krasnoperova, et al., 
2004; Leppänen, 2006; Leppänen et al., 2004; Leyman, De Raedt, Schacht, & Koster, 2007; 
Stuhrmann et al., 2011; Suslow et al., 2004). Future research specifically assessing the 
association between testosterone levels, mood and facial recognition involving fearful faces 




7.14.1.3.2 Reading the Mind in the Eyes Test  
In the current study, the RMET score did not significantly correlate with androgen levels (all p 
> 0.05). However, significant group differences were observed, with the PCOS group showing 
worse performance on the RMET compared with the control group, after controlling for NART. 
Previous studies examining the organisational effects of testosterone have found that high 
exposure to foetal testosterone may be negatively associated with empathic ability (see Chapter 
3, Section 3.4.3). Females have been shown to have a significant advantage in empathic ability 
compared with males (E. Chapman et al., 2006). Additionally, as noted in Chapter Three, 
elevated foetal testosterone levels have been found in individuals with autism. Individuals with 
autism have also been shown to experience difficulties in empathy, which has been recently 
been proposed as a broader neurocognitive construct (Baron-Cohen, 2002; Sucksmith, Allison, 
Baron-Cohen, Chakrabarti, & Hoekstra, 2013). In line with this, one study examining 
organisational effects of testosterone found females with abnormally high levels of testosterone 
in utero to show a higher number of autistic traits (including a lower empathic ability) compared 
with unaffected siblings (Knickmeyer et al., 2006), and another study found females with 
autism to have higher Free Testosterone levels compared with controls also suggesting the 
organisational effects of testosterone (Bejerot et al., 2012). However, since there are 
complications in investigating the organisational effects of pre-birth measures of testosterone, 
little research is found in this area. No cross-sectional study has used the RMET, so far, to 
assess emotion processing in females with PCOS. More research has been done using the 
RMET in interventional studies involving testosterone administration in healthy, reproductive-




7.14.1.4 Associations between mood and cognitive function: Correlation analyses  
In the current study, significant correlations were found between mood variables and some 
aspects of cognitive function, which is somewhat surprising since the sample in the current 
study experienced symptoms of depression of only mild-moderate severity. Thus, only a weak 
association with cognitive outcomes was expected. Analysis examining the association between 
mood and cognitive variables showed higher symptoms of depression to be significantly 
associated with poorer performance on the CVC Trial 1 and Digit Span variables, both of which 
measure verbal working memory. Additionally, greater symptoms of anxiety were significantly 
related to poorer performance on visuospatial learning and memory (errors on GMLT Trial 5).  
Taken together, these results suggest that higher levels of depression and anxiety are associated 
with worse performance on measures assessing aspects of verbal working memory, executive 
function and attention, and spatial learning and memory. Previous studies have shown 
significant cognitive deficits in learning and memory in individuals with MDD compared with 
healthy controls (Austin et al., 2001; Douglas et al., 2013; Golinkoff & Sweeney, 1989; Sarosi 
et al., 2008; Thomas et al., 2009). In the current study, although aspects of verbal learning and 
memory and attention and executive function were found to be significantly negatively 
associated with mood, no other cognitive domains were found to be significantly associated 




Table 7.24  
Summarising Correlations between Testosterone Variables and Mood and Anxiety Variables 
and Cognitive Function and Emotion Processing Variables across the Entire Sample (n = 
103) 
 Free Androgen Index Free Testosterone 
HADS-D 0.32**  
HADS Total Score 0.21*  
CVC Recognition Accuracy -0.206* -0.233* 
GMLT Total Errors Trial 5  -0.246* 
GMLT Total Errors Trials 1-5  -0.228* 
TCT (no of correct moves) -0.262** -0.310* 
Recognition accuracy-fearful faces -0.07*  
Note: Positive correlational values suggest an association between higher levels of depression and higher levels of 
testosterone, and negative correlational values suggest an association between worse cognitive function and higher levels of 
testosterone, **= p < 0.01, *= p < 0.05. 
HADS-D = Hospital Anxiety and Depression Scale (Depression sub-scale), CVC - Consonant Vowel Consonant Task, 
GMLT - Groton Maze Learning Test, TCT - Timed Chase Test 
 
7.15 STRENGTHS OF THE STUDY 
Previous findings related to the association between testosterone levels in females and mood 
and cognitive function are inconsistent, due to several factors. These include the inclusion of 
female samples with a broad age-range (including post-menopausal females), the inclusion of 
measures not suitable or adequately sensitive to detect the symptoms of depression unrelated to 
medical illness, small sample sizes, and an assessment of Total Testosterone but not Free 
Testosterone (unbound to plasma and the most important measure) or FAI levels. Strengths of 
the current study were: an inclusion of reproductive-aged females with PCOS together with a 
non-PCOS comparison group, and an inclusion of patients with varied physical and biochemical 
symptom profile seen through the wide spread of androgen levels. Another strength of the study 
was the use of a comprehensive mood and cognitive testing battery, including tasks assessing 
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emotion processing variables. Inclusion of the HADS (more suitable for assessing symptoms 
of depression and anxiety in a medical group such as PCOS) together with the interviewer-rated 
scale QIDS was a major strength of the current study. Importantly, this is the first known study 
to simultaneously investigate the relationship between androgen levels, mood, anxiety, 
cognitive function and emotion processing in females with PCOS. 
7.15.1  Critique of the Research   
7.15.1.1 Study design 
The current study was a naturalistic longitudinal study in that the treatment for PCOS was not 
altered from the standard clinical treatment patients would generally receive at the 
gynaecological endocrine clinic, as a result of their participation in the current research study. 
Recruitment of patients with PCOS was more challenging than anticipated.  The two main 
pathways to recruit females with PCOS were 1) referrals to gynaecological endocrine clinics, 
and 2) females responding to advertisements in local newspapers, following which they were 
assessed by the same treating Gynaecological-Endocrinologist (see Chapter Six, section 6.3.1). 
However, most patients with PCOS were recruited from clinics (n = 33), and thus, are likely to 
be representative of the population attending such clinics.  
Symptoms observed in PCOS patients were heterogeneous, for example, hyperandrogenism 
observed through symptoms of acne, hirsutism and alopecia, together with higher BMI values 
and metabolic complications observed in the syndrome. Controlling for BMI was, therefore, 
not thought to be useful since it is a symptom of the complex syndrome rather than a separate 




7.15.1.2  Medications at baseline 
A limitation of the current study was the heterogeneity of anti-androgen and other hormonal 
medication used by patients. At baseline, a large proportion of patients reported using the OCP 
or COCP (46%) and four percent of the group reported using anti-androgen medication (see 
Table 7.5). Therefore, not all patients were unexposed to prior hormonal treatment which is a 
limitation of the current study. However, 86% of females were unexposed to anti-androgen 
medication (and Metformin) at baseline. Some patients had been taking medication for a 
significant period of time before changing to a different medication, or changing the dose, after 
being recruited into the current study. There was considerable heterogeneity in the types and 
doses of hormonal medication at baseline and also over the period of the study. This meant it 
was not possible to explore the associations between mood and cognitive tests and specific 
hormonal agents. However, the study also included a proportion of patients who attended the 
clinic for a medication review, in which case the dose or type of treatment was altered, 
compared with receiving treatment for the first time. This indicates that the current sample was 
representative of the general PCOS population. 
7.15.1.3  Control group and sampling 
The main reason for recruiting a control group in the current study was to have a group without 
PCOS which would generally have lower levels of androgens and would, therefore, provide a 
spread of androgen levels in the correlation analysis. Additionally, the inclusion of a non-PCOS 
comparison group was a strength of the current study, as practice effects in cognitive testing 
were able to be controlled for. However, this group was not well-matched with the PCOS group 
in terms of total years of education, verbal IQ and BMI, which was a significant limitation of 
the current study. Optimally, the control group should differ from the PCOS group only in the 
presence of PCOS. Current depression or a history of depression was not an exclusion for the 
control group because we intended to recruit a group which was not ‘supernormal’. This was a 
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convenience group which was characterised by being the same age as the PCOS group but not 
having a diagnosis of PCOS. Most control participants did not endorse symptoms of depression, 
however, some participants in this group showed mild symptoms of depression, assessed by the 
HADS (see Table 7.3). Due to sampling bias, females in the control group had higher verbal IQ 
scores compared with the PCOS group (see Section 7.15.1.6). This was a significant weakness 
and required statistical correction. Recruitment of control participants was intended to be more 
representative of the general population, and therefore, we tried to recruit from online resources, 
shopping malls, gymnasiums, and sports centres, however, a higher number of females from a 
university setting responded to advertisements regarding participation in the current study. This 
will have contributed to significant differences between the control group and the PCOS group 
on verbal IQ (NART) at baseline. A better strategy would have been to institute methods of 
recruiting controls which attracted those with lower IQs. Ideally, a comparison group should be 
sampled randomly from the same population as the illness (PCOS) group. Participants from the 
control group were not randomly selected. Therefore, it is not clear, for example, that depression 
rates are higher in PCOS than in a matched population without PCOS. People with depression 
may have been, indeed, less likely to volunteer.  
7.15.1.4  Cognitive assessment 
An issue which could be considered a limitation of the current study was the lack of inclusion 
of tasks assessing visuospatial ability which have been consistently shown to be related to 
testosterone levels in testosterone administration studies. However, we opted to focus on tasks 
which have previously also been shown to have lower levels of performance in depression. The 
cognitive testing battery contained a variety of measures including traditional cognitive tasks 
and emotion processing tasks, many of which have not been used in PCOS samples. The CVC 
Task assesses verbal learning and memory and presents nonsense syllables rather than 
presenting words. This task appears to be more sensitive to deficits in verbal learning and 
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memory in MDD compared with other tasks such as the RAVLT (Bourke et al., 2012; Douglas 
et al., 2011), and therefore, inclusion of this task added strength to the current study. However, 
the CVC is not a well-validated task.  
7.15.1.5  The 2D:4D ratio 
A putative marker of foetal testosterone levels is the digit length ratio, also known as the 2D:4D 
ratio (see Chapter 3, Section 3.4.3). Since the study included a thorough assessment of hormonal 
levels (particularly testosterone levels) and other physical symptoms of PCOS, collecting 
information about the digit length ratio was not considered important. However, this could 
possibly have added information regarding the interaction between organisational and 
activational effects of androgens. Future research examining emotion processing and cognitive 
function in females with high androgen levels may be benefitted by including this measure to 
examine both organisational and activational effects of testosterone together with their 
interaction. 
7.15.1.6  Power/ Sample size  
The current study (including 50 patients and 53 controls) had 80% power to show a difference 
between the groups with an effect size of 0.6 (or above) as statistically significant, (two-tailed 
α=0.05). Therefore, if effect sizes obtained in the current results were smaller than 0.6, the study 
was not adequately powered to show a statistically significant difference. Previous studies 
examining cognitive function in relation to testosterone levels in females with and without PCOS 
have tended to have smaller sample sizes (often less than 30 participants in the PCOS group). In 
the current study, recruitment was less than expected, since at the beginning of the study, the 
Canterbury District health Board (CDHB) published new “pathways” for General Practitioners 
mandating that the first-line treatment for patients with PCOS should involve OCPs/COCPs, 
following which referrals would be considered, which affected the sample size included in the 
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study. Although recruiting a large number of patients with PCOS was a priority for the current 
study, a major strength of the current study was the longitudinal study design involving anti-
androgen treatment (discussed in Chapter 8, section 8.8).  
7.15.1.7  Multiple testing 
The issue of multiple outcome variables is important to consider. Given the exploratory nature 
of the study we opted not to utilise a statistical correction (for example, Bonferroni) for the 
number of statistical tests carried out. We opted instead to determine whether findings fitted a 
pattern and fitted with the literature. Thus, some findings may be likely to be attributed to 
chance (see Chapter 6, Section 6.11.1.1). It is important in the context of the current study to 
consider the possibility that the testing of multiple outcome variables may lead to the possibility 
of Type 1 errors, which means that statistically significant results could be chance findings. 
While acknowledging that many outcomes have been tested in this PCOS study, many of the 
outcomes are tested to confirm previous study results and additionally, individual statistically 
significant results are not discussed unless they fit into a coherent pattern with other significant 
results. The exploratory nature of much of the testing of associations is also acknowledged and 
significant results will need to be confirmed in future studies. 
 
7.16 CONCLUSIONS 
In the current study, symptoms of depression in the PCOS group were found to be significantly 
greater than those in the control group. This finding could be due to the high FAI levels found 
in females with PCOS. Indeed, this hypothesis was supported by the finding including a 
significant positive correlation between high FAI levels and greater symptoms of depression 
across the entire sample. Thus, this study provides evidence for a significant association 
between higher testosterone levels, specifically FAI levels, and mood in that higher FAI levels 
were found to be associated with greater depressive symptomatology.  
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Although the PCOS group did not perform significantly worse compared with the control group 
on most cognitive domains (except for psychomotor speed and emotion processing variables 
including recognition accuracy of fearful and sad faces, and the RMET), significant negative 
correlations were obtained between Free Testosterone and/or FAI levels and verbal learning 
and memory, visuospatial learning and memory, psychomotor speed and recognition accuracy 
(emotion processing) variables (see Table 7.24 for a summary of findings). These findings 
suggest that higher testosterone levels were associated with worse cognitive performance on 
measures of verbal learning and memory, spatial learning and memory, and psychomotor speed. 
However, multivariate analysis excluding BMI as a variable showed no significant associations 
between cognitive variables and Free Testosterone and/or FAI levels with the exception of a 
significant negative association between Free Testosterone levels and performance on the TCT 
(number of correct moves). Aspects of emotion processing were found to be impaired in the 
PCOS group compared with the control group. Testosterone levels were found to be 
significantly negatively correlated with emotion processing task variables. High levels of 
testosterone were associated with worse accuracy in recognising fearful facial expressions. 
Additionally, higher symptoms of depression were found to be significantly negatively 
associated with worse performance on verbal learning and memory and attention and executive 





STUDY 2: MOOD, ANXIETY, COGNITIVE FUNCTION AND 
EMOTION PROCESSING IN POLYCYSTIC OVARIAN SYNDROME 
FOLLOWING ANTI-ANDROGEN TREATMENT  
 
 
8.1 INTRODUCTION  
Chapter Seven presented baseline findings regarding symptoms of depression and anxiety, and 
cognitive function and emotion processing in females with PCOS compared with the control 
group and correlations between testosterone levels and symptoms of mood, cognitive function 
and emotion processing. The focus of the current chapter is whether symptoms of mood, 
anxiety, cognitive function and emotion processing change following anti-androgen treatment 
in the PCOS group compared with the non-PCOS control group receiving no treatment, and 
whether there is an association between change in mood and anxiety and change in cognitive 
function and emotion processing in the PCOS group following anti-androgen treatment. 
8.1.1 Aims 
Major aims of the current chapter are:  
 To compare the change between the PCOS group receiving treatment and the control 
group (non-PCOS comparison group not receiving treatment) on measures of mood, 
anxiety, cognitive function and emotion processing from the baseline to the follow-up 
(12-weeks after baseline) assessment. 
 To examine change within the PCOS group following anti-androgen treatment on 
measures of mood, anxiety, cognitive function and emotion processing. 
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 To determine whether there is an association between change in symptoms of mood 
and anxiety and change in cognitive function and emotion processing in the PCOS 
group following anti-androgen treatment. 
8.1.2  General hypotheses 
Until now, no known study has simultaneously investigated mood, cognitive function and 
emotion processing in females with PCOS. Furthermore, there has not been a concurrent 
examination of changes or improvements in symptoms of depression, anxiety, cognitive 
functioning and emotion processing over the course of anti-androgen treatment in females with 
PCOS. The current study hypothesised that: 
 Anti-androgen treatment in the PCOS group will be associated with improvement in 
symptoms of depression and anxiety. 
 Anti-androgen treatment in the PCOS group will be associated with improvement in 
cognitive function and emotion processing, 
 Improvement in symptoms of depression and anxiety will be associated with 
improvement in cognitive function and emotion processing in the PCOS group over 
twelve-weeks of anti-androgen treatment. 
8.1.3  Chapter outline 
The first part of this chapter will present a description of participants included in the 
longitudinal study. Following this, changes in symptoms of mood, anxiety, cognitive function 
and emotion processing measures over the course of anti-androgen treatment in the PCOS group 
compared with the control group will be presented. Additionally, changes within the PCOS 
group on measures of mood, anxiety, cognitive function and emotion processing from the 
baseline to the follow-up assessment will be presented. Cognitive findings will be categorised 
into five main domains: verbal learning and memory, visuospatial (non-verbal) learning and 
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memory, attention and executive functioning, psychomotor speed and emotion processing. The 
remainder of this chapter will discuss correlational analyses examining associations between 
change in mood, anxiety and change in cognitive function and emotion processing following 
anti-androgen treatment in the PCOS group. 
 
8.2  PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME 
Not all females with PCOS completed the current longitudinal study. Fifty patients completed 
the initial baseline assessment. Eight patients did not complete the follow-up assessment at the 
twelve-week time-point due to relocating away from Christchurch (n = 3), being away for work 
(n = 1), and non-compliance with medication (did not start medication after baseline cognitive 
assessment) (n = 4). Thus, 42 patients with PCOS completed all assessments, a retention rate 
of 82%. Of the 53 control participants included at baseline, three did not complete the second 
assessment due to relocating away from Christchurch (n = 2) and starting anti-androgen 
treatment as a cosmetic measure for treating acne (n = 1). Therefore, the final sample consisted 
of 92 participants in all, including 42 patients with PCOS and 50 control participants.  
Study completers (n = 42) were comparable to non-completers (n = 8) in the PCOS group on 
all demographic and clinical scales (see Table 8.1). The number of non-completers was small 
making statistical significance of any difference unlikely, and further examination of the data 
did not suggest any major group differences. 
In the control group, 78% reported being in the luteal phase of the menstrual cycle while 22% 
reported being in the follicular phase at baseline. At the follow-up assessment, 84% of females 
were in the luteal phase, which was not significantly different to the proportion at baseline (χ² 





Means (SD) for Demographic Variables in Study Completers (n = 42) Versus Non-
Completers (n = 8) in the PCOS group (n = 50) 
 Completers Non-completers   
 Mean SD Mean SD t p 
Demographic characteristics   
Age 28.74 6.60 30.13 8.32 -0.44 0.67 
BMI 27.42 8.19 29.84 7.37 -0.83 0.42 
Predicted Verbal IQ 
(NART) 
105.21 8.07 105.75 10.30 -0.14 0.89 
Total years of 
education 
8.36 2.14 7.00 4.00 0.93 0.38 
Clinical characteristics 
Baseline HADS  12.33 6.79 15.00 8.61 -0.83 0.93 
Baseline HADS-D 4.71 3.73 5.75 4.49 -0.61 0.56 
Baseline HADS-A 7.62 3.89 9.25 4.71 -0.92 0.38 
Baseline QIDS 5.24 3.94 9.25 5.82 -1.87 0.09 
Androgen measures 
Total Testosterone 2.05 0.66 1.99 0.44 0.34 0.74 
Free Testosterone  30.24 15.24 31.28 11.97 -0.20 0.84 
Free Androgen Index 54.55 40.76 53.28 34.35 0.08 0.93 
t - Independent samples t-test, HADS- Hospital Anxiety and Depression Scale, HADS-A- Hospital Anxiety and Depression 
Scale (Anxiety sub-scale), HADS-D- Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS- Quick 






8.2.1  Anti-androgen treatment profile of patients with Polycystic Ovarian Syndrome  
After baseline assessment, patients with PCOS were prescribed Metformin (n = 6), CPA (n = 
9), Spironolactone (n = 25), Flutamide (n = 1), and/or the OCP/COCP (n = 18). No patients 
with PCOS reported using antidepressant medication at the follow-up assessment. 
Nine control participants reported using the OCP as a birth control measure at baseline which 
did not change during the study period. Females in the control group also reported using 
antidepressant medication (Fluoxetine, n = 1; Escitalopram, n = 1; Citalopram, n = 2; 
Venlafaxine, n = 2), anti-psychotic medication prescribed in a low dose for insomnia 
(Quetiapine, (n = 1) (100 mg) and anxiety medication (Lorazepam, n = 1). One female in the 
control group reported using minoxidil (antihypertensive vasodilator medication) as part of 
treatment for alopecia during the second assessment. 
Table 8.2 
Hormonal Treatment Profile of Patients with Polycystic Ovarian Syndrome at Follow-up 
Hormonal medication  N (%) 
CPA  9 (3.78) 
Spironolactone  25 (10.5) 
Metformin   6 (2.52) 
OCP or COCP (Yasmin, Ginette)  18 (7.56) 






8.3  CHANGE IN SYMPTOMS OF DEPRESSION AND ANXIETY OVER THE 
COURSE OF TREATMENT IN THE POLYCYSTIC OVARIAN SYNDROME 
(n = 42) AND CONTROL (n = 50) GROUPS 
An independent samples t-test was conducted to compare change in symptoms of depression and 
anxiety over 12 weeks in the PCOS group receiving treatment compared with the control group 
(not exposed to treatment). No significant differences were found between the two groups on 
change in symptoms of depression (HADS) over time. The PCOS group showed a reduction in 
total HADS score (t = -1.84, p = 0.07) and score on the depression subscale of the HADS (HADS-
D) (t = -1.90, p = 0.06), however, at trend level, compared with the control group. No significant 
differences were found on change in the HADS-A (anxiety subscale) and the QIDS total score.  
A paired t-test was conducted to test the change within the PCOS group on symptoms of 
depression and anxiety following 12 weeks of treatment. Scores on all scales assessing depression 
and anxiety showed significant improvement over the twelve-week study (see Table 8.3).   
Table 8.3 
Change in Symptoms of Depression and Anxiety Over the Course of Treatment in the 
Polycystic Ovarian Syndrome (n = 42) and Control (n = 50) Groups 
 PCOS Control   
 Mean SD Mean SD t p d 
HADS total score 2.78** 5.74 0.72 4.85 -1.84 0.07 0.38 
HADS-A 1.11* 2.76 0.30 2.87 -1.39 0.17 0.28 
HADS-D 1.69** 3.55 0.42 2.69 -1.90 0.06 0.40 
QIDS total score 2.55*** 4.31 1.28 3.92 -1.46 0.15 0.30 
t -Independent samples t-test, d =Cohen’s d effect size, HADS = Hospital Anxiety and Depression Rating Scale, HADS-A- 
Hospital Anxiety and Depression Scale (Anxiety sub-scale), HADS-D - Hospital Anxiety and Depression Scale (Depression 
sub-scale), QIDS = Quick Inventory of Depression Symptoms, PCOS - Polycystic Ovarian Syndrome, *= p < 0.05, **= p < 
0.01, *** =p < 0.001, Asterisks values alongside the mean in the PCOS group represent significant change within the PCOS 




8.4  CHANGE IN COGNITIVE FUNCTION OVER THE COURSE OF TREATMENT 
FOR POLYCYSTIC OVARIAN SYNDROME  
Independent samples t-tests were conducted for all cognitive and emotion processing variables 
to determine whether there were any significant differences between the PCOS and control 
groups on change in cognitive functioning over the course of treatment. Effect sizes were 
calculated for the differences in change between the PCOS and control group from baseline to 
twelve-weeks (follow-up) for all cognitive measures.  
8.4.1  Verbal learning and memory 
8.4.1.1 Consonant-Vowel-Consonant Task  
Differences in the change scores on CVC variables including Trial 1, Trial 5, Total Learning, 
Delayed Recall Trial, Recognition accuracy on List A were not significant between the PCOS 
and the control groups. However, significant improvements were found within the PCOS group 
on CVC variables (Trial 1, Trial 5, CVC Total learning, Delayed Recall) (all p < 0.001), with 
the exception of the recognition accuracy (see Table 8.4). 
8.4.2  Visuospatial learning and memory 
8.4.2.1 Groton Maze Learning Test 
Differences in change on the GMLT variables including Total Errors on Trial 1, Trial 5, Trials 
1-5, and on the Delayed Recall Trial were not significant between the PCOS and the control 
groups. However, within the PCOS group, there was a significant improvement on Trial 1 (p < 





Means (SD) and Effect Sizes of Change in Consonant-Vowel-Consonant Task Variables 
following Anti-androgen Treatment in the Polycystic Ovarian Syndrome (n = 42) and Control 
(n = 50) Groups  
 PCOS Control    
 Mean SD Mean SD t p d 




































t =Independent samples t-test, d = Cohen’s d effect size, CVC= Consonant Vowel Consonant Task, PCOS= Polycystic Ovarian 
Syndrome, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, Asterisks values alongside the mean represent significant change 




Figure 8.1  
Change in scores displayed as mean (+SD) number of words recalled on Trial 1, 5 , 1-5 
(total learning) and Delayed Recall Trial of the Consonant Vowel Consonant Task in the 



































Table 8.5  
Means (SD) and Effect Sizes of Change in Groton Maze Learning Test Variables Following 
Anti-Androgen Treatment in the Polycystic Ovarian Syndrome (n = 42) and Control (n = 50) 
Groups  
 PCOS Control    
 Mean SD Mean SD t p d 
GMLT Total 
Errors Trial 1 
1.50* 3.98 0.46 4.41 -1.18 0.24 0.24 
GMLT Total 
Errors Trial 5  
0.38 4.13 0.10 3.25 -0.35 0.72 0.07 
GMLT Total 
Errors Trials 1-5  
4.83** 10.70 1.68 13.81 -1.23 0.22 0.25 
GMLT Delayed 
Trial (Trial 6)  
2.26*** 2.75 2.22 2.58 -0.75 0.94 0.01 
 T = Independent samples t-test, d = Cohen’s d effect size, GMLT = Groton Maze Learning Test, PCOS = Polycystic Ovarian 
Syndrome, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, Asterisks’ values alongside the mean represent significant change 
within the PCOS group from baseline to follow-up. Positive values denote improvement in performance on the spatial learning 
and memory task. 
 
  
Figure 8.2:  
Change in scores displayed as mean (± SD) total number of errors on the Groton Maze 
Learning Test variables in the Polycystic Ovarian Syndrome (n = 42) and control (n = 50) 





























8.4.3  Psychomotor Speed 
8.4.3.1 Timed Chase Test 
Significant differences were found between the PCOS and control groups on change in 
performance on the TCT (number of correct moves: t = 3.19, p < 0.01; total number of errors: 
t = -2.55, p < 0.01). The difference between groups on performance on the TCT over time was 
found to be significant, with the PCOS group showing better performance compared with the 
control group at the follow-up assessment. The control group was found to show worse 
performance over time. No significant change was observed within the PCOS group following 
anti-androgen treatment on the TCT. 
8.4.3.2 Trail Making Test-Part A 
With regards to the TMT- Part A (time taken), no significant differences in change were found 
between the two groups over time. Additionally, no significant change was observed within the 
PCOS group from baseline to follow-up on this task.  
Table 8.6 
Means (SD) and Effect Sizes of Change in Psychomotor Speed Variables Following Anti-
androgen Treatment in the Polycystic Ovarian Syndrome (n = 42) and Control (n = 50) 
Groups  
 PCOS Control  
 Mean SD Mean SD t p d 
TCT  (no of Correct moves)  1.59 7.40 -4.06 9.56 3.19 0.002 0.66 
TCT (total errors)  0.31 1.38 0.76 2.54 -2.55 0.01 0.52 
TMT – A (seconds)  6.16 20.28 5.40 15.33 -0.20 0.84 0.04 
t = Independent samples t-test, d = Cohen’s d effect size, * = p < 0.05, ** = p < 0.01, *** =p < 0.001, TCT = Timed Chase 
Test, TMT = Trail Making Test, PCOS = Polycystic Ovarian Syndrome. Positive values represent improvement on the task, 





8.4.4  Attention and executive functioning 
No significant differences were found between PCOS (n = 42) and control (n = 50) groups, or 
within the PCOS group, on any of the attention and executive function variables (TMT– Part 
B, COWAT, Digit Span subtests) over time (see Table 8.7). 
 
8.5 CHANGE IN EMOTION PROCESSING OVER THE COURSE OF TREATMENT 
FOR POLYCYSTIC OVARIAN SYNDROME  
8.5.1 Facial Expression Recognition Task 
8.5.1.1 Recognition accuracy 
No significant differences in change in recognition accuracy were observed between the PCOS 
(n = 42) and control (n = 50) groups over time for any facial expressions of emotion. However, 
a significant improvement in recognising disgusted facial expressions was observed within the 
PCOS group (p < 0.05) following anti-androgen treatment (see Table 8.8).  
8.5.1.2 Reaction time 
A significant difference was observed between the PCOS (n = 42) and control (n = 50) groups 
on change in reaction time to faces depicting fear over time (t = -2.21, p = 0.03). Significant 
improvement was found on change in reaction time for all facial expressions, with the exception 





Table 8.7  
Means (SD) and Effect Sizes of Change in Attention and Executive Function Variables in the Polycystic Ovarian Syndrome (n = 42) and Control 
(n = 50) Groups  
 PCOS Control  
 Mean SD Mean SD t p d 
TMT–B (seconds)  8.23 24.17 7.40 17.43 -0.20 0.84 0.04 
COWAT (total words)  1.00 7.32 0.58 8.47 0.25 0.80 0.05 
Digit Span Forward Total  -0.02 2.04 -0.14 1.54 0.30 0.76 0.06 
Digit Span Forward Span -0.14 1.11 -0.26 0.94 0.53 0.59 0.11 
Digit Span Backward Total  0.52 2.16 0.50 2.12 0.05 0.96 0.11 
Digit Span Backward Span 0.19 1.35 0.34 1.27 -0.54 0.59 0.11 
Digit Span Total Score 0.73 2.66 0.40 2.41 0.63 0.53 0.13 
t =Independent sample t-test, d = Cohen’s d effect size, TMT = Trail Making Test, COWAT = Controlled Oral Word Association Test, Positive values denote improvement in performance on attention 
and executive function variables
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Table 8.8  
Means (SD) and Effect Sizes of Change in Recognition Accuracy on the Facial Expression 
Recognition Task in the Polycystic Ovarian Syndrome (n = 42) and Control (n = 50) Groups  
 PCOS Control  
 Mean SD Mean SD t p d 
Angry 0.00 0.13 0.01 0.13 -0.74 0.46 0.07 
Disgusted 0.06* 0.16 0.05 0.19 0.36 0.71 0.05 
Fearful 0.02 0.11 0.01 0.09 0.35 0.73 0.09 
Happy 0.02 0.11 0.00 0.07 1.48 0.14 0.21 
Neutral 0.00 0.16 0.02 0.10 -0.38 0.71 0.14 
Sad 0.04 0.17 0.02 0.16 0.44 0.66 0.12 
Total accuracy 0.02 0.05 0.02 0.67 0.20 0.84 0. 
 t = Independent sample t-test, d = Cohen’s d effect size, PCOS = Polycystic Ovarian Syndrome, * = p < 0.05, ** = p < 0.01, 
***=p < 0.001. Asterisks’ values alongside the mean represent significant change within the PCOS group following anti-
androgen treatment. Positive mean values denote an improvement in recognition accuracy. 
 
  
Figure 8.3  
Change in scores displayed as mean (+SD) recognition accuracy for the five facial 
expressions of emotion and neutral expressions on the Facial Expression Recognition Task 























Table 8.9  
Means (SD) and Effect Sizes of Change in Reaction Time on the Facial Expression 
Recognition Task in the Polycystic Ovarian Syndrome (n = 42) and Control (n = 50) Groups  
 PCOS Control  
 Mean SD Mean SD t p d 
Angry 228.82** 447.56 170.85 764.38 -0.452 0.65 0.09 
Disgusted 319.73*** 384.00 183.23 636.46 -1.267 0.21 0.25 
Fearful 270.45*** 314.35 132.15 279.83 -2.209 0.03 0.46 
Sad 155.69** 355.28 133.82 616.47 -0.212 0.83 0.04 
Happy 73.73 279.76 14.33 299.93 -0.982 0.33 0.20 




235.90 130.72 338.08 -1.298 0.20 0.26 
t = Independent sample t-test, d = Cohen’s d effect size, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, Positive mean values 
indicate an improvement in reaction time. 
 
8.5.1.3 Neutral misinterpretation bias 
A significant difference was found between groups on change in the misinterpretation of neutral 
facial expressions over time, with the PCOS group becoming significantly less likely to 
interpret neutral faces as angry over time compared with the control group (t = -2.69, p = 0.009). 
Additionally, a significant change was found in the misinterpretation of neutral faces as angry 
within the PCOS group following anti-androgen treatment (see Table 8.10), with neutral faces 






Means (SD) and Effect Sizes of Change in Neutral Misinterpretation Bias on the Facial 
Expression Recognition Task in the Polycystic Ovarian Syndrome (n = 42) and Control (n = 
50) Groups  
 PCOS Control  
 Mean SD Mean SD t p d 
Anger 0.13* 0.32 0.02 0.21 -2.69 0.009** 0.55 
Disgust -0.03 0.18 0.01 0.18 0.47 0.63 0.11 
Fear -0.00 0.09 -0.00 0.13 0.46 0.64 0 
Happy -0.02 0.15 -0.01 0.12 1.17 0.24 0.22 
Sad -0.07 0.28 -0.02 0.24 1.65 0.10 0.34 
t -Independent sample t-test, d = Cohen’s d effect size, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. Asterisks’ values alongside 
the mean represent significant change within the PCOS group following anti-androgen treatment, positive mean values indicate 
that neutral faces were less likely to be interpreted as a particular emotion.  
 
 
Figure 8.4  
Change in scores displayed as mean (+SD) misinterpretation of neutral faces for the five 
facial expressions of emotion on the Facial Expression Recognition Task in the Polycystic 































8.5.2  Reading the Mind in the Eyes Test 
There was no significant difference between the PCOS (0.45+3.30) and control (0.24+2.76) 
groups vs (t = 0.33, p = 0.742) on change in RMET scores over time. Additionally, no 
significant change was observed within the PCOS group following anti-androgen treatment (t 
= 0.463, p = 0.68). 
 
8.6  CORRELATIONAL ANALYSES 
The following section will present findings of correlations between change in mood and 
anxiety, and change in cognitive function and emotion processing in the PCOS sample (n = 
42). Since the control group did not receive treatment following baseline assessment, no 
significant change in mood, cognitive function or emotion processing performance was 
expected in this group over time, therefore, analyses comprised of correlations only within the 
PCOS group. Results from these analyses will be discussed in the next section.  
8.6.1  Correlations between mood and anxiety variables and cognitive variables in the 
Polycystic Ovarian Syndrome Group  
A bivariate correlational analysis was conducted to investigate the relationship between change 
in scores on mood and anxiety variables and change in cognitive variables in the PCOS group 
following treatment. Findings from this analysis are presented in the following sections. 
8.6.1.1 Verbal learning and memory 
No significant associations were found between change in mood and anxiety variables, and 






Correlations between Change in Mood and Anxiety Variables and Change in Consonant-
Vowel-Consonant Task Variables Following Anti-androgen Treatment in the Polycystic 












HADS Total 0.14 0.03 -0.02 -0.05 0.04 
HADS-D  0.12 -0.02 -0.07 -0.07 0.12 
HADS-A  0.12 0.11 0.03 -0.00 -0.05 
QIDS 0.08 0.01 -0.04 -0.03 -0.10 
Pearson product-moment correlation (correlations are between changes in scores on mood/anxiety scales and changes in 
cognitive variables from baseline to follow-up), HADS = Hospital Anxiety and Depression Rating Scale, HADS-A- Hospital 
Anxiety and Depression Scale (Anxiety sub-scale), HADS-D- Hospital Anxiety and Depression Scale (Depression sub-scale), 
QIDS = Quick Inventory of Depression Symptoms, CVC- Consonant Vowel Consonant Test, Positive correlations suggest an 
association between improvement in symptoms of depression and anxiety and improvement in verbal learning and memory. 
 
8.6.1.2 Visuospatial learning and memory 
No significant correlations were found between changes in mood and anxiety variables and 
changes in performance on GMLT Task variables (see Table 8.12). 
8.6.1.3 Psychomotor speed  
Significant positive correlations were found between change in performance on the TCT 
(number of correct moves) and change in mood and anxiety variables (HADS Total, r = 0.37, 
p = 0.01; HADS-A, r = 0.37, p = 0.01; QIDS, r = 0.40, p = 0.009, and HADS-D, r = -0.31, p 
= 0.04). This indicated that improvement in symptoms of depression and anxiety were 
associated with better performance on the TCT (more number of correct moves) assessing 
psychomotor speed (see Table 8.13). A significant positive correlation was found between 
change in performance on the TMT- Part A (total time taken) and change in the symptoms of 
depression (QIDS) (r = 0.33, p = 0.03), suggesting that an improvement in symptoms of 




Correlations between Change in Mood and Anxiety Variables and Change in Groton Maze 
Learning Test Variables Following Anti-androgen Treatment in the Polycystic Ovarian 














HADS Total Score 0.09 -0.10 -0.08 -0.05 
HADS-D 0.13 -0.17 -0.12 -0.07 
HADS-A 0.03 -0.00 -0.01 -0.00 
QIDS -0.13 -0.04 -0.28 -0.03 
Pearson product-moment correlation (correlations are between changes in scores on mood/anxiety variables and cognitive 
variables from baseline to follow-up), HADS = Hospital Anxiety and Depression Rating Scale, HADS-A- Hospital Anxiety 
and Depression Scale (Anxiety sub-scale), HADS-D- Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS = 
Quick Inventory of Depression Symptoms, GMLT- Groton Maze Learning Test, Positive correlations indicate that 
improvement in symptoms of depression was associated with improvement in GMLT performance (less errors). 
 
8.6.1.4 Attention and executive function  
A significant positive correlation was found between change in performance on the TMT- Part 
B (total time taken) and change in the symptoms of depression (QIDS) (r = 0.30, p = 0.05). 
Significant positive correlations were also found between change in Total Forward score (Digit 
Span) and change in symptoms of depression (HADS Total, r = 0.31, p = 0.04; and HADS-A, 
r = 0.32, p = 0.04) and Forward Span score (Digit Span) and change in symptoms of depression 





Table 8.13  
Correlations between Change in Mood and Anxiety Variables and Change in Psychomotor 
Speed Variables Following Anti-androgen Treatment in the Polycystic Ovarian Syndrome (n 
= 42) and Control (n = 50) Groups 
 
TCT (no of  
correct moves) 
TCT (errors) 
TMT Part A 
(time) 
HADS Total Score 0.37** 0.16 0.28 
HADS-D 0.31* 0.08 0.29 
HADS-A 0.37** 0.23 0.19 
QIDS 0.40** 0.00 0.33* 
Pearson product-moment correlation (correlations are between changes in scores on mood/anxiety variables and cognitive 
variables from baseline to follow-up), HADS = Hospital Anxiety and Depression Rating Scale, HADS-A- Hospital Anxiety 
and Depression Scale (Anxiety sub-scale), HADS-D- Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS = 
Quick Inventory of Depression Symptoms, TCT-Timed Chase Test, TMT-Trail Making Task, * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, Positive correlations indicate improvement in symptoms of depression and anxiety and improvement in 
psychomotor speed over time.  
 
8.6.2  Correlations between mood and anxiety variables and emotion processing 
variables in the Polycystic Ovarian Syndrome Group  
The relationship between change in mood and anxiety variables and change on FER Task 
variables and RMET variables was examined using bivariate correlational analysis. These 
findings will be discussed in the following section. 
8.6.2.1 Recognition accuracy (Facial Expression Recognition Task) 
Significant positive correlations were found between change in recognition accuracy of fearful 
faces and change in HADS Total Score (r = 0.64, p = 0.001), HADS-D score (r = 0.60, p = 0.002) 
and HADS-A score (r = 0.58, p = 0.007), suggesting an association between improvement in 
symptoms of depression and anxiety and improvement in recognition accuracy of fearful faces. 
A significant positive correlation was found between change in symptoms of depression (HADS-
D) and change in performance on recognition of the facial expression of disgust (r = 0.32, p = 
0.04) on the FER Task. No other correlations were significant over time in the PCOS group. 
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Table 8.14  
Correlations between Change in Mood and Anxiety Variables and Change in Attention and Executive Function Variables following Anti-Androgen 
Treatment in the Polycystic Ovarian Syndrome Group (n = 42) 
 
















0.27 -0.05 0.31* 0.30* -0.01 0.01 0.20 
HADS-D 0.29 0.05 0.25 0.24 0.06 0.06 0.25 
HADS-A 0.19 -0.18 0.32* 0.31* -0.10 -0.05 0.09 
QIDS 0.30* -0.18 0.22 0.19 0.16 -0.19 0.02 
Pearson product-moment correlation (correlations are between changes in scores on mood/anxiety variables and cognitive variables from baseline to follow-up), ** = p < 0.01,* = p < 0.05, HADS - 
Hospital Anxiety and Depression Rating Scale, HADS-A- Hospital Anxiety and Depression Scale (Anxiety sub-scale), HADS-D- Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS - 
Quick Inventory of Depression Symptoms, TMT-Trail Making Test, COWAT-Controlled Oral Word Association Test, positive correlations indicate improvement in symptoms of depression and anxiety 




Table 8.15  
Correlations between Change in Mood and Anxiety Variables and Accuracy on the Facial 
Expression Recognition Task Following Anti-Androgen Treatment in the Polycystic Ovarian 
Syndrome Group (n = 42) 
 Angry Disgusted Fearful Happy Neutral Sad Total 
HADS Total 0.05 0.27 0.64*** 0.03 -0.21 0.07 0.13 
HADS-D 0.04 0.32* 0.60*** 0.01 -0.15 0.06 0.18 
HADS-A 0.03 0.14 0.58*** 0.04 -0.26 0.10 0.02 
QIDS 0.00 0.13 0.22 0.21 -0.19 -0.07 -0.04 
Pearson product-moment correlation (correlations are between the change in the score of mood/anxiety variables and cognitive 
variables from baseline to follow-up), * = p < 0.05, ** = p < 0.01, *** = p < 0.001, HADS = Hospital Anxiety and Depression 
Rating Scale, HADS-A = Hospital Anxiety and Depression Scale (Anxiety sub-scale), HADS-D = Hospital Anxiety and 
Depression Scale (Depression sub-scale), QIDS = Quick Inventory of Depression Symptoms, positive correlations suggest that 
improvement in symptoms of mood and anxiety was associated with improvement in recognition accuracy on the FER Task. 
 
8.6.2.2 Reaction time (Facial Expression Recognition Task) 
No significant correlations were found between change in reaction time on the FER Task and 
change in mood or anxiety variables (see Table 8.16).  
Table 8.16  
Correlations between Change in Mood and Anxiety Variables and Mean Reaction Time on 
the Facial Expression Recognition Task Following Anti-androgen Treatment in the 
Polycystic Ovarian Syndrome Group (n = 42) 
 Angry Disgusted Fearful Happy Neutral Sad Mean RT 
HADS Total 0.00 0.10 0.04 -0.16 -0.11 0.02 0.04 
HADS-D 0.02 0.16 0.03 -0.21 -0.05 0.10 0.04 
HADS-A -0.01 0.01 0.06 -0.08 -0.18 -0.08 0.04 
QIDS 0.13 0.15 0.03 0.00 0.09 -0.12 -0.01 
Pearson product-moment correlation (correlations are between changes in scores on mood and cognitive variables from baseline 
to follow-up), HADS = Hospital Anxiety and Depression Rating Scale, HADS-A = Hospital Anxiety and Depression Scale 
(Anxiety sub-scale), HADS-D = Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS = Quick Inventory of 
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Depression Symptoms, RT = reaction time, positive correlations suggest that improvement in symptoms of mood and anxiety 
was associated with improvement in reaction times on the FER Task. 
8.6.2.3 Neutral misinterpretation bias (Facial Expression Recognition Task) 
No correlations between change in mood and anxiety variables and change in neutral 
misinterpretation bias for each emotion were significant at the follow-up assessment (see Table 
8.17). 
Table 8.17  
Correlations between Change in Mood and Anxiety Variables and Neutral Misinterpretation 
Bias on the Facial Expression Recognition Task Following Anti-androgen Treatment in the 
Polycystic Ovarian Syndrome Group (n = 42) 
 Angry Disgusted Fearful Happy Sad 
HADS Total 0.15 -0.06 0.13 -0.30 -0.01 
HADS-D 0.23 -0.14 0.12 -0.26 -0.06 
HADS-A 0.02 0.05 0.12 -0.29 0.05 
QIDS 0.15 -0.09 -0.06 -0.14 -0.00 
Pearson product-moment correlation (correlations are between changes in scores on mood/anxiety variables and cognitive 
variables from baseline to follow-up), HADS = Hospital Anxiety and Depression Rating Scale, HADS-A = Hospital Anxiety 
and Depression Scale (Anxiety sub-scale), HADS-D = Hospital Anxiety and Depression Scale (Depression sub-scale), QIDS 
= Quick Inventory of Depression Symptoms, positive correlations suggest that improvement in symptoms of mood and anxiety 
was associated with reduced tendency to interpret neutral faces as expressing an emotion.  
 
8.6.2.4 Reading the Mind in the Eyes Test 
Change in the total RMET score was not significantly correlated with change in mood or 





8.7  DISCUSSION 
The aims of this chapter were: 
 To compare changes between the PCOS and the control groups on measures of mood, 
anxiety, cognitive function and emotion processing over time. 
 To determine whether there was a change in symptoms of depression, anxiety, cognitive 
function and emotion processing within the PCOS group following anti-androgen 
treatment over a period of 12 weeks. 
 To investigate the association between change in mood and anxiety variables and 
change in cognitive function and emotion processing variables in the PCOS group 
following anti-androgen treatment. 
The remainder of this chapter will discuss the main findings in relation to these aims. 
8.7.1  Main findings 
There was a trend for symptoms of depression to improve in the PCOS group following anti-
androgen treatment, compared with the control group receiving no treatment (p < 0.06). 
Significant improvement was found on all scales assessing symptoms of depression and anxiety 
within the PCOS group following anti-androgen treatment. Since anxiety levels were not found 
to be significantly different between groups at baseline, no significant change was expected in 
the PCOS group in comparison with the control group at the follow-up assessment. In line with 
this hypothesis, no significant improvements were observed in symptoms of anxiety following 
anti-androgen treatment in the PCOS group compared with the control group.  
The main results from correlational analyses were: 
 Change in symptoms of depression and anxiety significantly positively correlated with 
change in performance on the TCT (number of correct moves), indicating that improved 
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mood and anxiety levels were associated with better performance on the TCT, a measure 
of psychomotor speed.  
 Change in symptoms of depression (QIDS) significantly positively correlated with  
change in TMT - Part A (time), suggesting that improvement in mood symptoms was 
associated with improved  performance on the TMT - Part A, a measure of psychomotor 
speed.  
 Change in symptoms of depression (QIDS) significantly positively correlated with 
change in TMT- Part B, suggesting that improved mood was associated with improved 
performance on the TMT- Part B, assessing attention and executive function 
(specifically, cognitive flexibility). 
 Change in symptoms of depression and anxiety (HADS) significantly positively 
correlated with change in the two Digit Span Forward variables (Total Forward and 
Forward span), assessing attention and executive function (specifically, working 
memory), suggesting that as symptoms of depression improved, performance on this 
measure of attention and executive function improved too.  
 Change in symptoms of depression and anxiety (HADS) significantly positively 
correlated with change in recognition accuracy of fearful faces, suggesting that 
improvements in symptoms of depression and anxiety were associated with improved 
ability to recognise fearful facial expressions on the FER Task. 
 Change in symptoms of depression (HADS-D) significantly positively correlated with 
change in recognition accuracy of disgusted facial expressions, suggesting that 
improved depression symptoms was associated with improved recognition accuracy of 
disgusted facial expressions on the FER Task. 
At baseline, apart from a significant difference between the two groups on the TCT (ES = 0.76), 
no other differences were found between the two groups on any other cognitive variables, after 
controlling for NART scores. Therefore, a change in performance on the TCT would be an 
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expected cognitive outcome over time. In line with this hypothesis, over the study period, 
significant improvements were observed on change in this psychomotor speed variable. The 
PCOS group did not show significant improvements in performance on cognitive domains of 
verbal and visuospatial learning and memory and attention and executive function compared 
the control group.  
Regarding emotion processing, at baseline, univariate ANOVA found the PCOS group to be 
significantly less accurate in recognising facial expressions of fear (F = 1.93, p = 0.04) and 
sadness (F = 5.97, p = 0.004) and to perform significantly worse compared with the control 
group on the RMET (F = 8.14, p = 0.005) (26.78+0.47 vs 28.10+ 0.46; ES = 0.41) compared 
with the control group (values expressed in percentages, see Table 7.11). However, at baseline, 
no significant differences were found between the two groups on facial emotion processing 
variables including reaction time and neutral misinterpretation bias on the FER Task. Therefore, 
changes in the former variables at follow-up would be more likely compared with other emotion 
processing variables. However, no change in recognition accuracy of fearful or sad faces was 
found in the PCOS group compared with the control group over time. Somewhat unexpectedly, 
reaction time related to fearful faces improved in the PCOS group compared with the control 
group over the study period. As noted previously testosterone has been associated with a 
decreased sensitivity to fearful or threatening faces (see Chapters Five and Seven). The finding 
of improved (decreased) reaction time related to fearful faces in the PCOS group suggests an 
association with decreased testosterone levels found post-treatment. Additionally, it could be 
that since the PCOS group improved on other measures of psychomotor speed, an improvement 
in reaction time simply reflects better overall psychomotor speed. The PCOS group was also 
found to improve in neutral misinterpretation bias of angry faces (reduced tendency to interpret 
neutral facial expressions as angry) compared with the control group over time. Research 
suggests that testosterone administration is associated with a reduction in sensitivity toward 
negative or threatening faces (particularly fearful and angry faces) observed through reduced 
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gaze aversion and gaze avoidance (a socially anxious pattern) and increased attention toward 
negative faces (see Chapters Five and Seven). These results would suggest that anti-androgen 
treatment may increase sensitivity toward threatening faces, making it more likely to increase 
neutral misinterpretation bias (worse performance), contrary to current results. However, 
testosterone administration studies may not necessarily show the opposite results of studies 
involving anti-androgen administration (see section 8.7.1.1 for further discussion). 
Additionally, since the total score on RMET assessing “social intelligence” was found to be 
significantly different between the two groups at baseline, it was expected that anti-androgen 
treatment would affect this result at the follow-up assessment too. However, contrary to this 
hypothesis, no significant change in performance on RMET was found between the two groups, 
over time. 
Within the PCOS group, significant changes were observed on some cognitive and emotion 
processing measures following anti-androgen treatment. These included changes/improvement 
on tasks assessing verbal learning and memory, visuospatial learning and memory and 
recognition accuracy, reaction time and neutral misinterpretation bias on the FER Task. 
However, since performance on these domains was not always significantly different compared 
with the control group, these changes within the group may, therefore, be attributed largely to 
practice effects. A healthy control group is necessary when there are repeated cognitive 
assessments to examine the degree to which change in cognitive performance is related to 
symptom change (including mood and testosterone levels changing) as opposed to practice 
effects from repeated task administration. Despite the use of parallel forms, improvement may 
occur due to enhanced learning strategies, and therefore, results showing significant change 
within the PCOS group must be understood keeping the issue of practice effects in mind. 
However, given the correlations with change in mood, it is also possible that anti-androgen 
treatment may have resulted in subtle overall improvements in mood and cognitive function 
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within the PCOS group, which in comparison with changes in the control group, did not quite 
reach significance because of the small group sizes. 
Effect sizes of the difference between change in cognitive function in the PCOS group 
compared with change in cognitive function in the control group were found to be small to 
moderate (0.0 to 0.4) with the exception of the TCT which was moderate (0.6). The next section 
will discuss findings related to mood, anxiety and cognitive variables in comparison with 
previous studies. 
8.7.1.1 Findings related to mood and anxiety: group comparisons 
Until now, most studies and reviews have examined mood in females with PCOS at only one 
time-point, without a longitudinal assessment of mood (see Chapter 5 for a review of literature), 
and have found variable results related to the association between androgen levels and mood in 
females of reproductive age. The current study used a longitudinal study design to examine the 
effect of anti-androgen treatment on change in symptoms of depression, anxiety, cognitive 
function and emotion processing in females with PCOS. Anti-androgen treatment with different 
mechanisms of action included agents such as CPA, Spironolactone, OCPs, COCPs, and other 
medication included Metformin (aiming to improve metabolic abnormalities found in PCOS) 
(see Chapter 5, Section 4.7.2.4). Anti-androgen medication aims to prevent androgens including 
testosterone and DHT from acting on receptors by either blocking the androgen receptor or by 
inhibiting or suppressing androgen production (Escobar-Morreale et al., 2011; Falsetti et al., 
2000; Koulouri & Conway, 2008; Swiglo et al., 2008; Townsend & Marlowe, 2004; Van 
Zuuren & Fedorowicz, 2015; Venturoli et al., 1999; Yildiz, 2008). In the current study, CPA 
and Spironolactone were the main agents used in conjunction with the OCP (particularly in the 
case of sexually active females), as considered appropriate by the treating Gynaecological-
Endocrinologist based on each individual patient’s symptom profile (refer to Chapter 7, Section 
7.4.3, and Chapter 8, Section 8.2.2). CPA and Spironolactone show similar efficacy and are 
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androgen receptor antagonists that bind directly to and block the androgen receptor and reduce 
androgen biosynthesis (Erenus, Yucelten, Gurbuz, Durmusoglu, & Pekin, 1996; Menard, 
Stripp, & Gillette, 1974; Messina et al., 1983; Mowszowicz et al., 1984). Specifically, 
Spironolactone as an anti-androgen acts primarily at the periphery to inhibit 5-a-reductase 
activity, while CPA competitively inhibits the binding of testosterone and DHT to androgen 
receptors (Erenus et al., 1996). Spironolactone has the additional effect of preventing 
conversion of testosterone to DHT and CPA has a hypothalamic suppressive effect when used 
in moderate dose, continuously. Post-treatment testosterone levels may not necessarily indicate 
a decrease in testosterone levels but may work by blocking the androgen receptor. Since the 
current study included different treatment agents, measurement of post-treatment testosterone 
levels was not considered useful. Therefore, investigations only included correlations between 
changes in mood and anxiety and changes in cognitive function and emotion processing in the 
PCOS group following treatment and not correlations with testosterone levels. 
At baseline, the PCOS group showed greater symptoms of depression than the control group. 
Following anti-androgen treatment, symptoms of depression and anxiety were still higher in the 
PCOS group compared with the control group, however, differences between groups at the 
follow-up assessment on mood and anxiety measures were not significant. Additionally, 
significant improvement in symptoms of depression and anxiety was observed within the PCOS 
group following anti-androgen treatment (see Table 8.3). Although previous studies have 
suggested  an association between physical symptoms of PCOS such as hirsutism, acne, weight 
gain and infertility with symptoms of low mood and anxiety (Asik et al., 2015; Deeks et al., 
2010; Dunaif, 1997; Elsenbruch et al., 2006; Ferriman & Gallwey, 1961; Kitzinger & Willmott, 
2002; Mechanick & Dunaif, 1990; Moran et al., 2010; Polson et al., 1988; Sonino et al., 1993), 
other studies have not found a significant association between the physical symptoms of PCOS 
and symptoms of mood or anxiety (Barth et al., 1993; Hollinrake et al., 2007; Karjula et al., 
2017; Shulman et al., 1992). In the current study, the finding related to significant improvement 
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in mood within the PCOS group appears to be associated with direct effects of anti-androgen 
treatment on the brain, since physical symptoms of PCOS including hirsutism, weight gain and 
acne may not necessarily change with treatment at the twelve-week mark.  
There is very little available data from interventional studies related to the effect of treating 
testosterone-excess on symptoms of depression. It is also important to note that most studies 
until now have examined this relationship by including experimental study designs involving 
testosterone administration, to assess the effect of testosterone on mood and cognitive variables 
(see Chapter Five for a review). Prior research has shown that 0.5 mg of testosterone in 
reproductive-aged females results in an approximate ten-fold increase in blood Total 
Testosterone levels fifteen minutes post-administration, and a return to baseline levels in 90 
minutes has been found (Bos et al., 2013; Hermans et al., 2007; Postma et al., 2000; Schutter 
& van Honk, 2004; Tuiten et al., 2000; van Honk et al., 2005; van Honk et al., 2001). However, 
this result is limited to Total Testosterone levels and the effect of testosterone administration in 
terms of Free Testosterone levels is still unclear. It is not reasonable to suggest that testosterone 
administration studies are likely to have the opposite results of anti-androgen administration 
(see Chapter Five). The former increases testosterone for only a short period of time. It is clearly 
not just the opposite of treatment for PCOS. However, these studies can provide useful data 
regarding the effects of androgens in the brain. 
Only one small study so far has examined the effect of anti-androgen treatment on cognitive 
function and mood in females with PCOS (Schattmann & Sherwin, 2007a). Similar to the 
current study, Schattmann & Sherwin (2007a) examined the effect of anti-androgen treatment 
over a span of three months on mood and cognitive function in a sample of eight hirsute females 
with PCOS compared with 11 females with PCOS who did not receive anti-androgen treatment. 
In this small study, no significant differences were found on measures of mood (POMS-Bipolar 
Form) between the two groups at the baseline or the follow-up assessment. However, this study 
282 
 
did not have a healthy comparison group without PCOS. Additionally, this study used a self-
report scale (POMS-Bipolar Form) which is suitable for detecting rapid changes in mood at a 
very low level. It is not a clinical scale, compared with the current study which used 
standardised clinician-rated and self-reported depression-rating scales (QIDS and HADS) that 
are better able to detect sensitivity of symptoms of depression at a mild-moderate level of 
severity. An important methodological issue with Schattmann & Sherwin’s (2007a) study was 
a small sample size (treatment group = 8, no-treatment group = 11) in contrast to the current 
study including 42 females with PCOS and 50 controls.  
In summary, although there was only an indication of a difference but no significant difference 
between the PCOS and control groups on measures of mood and anxiety at the follow-up 
assessment, there was a significant improvement in symptoms of mood and anxiety within the 
PCOS group, most likely independent of significant change in physical symptoms, implying 
that anti-androgen treatment may benefit mood in females with PCOS. 
8.7.1.2 Associations between mood, anxiety and cognitive variables: group comparisons and 
correlation analyses  
The following sections will discuss findings related to differences between the PCOS and the 
control groups on changes in mood, cognitive function and emotion processing over time; and 
findings related to change in mood variables and change in cognitive and emotion processing 
variables within the PCOS group following anti-androgen treatment. 
8.7.1.2.1 Verbal learning and memory  
No significant differences were found between the PCOS and control groups on change in 
measures of verbal learning and memory over time. However, significant improvements were 
seen within the PCOS group on all CVC variables, except for recognition accuracy. 
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Additionally, no significant correlations were found between change in CVC variables and 
change in mood and anxiety variables following treatment in the PCOS group. 
There is little evidence of change or improvement in verbal learning and memory in patients 
with PCOS following anti-androgen treatment. Verbal memory is considered a female-superior 
domain (Halpern, 2000) and studies have hypothesised that high androgen levels would show 
reduced function in this domain, however, the superior female performance is likely to be 
related to the organisational effects of testosterone and not ambient testosterone levels. Only 
one interventional study has examined the effect of anti-androgen treatment on verbal learning 
and memory (RAVLT, Logical Memory Test, and Paired Associates Test) and found no 
significant change following treatment (Schattmann & Sherwin, 2007a). However, this study 
included two groups of females with PCOS, did not have a comparison group of healthy 
females, and was very small. Analysis consisted of comparisons between two groups with 
PCOS exposed either to the treatment (n = 8) or placebo condition (n = 11). In the current 
study, although an improvement in an aspect of verbal learning and memory together with an 
improvement in symptoms of depression and anxiety was observed within the PCOS group 
following treatment, correlational analysis showed no significant association between change 
in mood and change in CVC variables. Changes in mood are, therefore, unlikely to explain 
these results.  
8.7.1.2.2  Visuospatial learning and memory 
No significant differences were found between the PCOS group and control group on change 
in measures of visuospatial learning and memory (GMLT) from the baseline to follow-up 
assessment. However, significant improvements were observed within the PCOS group on most 
GMLT variables following treatment. No significant correlations were found between change 
in mood and change in GMLT variables following anti-androgen treatment in the PCOS group.   
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Regarding visuospatial learning and memory, few studies have examined the association 
between testosterone levels and visuospatial learning and memory (Gómez-Gil et al., 2009; 
Pintzka et al., 2016; Postma et al., 2000). Two interventional studies have shown a positive 
effect of testosterone, with testosterone administration related to significant improvement in 
some aspects of visuospatial learning and memory (Pintzka et al., 2016; Postma et al., 2000). 
However in Pintzka et al’s (2016) study, only one aspect of spatial learning was found to 
improve (improved representation of directions assessed by the Virtual Environment Learning 
and Navigating Task: Sense of Direction Test), and no differences in changes in navigation 
ability and strategies were observed between the testosterone (n = 21) and placebo (n = 21) 
groups. Similarly, in Postma et al’s (2000) study, testosterone administration did not have a 
significant effect on the first two conditions of the Spatial Memory Stimulus Task (Object-to-
position and the Positional Reconstruction condition), but had a positive effect on the combined 
condition following testosterone administration in this study. Furthermore, one small cross-
sectional study found better visual memory (Visual Paired Associates) in a testosterone-treated 
group (n = 9) compared with the no-treatment group (n = 10) in female-to-male transsexuals 
(Gómez-Gil et al., 2009). Taken together, these results suggest that testosterone administration 
improves some aspects of visuospatial learning and memory. However, as discussed in the 
previous part of the current section, studies involving testosterone administration would not 
necessarily imply that anti-androgen treatment (involving blocking or reduction of testosterone 
levels) would have an opposite effect on spatial learning and memory in the form of a negative 
or deleterious effect. Thus, the current results including no significant group differences on 
change in GMLT variables are expected, since at baseline, no significant differences were found 




8.7.1.2.3  Psychomotor speed 
Significant differences were found between the PCOS and control groups on change in one 
measure of psychomotor speed, the TCT. Following anti-androgen treatment, the PCOS group 
significantly improved on performance on the TCT compared with the control group. 
Additionally, the control group showed worse performance over time on the TCT (number of 
correct moves), which may be a chance finding, and which would have contributed to 
significant differences between groups. At baseline, the PCOS group showed significantly 
worse performance on the total number of correct moves on the TCT compared with the control 
group (ES = 0.70). However, no significant difference was observed within the PCOS group on 
change in performance on the TCT following treatment. Results, therefore, suggest that 
although significant differences were found between groups from baseline to follow-up 
assessment, this change was likely influenced by a worsening of performance observed in the 
control group over time. This result could be explained by the fact that the PCOS group may 
have been more motivated to perform well at the second testing session compared with the 
control group, considering that the former group received treatment (which may have been a 
motivating factor) in between the two sessions while the control group did not. Such a lack of 
motivation and investment in the control group, more likely to be experienced by the PCOS 
group, could be the reason for worse performance shown by the control group over time. 
Additionally, the TCT is a tedious and monotonous task requiring participants to chase a 
coloured moving tile, one tile at a time, through a 10 by 10 grid of grey tiles . Taken together, 
these reasons may help explain poorer performance on the TCT by the control group over time. 
No significant differences were found between the two groups or within the PCOS group on 
change in the TMT - Part A performance from baseline to follow-up. Overall, current results 
do not suggest that anti-androgen treatment may change psychomotor function. 
Significant correlations were found between improvement in symptoms of mood and anxiety 
and improved performance (more correct moves) on the TCT over time. A significant 
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correlation was also found between improved symptoms of depression (QIDS) and improved 
performance on the TMT - Part A. Thus, in the current study, improvements in mood and 
anxiety were associated with better performance on the two psychomotor speed task (TCT and 
TMT – Part A). These results are in line with a meta-analysis demonstrating significant 
correlations between depression severity and cognitive performance particularly in the domains 
of psychomotor speed, memory and executive function (McDermott & Ebmeier, 2009).  
In the current study, at baseline, Free Testosterone and FAI levels significantly negatively 
correlated with performance on the TCT, indicating that higher testosterone levels were 
associated with worse performance on the TCT. It was, therefore, expected that treatment 
aiming to normalise testosterone levels would be followed by improvement in measures of 
psychomotor speed. However, contrary to this hypothesis, no significant difference was 
observed within the PCOS group on change in performance on the TCT following treatment. 
Two interventional studies examined change in psychomotor speed following anti-androgen 
treatment in females with PCOS (n = 8) (Schattmann & Sherwin, 2007a), and androgen 
treatment in female-to-male transsexuals (n = 25) (Slabbekoorn et al., 1999), and found no 
significant change in performance over time. In their small interventional study, Schattman and 
Sherwin (2007a) found no significant change in psychomotor speed (Manual Dexterity and 
Perceptual Speed :Finding A’s, Purdue Pegboard) in females with PCOS receiving anti-
androgen treatment over a span of three months compared with an untreated group of PCOS 
females (n = 11) somewhat similar to the current study. In Slabbekoorn et al’s (1999) study, no 
significant effects were found on psychomotor speed (manual dexterity and perceptual speed: 
Fine motor Movement Task, Test D2 Task) following anti-androgen treatment in female-to-
male transsexuals (Slabbekoorn et al., 1999). Consistent with these findings, the current study 
did not find any significant change within the PCOS group on measures of psychomotor speed 
following anti-androgen treatment. However, correlational analysis indicated that reduced 
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symptoms of depression and anxiety were significantly associated with aspects of psychomotor 
speed in the PCOS group. 
8.7.1.2.4  Attention and executive function 
No significant differences were found between the two groups, or within the PCOS group, on 
change in any attention and executive function variables between baseline and follow-up. This 
was expected since no significant differences were found between the two groups at baseline 
on attention and executive function variables. However, a significant correlation was found 
between improvement on symptoms of depression (QIDS) and improvement on the TMT- Part 
B (assessing visual attention and cognitive flexibility). Additionally, significant correlations 
were found between improvement in two Digit Span variables (Total Forward and Forward 
Span; assessing working memory) and improvement in depression (HADS Total) and anxiety 
(HADS-A) symptoms.  
Interventional studies examining the effect of testosterone on attention and executive function 
suggest that testosterone may have a negative effect on verbal fluency (executive functioning) 
(Schattmann & Sherwin, 2007a). Two studies involving testosterone treatment found a 
worsening in performance in measures of verbal fluency (Van Goozen, Cohen-Kettenis, et al., 
1994; Van Goozen et al., 1995), and one study involving anti-androgen treatment found 
improvement in performance on verbal fluency following treatment (Schattmann & Sherwin, 
2007a). In a sample of hirsute females (Schattmann & Sherwin, 2007a), verbal fluency 
(COWAT) significantly improved following anti-androgen treatment (n = 8) compared with 
the placebo condition (n = 11), which may have been a chance finding, since in this study post-
treatment FAI levels were not significantly correlated with improved verbal fluency. Thus, the 
observed improvement in performance in verbal fluency may not have been directly related to 
reduced FAI levels, also found in the current study. Reduced verbal fluency (Word and 
Sentence Production) was found following testosterone treatment in two longitudinal studies 
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involving female-to-male transsexual samples (Van Goozen, Cohen-Kettenis, et al., 1994; Van 
Goozen et al., 1995). However, another study found no significant change in verbal fluency 
(Word and Sentence Task) following testosterone treatment in a sample of 25 female-to-male 
transsexuals (Slabbekoorn et al., 1999). All of the above-mentioned studies are, however, very 
small and potentially underpowered to generate findings.  
To summarise, although no significant group differences were found in change in attention and 
executive function variables in the current study, results suggest that improvement in mood in 
the PCOS group was associated with improvement in performance on measures assessing 
cognitive flexibility (TMT – Part B) and working memory (Digit Forwards variables).  
8.7.1.3 Associations between mood, anxiety and emotion processing variables: group 
comparisons and correlation analyses following anti-androgen treatment 
8.7.1.3.1 Recognition accuracy and reaction time: group comparisons and correlations  
No significant differences were found between the PCOS and control groups on change in 
recognition accuracy on the FER Task over the study period. However, a significant 
improvement was seen within the PCOS group following anti-androgen treatment in accurately 
recognising facial expressions of disgust. Significant differences were found between the PCOS 
and control groups on reaction time to fearful facial expressions over time. The PCOS group 
responded faster to fearful facial expressions compared with the control group over the study 
period. Within the PCOS group faster reaction time to all facial expressions with the exception 
of happiness was observed over treatment. As noted previously, it is possible that anti-androgen 
treatment results in increased emotional sensitivity by reducing or blocking testosterone levels, 
which may explain the current results including significant improvement in recognition 
accuracy related to disgusted facial expressions and reaction time related to fearful faces in the 
PCOS group. It could also be that significant improvement in symptoms of depression and 
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anxiety found in the PCOS group may be associated with improvement in aspects of emotion 
processing. In line with this hypothesis, significant correlations were found between 
improvement in symptoms of depression and anxiety (HADS) and improved recognition 
accuracy to facial expressions of negative faces (disgust and fear) in the PCOS group. However, 
no significant correlations were observed between change in mood and anxiety variables and 
change in reaction time on the FER Task in the PCOS group. 
Emotion processing is a crucial function required for successful interpersonal relationships and 
includes the ability to detect and decode facial emotional expressions (M. Phillips et al., 2003). 
There appear to be emotion-specific deficits in MDD (Bourke et al., 2010), including impaired 
general recognition accuracy of sad and happy faces, misinterpretation of neutral faces as sad, 
and negative attentional biases to sad faces (Bouhuys et al., 1999; Bourke et al., 2010; Roiser 
& Sahakian, 2013; Stuhrmann et al., 2011). Douglas and Porter (2010) found a specific deficit 
in individuals with severe depression in the recognition of facial expressions of disgust 
compared with controls. This is consistent with the current findings of improvement in disgust 
recognition in the PCOS group following anti-androgen treatment, which was related to 
improved mood symptoms within the PCOS group over treatment. Disgust recognition has also 
been found to be impaired in unmedicated patients with Parkinson’s disease, indicating an 
association with dopamine dysfunction, which has also been implicated in severe depression 
(Dunlop & Nemeroff, 2007; Sprengelmeyer et al., 2003). However, the PCOS sample included 
in the current study did not have severe depression. One animal study found significantly lower 
levels of dopamine in testosterone-induced PCOS rats compared with controls, suggesting that 
a decrease in dopamine levels may be related to increased serum testosterone levels found in 
PCOS, and also related to the high occurrence of mood and anxiety disorders found in this 
population (Chaudhari & Nampoothiri, 2017). However, this needs further examination as the 
finding related to recognition accuracy of disgusted faces in relation to mood has not been 
commonly reported in other studies with milder depression (Bourke et al., 2010).  
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An advancement of behavioural paradigms related to emotion processing, together with 
testosterone administration studies, has made it possible to further examine the relationship 
between emotion processing and testosterone in some detail. Literature suggests that 
testosterone administration is associated with a reduced response to threatening or aversive 
facial stimuli (particularly facial expressions of fear and anger) a decrease in gaze avoidance 
and gaze aversion (reduced gaze or attendance away from threatening or negative faces, 
resulting into a more enduring attendance) toward angry faces following testosterone 
administration in healthy females; indicating a reduced anxiety response (Bos et al., 2016; Bos 
et al., 2013; Enter et al., 2015; Hermans et al., 2007; Moukheiber et al., 2010; Olsson et al., 
2016; Terburg et al., 2012; van Honk et al., 2005; van Honk & Schutter, 2007; van Honk et al., 
2011; van Wingen et al., 2009) (as discussed in detail in Chapter Five). However, findings 
directly relating testosterone administration to anxiety rating scales are not clear. Additionally, 
experimental studies involving supraphysiological doses of testosterone in healthy females only 
bring about a short-term elevation of testosterone levels compared with the more chronically 
elevated levels as seen in PCOS, as discussed in previous sections, and therefore, do not 
replicate the stable and high levels of Free Testosterone (hyperandrogenism) observed in PCOS 
which manifest as physical symptoms such as hirsutism, acne and alopecia. Moreover, some 
studies have suggested a curvilinear relationship between testosterone and cognitive function 
(Moffat & Hampson, 1996; Romero-Martínez et al., 2015) and mood (Weiner et al., 2004). This 
suggests that increases in testosterone levels are associated with better mood or cognitive 
performance up to a certain point, and subsequently cognitive performance or mood decreases 
with further increasing levels of testosterone. Therefore, it could be that the exogenous doses 
of testosterone in healthy females may reach the cut-off point to have the strongest effect on 
mood or cognitive function following which such an effect may not be observed. Thus, in 
females with PCOS, with chronically abnormally elevated testosterone levels compared with 
the short-term elevated levels observed in healthy females following supraphysiological doses 
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of testosterone, the relationship between cognitive function and testosterone levels may be more 
challenging to investigate clearly.  
Regarding neuroimaging studies, only one study until now has examined emotion processing 
in females with PCOS (Marsh et al., 2013). In this small interventional study, baseline fMRI 
results showed greater limbic activation including areas implicated in depression such as the 
prefrontal cortex, anterior cingulate, amygdala, and ventral basal ganglia/nucleus accumbens 
(involved in the integration and evaluation of emotional information) in seven females with 
PCOS during an emotion processing task, compared with five healthy controls. However, 
activation reduced following Metformin treatment, which has been shown to be associated with 
decreased testosterone levels (Campagnoli et al., 2012; Kriplani & Agarwal, 2004). However, 
in Marsh et al’s (2013) study, post-treatment testosterone levels were not reported. 
Additionally, their study reported no differences between groups in performance on tasks 
assessing emotion processing involving pictures with emotional content. 
A substantial number of studies have shown the modulatory actions of testosterone on both 
subcortical and cortical brain regions (van Wingen et al., 2011), and its association with 
increased amygdala activity during recognition of facial stimuli including angry and fearful 
faces (Bos, Hermans, Ramsey, & van Honk, 2012; Hermans et al., 2008; van Wingen et al., 
2010) (see Chapter Five). Three brain-imaging studies involving testosterone administration in 
healthy females of reproductive-age found increased amygdala activity during emotion 
processing tasks, however, no significant change in performance on these tasks (emotion 
condition of the Blocked Design Task, Dynamic Facial Expression Task, adaptation of the 
RMET) was found (Bos et al., 2016; Bos et al., 2013; van Wingen et al., 2009). These results 
suggest that exogenous testosterone administration in healthy females with lower levels of 
testosterone, compared with females with PCOS with naturally elevated levels of testosterone, 
may affect amygdala activity differently; and that an increased activity may not lead to 
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substantial change in emotion processing measures. Conversely, anti-androgen treatment may 
decrease amygdala activity and, therefore, improve symptoms of low mood and improve 
performance on aspects of emotion processing, which was found in the current study.  
Previous studies in depression have found more sensitivity and faster reaction time related to 
recognition of fearful faces in individuals with depression and relatives of individuals with 
depression (Le Masurier, Cowen, & Harmer, 2007). Findings include reduced fear recognition 
following antidepressant treatment, suggesting that increased recognition of fearful faces may 
be a trait marker for MDD which may be normalised following treatment  (Bhagwagar et al., 
2004), reviewed by Bourke et al. (2010). However, some studies have suggested that 
antidepressant treatment increases testosterone levels previously found to be lower in depressed 
samples (Cohen, 1999; Giltay et al., 2012; Kumsar et al., 2014), which may be responsible for 
changes in emotion processing. It has also been suggested that social intelligence or empathy 
is negatively associated with testosterone administration (Olsson et al., 2016; van Honk et al., 
2011). The question remains whether the increase in testosterone levels following 
antidepressant treatment is related to the emotional numbing effect in some patients (Price, 
Cole, & Goodwin, 2009; Read, Cartwright, & Gibson, 2014). However, in the current study, 
testosterone levels were decreased/blocked and not increased and, therefore, results suggest that 
improved recognition of threatening or aversive faces (fearful and disgusted) may be due to 
improvement in mood and anxiety, and not directly due to the change in testosterone levels.  
To summarise, in the current study, significant differences were found between the two groups 
on change in reaction time related to fearful faces, with the PCOS group showing greater 
improvement in reaction time compared with the control group over the study period. No 
significant differences were observed between the two groups on recognition accuracy. 
Additionally, significant improvements were observed within the PCOS group in recognition 
accuracy related to disgusted faces and overall reaction time following anti-androgen treatment. 
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Significant positive correlations were found between improvements in symptoms of mood and 
anxiety (HADS) and improvement in recognition accuracy of fearful and disgusted faces on the 
FER Task in the PCOS group following anti-androgen treatment. These results suggest that an 
improvement in symptoms of depression and anxiety was associated with improved recognition 
of threatening or aversive facial expressions depicting fear and disgust.  
8.7.1.3.2 Neutral misinterpretation bias: Group comparisons and correlations 
In the current study, the PCOS group was less likely to interpret neutral faces as angry (weaker 
neutral misinterpretation bias), compared with the control group, over time. Additionally, a 
significantly weaker neutral misinterpretation bias related to angry faces was seen within the 
PCOS group following treatment. At baseline, no significant differences were found between 
the two groups in misinterpretation of neutral faces to anger, and therefore, this result is 
somewhat surprising. No significant correlations were observed between change in neutral 
misinterpretation bias and change in symptoms of depression or anxiety in the PCOS group.  
The current result of a reduced tendency to misinterpret neutral faces as angry over time in the 
PCOS group could be related to lowered testosterone or blockade of testosterone receptors 
following treatment. This is, however, a tentative explanation, since no other studies have 
examined emotion processing in relation to testosterone levels in females with or without PCOS 
until now. Prior research has shown a relationship between testosterone and anger, with findings 
including a single administration of testosterone inducing cardiac accelerative responses to 
angry faces in healthy females (van Honk et al., 2001), reduced sensitivity to recognising angry 
faces (van Honk & Schutter, 2007), a general decrease in aversion from threatening stimuli 
including angry faces (Wirth & Schultheiss, 2007) and androgen-administration followed by an 
increase in anger–proneness in females (Van Goozen, Frijda, & Van de Poll, 1994). It could be 
that normalising testosterone levels in the current study decreased the hypervigilance or anxiety 
response, which is generally responsible for scanning and responding to neutral stimuli as 
294 
 
threatening. Such a decreased hypervigilant anxiety response may help explain the finding of a 
reduced or weakened neutral misinterpretation bias, of being less likely to interpret neutral faces 
as angry following treatment. In the current study, although a significant improvement was 
found in symptoms of depression in the PCOS group following treatment, correlational analysis 
did not show a significant association between change in performance on the neutral 
misinterpretation bias aspect of the FER Task and change in mood symptoms. Improvement in 
mood would reduce a negative response bias towards stimuli, however, no study so far has 
found a neutral misinterpretation bias toward angry facial expressions in individuals with 
depression (Bourke et al., 2010). Consistent with these results, the current study did not find a 
significant correlation between chance in symptoms of mood and change in neutral 
misinterpretation bias in the PCOS group over time. 
8.7.1.3.3  Reading the Mind in the Eyes Test 
No significant differences were found between the PCOS and control groups, or within the 
PCOS group, on change in RMET performance over time. No significant correlations were 
observed between the change in RMET score and the change in mood and anxiety variables in 
the PCOS group following treatment. 
The RMET has not been used in a PCOS sample until now. It has previously been used by two 
interventional studies which found worse performance (lower empathy) on the RMET 
following testosterone administration, compared with the placebo condition, in healthy 
reproductive-aged females (Olsson et al., 2016; van Honk et al., 2011). Van Honk et al. (2011) 
in a double blind placebo controlled within subjects cross-over study including a group of 16 
females in total, reported a significant decrease on the RMET total score following testosterone 
administration compared with the placebo condition suggesting that testosterone administration 
was associated with worsened emotion processing. In the same study, a significant negative 
correlation was found between endogenous (baseline) Free Testosterone levels and RMET 
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scores in the placebo condition, suggesting an organisational effect of testosterone, in that 
higher levels of Free Testosterone were associated with worse scores on the RMET (lower 
empathy). Another randomised double-blind study including a total of 33 female participants 
exposed to both testosterone and placebo conditions found similar results, with significantly 
worse performance (less accuracy) on the RMET following testosterone administration 
compared with placebo condition (Olsson et al., 2016). Of interest, no significant effect was 
found on self-reported anxiety and/or mood following testosterone administration in these two 
studies (STAI, POMS). Results, thus, indicate that increasing testosterone levels in females 
may be related to worsening of “social intelligence” or empathy. Testosterone has also been 
shown to decrease females’ empathic mimicry of emotional facial expressions (Hermans et al., 
2006). In the current study, significant differences were found between the two groups on 
performance on the RMET at baseline, with the PCOS group performing significantly worse 
compared with the control group. It would, therefore, be hypothesised that performance on the 
RMET would improve following anti-androgen treatment. However, contrary to this 
expectation, no significant differences between the two groups were found over time. 
Additionally, improvement in mood was not found to be significantly correlated with change 
in performance on the RMET, suggesting no significant association between reduced symptoms 
of depression and improvement in empathy or social intelligence. It could be that the RMET is 
not sensitive enough to detect changes in relation to treatment response, which may explain 
current results with non-significant results. 
 
8.8  STRENGTHS AND LIMITATIONS OF THE CURRENT STUDY 
The current study investigated mood, anxiety, cognitive function and emotion processing in 
females with PCOS following anti-androgen treatment, compared with a non-PCOS 
comparison group which did not receive such treatment, over twelve weeks. The longitudinal 
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study design is a significant strength of the current study as it helped to analyse change in 
symptoms of mood, anxiety cognitive function and emotion processing, over time, for the 
patient group, and the entire sample as a whole, which would not have been possible in a cross-
sectional study. Additionally, the current study is also the first one to assess the relationship 
between change in mood and anxiety and change in cognitive function and emotion processing 
following anti-androgen treatment in the PCOS sample. However, limitations of the current 
study will be discussed in the following section. 
8.8.1  Limitations  
8.8.1.1  Anti-androgen medication 
After the first consultation with the Gynaecological-Endocrinologist, patients were prescribed 
medication including CPA, Spironolactone, OCPs and/or Metformin depending on their 
symptom profile. Medication was altered over the 12 week period as considered clinically 
appropriate. Thus, the PCOS sample differed substantially in the type and dose of the hormonal 
medication taken. Heterogeneity in hormonal medication meant that mood and cognitive tests 
which may have been sensitive to a certain type of anti-androgen agent were unlikely to have 
been identified within the whole PCOS sample. However, the current study did not aim to 
examine the effects of specific anti-androgen agents on mood and cognitive function, rather it 
focused on broad treatment response. It would have been unethical to treat all patients with the 
same anti-androgen agent, and findings from such a study would not have been generalisable 
to other PCOS samples. 
8.8.1.2  Androgen levels at follow-up 
One of the limitations of the current study was that androgen measures were not collected at 
the time of the follow-up assessment. The reason for this was that the treatment involved in the 
study included multiple anti-androgen agents (see Chapter Three and Chapter Eight, Section 
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8.2.2). Such anti-androgen agents have different mechanisms and correct symptoms of PCOS 
by either reducing or blocking testosterone levels. Therefore, post-treatment androgen levels 
may not necessarily have been decreased if the anti-androgen agent aimed to block levels rather 
than decrease testosterone levels.  
8.8.1.3  Study investigator 
The primary investigator in the current study (the author) was not blind to whether participants 
were in the PCOS or the control groups. The investigator was responsible for almost all aspects 
of the current study. This raised the possibility for an investigator bias to occur during the 
testing. For most cognitive measures, investigator bias was not possible as data were recorded 
automatically on computer software. The measure with greatest potential for bias by the 
investigator was the QIDS, a clinician-rated scale for assessing symptoms of depression. For 
the first assessment, since the investigator was aware of the group the participant belonged to, 
this could have potentially contributed to QIDS ratings. However, the current study also 
included the HADS, which is a self-report measure. This would reduce the possibility for bias 
in the overall assessment of symptoms of depression.  
8.8.1.4  Menstrual cycle 
Studies have shown that testosterone levels in females are subject to small but significant 
fluctuations during different menstrual phases (Goebelsmann et al., 1974; Judd & Yen, 1973) 
(See Chapter 5, Section 5.3). Goebelsmann et al. (1974) found Total Testosterone levels were 
highest around midcycle LH peak, and higher during the follicular compared with the luteal 
phase of the cycle. However, Free Testosterone levels were not assessed in this study. A recent 
review and meta-analysis did not find robust evidence related to the influence of menstrual 
cycle on cognitive function (Poromaa & Gingnell, 2014).  
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In the current study, it was impossible to match PCOS participants and non-PCOS control 
participants for phase of menstrual cycle since females with PCOS experience oligomenorrhea 
(absent or irregular menstrual period) which is also one of the diagnostic features of the 
syndrome (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004). 
Data related to menstrual phases was collected for all control participants at both time points, 
and results showed that majority of the participants were in the luteal phase at both cognitive 
assessments (See Section 8.2), which would have controlled for any differences that may 
contribute to cognitive outcome variables. 
8.8.1.5  Sample Size/Power 
The current study (including 42 patients and 50 controls) had 80% power to show an effect size 
difference between groups of 0.6 (or above) as significant (two-tailed α=0.05). Therefore, if the 
obtained effect sizes in the current results were smaller than 0.6, the study was not adequately 
powered to show a statistically significant difference. A larger sample size would be 
recommended for future research, which will be discussed in Chapter Nine (see Section 9.5.1). 
It is important in the context of the current study to consider the possibility that the testing of 
multiple outcome variables may lead to the possibility of Type 1 errors, which means that 
statistically significant results could be chance findings. While acknowledging that many 
outcomes have been tested in this PCOS study, many of the outcomes are tested to confirm 
previous study results and additionally, individual statistically significant results are not 
discussed unless they fit into a coherent pattern with other significant results. The exploratory 
nature of much of the testing of associations is also acknowledged and significant results will 





8.9  CONCLUSION 
Anti-androgen treatment over a period of twelve weeks was administered to females with 
PCOS. Mood and cognitive assessment was carried out before and following treatment. 
Symptoms of depression were found to improve following anti-androgen treatment within the 
PCOS group, however, no significant differences were found on change in mood between 
groups over the study period. No significant improvements were observed in symptoms of 
anxiety following anti-androgen treatment in the PCOS group compared with the control group. 
Significant differences were found between the two groups on a measure of psychomotor speed 
(TCT), with the PCOS group showing an improved performance over time. Additionally, 
reaction time related to recognising fearful faces on the FER Task improved in the PCOS group 
compared with the control group, and a neutral misinterpretation bias toward angry faces was 
found to improve (weaker bias) in the PCOS group compared with the control group over time. 
The PCOS group showed significant improvements in cognitive domains including verbal 
learning and memory, visuospatial learning and memory, and recognition accuracy of disgusted 
facial expressions, and overall reaction time (with the exception of happy faces) on the FER 
Task. It is possible that such an improvement in aspects of cognitive function may be associated 
with the effect of anti-androgen treatment in reducing the androgenic action on the brain, by 
reducing or blocking testosterone levels. However, it is also likely that improvement in aspects 
of cognitive function and emotion processing may be associated with improvement in 
symptoms of depression and anxiety, also observed following anti-androgen treatment in the 
patient group. The two effects are, however, difficult to disentangle. An improvement in tasks 
assessing specific aspects of cognitive function and emotion processing may be related to 
improvements in symptoms of mood and anxiety, or normalisation of androgen levels, or both 
of these factors 
Post-treatment correlational analyses showed significant correlations between improvements in 
symptoms of depression and anxiety and improvements in performance on psychomotor speed 
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variables, and attention and executive function variables (specifically, working memory and 
cognitive flexibility). Correlational analysis also suggested significant associations between 
improvement in symptoms of depression and anxiety and improvement in recognition accuracy 
of fearful and disgusted facial expressions. This is the first study to examine the association 
between change in mood and change in cognitive function and emotion processing following 
anti-androgen treatment in females with PCOS. The following chapter will include an overall 
summary of findings from both baseline and longitudinal findings of the current study, and will 





SUMMARY AND CONCLUSIONS 
 
 
9.1 STUDY OVERVIEW 
This thesis has presented findings from an observational, longitudinal study examining mood, 
anxiety, cognitive function and emotion processing in relation to testosterone levels in females 
of reproductive age with and without PCOS. The overall aim of the current study was to 
determine whether there was a direct relationship between androgen levels and mood, anxiety, 
cognitive function and emotion processing in females with PCOS, with abnormally elevated 
testosterone levels. In order to achieve this aim, the current study assessed androgen levels, 
symptoms of depression and anxiety, and associated cognitive function and emotion processing 
performance in females newly referred to a gynaecological-endocrine clinic in Christchurch, 
New Zealand. At baseline, correlations between androgen levels and symptoms of depression 
and anxiety and cognitive function and emotion processing were assessed across the whole 
sample. Inclusion of the entire sample with PCOS and non-PCOS control groups as a whole 
was beneficial, as this provided an opportunity to investigate the relationship between 
testosterone and mood and cognitive variables with the use of a broad range of androgen levels. 
Following this, an examination of the effects of standard clinical treatment of PCOS on 
symptoms of depression, anxiety, cognitive function and emotion processing was carried out 
by testing the group of females with PCOS before and following 12 weeks of anti-androgen 
treatment.  
For some females with depression, there may be an underlying hormonal abnormality, in the 
form of androgen excess. Therefore, it was anticipated that the results from the current research 
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may help benefit not only females with PCOS to select the most suitable treatment options, but 
also females with depression and abnormal androgen levels, who present to mental health 
services to be treated appropriately.  
Another aim of the study was to facilitate collaboration between psychiatrists and 
endocrinologists. Females with PCOS who are referred to endocrinologists often report 
difficulty with mood and anxiety. Results from this study indicate that normalising androgen 
levels improves symptoms of depression in females with PCOS. Results also suggest that 
cognitive function and emotion processing, which are associated with symptoms of depression, 
may be benefited, to a certain degree, from anti-androgen treatment in females with abnormal 
androgen levels. 
The main findings from the current study will be discussed in the following section.  
 
9.2 PRINCIPAL FINDINGS 
9.2.1 Baseline findings  
As expected, androgen levels were significantly higher in females with PCOS compared with 
controls. Verbal IQ (assessed by NART) was significantly different between the two groups, 
due to the nature of the control group. Females with PCOS had a lower estimated verbal IQ 
compared with control females, therefore, NART was considered as a covariate in final analyses 
using ANCOVA.  
9.2.1.1  Correlational findings 
After controlling for NART, the following significant correlations were found:  
 Higher FAI levels were significantly correlated with greater symptoms of depression 
(QIDS and HADS). 
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 Higher Free Testosterone and FAI levels were significantly correlated with worse 
verbal learning and memory (worse performance on recognition accuracy on the CVC 
Task).  
 Higher Free Testosterone levels were significantly correlated with worse visuospatial 
learning and memory (worse performance on GMLT variables [total errors on GMLT 
Trial 5 and GMLT Total Learning]).  
 Higher Free Testosterone and FAI levels were significantly correlated with worse 
psychomotor speed (worse performance on the TCT [number of correct moves]).  
 Higher FAI levels were significantly correlated with worse aspects of facial emotion 
processing (worse performance in recognising fearful facial expressions on the FER 
Task).  
The current study provides evidence for a significant association between testosterone levels, 
specifically, FAI levels, and mood, in that higher FAI levels were associated with higher 
symptoms of depression across the entire sample (n = 103). Additionally, higher levels of Free 
Testosterone and/or FAI levels were associated with worse performance on cognitive domains 
including verbal learning and memory (CVC recognition accuracy), visuospatial learning and 
memory (GMLT errors), psychomotor speed (number of correct moves on the TCT) and 
emotion processing (recognition accuracy of fearful faces). However, correlations were not 
consistent across all measures in these domains of functioning. 
9.2.1.2  Multivariate regression analysis findings 
Multivariate regression analysis was conducted to further determine whether the association 
between testosterone variables (Free Testosterone and FAI levels) and cognitive variables was 
independent of other relevant factors, including BMI, NART, age and symptoms of depression 
(HADS-D score). Free Testosterone levels were significantly associated with psychomotor 
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speed (TCT) (p = 0.03) when BMI was excluded from the analysis. Other correlations in 
multivariate regression analysis were not found to be significant. 
9.2.1.3  Correlations between mood and cognitive variables 
Additionally, the analysis examining the association between mood and cognitive variables 
showed: 
 A significant correlation between worse verbal learning and memory (CVC Trial 1) and 
greater symptoms of depression (HADS-D). 
 A significant correlation between worse visuospatial learning and memory (GMLT Trial 
5) and greater symptoms of anxiety (HADS-A). 
 Significant correlations between worse performance on attention and executive 
functioning variables (Digit Span Test variables assessing working memory) and greater 
symptoms of depression (HADS, HADS-D). 
These results suggest that higher levels of depression and anxiety are associated with worse 
selective aspects of cognitive function, particularly verbal and visuospatial learning and 
memory and attention and executive function. 
9.2.1.4  Comparative findings  
Significantly greater symptoms of depression were found in the PCOS group compared with 
the control group. No significant differences were found between groups on symptoms of 
anxiety. Significant differences were found between the PCOS and control groups on some 
cognitive measures, including worse performance by the PCOS group on psychomotor speed 
(TCT), worse (lower) recognition accuracy on fearful faces and worse RMET (social 
intelligence) total score after controlling for NART. 
Overall, the hypothesis that females with PCOS will show significant more symptoms of 
depression compared with control participants was supported by the current study. 
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Additionally, the hypothesis that higher androgen levels will be significantly associated with 
higher symptoms of depression was partially supported. The hypothesis that androgen levels 
will be significantly negatively correlated with worse performance on tasks assessing cognitive 
function and emotion processing was partially supported. 
9.2.2 Follow-up findings 
9.2.2.1  Correlational analyses  
Correlational analyses showed: 
 Greater improvement in symptoms of depression and anxiety significantly correlated 
with improvement in performance on the TCT (more number of correct moves), 
assessing psychomotor speed. 
 Improvement in mood symptoms (QIDS) significantly correlated with improved 
performance on the TMT - Part A (time), assessing psychomotor speed.  
 Improvement in mood symptoms (QIDS) significantly correlated with improved 
performance on the TMT- Part B, assessing attention and executive function 
(specifically, cognitive flexibility). 
 Improved symptoms of depression and anxiety (HADS) significantly correlated with 
improved performance on Digit Span Forwards variables (Total Forward and Forward 
span), assessing attention and executive function (specifically, working memory). 
 Improvements in symptoms of depression and anxiety (HADS) significantly correlated 
with improved recognition accuracy related to fearful faces on the FER Task. 
 Improvements in symptoms of depression (HADS-D) significantly correlated with 




9.2.2.2.  Comparative analysis 
Symptoms of depression were found to improve in the PCOS group compared with the control 
group over time, at trend level (p < 0.06). No significant improvements were observed in 
symptoms of anxiety following anti-androgen treatment in the PCOS group compared with the 
control group. Within the PCOS group, a significant improvement was found in symptoms of 
depression and anxiety following anti-androgen treatment.  
Over the study period, significant improvements were observed in some cognitive measures in 
the PCOS group compared with the control group. These measures included the TCT (number 
of correct moves), reaction time to fearful faces in the FER Task, and neutral misinterpretation 
bias related to angry faces (i.e., the PCOS group being less likely to interpret neutral faces as 
angry over time, compared with the control group). Within the PCOS group, significant 
improvements were observed following anti-androgen treatment in cognitive domains 
including verbal learning and memory (CVC Task) and visuospatial learning and memory 
(GMLT). Significant improvements were also observed on recognition accuracy related to 
disgusted faces, overall reaction time on the FER Task, and a reduced tendency to interpret 
neutral faces as angry (weaker neutral  misinterpretation bias), compared with baseline 
performance in the same group. 
Interpretation and discussion of specific study findings were presented at the end of the two 
previous chapters. The next section presents an overview of the current findings in relation to 






Comparison of Current Findings Related to Mood and Anxiety in Females with Polycystic Ovarian Syndrome with Previous Studies  
 Cross-sectional studies  Interventional studies Current study  
Mood In PCOS samples, three studies found a 
positive association between FAI and 
symptoms of depression (n = 580), one found 
a negative association (n = 35), one found a 
curvilinear association. Seven studies 
including PCOS samples found no significant 
association (n = 541). 
- FAI levels significantly positively 
correlated with symptoms of depression 
(QIDS, HADS) indicating higher 
testosterone levels were associated with 
higher symptoms of depression.  
Anxiety  In PCOS samples, five studies (n = 778) 
found a significant positive association 
between state anxiety and FAI levels, one 
found a negative association (n = 27), six 
remaining studies including PCOS samples 
found no significant association (n = 409). 
- No association between Free Testosterone 








Table 9.2  
Comparison of Current Findings Related to Cognitive Function and Emotion Processing with Previous Studies including Females With 
and Without Polycystic Ovarian Syndrome  
Cognitive 
domains 
Cross-sectional studies Interventional studies Current study 
Verbal learning 
and memory 
Two of seven studies found a significant 
relationship (n = 49), one a negative 
relationship (n = 25) (Wechsler Memory 
Scale), while the other a curvilinear 
association between Free Testosterone and 
verbal memory (n = 24) (RAVLT). 
One study assessed verbal learning and memory 
(RAVLT, Logical Memory Test, Paired 
Associates Test) and found no significant changes 
following anti-androgen treatment in a PCOS 
sample (n = 8). 
Significant negative correlation between 
Free Testosterone, FAI and CVC 
Recognition accuracy, suggesting that 
higher testosterone levels were associated 




One of four studies found significantly better 
visual memory performance (Visual Paired 
Associates) at baseline in the testosterone-
treated group (n = 9) compared with the no-
treatment (n = 10) group. 
One study (n = 8) found better performance on 
one aspect of a visuospatial learning and memory 
task (combined condition assessing immediate 
and delayed recall) following testosterone 
administration in healthy females, another study 
found better spatial learning and memory (Virtual 
Environment Learning and Navigating Task) in 
the testosterone group (n = 21) compared with 
controls (n = 21).  
Significant negative correlation between 
Free Testosterone levels and GMLT 
performance (total errors on GMLT Trial 5 
and GMLT Trials 1-5), indicating higher 
testosterone levels were associated with 
worse spatial learning and memory. 
Psychomotor 
speed 
One study found a negative correlation 
between FAI levels and motor speed (Purdue 
Pegboard Task) in a PCOS sample (n = 28), 
while another found a positive correlation 
between Free Testosterone and processing 
speed (Dart-throwing Task) (n = 30). 
No significant change in psychomotor speed 
following testosterone administration was found 
by two studies (one including a PCOS sample). 
Significant negative correlations between 
Free Testosterone, FAI levels and 
performance on the TCT (number of 
correct moves). 
At follow-up, a significant positive 
correlation between improvement in 
psychomotor speed (TCT, TMT - Part A) 









No evidence of an association found by five 
studies (n = 149).  
Results from two studies indicate worse 
performance on measures of verbal fluency 
following testosterone administration, however, 
one further study found no change in verbal 
fluency following testosterone treatment. 
No significant associations were seen 
between attention and executive function 
variables and Free Testosterone/FAI levels 
at baseline. 
At follow-up, a significant positive 
correlation between improvement in 
attention and executive function (TMT - 
Part B) and improvement in the symptoms 
of depression (QIDS). Significant positive 
correlation between improvement in 
executive function (Digit Span variables) 
and improvement in symptoms of 
depression and anxiety (HADS). 
Emotion 
processing 
One study found a negative association 
between emotion processing (attending away 
from angry faces) and testosterone levels; 
however, only limited to testosterone 
samples collected six hours prior to testing.  
Two studies found decreased empathy or “social 
intelligence” following testosterone 
administration in healthy females.  
Significant negative correlation between 
FAI levels and recognition accuracy of 
fearful faces, indicating that higher 
testosterone levels were associated with 
worse performance in recognising fearful 
facial expressions on the FER Task. At 
follow-up, a significant positive 
correlation between change in recognition 
accuracy of fearful and disgusted faces and 
change in the symptoms of depression and 
anxiety (HADS), indicating that as 
symptoms of depression improved 





9.3 IMPLICATIONS OF THE CURRENT RESEARCH 
The current project investigated the relationship between two very common and debilitating 
conditions in females, which while usually treated separately, were found to be closely linked. The 
purpose of this research was to examine, in detail, associations between androgens and symptoms 
of depression and anxiety and associated cognitive function and emotion processing in females of 
reproductive age.  
The current study was able to show significant correlations between higher testosterone levels 
(FAI) and lower mood. Additionally, high levels of FAI and/or Free Testosterone were 
significantly correlated with aspects of worse cognitive function including worse verbal learning 
and memory, visuospatial learning and memory, psychomotor speed and worse emotion processing 
(recognition accuracy of fearful and sad faces). Following anti-androgen treatment, symptoms of 
depression improved in the PCOS group and some aspects of cognitive function improved. While 
these are encouraging findings, there was less evidence that these cognitive domains improved 
significantly more in the PCOS group compared with the control group. Despite the symptom 
profile of patients with PCOS, including hirsutism, acne, alopecia, skin thickening, and obesity, 
not changing drastically over the period of twelve-weeks of treatment, improvements in symptoms 
of depression and cognitive function were observed. These results indicate that treating high 
testosterone levels could directly benefit mood and associated cognitive impairment, and change 
in mood may not be solely due to change in unwanted physical symptoms (which may not occur at 
the twelve-week mark). 
Overall, results from the study related to anti-androgen treatment benefitting mood and associated 
cognitive impairment are encouraging enough to warrant further investigation. These results also 




9.4 FUTURE RESEARCH 
9.4.1 Sample size 
It was the intention of the current study to include a larger sample, however, this was challenging 
since at the beginning of the study, the Canterbury District Health Board (CDHB) published new 
“pathways” for General Practitioners mandating that the first-line of treatment for patients with 
PCOS include OCPs/COCPs following which referrals would be considered, which affected the 
sample size included in the study (see Chapter Seven, section 7.15.1.7). Future research would be 
benefitted by including a larger sample which would provide greater power for conducting 
statistical comparisons for outcome measures.  
9.4.2  Longer-term follow-up 
It would be useful to study the longer-term effects of anti-androgen treatment on mood and 
cognitive function in females treated for PCOS. The only two studies that have assessed the effect 
of anti-androgen treatment on mood and cognitive function in females with PCOS have assessed 
these functions at baseline and following three months of treatment. However, since the physical 
symptoms involved in the syndrome may take longer to be treated and to show a visible difference, 
it would be of interest whether resolution of these symptoms has an impact on improvement in 
symptoms of depression. It is also possible that cognitive function may take longer to improve. 
Thus, in future studies, a further longer-term (six-month or a twelve-month) follow-up would be 




9.4.3 Cognitive measures 
Most cognitive measures included in the current study did not improve differentially in PCOS 
patients compared with control participants over the course of anti-androgen treatment for PCOS. 
However, a significant improvement was observed within the PCOS group on most cognitive and 
some emotion processing measures. A suggestion for future research would be to include tasks 
assessing visuospatial ability as part of the test battery, as prior research has shown a positive 
association between testosterone levels and spatial ability.  
9.4.4 Neuroimaging techniques 
Longitudinal neuroimaging studies could provide valuable information about the effect of anti-
androgen treatment on the brain. Until now, only one small neuroimaging study (Marsh et al., 2013) 
has examined emotion processing in females with PCOS and found significant results including 1) 
greater limbic activation in insulin-resistant PCOS females compared with controls, which resolved 
after Metformin treatment and, 2) positive correlations between fMRI limbic activation during 
emotion processing and mu-opioid binding potential. Future research may be benefitted by 
incorporating neuroimaging data together with cognitive assessment in samples with PCOS. 
9.4.5 Extending findings to other populations 
It may be useful to examine the percentage of female outpatients with depression who have 
abnormal androgen levels and the percentage of patients with treatment-resistant depression who 
have PCOS or PCOS-like symptoms. Since the current study found significant correlations 
between androgen levels and symptoms of depression, it would be of interest and value to 
investigate androgen abnormalities in females with depression. Additionally, it would be of interest 
to examine androgen levels in patients with depression who are treated with SSRIs and who have 
314 
 
experienced emotional numbing. This may elucidate whether SSRIs do in fact increase levels of 
testosterone and whether this is a significant factor in causing emotional numbing in some patients. 
9.5 CONCLUSION 
The current thesis has presented findings from a longitudinal study assessing PCOS patients and 
control participants on a broad range of mood and anxiety scales, cognitive tests, and emotion 
processing measures. This is the first study to simultaneously examine changes in mood, cognitive 
function and emotion processing following anti-androgen treatment in females with PCOS. Data 
support the hypothesis that females with PCOS experience more symptoms of depression and show 
worse cognitive function compared with non-PCOS control females. Data also support the 
hypothesis that chronically elevated androgen levels, specifically, Free Testosterone and FAI 
levels, characteristic of PCOS, are associated with more symptoms of depression and associated 
worsening in cognitive function, and that normalising androgen levels benefits symptoms of 
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Te Whare Wänanga o Otago 
 
A study investigating the relationship between sex 
hormones, mood and cognitive functioning in females 
attending gynaecological endocrine clinics in 
Christchurch 
 
Principal Investigator: Professor Richard Porter 









You are being invited to take part in a research study. It is important for you to understand 
why the research is being done and what it will involve. Please take the time to read over this 
information sheet carefully and to ask us if there is anything that is not clear to you or if you 
would like more information. You are free to discuss this study with others to help you come 
to a decision. You are welcome to ask a support person to join you in asking further questions 
about the study. This person may be a family member, a friend or a professional involved in 
your care. 
 
What is the purpose of the study? 
 
The current study will examine the link between sex hormone levels, mood and cognitive 
functioning in women. We believe that by understanding the relationship between sex 
hormones and mood symptoms, more suitable treatment options may be developed.  
 
If you agree to participate in the present study, you will complete several tasks measuring 
memory, learning, verbal fluency and how you process emotions. You will also be clinically 
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assessed for mood symptoms during your medical appointment at the Gynaecological 
Endocrinology Clinic. 
Who is running the study? 
 
This research is being conducted by Professor Richard Porter, Dr. Katie Douglas, Dr. Anna 
Fenton and Ms. Mayouri Sukhapure of the Department of Psychological Medicine, 
University of Otago, Christchurch. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and you will be asked to sign a consent form. If you decide 
to take part you are free to withdraw at any time without giving a reason, and this withdrawal 
will not result in any disadvantage to yourself or your healthcare. The data collected from you 
will be immediately destructed in such an event. 
 
If I participate, what will I be asked to do? 
 
If you indicate willingness to take part, then the PhD Student will ask you some more questions 
to check that you are suitable for the study. If so, you would have an opportunity to ask 
questions and if satisfied, to sign a consent form.  
 
We will ask you about your age and ethnic background, and will assess your mood and 
cognitive functioning, both at baseline and three months later.  As a part of your routine clinical 
care, we will collect information about your general health and take some blood tests to assess 
hormone levels and your metabolism.  
 
The cognitive tests will involve pen-and-paper tests and computerised tests assessing your 
verbal learning and memory, visual learning and memory, and your emotion processing 
ability. These assessments will be carried out by the PhD student. For example, you will be 
asked to listen to a list of words and will then be asked to recall them. During the course of 
the study, you will be assisted and given clear instructions regarding the procedures involved, 
which will aid your understanding of the tasks. The total duration of the assessment would 
require around 1.5 hours of your time. 
 
The results obtained from the study will be treated confidentially. You will be allocated with 
a research code number, protecting your anonymity. The results may be used for further 
research purposes only with your consent. 
 
What about my usual treatment? 
 
You will keep taking your usual medication which will be monitored by one of the 





What are the possible advantages of taking part? 
 
 The information we obtain from this study may help us to improve treatment in the future for 
patients with hormonal problems, which may be linked to mood and changes in brain function. 
At present, we have no information about whether the standard treatments for hormone 
imbalances help mood or brain function. The current study would help contribute to this 
knowledge. 
 
What are the risks involved in taking part in the study? 
 
We do not foresee any risks in participation. However, a clinician will be contacted if you 
became distressed during assessment or testing.  
 
Will I receive compensation for the time taken to be part of this study? 
 
You will receive compensation in the form of a $20 petrol voucher, to assist you in covering 
your travel related expenses. 
 
Will my taking part in this study be kept confidential? 
 
The current study is conducted within the Clinical Research Unit, in collaboration between the 
University of Otago, Christchurch and the Canterbury District Health Board. Two types of 
information will be collected from you – research information and clinical information. Research 
information is kept in a non-identifying form as described above. Usual CDHB policies are 
followed for confidentiality of clinical information. Health data is required to be stored for 10 
years. 
 
All material that you provide us will be treated in the utmost confidence. We will hold research 
information about you on a computer in the Department of Psychological Medicine in 
Christchurch. The study has a security system which ensures that all information you provide 
is stored in anonymous form on computer files and that no data that can be linked to an 
individual can be accessed without knowledge of this security system. Only those directly 
involved in the study will have access to this information and we will ensure that 
confidentiality is kept. Your identity will not be revealed in any reports based on this study. 
If during the course of the study, we discover information which is important to your continued 
health and safety, we will discuss this with you and ask your permission to convey this to your 
endocrinologist. 
What will happen to the results of the research? 
 
We plan to finish the study by the end of 2018 and to submit the results for publication in 
scientific journals and to present results at international conferences. No-one will be identified 




Where can I get information about the study? 
 




“This study has been approved of by the University of Otago Human Ethics Committee 
(Health). If you have any concerns about the ethical conduct of the research you may contact 
the Committee through the Human Ethics Committee Administrator (phone +64 3 479 8256 
or email gary.witte@otago.ac.nz).  Any issues you raise will be treated in confidence and 





















Te Whare Wänanga o Otago 
 
A study investigating the relationship between sex 
hormones, mood and cognitive functioning in females  
 
 
Principal Investigator: Professor Richard Porter 
 (sukma003@student.otago.ac.nz, 0272900960) 
 
 
  CONSENT FORM FOR PARTICIPANTS 
University of Otago – Department of Psychological Medicine 
 
 
PARTICIPANTS NAME:  
 
 I have been invited to take part in a study investigating whether sex hormones are 
associated with mood and cognitive functioning. This research is being conducted by 
Professor Richard Porter, Dr Katie Douglas, Dr Anna Fenton and Ms. Mayouri 
Sukhapure. 
 
 I have read the Information sheet and understood the description and aims of the above-
named project.  
 
 I have had the opportunity to discuss the project with others in order to come to this 
decision. 
 
 All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
 I also understand that my participation in the project is entirely voluntary and that I 
may withdraw from the project at any time without any disadvantage. In the event that 
I withdraw from this study, all data collected from me will be destroyed and will not 
be included in the study.  
 




 I know that as a participant, information pertaining to my medical records such as 
hormonal assessment/ bodily fluids or blood, blood samples, cognitive and 
neuropsychological tests, completed questionnaires will be required for the project. 
 I know that the questionnaires will explore my mood, thinking and feeling and that if 
the line of questioning  develops in such a way that I feel hesitant or uncomfortable I 
may decline to answer any particular question(s) , and /or may withdraw from the 
project without disadvantage of any kind. 
 I understand the nature and size of the risks of discomfort or harm which are 
explained in the Information Sheet. 
 I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from 
the project, and that these will be placed in secure storage and kept for at least ten 
years.  
 I understand that the results of the project may be published and be available in the 
University of Otago Library, but that I agree that any personal identifying 
information will remain confidential between myself and the researchers during the 
study, and will not appear in any spoken or written report of the study 
 
Signature of participant:  Date: 
   
   
Signature and name of witness:  Date: 
   
   
   
 













Flyers Used to Recruit Females with PCOS and Control Participants in the 






























We, at the Department of Psychological medicine, University of Otago, Christchurch, 
are looking for females with untreated Polycystic Ovarian syndrome (PCOS) symptoms 
to assist in a study examining the relationship between sex hormones, mood, and memory 
in females. We will assess mood and cognition in a 1.5 hour testing session, for which you 
will be reimbursed with a $ 20 petrol voucher. If you are considered eligible to participate 
in the study you will be assessed by an endocrinologist who will recommend appropriate 
treatment and refer you back to your G.P. 
 
If you are between 15-45 years of age and suspect you have PCOS (or have at least two 
of the following three symptoms) you will be eligible to participate in the study. 
 
1) No other known endocrinological conditions 
    2) Irregular periods, positive scan of ovarian cysts 
    3) Symptoms such as abnormal hair growth, severe acne, weight gain issues, infertility, 
and family history of PCOS.  




 1) No history of serious mental illness (e.g. Schizophrenia or Bipolar disorder) 
   2) No major neurological illness or severe head injury 
   3) Non-intact ovaries, pregnancy or menopause 
Some of the things you will do as part of the study include: 
 
    1) Completing questionnaires which measure mental health symptoms 
    2) Doing tests on the computer, and some pen-and-paper tasks to assess learning, memory 
& emotion processing. 
 
If you are interested in taking part, please call Mayouri: 



















Our research team at the University of Otago, Christchurch, is looking for healthy females to 
assist in a study examining sex hormones, mood, cognitive function and emotion processing 
in females. We have examined a group of patients who have been diagnosed with PCOS 
(Polycystic Ovarian syndrome) and we are now recruiting healthy female volunteers between 
the ages of 16-40 years. 
Participation includes completing questionnaires which measure mental health symptoms, 
doing tests on the computer as well as pen-and-paper tasks( which assess memory, attention 
and emotion processing) and getting a blood test done (to measure sex hormones levels). 
The healthy volunteers we are recruiting must:  
Be between the ages of 16-40 years. 
Not have a history of serious mental illness (e.g. Schizophrenia or Bipolar disorder) 
Have their ovaries intact 
Not be pregnant or menopausal  
 
You will receive compensation in the form of a $20 petrol voucher, to assist you in covering 
your travel related expenses. 
 
If you would like more information or are interested in assisting with this research, please 
contact Mayouri Sukhapure at: sukma003@student.otago.ac.nz/ 0273076502. 
 
 
This study has been approved of by the University of Otago Human Ethics Committee (Health). 
If you have any concerns about the ethical conduct of the research you may contact the 





















          ID No:                                                      Date:                            --                           --   
 
Polycystic Ovarian Syndrome Questionnaire 
 
Do you have any of the following conditions? 
 
1. Excess hair growth on the face/back/chest/abdominal region 
 
2. Irregular periods/Menstrual disturbances 
 
3. Problems with weight management or weight gain issues? 
 
   
 
4. Adult acne  
 
5. Male pattern baldness/ acute hair loss 
 
6. Have you ever had a scan of your ovaries? 
 
7. Have you had problems getting pregnant or had  
 
              miscarriages? 
 
8. A brown-discoloured velvety texture to the skin especially 
 near the neck or skin tags?  
       
       10. Is there a family history of PCOS?      
        
       11. Blood pressure  
 
     












































Dr R Porter 
Academic Services 





Department of Psychological Medicine (ChCh) 
Terrace House, 4 Oxford Terrace 






Dear Dr Porter, 
 
I  am  again  writing  to  you  concerning  your  proposal  entitled  “The  effect  of  abnormal androgen 
levels on mood symptoms, cognitive symptoms and depression in women based  in  
Christchurch:  A  correlational  study”,  Ethics  Committee  reference  number H14/047. 
 
Thank you for your letter of 3rd April 2014 addressing the issues raised by the Committee. 
 
 
The Committee appreciates the reconsideration of the proposed use of the three symptom measures 
noting that only two of the measures will now be used (one self-report (HADS) and an  interview  (QIDS))  
as  detailed  in  the  original  application.  You  note  that  the  90  minutes given  for  participants  to  
complete  the  study  would,  in  most  cases,  be  more  than  sufficient time. 
 
The Committee thanks you for attaching the Peer Review conducted by Associate Professor Chris 
Frampton and for the amendments made to the Information Sheet and Consent Form as requested. 
 
On the basis of this response, I am pleased to confirm that the proposal now has full ethical approval to 
proceed. 
 
Approval  is  for  up  to  three  years  from  the  date  of  this  letter.  If this project  has  not  been 
completed within three years from the date of this letter, re-approval must be requested.   If the nature, 








Mr Gary Witte 
Manager, Academic Committees 

























Te Whare Wänanga o Otago 
 
ID No:                                            
 
 
Voucher Payment Agreement 






I, ________________________________________ have received my first $20 petrol  
 
voucher to compensate for the time taken to be part of this study. 
 
 











I, ________________________________________ have received my second $20 
petrol  
 
voucher to compensate for the time taken to be part of this study. 
 
 
Signed: __________________________________ Date: -
____________________ 
 






























Recording Form for the National Adult Reading Test (NART) – 2nd Edition 
CHORD  IDYLL  
ACHE  NAÏVE  
DEPOT  CATACOMB  
AISLE  GAOLED  
BOUQUET  THYME  
PSALM  HEIR  
CAPON  RADIX  
DENY  ASSIGNATE  
NAUSEA  HIATUS  
DEBT  SUBTLE  
COURTEOUS  PROCREATE  
RAREFY  GIST  
EQUIVOCAL  GOUGE  
SUPERFLUOUS  PUERPERAL  
SIMILE  AVER  
BANAL  GAUCHE  
QUADRUPED  TOPIARY  
CELLIST  LEVIATHAN  
FAÇADE  BEATIFY  
ZEALOT  PRELATE  
DRACHM  SIDEREAL  
AEON  DEMESNE  
PLACEBO  SYNCOPE  
ABSTEMIOUS  LABILE  
DETENTE  CAMPANILE  
 
 




NART Conversion Table 
 
 
NART Errors Predicted Verbal IQ  NART Errors Predicted Verbal IQ 
0 127  26 98 
1 126  27 97 
2 125  28 95 
3 124  29 94 
4 123  30 93 
5 122  31 92 
6 121  32 91 
7 119  33 90 
8 118  34 89 
9 117  35 87 
10 116  36 86 
11 115  37 85 
12 114  38 84 
13 113  39 83 
14 111  40 82 
15 110  41 81 
16 109  42 80 
17 108  43 78 
18 107  44 77 
19 106  45 76 
20 105  46 75 
21 103  47 74 
22 102  48 73 
23 101  49 72 
24 100  50 70 





NART DEFINITIONS GUIDE 
 
CHORD  ...............................  harmonious combination of several different notes 
ACHE  ..................................  prolonged dull pain 
DEPOT  ...............................  storehouse, station, headquarters 
AISLE ..................................  passageway in a building 
BOUQUET  ..........................  bunch of flowers 
PSALM  ................................  sacred song or hymn 
CAPON  ...............................  castrated cock 
DENY  ..................................  declare untrue or non-existent 
NAUSEA  .............................  feeling of sickness with an inclination to vomit 
DEBT  ..................................  something that is owed 
COURTEOUS  .....................  kind or considerate in manner 
RAREFY  .............................  refine (air), become less dense 
EQUIVOCAL  .......................  uncertain nature 
NAÏVE  .................................  innocent 
CATACOMB  ........................  underground cemetery 
GAOLED  .............................  a jail 
THYME  ...............................  culinary herb 
HEIR  ...................................  legal successor or recipient of property/money/title 
RADIX  .................................  number of symbol used as the basis of a 
                                               numeration system - #10 
ASSIGNATE  .......................  appoint/assign a time/place/function 
HIATUS  ...............................  gap in a series 
SUBTLE  ..............................  evasive or mysterious, faint, delicate 
PROCREATE  ......................  process of reproduction 
GIST  ...................................  essence of the matter 
GOUGE  ..............................  groove made with a chisel 
SUPERFLUOUS  .................  not needed, more than enough 
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SIMILE  ................................  compare on thing to another to illustrate 
BANAL  ................................  trite 
QUADRUPED  .....................  four footed animal 
CELLIST  .............................  person who plays cello 
FAÇADE  .............................  face of a building, outward appearance 
ZEALOT  ..............................  uncompromising or extreme partisan, fanatic 
DRACHM  ............................  measure 1/8 fluid oz 
AEON ..................................  an age 
PLACEBO  ...........................  blank sample used as a control, a thing to calm/ 
                                               humour but does not address 
ABSTEMIOUS  ....................  sparing, moderate in food and drink 
DÉTENTE  ...........................  an easing of strained relations 
IDYLL  ..................................  blissful period or scene 
PUERPERAL  ......................  due to childbirth 
AVER  ..................................  assert, affirm 
GAUGE  ...............................  lacking ease or grace 
TOPIARY  ............................  to do with clipped shrubs 
LEVIATHAN  ........................  sea monster, huge ship, person of great power 
BEATIFY  .............................  make happy, ecclesiastical (announce the 
                                               beatification of) 
PRELATE  ...........................  high ecclesiastical dignitary 
SIDEREAL  ..........................  determined by the stars 
DEMENSE  ..........................  domain, territory, land owned by person or oneself 
SYNCOPE  ..........................  shorten by omission of interior letter/s (pacifist) 
LABILE  ................................  unstable 






























ID No:                                                                Date:                             
Demographic Questionnaire 
Androgen and Mood Study: Baseline 
 
1.  Age:   
 
2.  D.O.B.: .............................................................. 
 
4.  Years of secondary school education:  .............. 
 




6. Which ethnic group do you belong to? If you belong to multiple ethnic groups please tick 
appropriately (more than one box may be ticked): 
 
[  ]  New Zealand European 
[  ]  Maori 
[  ]  Samoan 
[  ]  Cook Island Maori 
[  ]  Tongan 
[  ]  Niuean 
[  ]  Chinese 
[  ]  Indian 
[  ]  Other (such as Dutch, Japanese, Tokelauan etc.) Please specify below: 
 
……………………………………………………………………………………………………………………. 





7. What is your current marital status? 
 
[  ] Single 
[  ] Married 
[  ] Widowed 
[  ] Separated / Divorced 
[  ] De facto 
 
8. If currently in a relationship, how long (in years) have you been in your relationship? 
 
 









11. (Current phase of menstruation cycle) 
 























15. Have you ever suffered from a significant brain injury?    
 
If so, was consciousness lost for more than 2 hours? 
 
 





Have you ever been diagnosed or seen a doctor/psychologist for a mental health condition  





Y   /   N 
Y   /   N 
Y   /   N 









How many cigarettes do you smoke per day? 
 
 
How long have you been smoking for? 
 


























Androgen and Mood Study: Follow-up 
 
Physical Health 























How many cigarettes do you smoke per day? 
 
How long have you been smoking for? 
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Our aim is to assist in the assessment and tracking of patients with greater efficiency and accuracy. Before action is taken on any 
data collected and processed by this program, it should be reviewed and interpreted by a licensed clinician. 
 
This program is not designed or intended to be used in the place of a full medical and psychiatric evaluation by a qualified 
licensed physician – psychiatrist. It is intended only as a tool to facilitate accurate data collection and processing of symptoms 
elicited by trained personnel. 
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Patient Name:    Patient Number:    
Date of Birth:    Time Interview Began:    
Interviewer’s Name:    Time Interview Ended:    
Date of Interview:    Total Time:    
 
MEETS 
MODULES TIME FRAME CRITERIA DSM-IV ICD-10 
 
A MAJOR DEPRESSIVE EPISODE Current (2 weeks) 
Recurrent 
 296.20-296.26 Single 





MDE WITH MELANCHOLIC FEATURES 
Optional 






B DYSTHYMIA Current (Past 2 years)  300.4 F34.1 ❒ 
C SUICIDALITY Current (Past Month) 
 ❒ 
Risk:  Low   Medium   High 
















 Past    






300.01/300.21 F40.01-F41.0 ❒ 
F AGORAPHOBIA Current  300.22 F40.00 ❒ 
G SOCIAL PHOBIA (Social Anxiety Disorder) Current (Past Month)  300.23 F40.1 ❒ 
H OBSESSIVE-COMPULSIVE DISORDER Current (Past Month)  300.3 F42.8 ❒ 
I POSTTRAUMATIC STRESS DISORDER Current (Past Month)  309.81 F43.1 ❒ 
J ALCOHOL DEPENDENCE Past 12 Months 
 
 303.9 F10.2x ❒ 
ALCOHOL ABUSE Past 12 Months  305.00 F10.1 ❒ 
K SUBSTANCE DEPENDENCE (Non-alcohol) Past 12 Months 
 
 304.00-.90/305.20-.90 F11.1-F19.1 ❒ 
SUBSTANCE ABUSE (Non-alcohol) Past 12 Months  304.00-.90/305.20-.90 F11.1-F19.1 ❒ 
L PSYCHOTIC DISORDERS Lifetime 
 
 295.10-295.90/297.1/ F20.xx-F29 ❒ 
 Current  297.3/293.81/293.82/  
   293.89/298.8/298.9  
MOOD DISORDER WITH PSYCHOTIC FEATURES Lifetime  296.24/296.34/296.44 F32.3/F33.3/ ❒ 
 Current  296.24/296.34/296.44 F30.2/F31.2/F31.5 
F31.8/F31.9/F39 ❒ 
M ANOREXIA NERVOSA Current (Past 3 Months)  307.1 F50.0 ❒ 
N BULIMIA NERVOSA Current (Past 3 Months)  307.51 F50.2 ❒ 
 
ANOREXIA NERVOSA, BINGE EATING/PURGING TYPE Current  307.1 F50.0 ❒ 
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O GENERALIZED ANXIETY DISORDER Current (Past 6 Months)  300.02 F41.1 ❒ 
P ANTISOCIAL PERSONALITY DISORDER Lifetime  301.7 F60.2 ❒ 
Optional 
 






The M.I.N.I. was designed as a brief structured interview for the major Axis I psychiatric disorders in DSM-IV and ICD-10. Validation 
and reliability studies have been done comparing the M.I.N.I. to the SCID-P for DSM-III-R and the CIDI (a structured interview developed 
by the World Health Organization for lay interviewers for ICD-10).  The results of these studies show that the 
M.I.N.I. has acceptably high validation and reliability scores, but can be administered in a much shorter period of time (mean 18.7 ± 
11.6 minutes, median 15 minutes) than the above referenced instruments. It can be used by clinicians, after a brief training session. Lay 
interviewers require more extensive training. 
 
INTERVIEW: 
In order to keep the interview as brief as possible, inform the patient that you will conduct a clinical interview that is more structured than 
usual, with very precise questions about psychological problems which require a yes or no answer. 
 
GENERAL FORMAT: 
The M.I.N.I. is divided into modules identified by letters, each corresponding to a diagnostic category. 
•At the beginning of each diagnostic module (except for psychotic disorders module), screening question(s) corresponding to the main 
criteria of the disorder are presented in a gray box. 
•At the end of each module, diagnostic box(es) permit the clinician to indicate whether diagnostic criteria are met. 
 
CONVENTIONS: 
Sentences written in « normal font » should be read exactly as written to the patient in order to standardize the assessment of diagnostic 
criteria. 
 
Sentences written in « CAPITALS » should not be read to the patient. They are instructions for the interviewer to assist in the scoring of the 
diagnostic algorithms. 
 
Sentences written in « bold » indicate the time frame being investigated. The interviewer should read them as often as necessary. Only 
symptoms occurring during the time frame indicated should be considered in scoring the responses. 
 
Answers with an arrow above them ({) indicate that one of the criteria necessary for the diagnosis(es) is not met. In this case, the 
interviewer should go to the end of the module, circle « NO » in all the diagnostic boxes and move to the next module. 
 
When terms are separated by a slash (/) the interviewer should read only those symptoms known to be present in the patient (for example, 
question H6). 
 




All questions must be rated. The rating is done at the right of each question by circling either Yes or No. Clinical judgment  by the rater 
should be used in coding the responses. The rater should ask for examples when necessary, to ensure accurate coding. The patient should 
be encouraged to ask for clarification on any question that is not absolutely clear. 
 
The clinician should be sure that each dimension of the question is taken into account by the patient (for example, time  frame, 
frequency, severity, and/or alternatives). 
Symptoms better accounted for by an organic cause or by the use of alcohol or drugs should not be coded positive in the 
M.I.N.I. The M.I.N.I. Plus has questions that investigate these issues. 
 
 
For any questions, suggestions, need for a training session, or information about updates of the M.I.N.I., please contact : 
 
David V Sheehan, M.D., M.B.A. Yves Lecrubier, M.D. / Thierry Hergueta, M.S. 
University of South Florida College of Medicine INSERM U302 
3515 East Fletcher Avenue Hôpital de la Salpétrière 
Tampa, FL USA 33613-4788 47, boulevard de l’Hôpital 
tel : +1 813 974 4544;  fax : +1 813 974 4575 F. 75651 PARIS, FRANCE 
e-mail : dsheehan@hsc.usf.edu tel : +33 (0) 1 42 16 16 59; fax : +33 (0) 1 45 85 28 00 
e-mail : hergueta@ext.jussieu.fr 
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A. MAJOR DEPRESSIVE EPISODE 
({ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
A1 Have you been consistently depressed or down, most of the day, nearly NO YES 
 every day, for the past two weeks?   
A2 In the past two weeks, have you been much less interested in most things or 








Over the past two weeks, when you felt depressed or uninterested: 
  
 
a Was your appetite decreased or increased nearly every day? Did your weight 
decrease or increase without trying intentionally (i.e., by ±5% of body weight or ±8 
lbs. or ±3.5 kgs., for a 160 lb./70 kg. person in a month)? 
IF YES TO EITHER, CODE YES. 
NO YES * 
 
b Did you have trouble sleeping nearly every night (difficulty falling asleep, waking up in 
the middle of the night, early morning wakening or sleeping excessively)? 
NO YES 
 
c Did you talk or move more slowly than normal or were you fidgety, restless or 
having trouble sitting still almost every day? 
NO YES * 
 
d Did you feel tired or without energy almost every day? NO YES 
 
e Did you feel worthless or guilty almost every day? NO YES 
 
f Did you have difficulty concentrating or making decisions almost every day? NO YES 
 









IF PATIENT HAS CURRENT MAJOR DEPRESSIVE EPISODE CONTINUE TO A4, 
OTHERWISE MOVE TO MODULE B: 
{ 
A4 a    During your lifetime, did you have other episodes of two weeks or more when you felt NO YES 
depressed or uninterested in most things, and had most of the problems we just talked about? 
 
 
b   In between 2 episodes of depression, did you ever have an interval of at 

















MAJOR DEPRESSIVE EPISODE WITH MELANCHOLIC FEATURES (optional) 
({ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 







During the most severe period of the current depressive episode, did you lose almost completely 







b During the most severe period of the current depressive episode, did 
you lose your ability to respond to things that previously gave you 
pleasure, or cheered you up? 
NO YES 
  IF NO: When something good happens does it fail to make you feel better, even temporarily?   
   {  




Over the past two week period, when you felt depressed and uninterested: 
    
 
a Did you feel depressed in a way that is different from the kind of feeling you 




b Did you feel regularly worse in the morning, almost every day? NO YES 
  
 
c Did you wake up at least 2 hours before the usual time of awakening and 




d IS A3c CODED YES (PSYCHOMOTOR RETARDATION OR AGITATION)? NO YES 
  
 
e IS A3a CODED YES FOR ANOREXIA OR WEIGHT LOSS? NO YES 
  
 
f Did you feel excessive guilt or guilt out of proportion to the reality of the situation? NO YES 
  
   
NO 
   
YES 
 











({ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 


















During this period of feeling depressed most of the time: 
    
 





























    {   























In the past month did you: 
 







 IF NO TO C1, SKIP TO C2; IF YES, ASK C1a,:    
C1a Plan or intend to hurt yourself in that accident either passively or actively? NO YES 0 
 IF NO TO C1a, SKIP TO C2: IF YES, ASK C1b,:    
C1b Did you intend to die as a result of this accident? NO YES 0 
C2 Think that you would be better off dead or wish you were dead? NO YES 1 
C3 Want to harm yourself or to hurt or to injure yourself? NO YES 2 
C4 Think about suicide? NO YES 6 
 




Can you control these impulses and state that you will not act on them while in this program? 
Only score 8 points if response is NO. NO YES 8 
C5 Have a suicide plan? NO YES 8 
C6 Take any active steps to prepare to injure yourself or to prepare for a suicide attempt 
in which you expected or intended to die? NO YES 9 
C7 Deliberately injure yourself without intending to kill yourself? NO YES 4 
C8 Attempt suicide? NO YES 10 
Hoped to be rescued / survive ❒ 
Expected / intended to die ❒ 
In your lifetime: 
 
C9 Did you ever make a suicide attempt? NO YES 4 
 
 
IS AT LEAST 1 OF THE ABOVE (EXCEPT C1) CODED YES? 
 
 
IF YES, ADD THE TOTAL NUMBER OF POINTS FOR THE ANSWERS (C1-C9) CHECKED 




MAKE ANY ADDITIONAL COMMENTS ABOUT YOUR ASSESSMENT OF THIS 










SUICIDE RISK CURRENT 
1-8 points Low ❒ 
9-16 points   Moderate ❒ 
> 17 points   High ❒ 
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D. (HYPO) MANIC EPISODE 
 
({ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
 
D1    a    Have you ever had a period of time when you were feeling 'up' or 'high' or ‘hyper’ NO YES 
or so full of energy or full of yourself that you got into trouble, or that 
other people thought you were not your usual self? (Do not consider times when 
you were intoxicated on drugs or alcohol.) 
 
IF PATIENT IS PUZZLED OR UNCLEAR ABOUT WHAT YOU MEAN 
BY 'UP' OR 'HIGH' OR ‘HYPER’, CLARIFY AS FOLLOWS: By 'up' or 'high' or ‘hyper’ 
I mean: having elated mood; increased energy; needing less sleep; having rapid thoughts; 
being full of ideas; having an increase in productivity, 
motivation, creativity, or impulsive behavior. 
 
IF NO, CODE NO TO D1b: IF YES ASK: 
 
b    Are you currently feeling ‘up’ or ‘high’ or ‘hyper’ or full of energy? NO YES 
 
D2    a    Have you ever been persistently irritable, for several days, so that you NO YES 
had arguments or verbal or physical fights, or shouted at people outside 
your family? Have you or others noticed that you have been more irritable or over 
reacted, compared to other people, even in situations that you felt were justified? 
 
IF NO, CODE NO TO D2b: IF YES ASK: 
 
b   Are you currently feeling persistently irritable? NO YES 
{ 
IS D1a OR D2a CODED YES? NO YES 
 
 
D3 IF D1b OR D2b = YES: EXPLORE THE CURRENT AND THE MOST SYMPTOMATIC PAST EPISODE, OTHERWISE 
IF D1b AND D2b = NO: EXPLORE ONLY THE MOST SYMPTOMATIC PAST EPISODE 
 
During the times when you felt high, full of energy, or irritable did you: 
Current Episode Past Episode 
 
a Feel that you could do things others couldn't do, or that you were an NO YES 
especially important person? 
IF YES, ASK FOR EXAMPLES. 
THE EXAMPLES ARE CONSISTENT WITH A DELUSIONAL IDEA. ❒ No ❒ Yes 
 







c Talk too much without stopping, or so fast that people had difficulty NO YES 
understanding? 
 





e Become easily distracted so that any little interruption could distract you? NO YES NO YES 
 
f Become so active or physically restless that others were worried about you? NO YES NO YES 
 
g Want so much to engage in pleasurable activities that you ignored the risks or NO YES 













(OR 4 OR MORE IF D1a IS NO (IN RATING PAST EPISODE) AND D1b IS NO (IN RATING CURRENT EPISODE)? 
RULE: ELATION/EXPANSIVENESS REQUIRES ONLY THREE D3 SYMPTOMS WHILE 
   
IRRITABLE MOOD ALONE REQUIRES 4 OF THE D3 SYMPTOMS.    
VERIFY IF THE SYMPTOMS OCCURRED DURING THE SAME TIME PERIOD. 
   
D4 Did these symptoms last at least a week and cause significant problems at home, NO YES NO YES 
at work, socially, or at school, or were you hospitalized for these problems? 
   
 
THE EPISODE EXPLORED WAS A: ❒ ❒ 








IS D4 CODED NO? 
 
 







IS D4 CODED YES? 
 
 




















 E. PANIC DISORDER  
({ MEANS :  CIRCLE NO IN E5, E6 AND E7 AND  SKIP TO F1) 
   {  
E1 a Have you, on more than one occasion, had spells or attacks when you suddenly 
felt anxious, frightened, uncomfortable or uneasy, even in situations where most 















  or occur in an unpredictable or unprovoked manner?   
E3 
 
Have you ever had one such attack followed by a month or more of persistent 
concern about having another attack, or worries about the consequences of the attack 
or did you make a significant change in your behavior because of the attacks (e.g., shopping 
only with a companion, not wanting to leave your house, visiting the emergency 




During the worst spell that you can remember: 
  
 
a Did you have skipping, racing or pounding of your heart? NO YES 
 
b Did you have sweating or clammy hands? NO YES 
 
c Were you trembling or shaking? NO YES 
 
d Did you have shortness of breath or difficulty breathing? NO YES 
 
e Did you have a choking sensation or a lump in your throat? NO YES 
 
f Did you have chest pain, pressure or discomfort? NO YES 
 
g Did you have nausea, stomach problems or sudden diarrhea? NO YES 
 
h Did you feel dizzy, unsteady, lightheaded or faint? NO YES 
 
i Did things around you feel strange, unreal, detached or unfamiliar, or did 
you feel outside of or detached from part or all of your body? 
NO YES 
 
j Did you fear that you were losing control or going crazy? NO YES 
 
k Did you fear that you were dying? NO YES 
 
l Did you have tingling or numbness in parts of your body? NO YES 
 
m Did you have hot flushes or chills? NO YES 
E5 
 
ARE BOTH E3, AND 4 OR MORE E4 ANSWERS, CODED YES? 
 






IF E5 = NO, ARE ANY E4 ANSWERS CODED YES? NO YES 
LIMITED SYMPTOM 
ATTACKS LIFETIME 





In the past month, did you have such attacks repeatedly (2 or more) followed by 











Do you feel anxious or uneasy in places or situations where you might have a panic attack or 
the panic-like symptoms we just spoke about, or where help might not be available or escape 
might be difficult: like being in a crowd, standing in a line (queue), 
when you are alone away from home or alone at home, or when crossing a bridge, traveling 







IF F1 = NO, CIRCLE NO IN F2. 
    
F2 Do you fear these situations so much that you avoid them, or suffer through 






      
  










































G. SOCIAL PHOBIA (Social Anxiety Disorder) 




G2 Is this social fear excessive or unreasonable? NO YES 
 
{ 










Do you fear and avoid 4 or more social situations? 
 
If YES Generalized social phobia (social anxiety disorder) 
 
If NO Non-generalized social phobia (social anxiety disorder) 
 
NOTE TO INTERVIEWER: PLEASE ASSESS WHETHER THE SUBJECT’S FEARS ARE 
RESTRICTED TO NON-GENERALIZED (“ONLY 1 OR SEVERAL”) SOCIAL SITUATIONS OR 
EXTEND TO GENERALIZED (“MOST”) SOCIAL SITUATIONS. “MOST” SOCIAL SITUATIONS IS 
USUALLY OPERATIONALIZED TO MEAN 4 OR MORE SOCIAL SITUATIONS, ALTHOUGH THE 
DSM-IV DOES NOT EXPLICITLY STATE THIS. 
 
EXAMPLES OF SUCH SOCIAL SITUATIONSTYPICALLY INCLUDE INITIATING OR 
MAINTAINING A CONVERSATION, PARTICIPATING IN SMALL GROUPS, DATING, SPEAKING 
TO AUTHORITY FIGURES, ATTENDING PARTIES, PUBLIC SPEAKING, EATING IN FRONT OF 




In the past month, were you fearful or embarrassed being watched, being 
the focus of attention, or fearful of being humiliated? This includes things 
like speaking in public, eating in public or with others, writing while someone 










H. OBSESSIVE-COMPULSIVE DISORDER 
({ MEANS:  GO TO THE DIAGNOSTIC BOX, CIRCLE NO AND MOVE TO THE NEXT MODULE) 
 
 
H1 In the past month, have you been bothered by recurrent thoughts, impulses, or images 






(For example, the idea that you were dirty, contaminated or had germs, or fear of SKIP TO H4 
contaminating others, or fear of harming someone even though you didn't want to, or fearing 
you would act on some impulse, or fear or superstitions that you would be responsible for 
things going wrong, or obsessions with sexual thoughts, images or impulses, or hoarding, 
collecting, or religious obsessions.) 
 (DO NOT INCLUDE SIMPLY EXCESSIVE WORRIES ABOUT REAL LIFE PROBLEMS. DO NOT 
INCLUDE OBSESSIONS DIRECTLY RELATED TO EATING DISORDERS, SEXUAL DEVIATIONS, 
PATHOLOGICAL GAMBLING, OR ALCOHOL OR DRUG ABUSE BECAUSE THE PATIENT MAY 
DERIVE PLEASURE FROM THE ACTIVITY AND MAY WANT TO RESIST IT ONLY BECAUSE OF 
ITS NEGATIVE CONSEQUENCES.) 
 
 
H2 Did they keep coming back into your mind even when you tried to ignore or get 














 they are not imposed from the outside?  obsessions  










 resist doing it, like washing or cleaning excessively, counting or checking  compulsions  
 things over and over, or repeating, collecting, arranging things, or other superstitious 
rituals? 
   
  {   
 
H5 
IS H3 OR H4 CODED YES? 







 compulsive behaviors were excessive or unreasonable?    
 
 
H6 Did these obsessive thoughts and/or compulsive behaviors significantly 
interfere with your normal routine, your work or school, your usual social activities, 






I. POSTTRAUMATIC STRESS DISORDER (optional) 
 














  event that included actual or threatened death or serious injury to you or someone else?    
  
EXAMPLES OF TRAUMATIC EVENTS INCLUDE: SERIOUS ACCIDENTS, SEXUAL OR PHYSICAL 
ASSAULT, A TERRORIST ATTACK, BEING HELD HOSTAGE, KIDNAPPING, FIRE, DISCOVERING 
   























In the past month: 
   
 
a Have you avoided thinking about or talking about the event ? NO YES 
 
 
b Have you avoided activities, places or people that remind you of the event? NO YES 
 
 
c Have you had trouble recalling some important part of what happened? NO YES 
 
 
d Have you become much less interested in hobbies or social activities? NO YES 
 
 
e Have you felt detached or estranged from others? NO YES 
 
 
f Have you noticed that your feelings are numbed? NO YES 
 
 




  ARE 3 OR MORE I4 ANSWERS CODED YES? NO YES  
I5 
 
In the past month: 
   
 
a Have you had difficulty sleeping? NO YES 
 
 
b Were you especially irritable or did you have outbursts of anger? NO YES 
 
 
c Have you had difficulty concentrating? NO YES 
 
 
d Were you nervous or constantly on your guard? NO YES 
 
 












I6 During the past month, have these problems significantly interfered with 





J. ALCOHOL ABUSE AND DEPENDENCE 
 
 ({ MEANS:  GO TO DIAGNOSTIC BOXES, CIRCLE NO IN BOTH AND MOVE TO THE NEXT MODULE)  
   {  
J1  In the past 12 months, have you had 3 or more alcoholic drinks within a 3 





In the past 12 months: 
  
 
a Did you need to drink more in order to get the same effect that you got when 
you first started drinking? 
NO YES 
 
b When you cut down on drinking did your hands shake, did you sweat or feel agitated? Did you 
drink to avoid these symptoms or to avoid being hungover, for example, "the shakes", 
sweating or agitation? 
NO YES 
  IF YES TO EITHER, CODE YES.   
 
c During the times when you drank alcohol, did you end up drinking more than 
you planned when you started? 
NO YES 
 
d Have you tried to reduce or stop drinking alcohol but failed? NO YES 
 
e On the days that you drank, did you spend substantial time in obtaining 
alcohol, drinking, or in recovering from the effects of alcohol? 
NO YES 
 
f Did you spend less time working, enjoying hobbies, or being with others 
because of your drinking? 
NO YES 
 
g Have you continued to drink even though you knew that the drinking caused you 
health or mental problems? 
NO YES 
 
ARE 3 OR MORE J2 ANSWERS CODED YES? 
 
* IF YES, SKIP J3 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX 
AND MOVE TO THE NEXT DISORDER. DEPENDENCE PREEMPTS ABUSE. 
 
J3 In the past 12 months: 
 
a Have you been intoxicated, high, or hungover more than once when you had other NO YES 
responsibilities at school, at work, or at home? Did this cause any problems? 
(CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
b Were you intoxicated more than once in any situation where you were physically at risk, NO YES 
for example, driving a car, riding a motorbike, using machinery, boating, etc.? 
 
c Did you have legal problems more than once because of your drinking, for example, NO YES 
an arrest or disorderly conduct? 
 
d Did you continue to drink even though your drinking caused problems with your NO YES 
family or other people? 
 
 






YES N/A NO 
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K. NON-ALCOHOL PSYCHOACTIVE SUBSTANCE USE DISORDERS 
({ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
 
CIRCLE EACH DRUG TAKEN: 
Stimulants: amphetamines, "speed", crystal meth, “crank”, "rush", Dexedrine, Ritalin, diet pills. 
Cocaine: snorting, IV, freebase, crack, "speedball". 
Narcotics: heroin, morphine, Dilaudid, opium, Demerol, methadone, codeine, Percodan, Darvon, OxyContin. Hallucinogens: 
LSD ("acid"), mescaline, peyote, PCP ("angel dust", "peace pill"), psilocybin, STP, "mushrooms", “ecstasy”, MDA, MDMA, or 
ketamine (“special K”). 
Inhalants: "glue", ethyl chloride, “rush”, nitrous oxide ("laughing gas"), amyl or butyl nitrate ("poppers"). 
Marijuana: hashish ("hash"), THC, "pot", "grass", "weed", "reefer". 
Tranquilizers: Quaalude, Seconal ("reds"), Valium, Xanax, Librium, Ativan, Dalmane, Halcion, barbiturates, Miltown, 
GHB, Roofinol, “Roofies”. 
Miscellaneous: steroids, nonprescription sleep or diet pills. Any others? 
SPECIFY MOST USED DRUG(S):     
 
CHECK ONE BOX 
ONLY ONE DRUG / DRUG CLASS HAS BEEN USED 
 
ONLY THE MOST USED DRUG CLASS IS INVESTIGATED. 
 
EACH DRUG CLASS USED IS EXAMINED SEPARATELY (PHOTOCOPY K2 AND K3 AS NEEDED) 
 
 b SPECIFY WHICH DRUG/DRUG CLASS WILL BE EXPLORED IN THE INTERVIEW BELOW IF THERE IS 
CONCURRENT OR SEQUENTIAL POLYSUBSTANCE USE:   
K2 
 
Considering your use of (NAME THE DRUG / DRUG CLASS SELECTED), in the past 12 months: 
 
a Have you found that you needed to use more (NAME OF DRUG / DRUG CLASS SELECTED) NO YES 
to get the same effect that you did when you first started taking it? 
 
b When you reduced or stopped using (NAME OF DRUG / DRUG CLASS SELECTED), did you have NO YES 
withdrawal symptoms (aches, shaking, fever, weakness, diarrhea, nausea, sweating, 
heart pounding, difficulty sleeping, or feeling agitated, anxious, irritable, or depressed)? 
Did you use any drug(s) to keep yourself from getting sick (withdrawal symptoms) or so 
that you would feel better? 
  
IF YES TO EITHER, CODE YES. 
 
c Have you often found that when you used (NAME OF DRUG / DRUG CLASS SELECTED), NO YES 
you ended up taking more than you thought you would? 
 
d Have you tried to reduce or stop taking (NAME OF DRUG / DRUG CLASS SELECTED) but failed? NO YES 
 
e On the days that you used (NAME OF DRUG / DRUG CLASS SELECTED), did you spend substantial NO YES 




Now I am going to show you / read to you a list of street drugs or medicines. 
 
K1  a   In the past 12 months, did you take any of these drugs more than once, 
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f Did you spend less time working, enjoying hobbies, or being with family 
or friends because of your drug use? 
NO YES 
g Have you continued to use (NAME OF DRUG / DRUG CLASS SELECTED), even though it caused 




ARE 3 OR MORE K2 ANSWERS CODED YES? 
 
SPECIFY DRUG(S):    
 
* IF YES, SKIP K3 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX FOR THIS SUBSTANCE 
AND MOVE TO THE NEXT DISORDER. 






Considering your use of (NAME THE DRUG CLASS SELECTED), in the past 12 months: 
 





 more than once, when you had other responsibilities at school, at work, or at home? 
Did this cause any problem? 
  
 
(CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
  
b Have you been high or intoxicated from (NAME OF DRUG / DRUG CLASS SELECTED) more 
than once in any situation where you were physically at risk (for example, driving 
a car, riding a motorbike, using machinery, boating, etc.)? 
NO YES 
c Did you have legal problems more than once because of your drug use, for example, an 
arrest or disorderly conduct? 
NO YES 
d Did you continue to use (NAME OF DRUG / DRUG CLASS SELECTED), even though it caused 




ARE 1 OR MORE K3 ANSWERS CODED YES? 
 
SPECIFY DRUG(S):    
SUBSTANCE DEPENDENCE 
CURRENT 
YES * NO 
SUBSTANCE ABUSE 
CURRENT 
YES N/A NO 
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L. PSYCHOTIC DISORDERS AND MOOD DISORDER WITH PSYCHOTIC 
FEATURES 
ASK FOR AN EXAMPLE OF EACH QUESTION ANSWERED POSITIVELY. CODE YES ONLY IF THE EXAMPLES CLEARLY SHOW A DISTORTION OF THOUGHT OR OF 
PERCEPTION OR IF THEY ARE NOT CULTURALLY APPROPRIATE. BEFORE CODING, INVESTIGATE WHETHER DELUSIONS QUALIFY AS "BIZARRE". 
 
DELUSIONS ARE "BIZARRE" IF: CLEARLY IMPLAUSIBLE, ABSURD, NOT UNDERSTANDABLE, AND CANNOT DERIVE FROM ORDINARY LIFE EXPERIENCE. 
 
HALLUCINATIONS ARE SCORED "BIZARRE" IF: A VOICE COMMENTS ON THE PERSON'S THOUGHTS OR BEHAVIOR, OR WHEN TWO OR MORE VOICES ARE 






Now I am going to ask you about unusual experiences that some people have. 
 
Have you ever believed that people were spying on you, or that someone was 








  NOTE: ASK FOR EXAMPLES TO RULE OUT ACTUAL STALKING.    
 
b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES 
     {L6 
L2 a Have you ever believed that someone was reading your mind or could hear 
your thoughts, or that you could actually read someone’s mind or hear what 
another person was thinking? 
NO YES YES 
 
b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES 
     {L6 
L3 a Have you ever believed that someone or some force outside of yourself put 
thoughts in your mind that were not your own, or made you act in a way 
that was not your usual self? Have you ever felt that you were possessed? 
CLINICIAN: ASK FOR EXAMPLES AND DISCOUNT ANY THAT ARE NOT PSYCHOTIC. 
NO YES YES 
 
b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES 
     {L6 
L4 a Have you ever believed that you were being sent special messages through 
the TV, radio, or newspaper, or that a person you did not personally know 
was particularly interested in you? 
NO YES YES 
 
b IF YES OR YES BIZARRE: do you currently believe these things? NO YES YES 
     {L6 
L5 a Have your relatives or friends ever considered any of your beliefs strange 
or unusual? 
NO YES YES 
  INTERVIEWER: ASK FOR EXAMPLES. ONLY CODE YES IF THE EXAMPLES ARE CLEARLY 
DELUSIONAL IDEAS NOT EXPLORED IN QUESTIONS L1 TO L4, FOR EXAMPLE, SOMATIC OR RELIGIOUS 
DELUSIONS OR DELUSIONS OF GRANDIOSITY, JEALOUSY, GUILT, RUIN OR DESTITIUTION, ETC. 
   
 
b IF YES OR YES BIZARRE: do they currently consider your beliefs strange? NO YES YES 
L6 a Have you ever heard things other people couldn't hear, such as voices? NO YES 
 
  HALLUCINATIONS ARE SCORED "BIZARRE" ONLY IF PATIENT ANSWERS YES TO THE FOLLOWING:    
  
IF YES: Did you hear a voice commenting on your thoughts or behavior or 





b IF YES OR YES BIZARRE TO L6a: have you heard these things in the past month? NO YES YES 
  HALLUCINATIONS ARE SCORED "BIZARRE" ONLY IF PATIENT ANSWERS YES TO THE FOLLOWING:   {L8b 
  Did you hear a voice commenting on your thoughts or behavior or 
did you hear two or more voices talking to each other? 
   
436 
 
L7 a Have you ever had visions when you were awake or have you ever seen things 
other people couldn't see? 
NO YES 
  CLINICIAN: CHECK TO SEE IF THESE ARE CULTURALLY INAPPROPRIATE.   
 




L8 b IS THE PATIENT CURRENTLY EXHIBITING INCOHERENCE, DISORGANIZED SPEECH, 
OR MARKED LOOSENING OF ASSOCIATIONS? 
NO YES 
L9 b IS THE PATIENT CURRENTLY EXHIBITING DISORGANIZED OR CATATONIC 
BEHAVIOR? 
NO YES 
L10 b ARE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA, E.G. SIGNIFICANT AFFECTIVE 
FLATTENING, POVERTY OF SPEECH (ALOGIA) OR AN INABILITY TO INITIATE OR 
PERSIST IN GOAL-DIRECTED ACTIVITIES (AVOLITION), PROMINENT DURING THE 
INTERVIEW? 
NO YES 
L11 a ARE 1 OR MORE « a » QUESTIONS FROM L1a TO L7a CODED YES OR YES BIZARRE 
AND IS EITHER: 
  
  
MAJOR DEPRESSIVE EPISODE, (CURRENT OR RECURRENT) 
  
  OR   
  MANIC OR HYPOMANIC EPISODE, (CURRENT OR PAST) CODED YES? NO YES 
  
IF NO TO L11 a, CIRCLE NO IN BOTH ‘MOOD DISORDER WITH PSYCHOTIC 
{L13  
  FEATURES’ DIAGNOSTIC BOXES AND MOVE TO L13.   
 
 
b  You told me earlier that you had period(s) when you felt (depressed/high/persistently 
irritable). 
 
Were the beliefs and experiences you just described (SYMPTOMS CODED YES FROM L1a TO L7a) 
restricted exclusively to times when you were feeling depressed/high/irritable? 
 
IF THE PATIENT EVER HAD A PERIOD OF AT LEAST 2 WEEKS OF HAVING THESE BELIEFS 
OR EXPERIENCES (PSYCHOTIC SYMPTOMS) WHEN THEY WERE NOT 
DEPRESSED/HIGH/IRRITABLE, CODE NO TO THIS DISORDER. 
 





L12 a ARE 1 OR MORE « b » QUESTIONS FROM L1b TO L7b CODED YES OR YES BIZARRE 
AND IS EITHER: 
 
MAJOR DEPRESSIVE EPISODE, (CURRENT) 
OR 
MANIC OR HYPOMANIC EPISODE, (CURRENT) CODED YES? 
 
 
IF THE ANSWER IS YES TO THIS DISORDER (LIFETIME OR CURRENT), CIRCLE 
NO TO L13 AND L14 AND MOVE TO THE NEXT MODULE. 















ARE 2 OR MORE « b » QUESTIONS FROM L1b TO L10b, CODED YES (RATHER THAN YES 
BIZARRE)? 
 













ARE 2 OR MORE « a » QUESTIONS FROM L1a TO L7a, CODED YES (RATHER THAN 
YES BIZARRE) 
 










M. ANOREXIA NERVOSA 
 
({ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
In the past 3 months: 
{ 
M2 In spite of this low weight, have you tried not to gain weight? NO YES 
{ 
M3 Have you intensely feared gaining weight or becoming fat, even though you were underweight? NO YES 
M4   a    Have you considered yourself too big / fat or that part of your body was too big / fat?  NO YES 
b    Has your body weight or shape greatly influenced how you felt about yourself? NO  YES 
c Have you thought that your current low body weight was normal or excessive? NO YES 
{ 
M5 ARE 1 OR MORE ITEMS FROM M4 CODED YES? NO YES 
{ 
M6 FOR WOMEN ONLY:  During the last 3 months, did you miss all your menstrual NO YES 




FOR WOMEN: ARE M5 AND M6 CODED YES? 
 





HEIGHT / WEIGHT TABLE CORRESPONDING TO A BMI THRESHOLD OF 17.5 KG/M2 
 
 
ft/in 4'9 4'10 4'11 5'0 5'1 5'2 5'3 5'4 5'5 5'6 5'7 5'8 5'9 5'10 
lbs. 81 84 87 89 92 96 99 102 105 108 112 115 118 122 
cm 145 147 150 152 155 158 160 163 165 168 170 173 175 178 
kgs 37 38 39 41 42 43 45 46 48 49 51 52 54 55 
 
 
ft/in 5'11 6'0 6'1 6'2 6'3 
lbs. 125 129 132 136 140 
cm 180 183 185 188 191 
kgs 57 59 60 62 64 
The weight thresholds above are calculated using a body mass index (BMI) equal to or below 17.5 kg/m2 for the patient's height. This is 
the threshold guideline below which a person is deemed underweight by the DSM-IV and the ICD-10 Diagnostic Criteria for Research 
for Anorexia Nervosa. 
 
YES NO c IS PATIENT’S WEIGHT EQUAL TO OR BELOW THE THRESHOLD CORRESPONDING TO HIS / HER 
HEIGHT? (SEE TABLE BELOW) 
ft in. 
  cm. 
  lbs. 
  kgs. 










N. BULIMIA NERVOSA 
({ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
N1 In the past three months, did you have eating binges or times when you ate 
{ 
NO YES 
 a very large amount of food within a 2-hour period?  
{ 
 
N2 In the last 3 months, did you have eating binges as often as twice a week? NO YES 
N3 During these binges, did you feel that your eating was out of control? 
{ 
NO YES 
N4 Did you do anything to compensate for, or to prevent a weight gain from these 
{ 
NO YES 
 binges, like vomiting, fasting, exercising or taking laxatives, enemas, diuretics (fluid 





N5 Does your body weight or shape greatly influence how you feel about yourself? NO YES 
N6 DO THE PATIENT’S SYMPTOMS MEET CRITERIA FOR ANOREXIA NERVOSA? NO 

YES 
Skip to N8 
 
N7 Do these binges occur only when you are under (  lbs./kgs.)? NO YES 
INTERVIEWER: WRITE IN THE ABOVE PARENTHESIS THE THRESHOLD WEIGHT FOR THIS PATIENT’S HEIGHT FROM 
THE HEIGHT / WEIGHT TABLE IN THE ANOREXIA NERVOSA MODULE. 
 
 

















O. GENERALIZED ANXIETY DISORDER 








   over the past 6 months?   
{ 
 
 b  Are these worries present most days? 






   TO, OR BETTER EXPLAINED BY, ANY DISORDER PRIOR TO THIS POINT?    
O2 
  




   your ability to focus on what you are doing?     
O3 
  
FOR THE FOLLOWING, CODE NO IF THE SYMPTOMS ARE CONFINED TO 
    
   FEATURES OF ANY DISORDER EXPLORED PRIOR TO THIS POINT.     
   
When you were anxious over the past 6 months, did you, most of the time: 
    
  

























f Have difficulty sleeping (difficulty falling asleep, waking up in the middle of 




    













P. ANTISOCIAL PERSONALITY DISORDER (optional) 
 
({ MEANS :  GO TO THE DIAGNOSTIC BOX AND CIRCLE NO.) 
 
P1 Before you were 15 years old, did you: 
 
a repeatedly skip school or run away from home overnight? NO YES 
 
b repeatedly lie, cheat, "con" others, or steal? NO YES 
 
c start fights or bully, threaten, or intimidate others? NO YES 
 
d deliberately destroy things or start fires? NO YES 
 
e deliberately hurt animals or people? NO YES 
 
f force someone to have sex with you? NO YES 
{ 
ARE 2 OR MORE P1 ANSWERS CODED YES? NO YES 
 
DO NOT CODE YES TO THE BEHAVIORS BELOW IF THEY ARE EXCLUSIVELY 
POLITICALLY OR RELIGIOUSLY MOTIVATED. 
 
P2 Since you were 15 years old, have you: 
 
a repeatedly behaved in a way that others would consider irresponsible, like NO YES 
failing to pay for things you owed, deliberately being impulsive or deliberately 
not working to support yourself? 
 
b done things that are illegal even if you didn't get caught (for example, destroying NO YES 
property, shoplifting, stealing, selling drugs, or committing a felony)? 
 
c been in physical fights repeatedly (including physical fights with your NO YES 
spouse or children)? 
 
d often lied or "conned" other people to get money or pleasure, or lied just NO YES 
for fun? 
 
e exposed others to danger without caring? NO YES 
 
f felt no guilt after hurting, mistreating, lying to, or stealing from others, or NO YES 
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Depression Rating Scales used in the Current Study- Hospital Anxiety and 










Hospital Anxiety and Depression Scale (HADS) 
 
Patients are asked to choose one response from the four given for each 
interview. They should give an immediate response and be dissuaded 
from thinking too long about their answers. The questions relating to 
anxiety are marked "A", and to depression "D". The score for each answer 
is given in the right column. Instruct the patient to answer how it currently 





A I feel tense or 'wound up':  
 Most of the time 3 
 A lot of the time 2 
 From time to time, 
occasionally 
1 






I still enjoy the things I used 
to enjoy: 
 
 Definitely as much 0 
 Not quite so much 1 
 Only a little 2 







I get a sort of frightened 
feeling as if something awful 
is about to happen: 
 
 Very definitely and quite 
badly 
3 
 Yes, but not too badly 2 
 A little, but it doesn't worry 
me 
1 







I can laugh and see the funny 
side of things: 
 
 As much as I always could 0 
 Not quite so much now 1 
 Definitely not so much now 2 






Worrying thoughts go 
through my mind: 
 
 A great deal of the time 3 
 A lot of the time 2 
 From time to time, but not 
too often 
1 





D I feel cheerful:  
 Not at all 3 
 Not often 2 
 Sometimes 1 






I can sit at ease and feel 
relaxed: 
 
 Definitely 0 
 Usually 1 
 Not Often 2 





D I feel as if I am slowed down:  
 Nearly all the time 3 
 Very often 2 
 Sometimes 1 







I get a sort of frightened 
feeling like 'butterflies' in 
the stomach: 
 
 Not at all 0 
 Occasionally 1 
 Quite Often 2 






I have lost interest in my 
appearance: 
 
 Definitely 3 
 I don't take as much care as I 
should 
2 
 I may not take quite as much 
care 
1 






I feel restless as I have to be 
on the move: 
 
 Very much indeed 3 
 Quite a lot 2 
 Not very much 1 






I look forward with 
enjoyment to things: 
 
 As much as I ever did 0 
 Rather less than I used to 1 
 Definitely less than I used to 2 






I get sudden feelings of 
panic: 
 
 Very often indeed 3 
 Quite often 2 
 Not very often 1 






I can enjoy a good book or 
radio or TV program: 
 
 Often 0 
 Sometimes 1 
 Not often 2 
 Very seldom 3 
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 Scoring (add the As = Anxiety. 
Add the Ds = Depression). The 
norms below will give you an 
idea of the level of Anxiety 
and Depression. 
 
 0-7 = Normal  
 8-10 = Borderline abnormal  
 11-21 = Abnormal  









QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (QIDS) 
Clinician Instructions: In making each rating, consider the frequency, duration, and intensity/severity of 
the symptom. The degree of functional impairment caused by the symptom may be important in the 
ratings of some items, but not all. If patient denies ever experiencing euthymic mood, ask them to 
compare the last week to a time that they felt their best or to compare to what they would consider to 
be a satisfactory level of functioning. 
 
INTRODUCTION: 
“I would like to ask you some questions about the past week, the last 7 days.” 
1) How have you been sleeping in the past week? Have you had trouble falling asleep when you 
go to bed? Right after you go to bed, how long does it take you to fall asleep? How many days 
in the past week have you had trouble falling asleep? 
2) During the past week, have you been waking in the middle of the night? 
IF YES: How often have you been waking up? How long do you stay awake? Do you get out of 
bed? What do you do? Are you able to fall right back to sleep? Have you felt your sleep has been 
restless or disturbed some nights? 
3) What time have you been waking up in the past week? With or without an alarm? Have you 
been waking earlier than you want to or need to? How much earlier than is normal for you? 
How many days? Are you able to go back to sleep? 
4) How many hours on average have you been sleeping in a 24-hour period in the past week?  Does 
that include naps?  Is that a normal amount for you?  What is the longest you've slept in a 24-hour 
period in the last week? 
5) How would you describe your mood in the past week? Have you been feeling down or depressed? 
Sad? In the past week, how much of the time have you felt  ? Every day? All day? 
6) How has your appetite been in the last week compared to your usual appetite? Have you had to 
force yourself to eat? Have others urged or reminded you to eat? In the past week, how often 
have you eaten? Every day? When you do eat, have you noticed that you eat less than usual? 
7) Have you found yourself eating more than usual? Every day? Have you noticed you eat more at 
meals? Have you noticed you are snacking or eating more in between meals? Have you felt 





8/9) Have you noticed any change in your weight? Are your clothes fitting differently than usual? How 
much has your weight changed in the past 2 weeks? 
10) Have you noticed any problems with your concentration in the past week? Have you been 
able to focus on what you have been doing (like reading or watching TV)? In the past week, 
have you noticed having problems making decisions? Were minor decisions more difficult 
than usual to make (what to wear, eat, or watch on TV)? In the past week, how often have 
you had problems with  ? 
11) In the past week, have you been feeling especially critical of yourself? Have you been feeling like 
you have done things wrong, let others down, or caused problems for others? IF YES: What have 
your thoughts been? In the past week, have you felt worthless? IF YES: How often have you felt 
worthless? Everyday? All day? 
12) In the past week, have you felt that life was not worth living, or that you’d be better off dead? 
What about thoughts of hurting or killing yourself? IF YES: How often do you think about  ? 
When you think about   , how long do you think about it? What 
have you thought about? Do you have a plan? Have you done anything to hurt yourself? What 
stops you? (THOROUGHLY ASSESS SUICIDE POTENTIAL.) 
13) How have you been spending your time this past week? How would you describe your level of 
interest and motivation to complete daily activities? Have you felt interested in doing those 
things or do you feel you have to push yourself to do them? Have you stopped doing anything 
you used to do? IF YES: Is there anything you look forward to doing? Have you been able to 
maintain your personal hygiene? 
14) How has your energy level been this past week? Have you been tired all the time? IF NO: Have you 
noticed you tire more easily than usual? This week have you had backaches, headaches, aches, or 
heaviness in your head or limbs? Has your lack of energy interfered with your ability to carry out 
most of your usual daily activities? 
15) Have you felt slowed down in your thinking, speaking, or movement in the past week?  Have 
others commented on this?  How many days in the past week have you felt  ?  When you feel  , 
how long does it last? 
16) Have you noticed feeling fidgety or speeded up during the past week? Have you found yourself 
unable to stay seated or needing to move around more than is typical for you?  How often do you 







































CVC Test: Recall Recording Sheet 
Date of 
Assessment 
 Participant Study 
Number 
 
    





Record CVCs in the order recalled. Include errors (CVCs not on list) and 
repetitions. 
 
Record all words that are said, even if they are incorrect. The score for each trial is the 
number of CVCs correctly recalled.  Mark CVCs that are repeated with ‘R’, and errors 
(CVCs not on the list) with ‘E’. 













1.        
2.        
3.        
4.        
5.        
6.        
7.        
8.        
9.        
10.       
11.       
12.       
13.       
14.       
15.       
16.       
17.       
18.       
19.       
20.       
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CVC Verbal Learning Test: 





 Participant Study 
Number 
 


















vev       
fol       
wat       
tib       
pum       
vob       
wis       
lec       
mub       
yaf       
zet       
nop       
jav       
guz       
kib       
Total       
 
Transfer each correct C-V-C from sheet 1. Record the C-V-C as a number 
depending on when it was recalled by the participant. Do not transfer 











 Participant Study 
Number 
 





Record CVCs in the order recalled. Include errors (CVCs not on list) and 
repetitions. 
 
Record all words that are said, even if they are incorrect. The score for each trial is the 
number of CVCs correctly recalled.  Mark CVCs that are repeated with ‘R’, and errors 














Delayed Recall  
List B 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      




CVC Verbal Learning Test: 





 Participant Study 
Number 
 


















jiz       
lut       
dav       
ked       
hif       
zab       
yoz       
sen       
zup       
gol       
vip       
jum       
nem       
caz       
       
Total       
 
Transfer each correct C-V-C from sheet 1. Record the C-V-C as a number 
depending on when it was recalled by the participant. Do not transfer 































VISUAL ANALOGUE SCALE 
 









1. Please rate the way you feel in terms of the dimension given below 
2. Regard the line as representing the full range of the dimension 
3. Rate your feelings as they are at the moment 
4. Mark clearly and perpendicularly across each line 
 
Example:    
 







































Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the 
circles are numbered 1 – 25, and the patient should draw lines to connect the numbers in ascending 
order. In Part B, the circles include both numbers (1 – 13) and letters (A – L); as in Part A, the patient 
draws lines to connect the circles in an ascending pattern, but with the added task of alternating 
between the numbers and letters (i.e., 1-A-2-B-3-C, etc.). The patient should be instructed to connect 
the circles as quickly as possible, without lifting the pen or pencil from the paper. Time the patient as he 
or she connects the "trail." If the patient makes an error, point it out immediately and allow the patient 
to correct it. Errors affect the patient's score only in that the correction of errors is included in the 
completion time for the task. It is unnecessary to continue the test if the patient has not completed 
both parts after five minutes have elapsed. 
 
Step 1: Give the patient a copy of the Trail Making Test Part A worksheet and a pen or pencil. 
Step 2: Demonstrate the test to the patient using the sample sheet (Trail Making Part A – 
SAMPLE). 
Step 3: Time the patient as he or she follows the “trail” made by the numbers on the test. Step 4:
 Record the time. 
Step 5: Repeat the procedure for Trail Making Test Part B. 
Scoring: 
Results for both TMT A and B are reported as the number of seconds required to complete the task; 
therefore, higher scores reveal greater impairment. 
 Average Deficient Rule of Thumb 





75 seconds > 273 seconds Most in 3 minutes 
 Corrigan JD, Hinkeldey MS. Relationships between parts A and B of the Trail Making Test. J Clin 
Psychol. 1987;43(4):402–409. 
 Gaudino EA, Geisler MW, Squires NK. Construct validity in the Trail Making Test: what makes 
Trail Making Test (TMT) Parts A & B 
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Part B harder? J Clin Exp Neuropsychol. 1995;17(4):529-535. 
 Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York: Oxford 
University Press; 2004. 






Patient’s Name:   Date:    
 













Patient’s Name:   Date:    


































Digit Span - Digits and Scoring Sheet - Baseline 
ID:              Date of test: ………………………………………   
 
DIGIT SPAN          Discontinue after failure on BOTH TRIALS of any item. 
   Administer BOTH TRIALS of each item, even if subject passes first trial 
 












1.  5 – 8 – 2   1.  2 - 4   
6 – 9 - 4   5 - 8   
2.  6 – 4 – 3 – 9   2
. 
6 – 2 - 9   
7 – 2 – 8 - 6   4 – 1 - 5   
3.  4 – 2 – 7 – 3 – 1   3
. 
3 – 2 - 7 - 9   
7 – 5 – 8 – 3 - 6   4 – 9 – 6 - 8   
4.  6 – 1 – 9 – 4 – 7 - 3   4
. 
1 – 5 – 2 – 8 - 6   
3 – 9 – 2 – 4 – 8 - 7   6 – 1 – 8 – 4 - 3   
5.  5 – 9 – 1 – 7 – 4 – 2 - 8   5
. 
5 – 3 – 9 – 4 – 1 - 8   
4 – 1 – 7 – 9 – 3 – 8 - 6   7 – 2 – 4 – 8 – 5 - 6   
6.  5 – 8 – 1 – 9 – 2 – 6 – 4 - 7   6
. 
8 – 1 – 2 – 9 – 3 – 6 - 5   
3 – 8 – 2 – 9 – 5 – 1 – 7 - 4   4 – 7 – 3 – 9 – 1 – 2 - 8   
7.  2 – 7 – 5 – 8 – 6 – 2 – 5 – 8 - 4   7
. 
9 – 4 – 3 – 7 – 6 – 2 – 5 - 8   
7 – 1 – 3 – 9 – 4 – 2 – 5 – 6 - 8   7 – 2 – 8 – 1 – 9 – 6 – 5 - 3   
 
Total forward: Max = 14         Total backward: Max = 14    Grand total: Max =28  
Forward span:Max = 9        Backward span: Max = 8    
 
*Administer DIGITS BACKWARD even if subject scores 0 on DIGITS FORWARDS 
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Digit Span - Digits and Scoring Sheet – 2nd testing session 
ID:              Date of test: ………………………………………   
 
DIGIT SPAN          Discontinue after failure on BOTH TRIALS of any item. 
















8.  4 – 7 – 1   2.  1 - 3   
5 – 8 - 3   4 - 7   
9.  5 – 3 – 2 – 8   2
. 
5 – 1 - 8   
6 – 1 – 7 - 5   3 – 9 - 4   
10.  3 – 1 – 6 – 2 – 9   3
. 
2 – 1 - 6 – 8   
6 – 4 – 7 – 2 - 5   3 – 8 – 5 – 7   
11.  5 – 9 – 8 – 3 – 6 – 2   4
. 
9 – 4 – 1 – 7 – 5   
2 – 8 – 1 – 3 – 7 – 6   5 – 9 – 7 – 3 – 2   
12.  4 – 1 – 9 – 6 – 3 – 1 – 7   5
. 
4 – 2 – 8 – 3 – 9 – 7   
3 – 9 – 6 – 1 – 2 – 7 – 5   6 – 1 – 3 – 7 – 4 – 5   
13.  4 – 7 – 1 – 9 – 3 – 5 – 2 – 6   6
. 
7 – 9 – 1 – 8 – 2 – 5 – 4   
2 – 7 – 1 – 8 – 4 – 9 – 6 – 3   3 – 6 – 2 – 8 – 9 – 1 – 7   
14.  1 – 6 – 4 – 7 – 5 – 1 – 4 – 7 – 3   7
. 
8 – 3 – 2 – 6 – 5 – 1 – 4 – 7   
6 – 9 – 2 – 8 – 3 – 1 – 4 – 5 - 7   6 – 1 – 7 – 9 – 8 – 5 – 4 - 2   
 
Total forward: Max = 14        Total backward: Max = 14    Grand total: Max =28  
Forward span:Max = 9        Backward span: Max = 8    
 































ID No:                                        Session:………………    Date:……………….  
COWAT word recording sheet (Baseline) 
Allow 90 seconds for each letter. If the participant discontinues before the end of the minute, encourage them 
to try and think of more words. If there is a silence of 15 seconds, repeat the basic instructions and the letter. 
Write down the words in the order in which they are produced. The score is the sum of all admissible words 
(exclude proper nouns, wrong words, variations, and repetitions). See normative data sheet for age and gender 
norms. 
 Letter C Letter F Letter L 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
Total:    




ID No:                                        Session:………………    Date:……………….  
COWAT word recording sheet (Follow-up) 
Allow 90 seconds for each letter. If the participant discontinues before the end of 90 seconds, 
encourage them to try and think of more words. If there is a silence of 15 seconds, repeat the basic 
instructions and the letter. Write down the words in the order in which they are produced. The score 
is the sum of all admissible words (exclude proper nouns, wrong words, variations, and repetitions).  
 Letter P Letter R Letter W 
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
Total:    














































































































arrogant                                                            annoyed 



























desire                                                               convinced 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Enclosed you will find 
 
the adult version of the above test 
the word definition handout, 
the correct answers. 
A copy of the paper describing the test in full 
 
As you know, publication details of the original version appeared in the Journal of Child 
Psychology and Psychiatry, 38, 813-822 (1997). The revised version which we have sent 
you was published in the Journal of Child Psychiatry and Psychiatry, 42, 241-252 
(2001). 
 
A child version of this test has also been developed and is available upon request. It was 
published in the Journal of Developmental and Learning Disorders, 5, 47-78 (2001). 
 



















For each set of eyes, choose and circle which word best describes what the person in the 
picture is thinking or feeling.   You may feel that more than one word is applicable but 
please choose just one word, the word which you consider to be most suitable.   Before 
making your choice, make sure that you have read all 4 words.  You should try to do the 
task as quickly as possible but you will not be timed.   If you really don’t know what a word 











ACCUSING                 blaming 
The policeman was accusing the man of stealing a wallet. 
 
AFFECTIONATE        showing fondness towards someone 
Most mothers are affectionate to their babies by giving them 
lots of kisses and cuddles. 
 
AGHAST                     horrified, astonished, alarmed 
Jane was aghast when she discovered her house had been 
burgled. 
 
ALARMED                  fearful, worried, filled with anxiety 
Claire was alarmed when she thought she was being followed 
home. 
 
AMUSED                    finding something funny 
I was amused by a funny joke someone told me. 
 
ANNOYED                  irritated, displeased 
Jack was annoyed when he found out he had missed the last 
bus home. 
 
ANTICIPATING         expecting 
At the start of the football match, the fans were anticipating a 
quick goal. 
 
ANXIOUS                   worried, tense, uneasy 
The student was feeling anxious before taking her final 
exams. 
 
APOLOGETIC            feeling sorry 
The waiter was very apologetic when he spilt soup all over the 
customer. 
 
ARROGANT               conceited, self-important, having a big opinion of oneself 
The arrogant man thought he knew more about politics than 
everyone else in the room. 
 
ASHAMED                  overcome with shame or guilt 
The boy felt ashamed when his mother discovered him 









ASSERTIVE                confident, dominant, sure of oneself 
The assertive woman demanded that the shop give her a 
refund. 
 
BAFFLED                    confused, puzzled, dumbfounded 
The detectives were completely baffled by the murder case. 
 
BEWILDERED           utterly confused, puzzled, dazed 
The child was bewildered when visiting the big city for the 
first time. 
 
CAUTIOUS                 careful, wary 
Sarah was always a bit cautious when talking to someone she 
did not know. 
 
COMFORTING           consoling, compassionate 
The nurse was comforting the wounded soldier. 
 
CONCERNED             worried, troubled 
The doctor was concerned when his patient took a turn for the 
worse. 
 
CONFIDENT               self-assured, believing in oneself 
The tennis player was feeling very confident about winning 
his match. 
 
CONFUSED                puzzled, perplexed 
Lizzie was so confused by the directions given to her, she got 
lost. 
 
CONTEMPLATIVE    reflective, thoughtful, considering 
John was in a contemplative mood on the eve of his 60th 
birthday. 
 
CONTENTED             satisfied 
After a nice walk and a good meal, David felt very contented. 
 
CONVINCED              certain, absolutely positive 
Richard was convinced he had come to the right decision. 
 
CURIOUS                    inquisitive, inquiring, prying 
Louise was curious about the strange shaped parcel. 
 
DECIDING                  making your mind up 









DECISIVE                   already made your mind up 
Jane looked very decisive as she walked into the polling 
station. 
 
DEFIANT                    insolent, bold, don’t care what anyone else thinks 
The animal protester remained defiant even after being sent to 
prison. 
 
DEPRESSED               miserable 
George was depressed when he didn't receive any birthday 
cards. 
 
DESIRE                       passion, lust, longing for 
Kate had a strong desire for chocolate. 
 
DESPONDENT           gloomy, despairing, without hope 
Gary was despondent when he did not get the job he wanted. 
 
DISAPPOINTED         displeased, disgruntled 
Manchester United fans were disappointed not to win the 
Championship. 
 
DISPIRITED                glum, miserable, low 
Adam was dispirited when he failed his exams. 
 
DISTRUSTFUL           suspicious, doubtful, wary 
The old woman was distrustful of the stranger at her door. 
 
DOMINANT                commanding, bossy 
The sergeant major looked dominant as he inspected the new 
recruits. 
 
DOUBTFUL                dubious, suspicious, not really believing 
Mary was doubtful that her son was telling the truth. 
 
DUBIOUS                   doubtful, suspicious 
Peter was dubious when offered a surprisingly cheap 
television in a pub. 
 
EAGER                        keen 
On Christmas morning, the children were eager to open their 
presents. 
 
EARNEST                   having a serious intention 









EMBARRASSED        ashamed 
After forgetting a colleague's name, Jenny felt very 
embarrassed. 
 
ENCOURAGING        hopeful, heartening, supporting 
All the parents were encouraging their children in the school 
sports day. 
 
ENTERTAINED          absorbed and amused or pleased by something 
I was very entertained by the magician. 
 
ENTHUSIASTIC         very eager, keen 
Susan felt very enthusiastic about her new fitness plan. 
 
FANTASIZING           daydreaming 
Emma was fantasizing about being a film star. 
 
FASCINATED            captivated, really interested 
At the seaside, the children were fascinated by the creatures 
in the rock pools. 
 
FEARFUL                    terrified, worried 
In the dark streets, the women felt fearful. 
 
FLIRTATIOUS            brazen, saucy, teasing, playful 
Connie was accused of being flirtatious when she winked at a 
stranger at a party. 
FLUSTERED               confused, nervous and upset 
Sarah felt a bit flustered when she realised how late she was 
for the meeting and that she had forgotten an important 
document. 
 
FRIENDLY                  sociable, amiable 
The friendly girl showed the tourists the way to the town 
centre. 
 
GRATEFUL                thankful 
Kelly was very grateful for the kindness shown by the 
stranger. 
 
GUILTY                      feeling sorry for doing something wrong 
Charlie felt guilty about having an affair. 
 
HATEFUL                   showing intense dislike 





HOPEFUL                   optimistic 
Larry was hopeful that the post would bring good news. 
 
HORRIFIED                terrified, appalled 
The man was horrified to discover that his new wife was 
already married. 
 
HOSTILE                     unfriendly 
The two neighbours were hostile towards each other because 
of an argument about loud music. 
 
IMPATIENT                restless, wanting something to happen soon 
Jane grew increasingly impatient as she waited for her friend 
who was already 20 minutes late. 
 
IMPLORING               begging, pleading 
Nicola looked imploring as she tried to persuade her dad to 
lend her the car. 
 
INCREDULOUS         not believing 
Simon was incredulous when he heard that he had won the 
lottery. 
 
INDECISIVE               unsure, hesitant, unable to make your mind up 
Tammy was so indecisive that she couldn't even decide what 
to have for lunch. 
 
INDIFFERENT            disinterested, unresponsive, don't care 
Terry was completely indifferent as to whether they went to 
the cinema or the pub. 
 
INSISTING                  demanding, persisting, maintaining 
After a work outing, Frank was insisting he paid the bill for 
everyone. 
 
INSULTING                rude, offensive 
The football crowd was insulting the referee after he gave a 
penalty. 
 
INTERESTED             inquiring, curious 
After seeing Jurassic Park, Hugh grew very interested in 
dinosaurs. 
 
INTRIGUED                very curious, very interested 




IRRITATED                exasperated, annoyed 
Frances was irritated by all the junk mail she received. 
 
JEALOUS                    envious 
Tony was jealous of all the taller, better-looking boys in his 
class. 
 
JOKING                       being funny, playful 
Gary was always joking with his friends. 
 
NERVOUS                  apprehensive, tense, worried 
Just before her job interview, Alice felt very nervous. 
 
OFFENDED                insulted, wounded, having hurt feelings 
When someone made a joke about her weight, Martha felt very 
offended. 
 
PANICKED                 distraught, feeling of terror or anxiety 
On waking to find the house on fire, the whole family was 
panicked. 
 
PENSIVE                     thinking about something slightly worrying 
Susie looked pensive on the way to meeting her boyfriend's 
parents for the first time. 
 
PERPLEXED               bewildered, puzzled, confused 
Frank was perplexed by the disappearance of his garden 
gnomes. 
 
PLAYFUL                   full of high spirits and fun 
Neil was feeling playful at his birthday party. 
 
PREOCCUPIED          absorbed, engrossed in one's own thoughts 
Worrying about her mother's illness made Debbie 
preoccupied at work 
 
PUZZLED                    perplexed, bewildered, confused 
After doing the crossword for an hour, June was still puzzled 
by one clue. 
 
REASSURING            supporting, encouraging, giving someone confidence 
Andy tried to look reassuring as he told his wife that her new 
dress did suit her. 
 
REFLECTIVE             contemplative, thoughtful 
George was in a reflective mood as he thought about what 
he'd done with his life. 
 
REGRETFUL              sorry 
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Lee was always regretful that he had never travelled when he 
was younger. 
 
RELAXED                   taking it easy, calm, carefree 
On holiday, Pam felt happy and relaxed. 
 
RELIEVED                  freed from worry or anxiety 
At the restaurant, Ray was relieved to find that he had not 
forgotten his wallet. 
 
RESENTFUL               bitter, hostile 
The businessman felt very resentful towards his younger 
colleague who had been promoted above him. 
 
SARCASTIC               cynical, mocking, scornful 
The comedian made a sarcastic comment when someone 
came into the theatre late. 
 
SATISFIED                 content, fulfilled 
Steve felt very satisfied after he had got his new flat just how 
he wanted it. 
 
SCEPTICAL                doubtful, suspicious, mistrusting 
Patrick looked sceptical as someone read out his horoscope to 
him. 
 
SERIOUS                     solemn, grave 
The bank manager looked serious as he refused Nigel an 
overdraft. 
 
STERN                         severe, strict, firm 
The teacher looked very stern as he told the class off. 
 
SUSPICIOUS              disbelieving, suspecting, doubting 
After Sam had lost his wallet for the second time at work, he 
grew suspicious of one of his colleagues. 
 
SYMPATHETIC         kind, compassionate 
The nurse looked sympathetic as she told the patient the bad 
news. 
 
TENTATIVE               hesitant, uncertain, cautious 
Andrew felt a bit tentative as he went into the room full of 
strangers. 
 
TERRIFIED                 alarmed, fearful 
The boy was terrified when he thought he saw a ghost. 
 
THOUGHTFUL          thinking about something 
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Phil looked thoughtful as he sat waiting for the girlfriend he 
was about to finish with. 
 
THREATENING         menacing, intimidating 
The large, drunken man was acting in a very threatening way. 
 
UNEASY                     unsettled, apprehensive, troubled 
Karen felt slightly uneasy about accepting a lift from the man 
she had only met that day. 
 
UPSET                         agitated, worried, uneasy 
The man was very upset when his mother died. 
 
WORRIED                   anxious, fretful, troubled 








P        jealous            panicked         arrogant          hateful 
1        playful            comforting      irritated           bored 
2        terrified           upset               arrogant          annoyed 
3        joking             flustered          desire              convinced 
4        joking             insisting          amused           relaxed 
5        irritated           sarcastic          worried           friendly 
6        aghast             fantasizing      impatient         alarmed 
7        apologetic       friendly           uneasy            dispirited 
8        despondent     relieved           shy                  excited 
9        annoyed          hostile             horrified          preoccupied 
10      cautious          insisting          bored              aghast 
11      terrified           amused           regretful          flirtatious 
12      indifferent       embarrassed    sceptical          dispirited 
13      decisive           anticipating     threatening      shy 
14      irritated           disappointed   depressed        accusing 
15      contemplative flustered          encouraging    amused 
16      irritated           thoughtful       encouraging    sympathetic 
17      doubtful          affectionate     playful            aghast 
18      decisive           amused           aghast             bored 
19      arrogant          grateful           sarcastic          tentative 
20      dominant         friendly           guilty              horrified 
21      embarrassed    fantasizing      confused         panicked 
22      preoccupied    grateful           insisting          imploring 
23      contented        apologetic       defiant             curious 
24      pensive            irritated           excited            hostile 
25      panicked         incredulous     despondent     interested 
26      alarmed           shy                  hostile             anxious 
27      joking             cautious          arrogant          reassuring 
28      interested        joking             affectionate     contented 
29      impatient         aghast             irritated           reflective 
30      grateful           flirtatious        hostile             disappointed 
31      ashamed          confident         joking             dispirited 
32      serious            ashamed          bewildered      alarmed 
33      embarrassed    guilty              fantasizing      concerned 
34      aghast             baffled             distrustful       terrified 
35      puzzled           nervous           insisting          contemplative 







Answers - Adults 
 
P         jealous               panicked           arrogant          hateful       M 
1         playful             comforting          irritated           bored        M 
2        terrified                 upset              arrogant        annoyed      M 
3          joking                flustered             desire        convinced     F 
4          joking                insisting            amused          relaxed      M 
5        irritated               sarcastic            worried         friendly      M 
6          aghast             fantasizing        impatient        alarmed       F 
7       apologetic             friendly             uneasy        dispirited     M 
8     despondent            relieved                shy             excited       M 
9        annoyed                hostile             horrified    preoccupied   F 
10       cautious              insisting              bored            aghast       M 
11       terrified               amused            regretful      flirtatious     M 
12     indifferent          embarrassed        sceptical       dispirited     M 
13       decisive           anticipating      threatening          shy          M 
14       irritated           disappointed       depressed       accusing     M 
15  contemplative         flustered        encouraging      amused       F 
16       irritated             thoughtful      encouraging sympathetic   M 
17       doubtful           affectionate          playful           aghast        F 
18       decisive               amused              aghast            bored        F 
19       arrogant               grateful            sarcastic       tentative      F 
20      dominant              friendly              guilty          horrified     M 
21    embarrassed         fantasizing         confused       panicked      F 
22   preoccupied           grateful            insisting       imploring     F 
23      contented            apologetic           defiant          curious      M 
24       pensive               irritated             excited           hostile       M 
25       panicked           incredulous       despondent    interested     F 
26       alarmed                   shy                 hostile          anxious      M 
27         joking                cautious           arrogant       reassuring     F 
28     interested              joking           affectionate    contented     F 
29      impatient               aghast              irritated       reflective     F 
30        grateful             flirtatious           hostile      disappointed   F 
31       ashamed             confident            joking         dispirited     F 
32        serious               ashamed         bewildered      alarmed      M 
33    embarrassed             guilty            fantasizing    concerned    M 
34         aghast                 baffled           distrustful      terrified       F 
35        puzzled               nervous            insisting    contemplative  F 
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NEUROPSYCHOLOGICAL BATTERY FOR THE SEX 
HORMONES, MOOD, COGNITIVE FUNCTION AND 
EMOTION PROCESSING STUDY 
 
SESSION #1 – PATIENT 
 
 
Date  .........................................................   MALE / FEMALE 
 
 










TESTS TO RUN 
 
 Demo Ques 
 NART 
 VAS Time 0 
 CVC- Immediate Trial 
 Trail Making  A & B 
 FER 
 CVC Delayed Trial+ Recognition 
 VAS Time 1 
 Timed Chase Test- CogState 
 GMLT immediate trial -CogState 
 COWAT 
 GMLT delay trial- CogState 
 Digit Span 
 R-MET 











Tables Showing Results Showing Associations between Testosterone Levels, 
Symptoms of Depression and Anxiety and Cognitive Function: Raw and 








Mean Scores (SD), Adjusted Means (SEM), and Effect Sizes on the Consonant-Vowel-




  Mean SD/  
SEM 
Mean SD /    
SEM 
F p d 





























































































Raw and adjusted means are presented, with the latter using NART as a covariate, , F=univariate ANCOVA, d= Cohen’s d 









Mean Total Errors (SD and SEM) and Effect Sizes for the Groton Maze Learning Test in 
in the Polycystic Ovarian Syndrome (n=50) and Control (n=53) Groups 
  PCOS  Controls    






















































































Adjusted means after covarying only for NART, F= univariate ANCOVA, d= Cohen’s d effect size, GMLT- Groton Maze 











Means (SD) and Effect Sizes for Psychomotor Speed Measures in the Polycystic Ovarian 
Syndrome (n=50) and Control (n=53) Groups 
  PCOS  Control    
  Mean SD Mean SD F p d 



























































Means (SD and SEM) and Effect Sizes on the Trail Making Test (List B), COWAT, and the Digit Span Task in the Polycystic Ovarian 
Syndrome (n=50) and Control (n=53) Groups 
 
Adjusted means after covarying for NART, F=univariate ANCOVA, d=
 
Cohen’s d effect size, COWAT- Controlled Oral Word Association 
Test, PCOS- Polycystic Ovarian Syndrome 
  PCOS  Controls    
  Mean SD Mean SD Fa pa db 



































































































































Correlations between Testosterone Variables and Depression and Anxiety Variables scores 
across the Entire Sample (n=103) 












































HADS= Hospital Anxiety and Depression Scale, HADS-A= Hospital Anxiety and Depression Scale (Anxiety sub-scale), 
HADS-D= Hospital Anxiety and Depression Scale (Depression sub-scale),QIDS=Quick inventory of Depressive 








Correlations between Testosterone Variables and Consonant Vowel Consonant Task 
(CVC) Variables across the Entire Sample (n=103) 






















































CVC- Consonant Vowel Consonant Task, FAI- Free Androgen Index, Free T- Free Testosterone, Total T- Total 







Correlations between Testosterone Variables and Groton Maze Learning Test Variables 
across the Entire Sample (n=103) 
  GMLT Total 
Errors Trial 1 
GMLT Total 









































GMLT- Groton Maze Learning Test, FAI- Free Androgen Index, Free T- Free Testosterone, Total T- Total Testosterone, 
*=<0.05, ** =<0.01 
 
Table 8 
Correlations between Testosterone Variables and Psychomotor Speed Variables across the 
Entire Sample (n=103) 









TMT List A 
(Errors) 






























TCT- Timed Chase Test, TMT- Trail Making Test (Part A), FAI- Free Androgen Index, Free T- Free Testosterone, Total 




Correlations between Androgen Variables and Attention and Executive Function Variables across the Entire Sample (n=103) 


















































































Scatterplot Showing Associations between Body Mass Index and Hospital 
Anxiety and Depression Scale- Depression Subscale Score In the Polycystic 





















Scatterplot Showing Associations between Body Mass Index and Hospital Anxiety and 
Depression Scale- Depression Subscale Score in the Polycystic Ovarian Syndrome (n = 







Correlations between Ferriman-Gallwey (FG) Score and Testosterone Levels, 





















Correlations between Ferriman-Gallwey Score and Testosterone Levels, Mood and 




FAI levels (pg/ml) at baseline 
(n = 24) 
0.021 
Free Testosterone levels (pg/ml) at baseline 
(n = 23) 
0.021 
Total Testosterone levels (ng/ml) at baseline 
(n = 26) 
0.280 
HADS-D score at baseline 
(n = 27) 
0.128 
Spearman’s r-value included in the table above, FAI= Free Androgen Index, HADS-D= 







Boxplot showing an Overlap between Free Androgen Index Levels across 





















Boxplot showing an Overlap between Free Androgen Index Levels across Polycystic 
Ovarian Syndrome (n = 50) and Control (n = 53) Groups 
 
